Sentence: Famotidine-associated delirium.
Entity: 8701013	0	10	Famotidine	Chemical	D015738
Entity: 8701013	22	30	delirium	Disease	D003693
Relation: 8701013	CID	0	10	D015738	22	30	D003693	true

Sentence: Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.
Entity: 8701013	0	10	Famotidine	Chemical	D015738
Entity: 8701013	101	107	ulcers	Disease	D014456
Relation: 8701013	CID	0	10	D015738	101	107	D014456	false

Sentence: Although all of the currently available H2-receptor antagonists have shown the propensity to cause delirium, only two previously reported cases have been associated with famotidine.
Entity: 8701013	99	107	delirium	Disease	D003693
Entity: 8701013	170	180	famotidine	Chemical	D015738
Relation: 8701013	CID	170	180	D015738	99	107	D003693	true

Sentence: The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.
Entity: 8701013	35	45	famotidine	Chemical	D015738
Entity: 8701013	57	65	delirium	Disease	D003693
Entity: 8701013	130	140	famotidine	Chemical	D015738
Relation: 8701013	CID	35	45	D015738	57	65	D003693	true
Relation: 8701013	CID	130	140	D015738	57	65	D003693	true

Sentence: Indomethacin induced hypotension in sodium and volume depleted rats.
Entity: 439781	0	12	Indomethacin	Chemical	D007213
Entity: 439781	21	32	hypotension	Disease	D007022
Entity: 439781	36	42	sodium	Chemical	D012964
Relation: 439781	CID	0	12	D007213	21	32	D007022	true
Relation: 439781	CID	36	42	D012964	21	32	D007022	false

Sentence: Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.
Entity: 22836123	11	35	scleroderma renal crisis	Disease	D007674
Entity: 22836123	47	57	tacrolimus	Chemical	D016559
Entity: 22836123	62	74	prednisolone	Chemical	D011239
Relation: 22836123	CID	47	57	D016559	11	35	D007674	false
Relation: 22836123	CID	62	74	D011239	11	35	D007674	false

Sentence: Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.
Entity: 22836123	22	36	corticosteroid	Chemical	D000305
Entity: 22836123	82	85	SRC	Disease	D007674
Relation: 22836123	CID	22	36	D000305	82	85	D007674	false

Sentence: Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.
Entity: 22836123	40	66	thrombotic microangiopathy	Disease	D057049
Entity: 22836123	83	95	cyclosporine	Chemical	D016572
Entity: 22836123	113	116	SSc	Disease	D012595
Relation: 22836123	CID	83	95	D016572	40	66	D057049	true
Relation: 22836123	CID	83	95	D016572	113	116	D012595	false

Sentence: In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.
Entity: 22836123	42	45	SRC	Disease	D007674
Entity: 22836123	57	67	tacrolimus	Chemical	D016559
Entity: 22836123	72	87	corticosteroids	Chemical	D000305
Relation: 22836123	CID	57	67	D016559	42	45	D007674	false
Relation: 22836123	CID	72	87	D000305	42	45	D007674	false

Sentence: The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
Entity: 23433219	35	50	methamphetamine	Chemical	D008694
Entity: 23433219	51	60	psychosis	Disease	D011605
Entity: 23433219	64	79	methamphetamine	Chemical	D008694
Relation: 23433219	CID	35	50	D008694	51	60	D011605	true
Relation: 23433219	CID	64	79	D008694	51	60	D011605	true

Sentence: OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine induced psychosis in patients with methamphetamine dependence.
Entity: 23433219	89	104	methamphetamine	Chemical	D008694
Entity: 23433219	113	122	psychosis	Disease	D011605
Entity: 23433219	140	155	methamphetamine	Chemical	D008694
Relation: 23433219	CID	89	104	D008694	113	122	D011605	true
Relation: 23433219	CID	140	155	D008694	113	122	D011605	true

Sentence: The association between psychiatric co-morbidity and methamphetamine induced psychosis was also studied.
Entity: 23433219	53	68	methamphetamine	Chemical	D008694
Entity: 23433219	77	86	psychosis	Disease	D011605
Relation: 23433219	CID	53	68	D008694	77	86	D011605	true

Sentence: I.) for methamphetamine induced psychosis and other Axis I psychiatric disorders.
Entity: 23433219	8	23	methamphetamine	Chemical	D008694
Entity: 23433219	32	41	psychosis	Disease	D011605
Entity: 23433219	59	80	psychiatric disorders	Disease	D001523
Relation: 23433219	CID	8	23	D008694	32	41	D011605	true
Relation: 23433219	CID	8	23	D008694	59	80	D001523	false

Sentence: Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine induced psychosis after adjusted for other factors.
Entity: 23433219	16	35	depressive disorder	Disease	D003866
Entity: 23433219	67	83	bipolar disorder	Disease	D001714
Entity: 23433219	117	148	antisocial personality disorder	Disease	D000987
Entity: 23433219	191	206	methamphetamine	Chemical	D008694
Entity: 23433219	256	271	methamphetamine	Chemical	D008694
Entity: 23433219	280	289	psychosis	Disease	D011605
Relation: 23433219	CID	191	206	D008694	16	35	D003866	false
Relation: 23433219	CID	191	206	D008694	67	83	D001714	true
Relation: 23433219	CID	191	206	D008694	117	148	D000987	true
Relation: 23433219	CID	191	206	D008694	280	289	D011605	true
Relation: 23433219	CID	256	271	D008694	16	35	D003866	false
Relation: 23433219	CID	256	271	D008694	67	83	D001714	true
Relation: 23433219	CID	256	271	D008694	117	148	D000987	true
Relation: 23433219	CID	256	271	D008694	280	289	D011605	true

Sentence: CONCLUSION: There was a high risk of psychosis in patients with methamphetamine dependence.
Entity: 23433219	37	46	psychosis	Disease	D011605
Entity: 23433219	64	79	methamphetamine	Chemical	D008694
Relation: 23433219	CID	64	79	D008694	37	46	D011605	true

Sentence: It was associated with co-morbid affective disorder, antisocial personality, and heavy methamphetamine use.
Entity: 23433219	33	51	affective disorder	Disease	D019964
Entity: 23433219	53	75	antisocial personality	Disease	D000987
Entity: 23433219	87	102	methamphetamine	Chemical	D008694
Relation: 23433219	CID	87	102	D008694	33	51	D019964	false
Relation: 23433219	CID	87	102	D008694	53	75	D000987	true

Sentence: The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa induced dyskinesias (LIDs) is severely impaired.
Entity: 23535177	61	80	Parkinson's disease	Disease	D010300
Entity: 23535177	82	84	PD	Disease	D010300
Entity: 23535177	90	98	levodopa	Chemical	D007980
Entity: 23535177	107	118	dyskinesias	Disease	D004409
Entity: 23535177	120	124	LIDs	Disease	D004409
Relation: 23535177	CID	90	98	D007980	61	80	D010300	false
Relation: 23535177	CID	90	98	D007980	82	84	D010300	false
Relation: 23535177	CID	90	98	D007980	107	118	D004409	true
Relation: 23535177	CID	90	98	D007980	120	124	D004409	true

Sentence: The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide induced cystitis in rats.
Entity: 23666265	62	78	cyclophosphamide	Chemical	D003520
Entity: 23666265	87	95	cystitis	Disease	D003556
Relation: 23666265	CID	62	78	D003520	87	95	D003556	true

Sentence: PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP) induced cystitis in rats.
Entity: 23666265	102	118	cyclophosphamide	Chemical	D003520
Entity: 23666265	120	123	CYP	Chemical	D003520
Entity: 23666265	133	141	cystitis	Disease	D003556
Relation: 23666265	CID	102	118	D003520	133	141	D003556	true
Relation: 23666265	CID	120	123	D003520	133	141	D003556	true

Sentence: Spontaneous pain behaviors following the administration of CYP were observed.
Entity: 23666265	12	16	pain	Disease	D010146
Entity: 23666265	59	62	CYP	Chemical	D003520
Relation: 23666265	CID	59	62	D003520	12	16	D010146	true

Sentence: RESULTS: Cyclophosphamide treatment increased the spontaneous pain behaviors scores.
Entity: 23666265	9	25	Cyclophosphamide	Chemical	D003520
Entity: 23666265	62	66	pain	Disease	D010146
Relation: 23666265	CID	9	25	D003520	62	66	D010146	true

Sentence: Acute hepatitis associated with clopidogrel: a case report and review of the literature.
Entity: 23846525	6	15	hepatitis	Disease	D056486
Entity: 23846525	32	43	clopidogrel	Chemical	C055162
Relation: 23846525	CID	32	43	C055162	6	15	D056486	true

Sentence: We describe a case of clopidogrel-related acute hepatitis.
Entity: 23846525	22	33	clopidogrel	Chemical	C055162
Entity: 23846525	48	57	hepatitis	Disease	D056486
Relation: 23846525	CID	22	33	C055162	48	57	D056486	true

Sentence: Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years, after the increased use of this drug.
Entity: 23846525	23	37	hepatotoxicity	Disease	D056486
Entity: 23846525	45	56	clopidogrel	Chemical	C055162
Relation: 23846525	CID	45	56	C055162	23	37	D056486	true

Sentence: Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Entity: 23864035	0	10	Bortezomib	Chemical	C400082
Entity: 23864035	15	28	dexamethasone	Chemical	D003907
Entity: 23864035	85	101	multiple myeloma	Disease	D009101
Relation: 23864035	CID	0	10	C400082	85	101	D009101	false
Relation: 23864035	CID	15	28	D003907	85	101	D009101	false

Sentence: Bortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).
Entity: 23864035	0	10	Bortezomib	Chemical	C400082
Entity: 23864035	12	16	bort	Chemical	C400082
Entity: 23864035	18	31	dexamethasone	Chemical	D003907
Entity: 23864035	33	36	dex	Chemical	D003907
Entity: 23864035	92	108	multiple myeloma	Disease	D009101
Entity: 23864035	110	112	MM	Disease	D009101
Relation: 23864035	CID	0	10	C400082	92	108	D009101	false
Relation: 23864035	CID	0	10	C400082	110	112	D009101	false
Relation: 23864035	CID	12	16	C400082	92	108	D009101	false
Relation: 23864035	CID	12	16	C400082	110	112	D009101	false
Relation: 23864035	CID	18	31	D003907	92	108	D009101	false
Relation: 23864035	CID	18	31	D003907	110	112	D009101	false
Relation: 23864035	CID	33	36	D003907	92	108	D009101	false
Relation: 23864035	CID	33	36	D003907	110	112	D009101	false

Sentence: This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.
Entity: 23864035	57	61	bort	Chemical	C400082
Entity: 23864035	118	121	dex	Chemical	D003907
Entity: 23864035	161	165	bort	Chemical	C400082
Entity: 23864035	212	214	MM	Disease	D009101
Relation: 23864035	CID	57	61	C400082	212	214	D009101	false
Relation: 23864035	CID	118	121	D003907	212	214	D009101	false
Relation: 23864035	CID	161	165	C400082	212	214	D009101	false

Sentence: Pubertal exposure to Bisphenol A increases anxiety-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.
Entity: 23871786	21	32	Bisphenol A	Chemical	C006780
Entity: 23871786	43	50	anxiety	Disease	D001008
Relation: 23871786	CID	21	32	C006780	43	50	D001008	true

Sentence: Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to BPA.
Entity: 23871786	55	62	anxiety	Disease	D001008
Entity: 23871786	110	113	BPA	Chemical	C006780
Relation: 23871786	CID	110	113	C006780	55	62	D001008	true

Sentence: Our findings showed that pubertal BPA exposure increased anxiety-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.
Entity: 23871786	34	37	BPA	Chemical	C006780
Entity: 23871786	57	64	anxiety	Disease	D001008
Relation: 23871786	CID	34	37	C006780	57	64	D001008	true

Sentence: The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol induced cardiotoxicity in rats.
Entity: 23872883	107	120	isoproterenol	Chemical	D007545
Entity: 23872883	129	143	cardiotoxicity	Disease	D066126
Relation: 23872883	CID	107	120	D007545	129	143	D066126	true

Sentence: "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Entity: 23892921	48	60	lenalidomide	Chemical	C467567
Entity: 23892921	65	78	dexamethasone	Chemical	D003907
Entity: 23892921	116	132	multiple myeloma	Disease	D009101
Entity: 23892921	216	223	Myeloma	Disease	D009101
Relation: 23892921	CID	48	60	C467567	116	132	D009101	false
Relation: 23892921	CID	48	60	C467567	216	223	D009101	false
Relation: 23892921	CID	65	78	D003907	116	132	D009101	false
Relation: 23892921	CID	65	78	D003907	216	223	D009101	false

Sentence: Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.
Entity: 23892921	0	12	Lenalidomide	Chemical	C467567
Entity: 23892921	17	30	dexamethasone	Chemical	D003907
Entity: 23892921	32	34	RD	Chemical	C467567
Entity: 23892921	32	34	RD	Chemical	D003907
Entity: 23892921	82	98	multiple myeloma	Disease	D009101
Entity: 23892921	100	104	RRMM	Disease	D009101
Relation: 23892921	CID	0	12	C467567	82	98	D009101	false
Relation: 23892921	CID	0	12	C467567	100	104	D009101	false
Relation: 23892921	CID	17	30	D003907	82	98	D009101	false
Relation: 23892921	CID	17	30	D003907	100	104	D009101	false
Relation: 23892921	CID	32	34	C467567	82	98	D009101	false
Relation: 23892921	CID	32	34	C467567	100	104	D009101	false
Relation: 23892921	CID	32	34	D003907	82	98	D009101	false
Relation: 23892921	CID	32	34	D003907	100	104	D009101	false

Sentence: We studied 212 RRMM patients who received RD in RW.
Entity: 23892921	15	19	RRMM	Disease	D009101
Entity: 23892921	42	44	RD	Chemical	C467567
Entity: 23892921	42	44	RD	Chemical	D003907
Relation: 23892921	CID	42	44	C467567	15	19	D009101	false
Relation: 23892921	CID	42	44	D003907	15	19	D009101	false

Sentence: Risk factors and predictors of levodopa induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
Entity: 23952588	31	39	levodopa	Chemical	D007980
Entity: 23952588	48	58	dyskinesia	Disease	D004409
Entity: 23952588	93	112	Parkinson's disease	Disease	D010300
Relation: 23952588	CID	31	39	D007980	48	58	D004409	true
Relation: 23952588	CID	31	39	D007980	93	112	D010300	false

Sentence: Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.
Entity: 23952588	18	26	levodopa	Chemical	D007980
Entity: 23952588	39	58	Parkinson's disease	Disease	D010300
Entity: 23952588	60	62	PD	Disease	D010300
Entity: 23952588	115	125	dyskinesia	Disease	D004409
Relation: 23952588	CID	18	26	D007980	39	58	D010300	false
Relation: 23952588	CID	18	26	D007980	60	62	D010300	false
Relation: 23952588	CID	18	26	D007980	115	125	D004409	true

Sentence: We studied the prevalence and predictors of levodopa induced dyskinesia among multiethnic Malaysian patients with PD.
Entity: 23952588	44	52	levodopa	Chemical	D007980
Entity: 23952588	61	71	dyskinesia	Disease	D004409
Entity: 23952588	114	116	PD	Disease	D010300
Relation: 23952588	CID	44	52	D007980	61	71	D004409	true
Relation: 23952588	CID	44	52	D007980	114	116	D010300	false

Sentence: METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.
Entity: 23952588	68	70	PD	Disease	D010300
Entity: 23952588	88	96	levodopa	Chemical	D007980
Relation: 23952588	CID	88	96	D007980	68	70	D010300	false

Sentence: Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.
Entity: 23952588	0	10	Dyskinesia	Disease	D004409
Entity: 23952588	51	59	levodopa	Chemical	D007980
Relation: 23952588	CID	51	59	D007980	0	10	D004409	true

Sentence: Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p < 0.001), and higher total UPDRS scores ( p = 0.005) than patients without dyskinesia.
Entity: 23952588	14	24	dyskinesia	Disease	D004409
Entity: 23952588	78	86	levodopa	Chemical	D007980
Entity: 23952588	166	174	levodopa	Chemical	D007980
Entity: 23952588	259	269	dyskinesia	Disease	D004409
Relation: 23952588	CID	78	86	D007980	14	24	D004409	true
Relation: 23952588	CID	78	86	D007980	259	269	D004409	true
Relation: 23952588	CID	166	174	D007980	14	24	D004409	true
Relation: 23952588	CID	166	174	D007980	259	269	D004409	true

Sentence: The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.
Entity: 23952588	36	46	dyskinesia	Disease	D004409
Entity: 23952588	64	72	levodopa	Chemical	D007980
Entity: 23952588	109	117	levodopa	Chemical	D007980
Relation: 23952588	CID	64	72	D007980	36	46	D004409	true
Relation: 23952588	CID	109	117	D007980	36	46	D004409	true

Sentence: CONCLUSIONS: The prevalence of levodopa induced dyskinesia in our patients was 44%.
Entity: 23952588	31	39	levodopa	Chemical	D007980
Entity: 23952588	48	58	dyskinesia	Disease	D004409
Relation: 23952588	CID	31	39	D007980	48	58	D004409	true

Sentence: An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.
Entity: 24040781	59	70	proteinuria	Disease	D011507
Entity: 24040781	84	94	everolimus	Chemical	C107135
Entity: 24040781	96	98	AL	Disease	D000686
Entity: 24040781	99	110	amyloidosis	Disease	D000686
Relation: 24040781	CID	84	94	C107135	59	70	D011507	true
Relation: 24040781	CID	84	94	C107135	96	98	D000686	true
Relation: 24040781	CID	84	94	C107135	99	110	D000686	true

Sentence: Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i).
Entity: 24040781	0	11	Proteinuria	Disease	D011507
Entity: 24040781	96	105	rapamycin	Chemical	D020123
Relation: 24040781	CID	96	105	D020123	0	11	D011507	false

Sentence: An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).
Entity: 24067251	35	48	kidney injury	Disease	D007674
Entity: 24067251	84	113	tenofovir disoproxil fumarate	Chemical	C418563
Relation: 24067251	CID	84	113	C418563	35	48	D007674	false

Sentence: Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.
Entity: 24067251	68	71	TDF	Chemical	C418563
Entity: 24067251	80	94	kidney disease	Disease	D007674
Entity: 24067251	130	156	kidney tubular dysfunction	Disease	D007674
Entity: 24067251	198	220	glomerular dysfunction	Disease	D007674
Entity: 24067251	238	254	Fanconi syndrome	Disease	D005198
Relation: 24067251	CID	68	71	C418563	80	94	D007674	false
Relation: 24067251	CID	68	71	C418563	130	156	D007674	false
Relation: 24067251	CID	68	71	C418563	198	220	D007674	false
Relation: 24067251	CID	68	71	C418563	238	254	D005198	true

Sentence: The incidence of hospitalisation for TDF kidney adverse effects was high, particularly amongst patients with features of Fanconi syndrome.
Entity: 24067251	37	40	TDF	Chemical	C418563
Entity: 24067251	121	137	Fanconi syndrome	Disease	D005198
Relation: 24067251	CID	37	40	C418563	121	137	D005198	true

Sentence: The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02).
Entity: 24068571	11	22	thiopentone	Chemical	D013874
Entity: 24068571	87	95	delirium	Disease	D003693
Entity: 24068571	108	116	propofol	Chemical	D015742
Relation: 24068571	CID	11	22	D013874	87	95	D003693	true
Relation: 24068571	CID	108	116	D015742	87	95	D003693	false

Sentence: A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.
Entity: 24072398	9	19	neurotoxic	Disease	D020258
Entity: 24072398	28	43	methamphetamine	Chemical	D008694
Entity: 24072398	67	77	depressive	Disease	D003866
Relation: 24072398	CID	28	43	D008694	9	19	D020258	false
Relation: 24072398	CID	28	43	D008694	67	77	D003866	true

Sentence: Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.
Entity: 24072398	0	15	Methamphetamine	Chemical	D008694
Entity: 24072398	17	21	METH	Chemical	D008694
Entity: 24072398	77	81	METH	Chemical	D008694
Entity: 24072398	133	152	depressive symptoms	Disease	D003866
Relation: 24072398	CID	0	15	D008694	133	152	D003866	true
Relation: 24072398	CID	17	21	D008694	133	152	D003866	true
Relation: 24072398	CID	77	81	D008694	133	152	D003866	true

Sentence: However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits.
Entity: 24072398	62	66	METH	Chemical	D008694
Entity: 24072398	94	104	depressive	Disease	D003866
Relation: 24072398	CID	62	66	D008694	94	104	D003866	true

Sentence: Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.).
Entity: 24072398	26	36	depressive	Disease	D003866
Entity: 24072398	115	119	METH	Chemical	D008694
Relation: 24072398	CID	115	119	D008694	26	36	D003866	true

Sentence: This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.
Entity: 24072398	5	15	depressive	Disease	D003866
Entity: 24072398	40	44	METH	Chemical	D008694
Entity: 24072398	192	200	dopamine	Chemical	D004298
Entity: 24072398	202	207	DOPAC	Chemical	D015102
Entity: 24072398	212	215	HVA	Chemical	D006719
Entity: 24072398	217	225	tyrosine	Chemical	D014443
Entity: 24072398	242	251	serotonin	Chemical	D012701
Relation: 24072398	CID	40	44	D008694	5	15	D003866	true
Relation: 24072398	CID	192	200	D004298	5	15	D003866	false
Relation: 24072398	CID	202	207	D015102	5	15	D003866	false
Relation: 24072398	CID	212	215	D006719	5	15	D003866	false
Relation: 24072398	CID	217	225	D014443	5	15	D003866	false
Relation: 24072398	CID	242	251	D012701	5	15	D003866	false

Sentence: Linezolid induced optic neuropathy.
Entity: 24088636	0	9	Linezolid	Chemical	C098010
Entity: 24088636	18	34	optic neuropathy	Disease	D009901
Relation: 24088636	CID	0	9	C098010	18	34	D009901	true

Sentence: We describe a case of progressive loss of vision associated with linezolid therapy.
Entity: 24088636	34	48	loss of vision	Disease	D014786
Entity: 24088636	65	74	linezolid	Chemical	C098010
Relation: 24088636	CID	65	74	C098010	34	48	D014786	false

Sentence: A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.
Entity: 24088636	107	116	linezolid	Chemical	C098010
Entity: 24088636	121	131	ethambutol	Chemical	D004977
Entity: 24088636	136	175	extensively drug-resistant tuberculosis	Disease	D054908
Entity: 24088636	177	183	XDR-TB	Disease	D054908
Entity: 24088636	227	241	loss of vision	Disease	D014786
Relation: 24088636	CID	107	116	C098010	136	175	D054908	false
Relation: 24088636	CID	107	116	C098010	177	183	D054908	false
Relation: 24088636	CID	107	116	C098010	227	241	D014786	false
Relation: 24088636	CID	121	131	D004977	136	175	D054908	false
Relation: 24088636	CID	121	131	D004977	177	183	D054908	false
Relation: 24088636	CID	121	131	D004977	227	241	D014786	false

Sentence: Ethambutol induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn.
Entity: 24088636	0	10	Ethambutol	Chemical	D004977
Entity: 24088636	19	41	toxic optic neuropathy	Disease	D009901
Entity: 24088636	67	77	ethambutol	Chemical	D004977
Relation: 24088636	CID	0	10	D004977	19	41	D009901	false
Relation: 24088636	CID	67	77	D004977	19	41	D009901	false

Sentence: Deterioration of vision occurred despite withdrawal of ethambutol.
Entity: 24088636	0	23	Deterioration of vision	Disease	D015354
Entity: 24088636	55	65	ethambutol	Chemical	D004977
Relation: 24088636	CID	55	65	D004977	0	23	D015354	false

Sentence: Resuscitation with lipid, epinephrine, or both in levobupivacaine induced cardiac toxicity in newborn piglets.
Entity: 24091473	26	37	epinephrine	Chemical	D004837
Entity: 24091473	50	65	levobupivacaine	Chemical	C476513
Entity: 24091473	74	90	cardiac toxicity	Disease	D066126
Relation: 24091473	CID	26	37	D004837	74	90	D066126	false
Relation: 24091473	CID	50	65	C476513	74	90	D066126	false

Sentence: BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST).
Entity: 24091473	59	70	epinephrine	Chemical	D004837
Entity: 24091473	154	162	toxicity	Disease	D064420
Relation: 24091473	CID	59	70	D004837	154	162	D064420	false

Sentence: METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.
Entity: 24091473	34	49	levobupivacaine	Chemical	C476513
Entity: 24091473	56	79	cardiovascular collapse	Disease	D002318
Relation: 24091473	CID	34	49	C476513	56	79	D002318	true

Sentence: Incidence of heparin induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.
Entity: 24100055	13	20	heparin	Chemical	D006493
Entity: 24100055	29	53	thrombocytopenia type II	Disease	D013921
Relation: 24100055	CID	13	20	D006493	29	53	D013921	true

Sentence: The impact of immune-mediated heparin induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.
Entity: 24100055	30	37	heparin	Chemical	D006493
Entity: 24100055	46	70	thrombocytopenia type II	Disease	D013921
Entity: 24100055	72	83	HIT type II	Disease	D013921
Entity: 24100055	99	115	thrombocytopenia	Disease	D013921
Relation: 24100055	CID	30	37	D006493	46	70	D013921	true
Relation: 24100055	CID	30	37	D006493	72	83	D013921	true
Relation: 24100055	CID	30	37	D006493	99	115	D013921	true

Sentence: Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.
Entity: 24100257	0	18	Takotsubo syndrome	Disease	D054549
Entity: 24100257	23	49	apical ballooning syndrome	Disease	D054549
Entity: 24100257	64	76	Zolmitriptan	Chemical	C089750
Relation: 24100257	CID	64	76	C089750	0	18	D054549	true
Relation: 24100257	CID	64	76	C089750	23	49	D054549	true

Sentence: Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.
Entity: 24100257	73	85	zolmitriptan	Chemical	C089750
Entity: 24100257	114	123	migraines	Disease	D008881
Relation: 24100257	CID	73	85	C089750	114	123	D008881	false

Sentence: But before this event, she was taking zolmitriptan 2-3 times daily for several days because of a persistent migraine headache.
Entity: 24100257	38	50	zolmitriptan	Chemical	C089750
Entity: 24100257	108	125	migraine headache	Disease	D008881
Relation: 24100257	CID	38	50	C089750	108	125	D008881	false

Sentence: Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Entity: 24114426	0	10	Depression	Disease	D003866
Entity: 24114426	12	25	impulsiveness	Disease	D010554
Entity: 24114426	83	116	3,4-methylenedioxymethamphetamine	Chemical	D018817
Entity: 24114426	118	122	MDMA	Chemical	D018817
Entity: 24114426	124	131	ecstasy	Chemical	D018817
Relation: 24114426	CID	83	116	D018817	0	10	D003866	true
Relation: 24114426	CID	83	116	D018817	12	25	D010554	true
Relation: 24114426	CID	118	122	D018817	0	10	D003866	true
Relation: 24114426	CID	118	122	D018817	12	25	D010554	true
Relation: 24114426	CID	124	131	D018817	0	10	D003866	true
Relation: 24114426	CID	124	131	D018817	12	25	D010554	true

Sentence: Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.
Entity: 24126708	59	67	levodopa	Chemical	D007980
Entity: 24126708	87	106	Parkinson's disease	Disease	D010300
Relation: 24126708	CID	59	67	D007980	87	106	D010300	false

Sentence: Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.
Entity: 24126708	0	8	Levodopa	Chemical	D007980
Entity: 24126708	55	74	Parkinson's disease	Disease	D010300
Entity: 24126708	164	174	dyskinesia	Disease	D004409
Entity: 24126708	179	200	visual hallucinations	Disease	D006212
Relation: 24126708	CID	0	8	D007980	55	74	D010300	false
Relation: 24126708	CID	0	8	D007980	164	174	D004409	true
Relation: 24126708	CID	0	8	D007980	179	200	D006212	true

Sentence: Crocin reduced inhibition of ERK activation and diazinon induced hyperlipemia and increased levels of LDLr transcript.
Entity: 24132704	0	6	Crocin	Chemical	C029036
Entity: 24132704	48	56	diazinon	Chemical	D003976
Entity: 24132704	65	77	hyperlipemia	Disease	D006949
Relation: 24132704	CID	0	6	C029036	65	77	D006949	false
Relation: 24132704	CID	48	56	D003976	65	77	D006949	true

Sentence: GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Entity: 24158386	0	3	GEM	Chemical	C056507
Entity: 24158386	58	74	Hodgkin lymphoma	Disease	D006689
Relation: 24158386	CID	0	3	C056507	58	74	D006689	false

Sentence: Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.
Entity: 24158386	0	11	Gemcitabine	Chemical	C056507
Entity: 24158386	16	25	cisplatin	Chemical	D002945
Entity: 24158386	43	45	HL	Disease	D006689
Entity: 24158386	63	71	toxicity	Disease	D064420
Relation: 24158386	CID	0	11	C056507	43	45	D006689	false
Relation: 24158386	CID	0	11	C056507	63	71	D064420	false
Relation: 24158386	CID	16	25	D002945	43	45	D006689	false
Relation: 24158386	CID	16	25	D002945	63	71	D064420	false

Sentence: In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included.
Entity: 24158386	83	85	HL	Disease	D006689
Entity: 24158386	99	110	gemcitabine	Chemical	C056507
Entity: 24158386	147	165	methylprednisolone	Chemical	D008775
Entity: 24158386	185	194	cisplatin	Chemical	D002945
Entity: 24158386	227	230	GEM	Chemical	C056507
Relation: 24158386	CID	99	110	C056507	83	85	D006689	false
Relation: 24158386	CID	147	165	D008775	83	85	D006689	false
Relation: 24158386	CID	185	194	D002945	83	85	D006689	false
Relation: 24158386	CID	227	230	C056507	83	85	D006689	false

Sentence: RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction.
Entity: 24190587	11	18	Ecstasy	Chemical	D018817
Entity: 24190587	20	24	MDMA	Chemical	D018817
Entity: 24190587	90	118	psychobiological dysfunction	Disease	D008107
Relation: 24190587	CID	11	18	D018817	90	118	D008107	false
Relation: 24190587	CID	20	24	D018817	90	118	D008107	false

Sentence: CONCLUSIONS: The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users.
Entity: 24190587	30	37	anxiety	Disease	D001008
Entity: 24190587	42	52	depression	Disease	D003866
Entity: 24190587	108	115	ecstasy	Chemical	D018817
Relation: 24190587	CID	108	115	D018817	30	37	D001008	false
Relation: 24190587	CID	108	115	D018817	42	52	D003866	true

Sentence: Ifosfamide related encephalopathy: the need for a timely EEG evaluation.
Entity: 24209900	0	10	Ifosfamide	Chemical	D007069
Entity: 24209900	19	33	encephalopathy	Disease	D001927
Relation: 24209900	CID	0	10	D007069	19	33	D001927	false

Sentence: BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.
Entity: 24209900	12	22	Ifosfamide	Chemical	D007069
Entity: 24209900	89	96	cancers	Disease	D009369
Entity: 24209900	107	115	sarcomas	Disease	D012509
Entity: 24209900	117	125	lymphoma	Disease	D008223
Entity: 24209900	127	161	gynecologic and testicular cancers	Disease	D009369
Relation: 24209900	CID	12	22	D007069	89	96	D009369	false
Relation: 24209900	CID	12	22	D007069	107	115	D012509	false
Relation: 24209900	CID	12	22	D007069	117	125	D008223	false
Relation: 24209900	CID	12	22	D007069	127	161	D009369	false

Sentence: Encephalopathy has been reported in 10-40% of patients receiving high-dose IV ifosfamide.
Entity: 24209900	0	14	Encephalopathy	Disease	D001927
Entity: 24209900	78	88	ifosfamide	Chemical	D007069
Relation: 24209900	CID	78	88	D007069	0	14	D001927	false

Sentence: OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of ifosfamide related encephalopathy.
Entity: 24209900	104	114	ifosfamide	Chemical	D007069
Entity: 24209900	123	137	encephalopathy	Disease	D001927
Relation: 24209900	CID	104	114	D007069	123	137	D001927	false

Sentence: METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.
Entity: 24209900	130	136	Cancer	Disease	D009369
Entity: 24209900	187	197	ifosfamide	Chemical	D007069
Entity: 24209900	212	226	encephalopathy	Disease	D001927
Relation: 24209900	CID	187	197	D007069	130	136	D009369	false
Relation: 24209900	CID	187	197	D007069	212	226	D001927	false

Sentence: RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ifosfamide.
Entity: 24209900	51	65	encephalopathy	Disease	D001927
Entity: 24209900	108	118	ifosfamide	Chemical	D007069
Relation: 24209900	CID	108	118	D007069	51	65	D001927	false

Sentence: CONCLUSIONS: Severity of ifosfamide related encephalopathy correlates with EEG changes.
Entity: 24209900	25	35	ifosfamide	Chemical	D007069
Entity: 24209900	44	58	encephalopathy	Disease	D001927
Relation: 24209900	CID	25	35	D007069	44	58	D001927	false

Sentence: Incidence of contrast induced nephropathy in hospitalised patients with cancer.
Entity: 24220752	13	21	contrast	Chemical	D003287
Entity: 24220752	30	41	nephropathy	Disease	D007674
Entity: 24220752	72	78	cancer	Disease	D009369
Relation: 24220752	CID	13	21	D003287	30	41	D007674	true
Relation: 24220752	CID	13	21	D003287	72	78	D009369	false

Sentence: OBJECTIVES: To determine the frequency of and possible factors related to contrast induced nephropathy (CIN) in hospitalised patients with cancer.
Entity: 24220752	74	82	contrast	Chemical	D003287
Entity: 24220752	91	102	nephropathy	Disease	D007674
Entity: 24220752	139	145	cancer	Disease	D009369
Relation: 24220752	CID	74	82	D003287	91	102	D007674	true
Relation: 24220752	CID	74	82	D003287	139	145	D009369	false

Sentence: CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with hypertension (P = 0.044).
Entity: 24220752	48	59	bevacizumab	Chemical	-1
Entity: 24220752	60	70	irinotecan	Chemical	C051890
Entity: 24220752	104	116	hypertension	Disease	D006973
Relation: 24220752	CID	48	59	-1	104	116	D006973	false
Relation: 24220752	CID	60	70	C051890	104	116	D006973	false

Sentence: Hypertension and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development.
Entity: 24220752	0	12	Hypertension	Disease	D006973
Entity: 24220752	36	47	bevacizumab	Chemical	-1
Entity: 24220752	48	58	irinotecan	Chemical	C051890
Relation: 24220752	CID	36	47	-1	0	12	D006973	false
Relation: 24220752	CID	48	58	C051890	0	12	D006973	false

Sentence: Contrast induced nephropathy (CIN) is a concern for oncological patients undergoing CT. .
Entity: 24220752	0	8	Contrast	Chemical	D003287
Entity: 24220752	17	28	nephropathy	Disease	D007674
Relation: 24220752	CID	0	8	D003287	17	28	D007674	true

Sentence: Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.
Entity: 24234943	0	46	Syndrome of inappropriate antidiuretic hormone	Disease	D007177
Entity: 24234943	73	87	desvenlafaxine	Chemical	C086816
Relation: 24234943	CID	73	87	C086816	0	46	D007177	true

Sentence: OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with desvenlafaxine.
Entity: 24234943	31	78	syndrome of inappropriate anti-diuretic hormone	Disease	D007177
Entity: 24234943	80	85	SIADH	Disease	D007177
Entity: 24234943	113	127	desvenlafaxine	Chemical	C086816
Relation: 24234943	CID	113	127	C086816	31	78	D007177	true
Relation: 24234943	CID	113	127	C086816	80	85	D007177	true

Sentence: Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.
Entity: 24234943	25	39	desvenlafaxine	Chemical	C086816
Entity: 24234943	63	69	nausea	Disease	D009325
Entity: 24234943	71	78	anxiety	Disease	D001008
Entity: 24234943	83	92	confusion	Disease	D003221
Relation: 24234943	CID	25	39	C086816	63	69	D009325	true
Relation: 24234943	CID	25	39	C086816	71	78	D001008	true
Relation: 24234943	CID	25	39	C086816	83	92	D003221	true

Sentence: The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH.
Entity: 24234943	10	16	sodium	Chemical	D012964
Entity: 24234943	123	129	sodium	Chemical	D012964
Entity: 24234943	172	177	SIADH	Disease	D007177
Relation: 24234943	CID	10	16	D012964	172	177	D007177	false
Relation: 24234943	CID	123	129	D012964	172	177	D007177	false

Sentence: This case report suggests that desvenlafaxine might cause clinically significant hyponatremia.
Entity: 24234943	31	45	desvenlafaxine	Chemical	C086816
Entity: 24234943	81	93	hyponatremia	Disease	D007010
Relation: 24234943	CID	31	45	C086816	81	93	D007010	true

Sentence: Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
Entity: 24275640	20	34	cardiotoxicity	Disease	D066126
Entity: 24275640	85	96	doxorubicin	Chemical	D004317
Relation: 24275640	CID	85	96	D004317	20	34	D066126	true

Sentence: The mechanism of doxorubicin (DOX) induced cardiotoxicity remains controversial.
Entity: 24275640	17	28	doxorubicin	Chemical	D004317
Entity: 24275640	30	33	DOX	Chemical	D004317
Entity: 24275640	43	57	cardiotoxicity	Disease	D066126
Relation: 24275640	CID	17	28	D004317	43	57	D066126	true
Relation: 24275640	CID	30	33	D004317	43	57	D066126	true

Sentence: Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.
Entity: 24275640	15	18	DOX	Chemical	D004317
Entity: 24275640	49	71	cardiac disarrangement	Disease	D006331
Entity: 24275640	73	81	necrosis	Disease	D009336
Relation: 24275640	CID	15	18	D004317	49	71	D006331	false
Relation: 24275640	CID	15	18	D004317	73	81	D009336	true

Sentence: Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only.
Entity: 24275640	67	81	cardiotoxicity	Disease	D066126
Entity: 24275640	110	113	DOX	Chemical	D004317
Relation: 24275640	CID	110	113	D004317	67	81	D066126	true

Sentence: Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience.
Entity: 24283660	0	10	Tacrolimus	Chemical	D016559
Entity: 24283660	19	26	seizure	Disease	D012640
Relation: 24283660	CID	0	10	D016559	19	26	D012640	true

Sentence: Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.
Entity: 24283660	65	73	seizures	Disease	D012640
Entity: 24283660	120	143	end-stage liver disease	Disease	D058625
Entity: 24283660	211	220	bilirubin	Chemical	D001663
Entity: 24283660	247	250	TAC	Chemical	D016559
Relation: 24283660	CID	211	220	D001663	65	73	D012640	false
Relation: 24283660	CID	211	220	D001663	120	143	D058625	false
Relation: 24283660	CID	247	250	D016559	65	73	D012640	true
Relation: 24283660	CID	247	250	D016559	120	143	D058625	false

Sentence: Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures.
Entity: 24283660	41	44	TAC	Chemical	D016559
Entity: 24283660	108	116	seizures	Disease	D012640
Relation: 24283660	CID	41	44	D016559	108	116	D012640	true

Sentence: High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT.
Entity: 24283660	12	15	TAC	Chemical	D016559
Entity: 24283660	69	77	seizures	Disease	D012640
Relation: 24283660	CID	12	15	D016559	69	77	D012640	true

Sentence: Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition).
Entity: 24284476	13	21	apigenin	Chemical	D047310
Entity: 24284476	42	49	amnesia	Disease	D000647
Entity: 24284476	61	72	scopolamine	Chemical	D012601
Relation: 24284476	CID	13	21	D047310	42	49	D000647	false
Relation: 24284476	CID	61	72	D012601	42	49	D000647	true

Sentence: We have previously reported that CCK-8 significantly alleviated morphine induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.
Entity: 24309294	33	38	CCK-8	Chemical	D012844
Entity: 24309294	64	72	morphine	Chemical	D009020
Entity: 24309294	81	88	amnesia	Disease	D000647
Entity: 24309294	166	174	morphine	Chemical	D009020
Relation: 24309294	CID	33	38	D012844	81	88	D000647	false
Relation: 24309294	CID	64	72	D009020	81	88	D000647	true
Relation: 24309294	CID	166	174	D009020	81	88	D000647	true

Sentence: Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.
Entity: 24333387	35	48	neurotoxicity	Disease	D020258
Entity: 24333387	68	82	Streptozotocin	Chemical	D013311
Entity: 24333387	97	114	memory impairment	Disease	D008569
Relation: 24333387	CID	68	82	D013311	35	48	D020258	false
Relation: 24333387	CID	68	82	D013311	97	114	D008569	true

Sentence: In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.
Entity: 24333387	68	76	toxicity	Disease	D064420
Entity: 24333387	84	98	Streptozotocin	Chemical	D013311
Entity: 24333387	100	103	STZ	Chemical	D013311
Entity: 24333387	113	128	memory impaired	Disease	D008569
Relation: 24333387	CID	84	98	D013311	68	76	D064420	false
Relation: 24333387	CID	84	98	D013311	113	128	D008569	true
Relation: 24333387	CID	100	103	D013311	68	76	D064420	false
Relation: 24333387	CID	100	103	D013311	113	128	D008569	true

Sentence: In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.
Entity: 24333387	24	38	Memory deficit	Disease	D008569
Entity: 24333387	95	98	STZ	Chemical	D013311
Relation: 24333387	CID	95	98	D013311	24	38	D008569	true

Sentence: STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.
Entity: 24333387	0	3	STZ	Chemical	D013311
Entity: 24333387	89	106	neuroinflammation	Disease	D007249
Relation: 24333387	CID	0	3	D013311	89	106	D007249	true

Sentence: STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity.
Entity: 24333387	0	3	STZ	Chemical	D013311
Entity: 24333387	51	58	nitrite	Chemical	D009573
Entity: 24333387	60	62	Ca	Chemical	D002118
Entity: 24333387	175	189	excitotoxicity	Disease	D064420
Relation: 24333387	CID	0	3	D013311	175	189	D064420	false
Relation: 24333387	CID	51	58	D009573	175	189	D064420	false
Relation: 24333387	CID	60	62	D002118	175	189	D064420	false

Sentence: STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.
Entity: 24333387	0	3	STZ	Chemical	D013311
Entity: 24333387	209	222	neurotoxicity	Disease	D020258
Relation: 24333387	CID	0	3	D013311	209	222	D020258	false

Sentence: Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.
Entity: 24333387	20	29	Memantine	Chemical	D008559
Entity: 24333387	44	53	Ibuprofen	Chemical	D007052
Entity: 24333387	94	97	STZ	Chemical	D013311
Entity: 24333387	163	176	neurotoxicity	Disease	D020258
Relation: 24333387	CID	20	29	D008559	163	176	D020258	false
Relation: 24333387	CID	44	53	D007052	163	176	D020258	false
Relation: 24333387	CID	94	97	D013311	163	176	D020258	false

Sentence: Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast induced nephropathy.
Entity: 24341598	34	49	sodium chloride	Chemical	D012965
Entity: 24341598	55	64	diltiazem	Chemical	D004110
Entity: 24341598	82	90	contrast	Chemical	D003287
Entity: 24341598	99	110	nephropathy	Disease	D007674
Relation: 24341598	CID	34	49	D012965	99	110	D007674	false
Relation: 24341598	CID	55	64	D004110	99	110	D007674	false
Relation: 24341598	CID	82	90	D003287	99	110	D007674	false

Sentence: INTRODUCTION AND OBJECTIVE: Contrast induced nephropathy (CIN) significantly increases the morbidity and mortality of patients.
Entity: 24341598	28	36	Contrast	Chemical	D003287
Entity: 24341598	45	56	nephropathy	Disease	D007674
Relation: 24341598	CID	28	36	D003287	45	56	D007674	false

Sentence: Among a total of 60 patients included in the study, 16 patients developed acute renal failure (ARF) on the second day after contrast material was injected (26.6%).
Entity: 24341598	74	93	acute renal failure	Disease	D058186
Entity: 24341598	95	98	ARF	Disease	D058186
Entity: 24341598	124	132	contrast	Chemical	D003287
Relation: 24341598	CID	124	132	D003287	74	93	D058186	true
Relation: 24341598	CID	124	132	D003287	95	98	D058186	true

Sentence: Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence.
Entity: 24345882	171	199	acute lymphoblastic leukemia	Disease	D054198
Entity: 24345882	224	236	methotrexate	Chemical	D008727
Relation: 24345882	CID	224	236	D008727	171	199	D054198	false

Sentence: Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.
Entity: 24345882	25	37	methotrexate	Chemical	D008727
Entity: 24345882	39	42	MTX	Chemical	D008727
Entity: 24345882	44	57	neurotoxicity	Disease	D020258
Entity: 24345882	166	169	MTX	Chemical	D008727
Entity: 24345882	202	230	acute lymphoblastic leukemia	Disease	D054198
Relation: 24345882	CID	25	37	D008727	44	57	D020258	false
Relation: 24345882	CID	25	37	D008727	202	230	D054198	false
Relation: 24345882	CID	39	42	D008727	44	57	D020258	false
Relation: 24345882	CID	39	42	D008727	202	230	D054198	false
Relation: 24345882	CID	166	169	D008727	44	57	D020258	false
Relation: 24345882	CID	166	169	D008727	202	230	D054198	false

Sentence: Tranexamic acid overdosage induced generalized seizure in renal failure.
Entity: 24434397	0	15	Tranexamic acid	Chemical	D014148
Entity: 24434397	47	54	seizure	Disease	D012640
Entity: 24434397	58	71	renal failure	Disease	D051437
Relation: 24434397	CID	0	15	D014148	47	54	D012640	false
Relation: 24434397	CID	0	15	D014148	58	71	D051437	false

Sentence: Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum.
Entity: 24434397	0	15	Tranexamic acid	Chemical	D014148
Entity: 24434397	17	20	TNA	Chemical	D014148
Entity: 24434397	70	78	bleeding	Disease	D006470
Relation: 24434397	CID	0	15	D014148	70	78	D006470	false
Relation: 24434397	CID	17	20	D014148	70	78	D006470	false

Sentence: Two hours after the sixth dose of TNA, she had an episode of generalized tonic clonic convulsions.
Entity: 24434397	34	37	TNA	Chemical	D014148
Entity: 24434397	73	97	tonic clonic convulsions	Disease	D004830
Relation: 24434397	CID	34	37	D014148	73	97	D004830	true

Sentence: Pre-treatment of bupivacaine induced cardiovascular depression using different lipid formulations of propofol.
Entity: 24438483	17	28	bupivacaine	Chemical	D002045
Entity: 24438483	37	62	cardiovascular depression	Disease	D002318
Entity: 24438483	101	109	propofol	Chemical	D015742
Relation: 24438483	CID	17	28	D002045	37	62	D002318	false
Relation: 24438483	CID	101	109	D015742	37	62	D002318	false

Sentence: BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine induced cardiotoxicity.
Entity: 24438483	90	101	bupivacaine	Chemical	D002045
Entity: 24438483	128	136	propofol	Chemical	D015742
Entity: 24438483	151	162	bupivacaine	Chemical	D002045
Entity: 24438483	171	185	cardiotoxicity	Disease	D066126
Relation: 24438483	CID	90	101	D002045	171	185	D066126	true
Relation: 24438483	CID	128	136	D015742	171	185	D066126	false
Relation: 24438483	CID	151	162	D002045	171	185	D066126	true

Sentence: The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine induced cardiotoxicity.
Entity: 24438483	55	63	propofol	Chemical	D015742
Entity: 24438483	105	116	bupivacaine	Chemical	D002045
Entity: 24438483	125	139	cardiotoxicity	Disease	D066126
Relation: 24438483	CID	55	63	D015742	125	139	D066126	false
Relation: 24438483	CID	105	116	D002045	125	139	D066126	true

Sentence: We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.
Entity: 24438483	26	37	dysrhythmia	Disease	D001145
Entity: 24438483	155	163	asystole	Disease	D006323
Entity: 24438483	184	195	bupivacaine	Chemical	D002045
Relation: 24438483	CID	184	195	D002045	26	37	D001145	false
Relation: 24438483	CID	184	195	D002045	155	163	D006323	true

Sentence: CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine induced cardiotoxic effects as well as reduced plasma bupivacaine levels.
Entity: 24438483	48	56	propofol	Chemical	D015742
Entity: 24438483	86	94	propofol	Chemical	D015742
Entity: 24438483	141	152	bupivacaine	Chemical	D002045
Entity: 24438483	161	172	cardiotoxic	Disease	D066126
Entity: 24438483	207	218	bupivacaine	Chemical	D002045
Relation: 24438483	CID	48	56	D015742	161	172	D066126	false
Relation: 24438483	CID	86	94	D015742	161	172	D066126	false
Relation: 24438483	CID	141	152	D002045	161	172	D066126	true
Relation: 24438483	CID	207	218	D002045	161	172	D066126	true

Sentence: Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.
Entity: 24451297	0	31	Drug-Induced Acute Liver Injury	Disease	D056486
Entity: 24451297	54	65	Fluvastatin	Chemical	C065180
Relation: 24451297	CID	54	65	C065180	0	31	D056486	true

Sentence: Although statins are generally well-tolerated drugs, recent cases of drug induced liver injury associated with their use have been reported.
Entity: 24451297	9	16	statins	Chemical	D019161
Entity: 24451297	69	94	drug-induced liver injury	Disease	D056486
Relation: 24451297	CID	9	16	D019161	69	94	D056486	false

Sentence: A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin.
Entity: 24451297	40	52	liver damage	Disease	D056486
Entity: 24451297	109	120	fluvastatin	Chemical	C065180
Relation: 24451297	CID	109	120	C065180	40	52	D056486	true

Sentence: Fluconazole associated agranulocytosis and thrombocytopenia.
Entity: 24459006	0	11	Fluconazole	Chemical	D015725
Entity: 24459006	23	38	agranulocytosis	Disease	D000380
Entity: 24459006	43	59	thrombocytopenia	Disease	D013921
Relation: 24459006	CID	0	11	D015725	23	38	D000380	true
Relation: 24459006	CID	0	11	D015725	43	59	D013921	true

Sentence: CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.
Entity: 24459006	35	46	fluconazole	Chemical	D015725
Entity: 24459006	58	73	agranulocytosis	Disease	D000380
Entity: 24459006	79	95	thrombocytopenia	Disease	D013921
Relation: 24459006	CID	35	46	D015725	58	73	D000380	true
Relation: 24459006	CID	35	46	D015725	79	95	D013921	true

Sentence: CONCLUSION: According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.
Entity: 24459006	79	94	agranulocytosis	Disease	D000380
Entity: 24459006	99	115	thrombocytopenia	Disease	D013921
Entity: 24459006	153	164	fluconazole	Chemical	D015725
Relation: 24459006	CID	153	164	D015725	79	94	D000380	true
Relation: 24459006	CID	153	164	D015725	99	115	D013921	true

Sentence: Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Entity: 24464946	135	149	cardiotoxicity	Disease	D066126
Entity: 24464946	157	168	epirubicine	Chemical	D015251
Relation: 24464946	CID	157	168	D015251	135	149	D066126	true

Sentence: AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.
Entity: 24464946	44	61	myocardial strain	Disease	D009202
Entity: 24464946	128	147	cardiac dysfunction	Disease	D006331
Entity: 24464946	166	176	epirubicin	Chemical	D015251
Relation: 24464946	CID	166	176	D015251	44	61	D009202	false
Relation: 24464946	CID	166	176	D015251	128	147	D006331	false

Sentence: METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with epirubicin were studied.
Entity: 24464946	36	56	non-Hodgkin lymphoma	Disease	D008228
Entity: 24464946	70	80	epirubicin	Chemical	D015251
Relation: 24464946	CID	70	80	D015251	36	56	D008228	false

Sentence: Prevention of etomidate induced myoclonus: which is superior: Fentanyl, midazolam, or a combination.
Entity: 24535067	14	23	etomidate	Chemical	D005045
Entity: 24535067	32	41	myoclonus	Disease	D009207
Entity: 24535067	62	70	Fentanyl	Chemical	D005283
Entity: 24535067	72	81	midazolam	Chemical	D008874
Relation: 24535067	CID	14	23	D005045	32	41	D009207	true
Relation: 24535067	CID	62	70	D005283	32	41	D009207	false
Relation: 24535067	CID	72	81	D008874	32	41	D009207	false

Sentence: BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate induced myoclonus.
Entity: 24535067	94	102	fentanyl	Chemical	D005283
Entity: 24535067	104	113	midazolam	Chemical	D008874
Entity: 24535067	136	144	fentanyl	Chemical	D005283
Entity: 24535067	149	158	midazolam	Chemical	D008874
Entity: 24535067	170	179	etomidate	Chemical	D005045
Entity: 24535067	188	197	myoclonus	Disease	D009207
Relation: 24535067	CID	94	102	D005283	188	197	D009207	false
Relation: 24535067	CID	104	113	D008874	188	197	D009207	false
Relation: 24535067	CID	136	144	D005283	188	197	D009207	false
Relation: 24535067	CID	149	158	D008874	188	197	D009207	false
Relation: 24535067	CID	170	179	D005045	188	197	D009207	true

Sentence: Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.
Entity: 24535067	0	19	Myoclonic movements	Disease	D009069
Entity: 24535067	124	133	etomidate	Chemical	D005045
Relation: 24535067	CID	124	133	D005045	0	19	D009069	false

Sentence: The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.
Entity: 24535067	16	20	pain	Disease	D010146
Entity: 24535067	28	37	etomidate	Chemical	D005045
Relation: 24535067	CID	28	37	D005045	16	20	D010146	false

Sentence: Cholestatic presentation of yellow phosphorus poisoning.
Entity: 24554916	0	11	Cholestatic	Disease	D002779
Entity: 24554916	35	45	phosphorus	Chemical	D010758
Entity: 24554916	46	55	poisoning	Disease	D011041
Relation: 24554916	CID	35	45	D010758	0	11	D002779	true
Relation: 24554916	CID	35	45	D010758	46	55	D011041	false

Sentence: Yellow phosphorus, a component of certain pesticide pastes and fireworks, is well known to cause hepatotoxicity.
Entity: 24554916	7	17	phosphorus	Chemical	D010758
Entity: 24554916	97	111	hepatotoxicity	Disease	D056486
Relation: 24554916	CID	7	17	D010758	97	111	D056486	false

Sentence: Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation.
Entity: 24554916	0	9	Poisoning	Disease	D011041
Entity: 24554916	22	32	phosphorus	Chemical	D010758
Entity: 24554916	60	75	acute hepatitis	Disease	D006505
Entity: 24554916	87	106	acute liver failure	Disease	D017114
Relation: 24554916	CID	22	32	D010758	0	9	D011041	false
Relation: 24554916	CID	22	32	D010758	60	75	D006505	true
Relation: 24554916	CID	22	32	D010758	87	106	D017114	true

Sentence: Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.
Entity: 24571687	0	17	Vasovagal syncope	Disease	D019462
Entity: 24571687	29	40	bradycardia	Disease	D001919
Entity: 24571687	62	77	dexmedetomidine	Chemical	D020927
Relation: 24571687	CID	62	77	D020927	0	17	D019462	true
Relation: 24571687	CID	62	77	D020927	29	40	D001919	true

Sentence: We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.
Entity: 24571687	10	17	syncope	Disease	D013575
Entity: 24571687	22	33	bradycardia	Disease	D001919
Entity: 24571687	96	111	dexmedetomidine	Chemical	D020927
Relation: 24571687	CID	96	111	D020927	10	17	D013575	false
Relation: 24571687	CID	96	111	D020927	22	33	D001919	true

Sentence: Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.
Entity: 24582773	19	28	agitation	Disease	D011595
Entity: 24582773	58	68	quetiapine	Chemical	C069541
Entity: 24582773	72	97	schizo-affective disorder	Disease	D011618
Relation: 24582773	CID	58	68	C069541	19	28	D011595	true
Relation: 24582773	CID	58	68	C069541	72	97	D011618	false

Sentence: We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l).
Entity: 24582773	59	84	schizo-affective disorder	Disease	D011618
Entity: 24582773	173	187	zuclopenthixol	Chemical	D003006
Entity: 24582773	205	212	lithium	Chemical	D008094
Entity: 24582773	234	241	lithium	Chemical	D008094
Relation: 24582773	CID	173	187	D003006	59	84	D011618	false
Relation: 24582773	CID	205	212	D008094	59	84	D011618	false
Relation: 24582773	CID	234	241	D008094	59	84	D011618	false

Sentence: Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.
Entity: 24582773	54	64	quetiapine	Chemical	C069541
Entity: 24582773	114	123	agitation	Disease	D011595
Entity: 24582773	207	221	aggressiveness	Disease	D010554
Entity: 24582773	225	245	personality disorder	Disease	D010554
Relation: 24582773	CID	54	64	C069541	114	123	D011595	true
Relation: 24582773	CID	54	64	C069541	207	221	D010554	false
Relation: 24582773	CID	54	64	C069541	225	245	D010554	false

Sentence: Antioxidant effects of bovine lactoferrin on dexamethasone induced hypertension in rat.
Entity: 24587916	45	58	dexamethasone	Chemical	D003907
Entity: 24587916	67	79	hypertension	Disease	D006973
Relation: 24587916	CID	45	58	D003907	67	79	D006973	true

Sentence: Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.
Entity: 24587916	0	13	Dexamethasone	Chemical	D003907
Entity: 24587916	16	19	Dex	Chemical	D003907
Entity: 24587916	30	42	hypertension	Disease	D006973
Relation: 24587916	CID	0	13	D003907	30	42	D006973	true
Relation: 24587916	CID	16	19	D003907	30	42	D006973	true

Sentence: In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.
Entity: 24587916	98	110	hypertension	Disease	D006973
Entity: 24587916	116	119	Dex	Chemical	D003907
Relation: 24587916	CID	116	119	D003907	98	110	D006973	true

Sentence: LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex induced hypertension.
Entity: 24587916	65	68	Dex	Chemical	D003907
Entity: 24587916	77	89	hypertension	Disease	D006973
Relation: 24587916	CID	65	68	D003907	77	89	D006973	true

Sentence: LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.
Entity: 24587916	18	29	weight loss	Disease	D015431
Entity: 24587916	76	80	H2O2	Chemical	D006861
Relation: 24587916	CID	76	80	D006861	18	29	D015431	false

Sentence: The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.
Entity: 24588023	24	39	tranexamic acid	Chemical	D014148
Entity: 24588023	44	54	convulsive	Disease	D012640
Entity: 24588023	55	63	seizures	Disease	D012640
Relation: 24588023	CID	24	39	D014148	44	54	D012640	true
Relation: 24588023	CID	24	39	D014148	55	63	D012640	true

Sentence: Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.
Entity: 24588023	40	48	seizures	Disease	D012640
Entity: 24588023	131	155	congestive heart failure	Disease	D006333
Entity: 24588023	162	173	hypothermic	Disease	D007035
Entity: 24588023	229	244	tranexamic acid	Chemical	D014148
Relation: 24588023	CID	229	244	D014148	40	48	D012640	true
Relation: 24588023	CID	229	244	D014148	131	155	D006333	false
Relation: 24588023	CID	229	244	D014148	162	173	D007035	false

Sentence: When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).
Entity: 24588023	51	66	tranexamic acid	Chemical	D014148
Entity: 24588023	105	113	seizures	Disease	D012640
Relation: 24588023	CID	51	66	D014148	105	113	D012640	true

Sentence: Dysfunctional overnight memory consolidation in ecstasy users.
Entity: 24595967	0	30	Dysfunctional overnight memory	Disease	D008569
Entity: 24595967	48	55	ecstasy	Chemical	D018817
Relation: 24595967	CID	48	55	D018817	0	30	D008569	true

Sentence: Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep-related impairments.
Entity: 24595967	31	38	ecstasy	Chemical	D018817
Entity: 24595967	91	116	sleep-related impairments	Disease	D012893
Relation: 24595967	CID	31	38	D018817	91	116	D012893	true

Sentence: Ecstasy users demonstrated impaired overnight memory consolidation, a finding that was more pronounced following associative interference.
Entity: 24595967	0	7	Ecstasy	Chemical	D018817
Entity: 24595967	27	52	impaired overnight memory	Disease	D008569
Relation: 24595967	CID	0	7	D018817	27	52	D008569	true

Sentence: Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms.
Entity: 24614773	15	29	encephalopathy	Disease	D001927
Entity: 24614773	38	47	valproate	Chemical	D014635
Relation: 24614773	CID	38	47	D014635	15	29	D001927	false

Sentence: In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.
Entity: 24614773	90	101	hemiparesis	Disease	D010291
Entity: 24614773	145	154	valproate	Chemical	D014635
Entity: 24614773	168	187	hemiplegic migraine	Disease	D020325
Relation: 24614773	CID	145	154	D014635	90	101	D010291	false
Relation: 24614773	CID	145	154	D014635	168	187	D020325	false

Sentence: EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre N-methyl-D-aspartate (NMDA) receptor antibodies were present in this patient.
Entity: 24614773	68	82	encephalopathy	Disease	D001927
Entity: 24614773	98	118	N-methyl-D-aspartate	Chemical	D016202
Entity: 24614773	120	124	NMDA	Chemical	D016202
Relation: 24614773	CID	98	118	D016202	68	82	D001927	false
Relation: 24614773	CID	120	124	D016202	68	82	D001927	false

Sentence: Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.
Entity: 24618873	0	10	Cerebellar	Disease	D002526
Entity: 24618873	15	25	oculomotor	Disease	D005128
Entity: 24618873	67	76	pethidine	Chemical	D008614
Relation: 24618873	CID	67	76	D008614	0	10	D002526	false
Relation: 24618873	CID	67	76	D008614	15	25	D005128	false

Sentence: Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors.
Entity: 24618873	0	9	Pethidine	Chemical	D008614
Entity: 24618873	67	71	pain	Disease	D010146
Relation: 24618873	CID	0	9	D008614	67	71	D010146	false

Sentence: In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.
Entity: 24618873	17	25	impaired	Disease	D051437
Entity: 24618873	17	25	impaired	Disease	D017093
Entity: 24618873	81	85	pain	Disease	D010146
Entity: 24618873	95	104	pethidine	Chemical	D008614
Entity: 24618873	175	185	neurotoxic	Disease	D020258
Entity: 24618873	198	210	norpethidine	Chemical	C002752
Entity: 24618873	225	237	irritability	Disease	D001523
Entity: 24618873	242	249	seizure	Disease	D012640
Relation: 24618873	CID	95	104	D008614	17	25	D051437	false
Relation: 24618873	CID	95	104	D008614	17	25	D017093	false
Relation: 24618873	CID	95	104	D008614	81	85	D010146	false
Relation: 24618873	CID	95	104	D008614	175	185	D020258	false
Relation: 24618873	CID	95	104	D008614	225	237	D001523	false
Relation: 24618873	CID	95	104	D008614	242	249	D012640	false
Relation: 24618873	CID	198	210	C002752	17	25	D051437	false
Relation: 24618873	CID	198	210	C002752	17	25	D017093	false
Relation: 24618873	CID	198	210	C002752	81	85	D010146	false
Relation: 24618873	CID	198	210	C002752	175	185	D020258	false
Relation: 24618873	CID	198	210	C002752	225	237	D001523	false
Relation: 24618873	CID	198	210	C002752	242	249	D012640	true

Sentence: Baboon syndrome induced by ketoconazole.
Entity: 24641119	0	15	Baboon syndrome	Disease	-1
Entity: 24641119	27	39	ketoconazole	Chemical	D007654
Relation: 24641119	CID	27	39	D007654	0	15	-1	false

Sentence: A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole.
Entity: 24641119	44	66	maculopapular eruption	Disease	D003875
Entity: 24641119	119	131	ketoconazole	Chemical	D007654
Relation: 24641119	CID	119	131	D007654	44	66	D003875	true

Sentence: The patient was diagnosed with drug induced baboon syndrome based on his history, which included prior sensitivity to topical ketoconazole, a physical examination, and histopathological findings.
Entity: 24641119	44	59	baboon syndrome	Disease	-1
Entity: 24641119	126	138	ketoconazole	Chemical	D007654
Relation: 24641119	CID	126	138	D007654	44	59	-1	false

Sentence: A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.
Entity: 24653743	10	30	Sudden Cardiac Death	Disease	D016757
Entity: 24653743	38	50	Pilsicainide	Chemical	C042288
Entity: 24653743	59	78	Torsades de Pointes	Disease	D016171
Relation: 24653743	CID	38	50	C042288	10	30	D016757	true
Relation: 24653743	CID	38	50	C042288	59	78	D016171	true

Sentence: An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.
Entity: 24653743	34	46	pilsicainide	Chemical	C042288
Entity: 24653743	55	61	sodium	Chemical	D012964
Entity: 24653743	133	152	atrial fibrillation	Disease	D001281
Entity: 24653743	194	214	sudden cardiac death	Disease	D016757
Relation: 24653743	CID	34	46	C042288	133	152	D001281	false
Relation: 24653743	CID	34	46	C042288	194	214	D016757	true
Relation: 24653743	CID	55	61	D012964	133	152	D001281	false
Relation: 24653743	CID	55	61	D012964	194	214	D016757	false

Sentence: Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of pilsicainide may have been high, which can produce torsades de pointes in the octogenarian.
Entity: 24653743	78	90	pilsicainide	Chemical	C042288
Entity: 24653743	128	140	pilsicainide	Chemical	C042288
Entity: 24653743	179	198	torsades de pointes	Disease	D016171
Relation: 24653743	CID	78	90	C042288	179	198	D016171	true
Relation: 24653743	CID	128	140	C042288	179	198	D016171	true

Sentence: All-trans retinoic acid induced inflammatory myositis in a patient with acute promyelocytic leukemia.
Entity: 24658375	0	23	All-trans retinoic acid	Chemical	D014212
Entity: 24658375	45	53	myositis	Disease	D009220
Entity: 24658375	72	100	acute promyelocytic leukemia	Disease	D015473
Relation: 24658375	CID	0	23	D014212	45	53	D009220	true
Relation: 24658375	CID	0	23	D014212	72	100	D015473	false

Sentence: All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.
Entity: 24658375	0	23	All-trans retinoic acid	Chemical	D014212
Entity: 24658375	25	29	ATRA	Chemical	D014212
Entity: 24658375	68	96	acute promyelocytic leukemia	Disease	D015473
Entity: 24658375	98	101	APL	Disease	D015473
Relation: 24658375	CID	0	23	D014212	68	96	D015473	false
Relation: 24658375	CID	0	23	D014212	98	101	D015473	false
Relation: 24658375	CID	25	29	D014212	68	96	D015473	false
Relation: 24658375	CID	25	29	D014212	98	101	D015473	false

Sentence: Only a handful of cases of ATRA induced myositis in children have been reported, and none in the radiology literature.
Entity: 24658375	27	31	ATRA	Chemical	D014212
Entity: 24658375	40	48	myositis	Disease	D009220
Relation: 24658375	CID	27	31	D014212	40	48	D009220	true

Sentence: Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Entity: 24659727	16	25	lomustine	Chemical	D008130
Entity: 24659727	46	62	cyclophosphamide	Chemical	D003520
Entity: 24659727	76	84	lymphoma	Disease	D008223
Relation: 24659727	CID	16	25	D008130	76	84	D008223	false
Relation: 24659727	CID	46	62	D003520	76	84	D008223	false

Sentence: This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.
Entity: 24659727	35	43	toxicity	Disease	D064420
Entity: 24659727	74	83	lomustine	Chemical	D008130
Entity: 24659727	85	89	CCNU	Chemical	D008130
Entity: 24659727	95	111	cyclophosphamide	Chemical	D003520
Entity: 24659727	113	116	CTX	Chemical	D003520
Entity: 24659727	131	139	lymphoma	Disease	D008223
Relation: 24659727	CID	74	83	D008130	35	43	D064420	false
Relation: 24659727	CID	74	83	D008130	131	139	D008223	false
Relation: 24659727	CID	85	89	D008130	35	43	D064420	false
Relation: 24659727	CID	85	89	D008130	131	139	D008223	false
Relation: 24659727	CID	95	111	D003520	35	43	D064420	false
Relation: 24659727	CID	95	111	D003520	131	139	D008223	false
Relation: 24659727	CID	113	116	D003520	35	43	D064420	false
Relation: 24659727	CID	113	116	D003520	131	139	D008223	false

Sentence: Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).
Entity: 24659727	0	11	Neutropenia	Disease	D009503
Entity: 24659727	81	92	neutropenia	Disease	D009503
Entity: 24659727	122	126	CCNU	Chemical	D008130
Entity: 24659727	127	130	CTX	Chemical	D003520
Relation: 24659727	CID	122	126	D008130	0	11	D009503	true
Relation: 24659727	CID	122	126	D008130	81	92	D009503	true
Relation: 24659727	CID	127	130	D003520	0	11	D009503	true
Relation: 24659727	CID	127	130	D003520	81	92	D009503	true

Sentence: Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
Entity: 24664478	0	10	Nelarabine	Chemical	C104457
Entity: 24664478	11	24	neurotoxicity	Disease	D020258
Relation: 24664478	CID	0	10	C104457	11	24	D020258	false

Sentence: Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported.
Entity: 24664478	7	17	nelarabine	Chemical	C104457
Entity: 24664478	18	31	neurotoxicity	Disease	D020258
Relation: 24664478	CID	7	17	C104457	18	31	D020258	false

Sentence: Valproate induced hyperammonemic encephalopathy in a renal transplanted patient.
Entity: 24665854	0	9	Valproate	Chemical	D014635
Entity: 24665854	18	32	hyperammonemic	Disease	D022124
Entity: 24665854	33	47	encephalopathy	Disease	D001927
Relation: 24665854	CID	0	9	D014635	18	32	D022124	true
Relation: 24665854	CID	0	9	D014635	33	47	D001927	false

Sentence: Valproate induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.
Entity: 24665854	0	9	Valproate	Chemical	D014635
Entity: 24665854	18	32	hyperammonemic	Disease	D022124
Entity: 24665854	33	47	encephalopathy	Disease	D001927
Entity: 24665854	85	94	valproate	Chemical	D014635
Relation: 24665854	CID	0	9	D014635	18	32	D022124	true
Relation: 24665854	CID	0	9	D014635	33	47	D001927	false
Relation: 24665854	CID	85	94	D014635	18	32	D022124	true
Relation: 24665854	CID	85	94	D014635	33	47	D001927	false

Sentence: Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.
Entity: 24665854	85	94	valproate	Chemical	D014635
Entity: 24665854	102	110	epilepsy	Disease	D004827
Entity: 24665854	124	146	impaired consciousness	Disease	D003244
Entity: 24665854	152	166	hyperammonemia	Disease	D022124
Relation: 24665854	CID	85	94	D014635	102	110	D004827	false
Relation: 24665854	CID	85	94	D014635	124	146	D003244	true
Relation: 24665854	CID	85	94	D014635	152	166	D022124	true

Sentence: Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.
Entity: 24671324	0	21	Necrotising fasciitis	Disease	D019115
Entity: 24671324	28	38	bortezomib	Chemical	C400082
Entity: 24671324	43	56	dexamethasone	Chemical	D003907
Entity: 24671324	101	131	Waldenstrom macroglobulinaemia	Disease	D008258
Relation: 24671324	CID	28	38	C400082	0	21	D019115	true
Relation: 24671324	CID	28	38	C400082	101	131	D008258	false
Relation: 24671324	CID	43	56	D003907	0	21	D019115	true
Relation: 24671324	CID	43	56	D003907	101	131	D008258	false

Sentence: Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.
Entity: 24671324	0	10	Bortezomib	Chemical	C400082
Entity: 24671324	25	38	dexamethasone	Chemical	D003907
Entity: 24671324	116	136	bacterial infections	Disease	D001424
Entity: 24671324	161	173	malignancies	Disease	D009369
Relation: 24671324	CID	0	10	C400082	116	136	D001424	false
Relation: 24671324	CID	0	10	C400082	161	173	D009369	false
Relation: 24671324	CID	25	38	D003907	116	136	D001424	false
Relation: 24671324	CID	25	38	D003907	161	173	D009369	false

Sentence: We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.
Entity: 24671324	43	73	Waldenstrom macroglobulinaemia	Disease	D008258
Entity: 24671324	87	108	necrotising fasciitis	Disease	D019115
Entity: 24671324	117	128	neutropenia	Disease	D009503
Entity: 24671324	166	176	bortezomib	Chemical	C400082
Entity: 24671324	188	201	dexamethasone	Chemical	D003907
Relation: 24671324	CID	166	176	C400082	43	73	D008258	false
Relation: 24671324	CID	166	176	C400082	87	108	D019115	true
Relation: 24671324	CID	166	176	C400082	117	128	D009503	false
Relation: 24671324	CID	188	201	D003907	43	73	D008258	false
Relation: 24671324	CID	188	201	D003907	87	108	D019115	true
Relation: 24671324	CID	188	201	D003907	117	128	D009503	false

Sentence: An integrated characterization of serological, pathological, and functional events in doxorubicin induced cardiotoxicity.
Entity: 24675088	86	97	doxorubicin	Chemical	D004317
Entity: 24675088	106	120	cardiotoxicity	Disease	D066126
Relation: 24675088	CID	86	97	D004317	106	120	D066126	false

Sentence: In this study, we have utilized a rat model of progressive doxorubicin (DOX) induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.
Entity: 24675088	59	70	doxorubicin	Chemical	D004317
Entity: 24675088	72	75	DOX	Chemical	D004317
Entity: 24675088	85	99	cardiomyopathy	Disease	D009202
Entity: 24675088	328	336	toxicity	Disease	D064420
Relation: 24675088	CID	59	70	D004317	85	99	D009202	true
Relation: 24675088	CID	59	70	D004317	328	336	D064420	false
Relation: 24675088	CID	72	75	D004317	85	99	D009202	true
Relation: 24675088	CID	72	75	D004317	328	336	D064420	false

Sentence: Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction.
Entity: 24675088	62	72	gadolinium	Chemical	D005682
Entity: 24675088	126	147	diastolic dysfunction	Disease	D018754
Relation: 24675088	CID	62	72	D005682	126	147	D018754	false

Sentence: Intradermal glutamate and capsaicin injections: intra- and interindividual variability of provoked hyperalgesia and allodynia.
Entity: 24684312	12	21	glutamate	Chemical	D018698
Entity: 24684312	26	35	capsaicin	Chemical	D002211
Entity: 24684312	99	111	hyperalgesia	Disease	D006930
Entity: 24684312	116	125	allodynia	Disease	D006930
Relation: 24684312	CID	12	21	D018698	99	111	D006930	false
Relation: 24684312	CID	12	21	D018698	116	125	D006930	false
Relation: 24684312	CID	26	35	D002211	99	111	D006930	true
Relation: 24684312	CID	26	35	D002211	116	125	D006930	true

Sentence: Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.
Entity: 24684312	26	35	glutamate	Chemical	D018698
Entity: 24684312	40	49	capsaicin	Chemical	D002211
Entity: 24684312	94	98	pain	Disease	D010146
Entity: 24684312	114	126	hyperalgesia	Disease	D006930
Entity: 24684312	131	140	allodynia	Disease	D006930
Entity: 24684312	176	190	pain disorders	Disease	D013001
Relation: 24684312	CID	26	35	D018698	94	98	D010146	false
Relation: 24684312	CID	26	35	D018698	114	126	D006930	false
Relation: 24684312	CID	26	35	D018698	131	140	D006930	false
Relation: 24684312	CID	26	35	D018698	176	190	D013001	false
Relation: 24684312	CID	40	49	D002211	94	98	D010146	false
Relation: 24684312	CID	40	49	D002211	114	126	D006930	true
Relation: 24684312	CID	40	49	D002211	131	140	D006930	true
Relation: 24684312	CID	40	49	D002211	176	190	D013001	false

Sentence: Secondary pinprick hyperalgesia was observed as a marked increase in the visual analogue scale (VAS) response to von Frey gauges 60 and 100 g (P < 0.001) after glutamate injection.
Entity: 24684312	19	31	hyperalgesia	Disease	D006930
Entity: 24684312	160	169	glutamate	Chemical	D018698
Relation: 24684312	CID	160	169	D018698	19	31	D006930	false

Sentence: For capsaicin, secondary pinprick hyperalgesia was detected with all von Frey gauges (P < 0.001).
Entity: 24684312	4	13	capsaicin	Chemical	D002211
Entity: 24684312	34	46	hyperalgesia	Disease	D006930
Relation: 24684312	CID	4	13	D002211	34	46	D006930	true

Sentence: Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).
Entity: 24684312	0	9	Capsaicin	Chemical	D002211
Entity: 24684312	41	63	secondary hyperalgesia	Disease	D006930
Entity: 24684312	81	90	allodynia	Disease	D006930
Relation: 24684312	CID	0	9	D002211	41	63	D006930	true
Relation: 24684312	CID	0	9	D002211	81	90	D006930	true

Sentence: Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid induced glaucoma in human patients.
Entity: 24691439	46	59	dexamethasone	Chemical	D003907
Entity: 24691439	142	158	retinal ganglion	Disease	D012173
Entity: 24691439	170	189	axonal degeneration	Disease	D009410
Entity: 24691439	225	233	glaucoma	Disease	D005901
Relation: 24691439	CID	46	59	D003907	142	158	D012173	false
Relation: 24691439	CID	46	59	D003907	170	189	D009410	true
Relation: 24691439	CID	46	59	D003907	225	233	D005901	true

Sentence: Furthermore, dexamethasone induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM).
Entity: 24691439	13	26	dexamethasone	Chemical	D003907
Entity: 24691439	35	54	ocular hypertension	Disease	D009798
Relation: 24691439	CID	13	26	D003907	35	54	D009798	true

Sentence: Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone induced ocular hypertension.
Entity: 24691439	0	13	Dexamethasone	Chemical	D003907
Entity: 24691439	187	200	dexamethasone	Chemical	D003907
Entity: 24691439	209	228	ocular hypertension	Disease	D009798
Relation: 24691439	CID	0	13	D003907	209	228	D009798	true
Relation: 24691439	CID	187	200	D003907	209	228	D009798	true

Sentence: Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone induced ocular hypertension in WT mice.
Entity: 24691439	51	74	sodium 4-phenylbutyrate	Chemical	C075773
Entity: 24691439	85	98	dexamethasone	Chemical	D003907
Entity: 24691439	107	126	ocular hypertension	Disease	D009798
Relation: 24691439	CID	51	74	C075773	107	126	D009798	false
Relation: 24691439	CID	85	98	D003907	107	126	D009798	true

Sentence: Effects of ginsenosides on opioid induced hyperalgesia in mice.
Entity: 24709919	11	23	ginsenosides	Chemical	D036145
Entity: 24709919	42	54	hyperalgesia	Disease	D006930
Relation: 24709919	CID	11	23	D036145	42	54	D006930	false

Sentence: In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.
Entity: 24709919	46	75	Re, Rg1, and Rb1 ginsenosides	Chemical	C049864|C035054|C442759
Entity: 24709919	117	120	OIH	Disease	D006930
Relation: 24709919	CID	46	75	C049864|C035054|C442759	117	120	D006930	false

Sentence: OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.
Entity: 24709919	0	3	OIH	Disease	D006930
Entity: 24709919	62	70	morphine	Chemical	D009020
Relation: 24709919	CID	62	70	D009020	0	3	D006930	true

Sentence: Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid induced writhing test.
Entity: 24709919	0	2	Re	Chemical	C049864
Entity: 24709919	25	28	OIH	Disease	D006930
Entity: 24709919	74	85	acetic acid	Chemical	D019342
Relation: 24709919	CID	0	2	C049864	25	28	D006930	false
Relation: 24709919	CID	74	85	D019342	25	28	D006930	false

Sentence: However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.
Entity: 24709919	13	16	Rg1	Chemical	C035054
Entity: 24709919	21	24	Rb1	Chemical	C442759
Entity: 24709919	56	59	OIH	Disease	D006930
Relation: 24709919	CID	13	16	C035054	56	59	D006930	false
Relation: 24709919	CID	21	24	C442759	56	59	D006930	false

Sentence: Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid induced writhing test.
Entity: 24709919	13	16	Rg1	Chemical	C035054
Entity: 24709919	48	51	OIH	Disease	D006930
Entity: 24709919	59	70	acetic acid	Chemical	D019342
Relation: 24709919	CID	13	16	C035054	48	51	D006930	false
Relation: 24709919	CID	59	70	D019342	48	51	D006930	false

Sentence: CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.
Entity: 24717468	20	31	hypotension	Disease	D007022
Entity: 24717468	36	47	bradycardia	Disease	D001919
Entity: 24717468	119	134	dexmedetomidine	Chemical	D020927
Entity: 24717468	138	146	propofol	Chemical	D015742
Relation: 24717468	CID	119	134	D020927	20	31	D007022	true
Relation: 24717468	CID	119	134	D020927	36	47	D001919	true
Relation: 24717468	CID	138	146	D015742	20	31	D007022	true
Relation: 24717468	CID	138	146	D015742	36	47	D001919	true

Sentence: Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin induced cardiotoxicity in rats with breast cancer.
Entity: 24727461	0	14	Hydroxytyrosol	Chemical	C005975
Entity: 24727461	48	73	mitochondrial dysfunction	Disease	D028361
Entity: 24727461	77	88	doxorubicin	Chemical	D004317
Entity: 24727461	97	111	cardiotoxicity	Disease	D066126
Entity: 24727461	125	138	breast cancer	Disease	D001943
Relation: 24727461	CID	0	14	C005975	48	73	D028361	false
Relation: 24727461	CID	0	14	C005975	97	111	D066126	false
Relation: 24727461	CID	0	14	C005975	125	138	D001943	false
Relation: 24727461	CID	77	88	D004317	48	73	D028361	false
Relation: 24727461	CID	77	88	D004317	97	111	D066126	false
Relation: 24727461	CID	77	88	D004317	125	138	D001943	false

Sentence: Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.
Entity: 24727461	60	66	cancer	Disease	D009369
Entity: 24727461	78	100	cardiovascular disease	Disease	D002318
Entity: 24727461	175	186	doxorubicin	Chemical	D004317
Relation: 24727461	CID	175	186	D004317	60	66	D009369	false
Relation: 24727461	CID	175	186	D004317	78	100	D002318	false

Sentence: Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction.
Entity: 24727461	0	11	Doxorubicin	Chemical	D004317
Entity: 24727461	31	45	cardiotoxicity	Disease	D066126
Entity: 24727461	104	129	mitochondrial dysfunction	Disease	D028361
Relation: 24727461	CID	0	11	D004317	31	45	D066126	false
Relation: 24727461	CID	0	11	D004317	104	129	D028361	false

Sentence: Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.
Entity: 24727461	31	42	doxorubicin	Chemical	D004317
Entity: 24727461	62	78	cardiac toxicity	Disease	D066126
Entity: 24727461	119	133	hydroxytyrosol	Chemical	C005975
Entity: 24727461	147	160	breast cancer	Disease	D001943
Relation: 24727461	CID	31	42	D004317	62	78	D066126	false
Relation: 24727461	CID	31	42	D004317	147	160	D001943	false
Relation: 24727461	CID	119	133	C005975	62	78	D066126	false
Relation: 24727461	CID	119	133	C005975	147	160	D001943	false

Sentence: Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.
Entity: 24727461	24	37	breast tumors	Disease	D001943
Entity: 24727461	94	108	hydroxytyrosol	Chemical	C005975
Entity: 24727461	133	144	doxorubicin	Chemical	D004317
Entity: 24727461	164	175	doxorubicin	Chemical	D004317
Entity: 24727461	181	195	hydroxytyrosol	Chemical	C005975
Relation: 24727461	CID	94	108	C005975	24	37	D001943	false
Relation: 24727461	CID	133	144	D004317	24	37	D001943	false
Relation: 24727461	CID	164	175	D004317	24	37	D001943	false
Relation: 24727461	CID	181	195	C005975	24	37	D001943	false

Sentence: Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.
Entity: 24727461	0	14	Hydroxytyrosol	Chemical	C005975
Entity: 24727461	28	48	cardiac disturbances	Disease	D006331
Entity: 24727461	61	72	doxorubicin	Chemical	D004317
Relation: 24727461	CID	0	14	C005975	28	48	D006331	false
Relation: 24727461	CID	61	72	D004317	28	48	D006331	true

Sentence: Amiodarone induced myxoedema coma.
Entity: 24729111	0	10	Amiodarone	Chemical	D000638
Entity: 24729111	19	28	myxoedema	Disease	D007037
Entity: 24729111	29	33	coma	Disease	D003128
Relation: 24729111	CID	0	10	D000638	19	28	D007037	true
Relation: 24729111	CID	0	10	D000638	29	33	D003128	true

Sentence: A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.
Entity: 24729111	36	47	bradycardia	Disease	D001919
Entity: 24729111	49	60	hypothermia	Disease	D007035
Entity: 24729111	65	84	respiratory failure	Disease	D012131
Entity: 24729111	113	123	amiodarone	Chemical	D000638
Entity: 24729111	136	155	atrial fibrillation	Disease	D001281
Relation: 24729111	CID	113	123	D000638	36	47	D001919	true
Relation: 24729111	CID	113	123	D000638	49	60	D007035	true
Relation: 24729111	CID	113	123	D000638	65	84	D012131	true
Relation: 24729111	CID	113	123	D000638	136	155	D001281	false

Sentence: The only two cases of amiodarone induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement.
Entity: 24729111	22	32	amiodarone	Chemical	D000638
Entity: 24729111	41	50	myxoedema	Disease	D007037
Entity: 24729111	51	55	coma	Disease	D003128
Relation: 24729111	CID	22	32	D000638	41	50	D007037	true
Relation: 24729111	CID	22	32	D000638	51	55	D003128	true

Sentence: Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin induced thrombocytopenia with thrombosis.
Entity: 24733133	7	17	argatroban	Chemical	C031942
Entity: 24733133	40	52	thrombolysis	Disease	D055499
Entity: 24733133	96	103	heparin	Chemical	D006493
Entity: 24733133	112	128	thrombocytopenia	Disease	D013921
Entity: 24733133	134	144	thrombosis	Disease	D013927
Relation: 24733133	CID	7	17	C031942	40	52	D055499	false
Relation: 24733133	CID	7	17	C031942	112	128	D013921	false
Relation: 24733133	CID	7	17	C031942	134	144	D013927	false
Relation: 24733133	CID	96	103	D006493	40	52	D055499	false
Relation: 24733133	CID	96	103	D006493	112	128	D013921	true
Relation: 24733133	CID	96	103	D006493	134	144	D013927	false

Sentence: PURPOSE: The case of an oncology patient who developed heparin induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.
Entity: 24733133	55	62	heparin	Chemical	D006493
Entity: 24733133	71	87	thrombocytopenia	Disease	D013921
Entity: 24733133	93	103	thrombosis	Disease	D013927
Entity: 24733133	105	109	HITT	Disease	D013921
Entity: 24733133	105	109	HITT	Disease	D013927
Entity: 24733133	132	142	argatroban	Chemical	C031942
Entity: 24733133	166	178	thrombolysis	Disease	D055499
Relation: 24733133	CID	55	62	D006493	71	87	D013921	true
Relation: 24733133	CID	55	62	D006493	93	103	D013927	false
Relation: 24733133	CID	55	62	D006493	105	109	D013921	true
Relation: 24733133	CID	55	62	D006493	105	109	D013927	false
Relation: 24733133	CID	55	62	D006493	166	178	D055499	false
Relation: 24733133	CID	132	142	C031942	71	87	D013921	false
Relation: 24733133	CID	132	142	C031942	93	103	D013927	false
Relation: 24733133	CID	132	142	C031942	105	109	D013921	false
Relation: 24733133	CID	132	142	C031942	105	109	D013927	false
Relation: 24733133	CID	132	142	C031942	166	178	D055499	false

Sentence: SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin induced thrombocytopenia.
Entity: 24733133	48	59	amyloidosis	Disease	D000686
Entity: 24733133	178	216	upper-extremity deep venous thrombosis	Disease	D056824
Entity: 24733133	218	221	DVT	Disease	D020246
Entity: 24733133	227	245	pulmonary embolism	Disease	D011655
Entity: 24733133	259	266	heparin	Chemical	D006493
Entity: 24733133	275	291	thrombocytopenia	Disease	D013921
Relation: 24733133	CID	259	266	D006493	48	59	D000686	false
Relation: 24733133	CID	259	266	D006493	178	216	D056824	false
Relation: 24733133	CID	259	266	D006493	218	221	D020246	true
Relation: 24733133	CID	259	266	D006493	227	245	D011655	true
Relation: 24733133	CID	259	266	D006493	275	291	D013921	true

Sentence: The epistaxis resolved the next day, and the patient was restarted on argatroban.
Entity: 24733133	4	13	epistaxis	Disease	D004844
Entity: 24733133	70	80	argatroban	Chemical	C031942
Relation: 24733133	CID	70	80	C031942	4	13	D004844	false

Sentence: Effects of dehydroepiandrosterone in amphetamine induced schizophrenia models in mice.
Entity: 24739405	11	33	dehydroepiandrosterone	Chemical	D003687
Entity: 24739405	37	48	amphetamine	Chemical	D000661
Entity: 24739405	57	70	schizophrenia	Disease	D012559
Relation: 24739405	CID	11	33	D003687	57	70	D012559	false
Relation: 24739405	CID	37	48	D000661	57	70	D012559	true

Sentence: OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia.
Entity: 24739405	37	59	dehydroepiandrosterone	Chemical	D003687
Entity: 24739405	61	65	DHEA	Chemical	D003687
Entity: 24739405	87	100	schizophrenia	Disease	D012559
Relation: 24739405	CID	37	59	D003687	87	100	D012559	false
Relation: 24739405	CID	61	65	D003687	87	100	D012559	false

Sentence: Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.
Entity: 24739405	0	11	Amphetamine	Chemical	D000661
Entity: 24739405	33	38	hyper	Disease	D006948
Entity: 24739405	51	62	apomorphine	Chemical	D001058
Entity: 24739405	117	128	haloperidol	Chemical	D006220
Entity: 24739405	152	161	catalepsy	Disease	D002375
Entity: 24739405	198	211	schizophrenia	Disease	D012559
Relation: 24739405	CID	0	11	D000661	33	38	D006948	false
Relation: 24739405	CID	0	11	D000661	152	161	D002375	false
Relation: 24739405	CID	0	11	D000661	198	211	D012559	true
Relation: 24739405	CID	51	62	D001058	33	38	D006948	false
Relation: 24739405	CID	51	62	D001058	152	161	D002375	false
Relation: 24739405	CID	51	62	D001058	198	211	D012559	true
Relation: 24739405	CID	117	128	D006220	33	38	D006948	false
Relation: 24739405	CID	117	128	D006220	152	161	D002375	true
Relation: 24739405	CID	117	128	D006220	198	211	D012559	true

Sentence: There was a significant difference between groups in the haloperidol induced catalepsy test (p<0.05).
Entity: 24739405	57	68	haloperidol	Chemical	D006220
Entity: 24739405	77	86	catalepsy	Disease	D002375
Relation: 24739405	CID	57	68	D006220	77	86	D002375	true

Sentence: CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior.
Entity: 24739405	29	33	DHEA	Chemical	D003687
Entity: 24739405	75	84	catalepsy	Disease	D002375
Relation: 24739405	CID	29	33	D003687	75	84	D002375	false

Sentence: Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD). hiPS-CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval.
Entity: 24742750	27	38	Terfenadine	Chemical	D016593
Entity: 24742750	43	53	Citalopram	Chemical	D015283
Entity: 24742750	83	101	Torsade de Pointes	Disease	D016171
Entity: 24742750	103	106	TdP	Disease	D016171
Relation: 24742750	CID	27	38	D016593	83	101	D016171	true
Relation: 24742750	CID	27	38	D016593	103	106	D016171	true
Relation: 24742750	CID	43	53	D015283	83	101	D016171	true
Relation: 24742750	CID	43	53	D015283	103	106	D016171	true

Sentence: BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.
Entity: 24753331	12	19	S-53482	Chemical	C106487
Entity: 24753331	24	31	S-23121	Chemical	C083440
Entity: 24753331	74	89	embryolethality	Disease	D020964
Entity: 24753331	91	105	teratogenicity	Disease	D064793
Entity: 24753331	114	140	ventricular septal defects	Disease	D006345
Entity: 24753331	161	179	growth retardation	Disease	D005317
Entity: 24753331	223	231	toxicity	Disease	D064420
Relation: 24753331	CID	12	19	C106487	74	89	D020964	true
Relation: 24753331	CID	12	19	C106487	91	105	D064793	true
Relation: 24753331	CID	12	19	C106487	114	140	D006345	true
Relation: 24753331	CID	12	19	C106487	161	179	D005317	true
Relation: 24753331	CID	12	19	C106487	223	231	D064420	false
Relation: 24753331	CID	24	31	C083440	74	89	D020964	true
Relation: 24753331	CID	24	31	C083440	91	105	D064793	true
Relation: 24753331	CID	24	31	C083440	114	140	D006345	true
Relation: 24753331	CID	24	31	C083440	161	179	D005317	true
Relation: 24753331	CID	24	31	C083440	223	231	D064420	false

Sentence: RESULTS: Dermal exposure of rats to S-53482 at 300 mg/kg produced patterns of developmental toxicity similar to those resulting from oral exposure.
Entity: 24753331	36	43	S-53482	Chemical	C106487
Entity: 24753331	92	100	toxicity	Disease	D064420
Relation: 24753331	CID	36	43	C106487	92	100	D064420	false

Sentence: Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.
Entity: 24753331	25	32	S-23121	Chemical	C083440
Entity: 24753331	84	99	embryonic death	Disease	D020964
Entity: 24753331	104	129	ventricular septal defect	Disease	D006345
Entity: 24753331	211	218	S-23121	Chemical	C083440
Relation: 24753331	CID	25	32	C083440	84	99	D020964	true
Relation: 24753331	CID	25	32	C083440	104	129	D006345	true
Relation: 24753331	CID	211	218	C083440	84	99	D020964	true
Relation: 24753331	CID	211	218	C083440	104	129	D006345	true

Sentence: Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.
Entity: 24778426	9	23	Renal Toxicity	Disease	D007674
Entity: 24778426	27	33	Cancer	Disease	D009369
Entity: 24778426	53	62	Cisplatin	Chemical	D002945
Entity: 24778426	80	88	Mannitol	Chemical	D008353
Relation: 24778426	CID	53	62	D002945	9	23	D007674	false
Relation: 24778426	CID	53	62	D002945	27	33	D009369	false
Relation: 24778426	CID	80	88	D008353	9	23	D007674	false
Relation: 24778426	CID	80	88	D008353	27	33	D009369	false

Sentence: One of the major complications of cisplatin use is dose-limiting nephrotoxicity.
Entity: 24778426	34	43	cisplatin	Chemical	D002945
Entity: 24778426	65	79	nephrotoxicity	Disease	D007674
Relation: 24778426	CID	34	43	D002945	65	79	D007674	false

Sentence: There are many strategies to prevent this toxicity, including the use of mannitol as a nephroprotectant in combination with hydration.
Entity: 24778426	42	50	toxicity	Disease	D064420
Entity: 24778426	73	81	mannitol	Chemical	D008353
Relation: 24778426	CID	73	81	D008353	42	50	D064420	false

Sentence: OBJECTIVE: We aimed to evaluate the rates of cisplatin induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.
Entity: 24778426	45	54	cisplatin	Chemical	D002945
Entity: 24778426	63	77	nephrotoxicity	Disease	D007674
Entity: 24778426	81	87	cancer	Disease	D009369
Entity: 24778426	120	129	cisplatin	Chemical	D002945
Entity: 24778426	147	155	mannitol	Chemical	D008353
Relation: 24778426	CID	45	54	D002945	63	77	D007674	false
Relation: 24778426	CID	45	54	D002945	81	87	D009369	false
Relation: 24778426	CID	120	129	D002945	63	77	D007674	false
Relation: 24778426	CID	120	129	D002945	81	87	D009369	false
Relation: 24778426	CID	147	155	D008353	63	77	D007674	false
Relation: 24778426	CID	147	155	D008353	81	87	D009369	false

Sentence: Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012.
Entity: 24778426	29	35	cancer	Disease	D009369
Entity: 24778426	68	77	cisplatin	Chemical	D002945
Relation: 24778426	CID	68	77	D002945	29	35	D009369	false

Sentence: RESULTS: We evaluated 143 patients who received single-agent cisplatin; 97.2% of patients had head and neck cancer as their primary malignancy.
Entity: 24778426	61	70	cisplatin	Chemical	D002945
Entity: 24778426	94	114	head and neck cancer	Disease	D006258
Entity: 24778426	132	142	malignancy	Disease	D009369
Relation: 24778426	CID	61	70	D002945	94	114	D006258	false
Relation: 24778426	CID	61	70	D002945	132	142	D009369	false

Sentence: Patients who did not receive mannitol were more likely to develop nephrotoxicity: odds ratio [OR] = 2.646 (95% CI = 1.008, 6.944; P = 0.048).
Entity: 24778426	29	37	mannitol	Chemical	D008353
Entity: 24778426	66	80	nephrotoxicity	Disease	D007674
Relation: 24778426	CID	29	37	D008353	66	80	D007674	false

Sentence: CONCLUSIONS: When limited quantities of mannitol are available, it should preferentially be given to patients at particularly high risk of nephrotoxicity.
Entity: 24778426	40	48	mannitol	Chemical	D008353
Entity: 24778426	139	153	nephrotoxicity	Disease	D007674
Relation: 24778426	CID	40	48	D008353	139	153	D007674	false

Sentence: Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole induced kindling in mice.
Entity: 24802403	0	9	Metformin	Chemical	D008687
Entity: 24802403	27	35	seizures	Disease	D012640
Entity: 24802403	37	45	learning	Disease	D007859
Entity: 24802403	50	56	memory	Disease	D008569
Entity: 24802403	101	119	pentylenetetrazole	Chemical	D010433
Relation: 24802403	CID	0	9	D008687	27	35	D012640	false
Relation: 24802403	CID	0	9	D008687	37	45	D007859	false
Relation: 24802403	CID	0	9	D008687	50	56	D008569	false
Relation: 24802403	CID	101	119	D010433	27	35	D012640	true
Relation: 24802403	CID	101	119	D010433	37	45	D007859	true
Relation: 24802403	CID	101	119	D010433	50	56	D008569	true

Sentence: This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole induced kindling animals.
Entity: 24802403	64	73	metformin	Chemical	D008687
Entity: 24802403	77	85	seizures	Disease	D012640
Entity: 24802403	87	107	cognitive impairment	Disease	D003072
Entity: 24802403	155	173	pentylenetetrazole	Chemical	D010433
Relation: 24802403	CID	64	73	D008687	77	85	D012640	false
Relation: 24802403	CID	64	73	D008687	87	107	D003072	false
Relation: 24802403	CID	155	173	D010433	77	85	D012640	true
Relation: 24802403	CID	155	173	D010433	87	107	D003072	true

Sentence: We found that metformin suppressed the progression of kindling, ameliorated the cognitive impairment and decreased brain oxidative stress.
Entity: 24802403	14	23	metformin	Chemical	D008687
Entity: 24802403	80	100	cognitive impairment	Disease	D003072
Relation: 24802403	CID	14	23	D008687	80	100	D003072	false

Sentence: P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
Entity: 24812279	38	51	anthracycline	Chemical	D018943
Entity: 24812279	52	66	cardiotoxicity	Disease	D066126
Relation: 24812279	CID	38	51	D018943	52	66	D066126	false

Sentence: AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.
Entity: 24812279	6	17	Doxorubicin	Chemical	D004317
Entity: 24812279	19	22	DOX	Chemical	D004317
Entity: 24812279	45	51	cancer	Disease	D009369
Entity: 24812279	114	128	cardiotoxicity	Disease	D066126
Relation: 24812279	CID	6	17	D004317	45	51	D009369	false
Relation: 24812279	CID	6	17	D004317	114	128	D066126	false
Relation: 24812279	CID	19	22	D004317	45	51	D009369	false
Relation: 24812279	CID	19	22	D004317	114	128	D066126	false

Sentence: Children are particularly sensitive to DOX induced heart failure.
Entity: 24812279	39	42	DOX	Chemical	D004317
Entity: 24812279	51	64	heart failure	Disease	D006333
Relation: 24812279	CID	39	42	D004317	51	64	D006333	true

Sentence: Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile model.
Entity: 24812279	59	62	DOX	Chemical	D004317
Entity: 24812279	63	77	cardiotoxicity	Disease	D066126
Relation: 24812279	CID	59	62	D004317	63	77	D066126	false

Sentence: Metronidazole induced encephalopathy: an uncommon scenario.
Entity: 24816962	0	13	Metronidazole	Chemical	D008795
Entity: 24816962	22	36	encephalopathy	Disease	D001927
Relation: 24816962	CID	0	13	D008795	22	36	D001927	true

Sentence: We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake.
Entity: 24816962	56	70	encephalopathy	Disease	D001927
Entity: 24816962	91	104	metronidazole	Chemical	D008795
Relation: 24816962	CID	91	104	D008795	56	70	D001927	true

Sentence: Aconitine induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.
Entity: 24840785	0	9	Aconitine	Chemical	D000157
Entity: 24840785	18	20	Ca	Chemical	D002118
Entity: 24840785	39	49	arrhythmia	Disease	D001145
Relation: 24840785	CID	0	9	D000157	39	49	D001145	true
Relation: 24840785	CID	18	20	D002118	39	49	D001145	false

Sentence: Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.
Entity: 24840785	51	53	Na	Chemical	D012964
Entity: 24840785	92	106	cardiotoxicity	Disease	D066126
Entity: 24840785	110	119	aconitine	Chemical	D000157
Relation: 24840785	CID	51	53	D012964	92	106	D066126	false
Relation: 24840785	CID	110	119	D000157	92	106	D066126	true

Sentence: However, no reports are available on the role of Ca(2+) in aconitine poisoning.
Entity: 24840785	49	51	Ca	Chemical	D002118
Entity: 24840785	59	68	aconitine	Chemical	D000157
Entity: 24840785	69	78	poisoning	Disease	D011041
Relation: 24840785	CID	49	51	D002118	69	78	D011041	false
Relation: 24840785	CID	59	68	D000157	69	78	D011041	true

Sentence: In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.
Entity: 24840785	58	60	Ca	Chemical	D002118
Entity: 24840785	78	87	aconitine	Chemical	D000157
Entity: 24840785	88	97	poisoning	Disease	D011041
Relation: 24840785	CID	58	60	D002118	88	97	D011041	false
Relation: 24840785	CID	78	87	D000157	88	97	D011041	true

Sentence: We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats.
Entity: 24840785	14	16	Ca	Chemical	D002118
Entity: 24840785	110	120	arrhythmia	Disease	D001145
Relation: 24840785	CID	14	16	D002118	110	120	D001145	false

Sentence: To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.
Entity: 24840785	26	35	aconitine	Chemical	D000157
Entity: 24840785	39	56	myocardial injury	Disease	D009202
Entity: 24840785	71	83	cytotoxicity	Disease	D064420
Entity: 24840785	156	163	lactate	Chemical	D019344
Relation: 24840785	CID	26	35	D000157	39	56	D009202	false
Relation: 24840785	CID	26	35	D000157	71	83	D064420	false
Relation: 24840785	CID	156	163	D019344	39	56	D009202	false
Relation: 24840785	CID	156	163	D019344	71	83	D064420	false

Sentence: The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently.
Entity: 24840785	24	33	aconitine	Chemical	D000157
Entity: 24840785	46	63	myocardial injury	Disease	D009202
Relation: 24840785	CID	24	33	D000157	46	63	D009202	false

Sentence: Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.
Entity: 24842192	23	32	metformin	Chemical	D008687
Entity: 24842192	90	118	left ventricular dysfunction	Disease	D018487
Entity: 24842192	129	150	myocardial infarction	Disease	D009203
Relation: 24842192	CID	23	32	D008687	90	118	D018487	false
Relation: 24842192	CID	23	32	D008687	129	150	D009203	false

Sentence: Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).
Entity: 24842192	21	30	metformin	Chemical	D008687
Entity: 24842192	58	79	myocardial infarction	Disease	D009203
Entity: 24842192	142	145	AMP	Chemical	D000667
Relation: 24842192	CID	21	30	D008687	58	79	D009203	false
Relation: 24842192	CID	142	145	D000667	58	79	D009203	false

Sentence: In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.
Entity: 24842192	63	72	metformin	Chemical	D008687
Entity: 24842192	76	95	cardiac dysfunction	Disease	D006331
Entity: 24842192	149	170	myocardial infarction	Disease	D009203
Relation: 24842192	CID	63	72	D008687	76	95	D006331	false
Relation: 24842192	CID	63	72	D008687	149	170	D009203	false

Sentence: Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.
Entity: 24842192	0	13	Isoproterenol	Chemical	D007545
Entity: 24842192	89	116	acute myocardial infarction	Disease	D009203
Relation: 24842192	CID	0	13	D007545	89	116	D009203	true

Sentence: The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of metformin.
Entity: 24842192	4	32	left ventricular dysfunction	Disease	D018487
Entity: 24842192	102	111	metformin	Chemical	D008687
Relation: 24842192	CID	102	111	D008687	4	32	D018487	false

Sentence: Metfromin markedly lowered isoproterenol induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.
Entity: 24842192	27	40	isoproterenol	Chemical	D007545
Entity: 24842192	131	136	tumor	Disease	D009369
Entity: 24842192	137	145	necrosis	Disease	D009336
Relation: 24842192	CID	27	40	D007545	131	136	D009369	false
Relation: 24842192	CID	27	40	D007545	137	145	D009336	false

Sentence: Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.
Entity: 24881749	0	30	Neuroleptic malignant syndrome	Disease	D009459
Entity: 24881749	67	80	tetrabenazine	Chemical	D013747
Entity: 24881749	85	93	tiapride	Chemical	D063325
Entity: 24881749	121	141	Huntington's disease	Disease	D006816
Entity: 24881749	177	190	breast cancer	Disease	D001943
Relation: 24881749	CID	67	80	D013747	0	30	D009459	true
Relation: 24881749	CID	67	80	D013747	121	141	D006816	false
Relation: 24881749	CID	67	80	D013747	177	190	D001943	false
Relation: 24881749	CID	85	93	D063325	0	30	D009459	true
Relation: 24881749	CID	85	93	D063325	121	141	D006816	false
Relation: 24881749	CID	85	93	D063325	177	190	D001943	false

Sentence: We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.
Entity: 24881749	66	96	neuroleptic malignant syndrome	Disease	D009459
Entity: 24881749	168	176	tiapride	Chemical	D063325
Entity: 24881749	193	206	tetrabenazine	Chemical	D013747
Entity: 24881749	225	245	Huntington's disease	Disease	D006816
Relation: 24881749	CID	168	176	D063325	66	96	D009459	true
Relation: 24881749	CID	168	176	D063325	225	245	D006816	false
Relation: 24881749	CID	193	206	D013747	66	96	D009459	true
Relation: 24881749	CID	193	206	D013747	225	245	D006816	false

Sentence: To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.
Entity: 24881749	48	78	neuroleptic malignant syndrome	Disease	D009459
Entity: 24881749	111	124	tetrabenazine	Chemical	D013747
Entity: 24881749	129	137	tiapride	Chemical	D063325
Relation: 24881749	CID	111	124	D013747	48	78	D009459	true
Relation: 24881749	CID	129	137	D063325	48	78	D009459	true

Sentence: A metoprolol-terbinafine combination induced bradycardia.
Entity: 24894748	2	12	metoprolol	Chemical	D008790
Entity: 24894748	13	24	terbinafine	Chemical	C041359
Entity: 24894748	45	56	bradycardia	Disease	D001919
Relation: 24894748	CID	2	12	D008790	45	56	D001919	true
Relation: 24894748	CID	13	24	C041359	45	56	D001919	true

Sentence: To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.
Entity: 24894748	12	29	sinus bradycardia	Disease	D012804
Entity: 24894748	41	51	metoprolol	Chemical	D008790
Entity: 24894748	56	67	terbinafine	Chemical	C041359
Relation: 24894748	CID	41	51	D008790	12	29	D012804	false
Relation: 24894748	CID	56	67	C041359	12	29	D012804	false

Sentence: A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.
Entity: 24894748	31	41	metoprolol	Chemical	D008790
Entity: 24894748	64	87	coronary artery disease	Disease	D003324
Entity: 24894748	127	138	terbinafine	Chemical	C041359
Entity: 24894748	154	167	onychomycosis	Disease	D014009
Relation: 24894748	CID	31	41	D008790	64	87	D003324	false
Relation: 24894748	CID	31	41	D008790	154	167	D014009	false
Relation: 24894748	CID	127	138	C041359	64	87	D003324	false
Relation: 24894748	CID	127	138	C041359	154	167	D014009	false

Sentence: On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls.
Entity: 24894748	19	30	terbinafine	Chemical	C041359
Entity: 24894748	121	130	confusion	Disease	D003221
Relation: 24894748	CID	19	30	C041359	121	130	D003221	false

Sentence: A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.
Entity: 24894748	28	49	adverse drug reaction	Disease	D064420
Entity: 24894748	124	141	sinus bradycardia	Disease	D012804
Entity: 24894748	175	185	metoprolol	Chemical	D008790
Entity: 24894748	190	201	terbinafine	Chemical	C041359
Relation: 24894748	CID	175	185	D008790	28	49	D064420	false
Relation: 24894748	CID	175	185	D008790	124	141	D012804	false
Relation: 24894748	CID	190	201	C041359	28	49	D064420	false
Relation: 24894748	CID	190	201	C041359	124	141	D012804	false

Sentence: Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment.
Entity: 24897009	19	40	peripheral neuropathy	Disease	D010523
Entity: 24897009	48	58	ethambutol	Chemical	D004977
Relation: 24897009	CID	48	58	D004977	19	40	D010523	false

Sentence: Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.
Entity: 24897009	0	10	Ethambutol	Chemical	D004977
Entity: 24897009	29	45	optic neuropathy	Disease	D009901
Entity: 24897009	71	85	polyneuropathy	Disease	D011115
Relation: 24897009	CID	0	10	D004977	29	45	D009901	true
Relation: 24897009	CID	0	10	D004977	71	85	D011115	true

Sentence: We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.
Entity: 24897009	111	122	visual loss	Disease	D014786
Entity: 24897009	127	139	paresthesias	Disease	D010292
Entity: 24897009	197	207	ethambutol	Chemical	D004977
Relation: 24897009	CID	197	207	D004977	111	122	D014786	true
Relation: 24897009	CID	197	207	D004977	127	139	D010292	true

Sentence: Testosterone ameliorates streptozotocin induced memory impairment in male rats.
Entity: 24902786	0	12	Testosterone	Chemical	D013739
Entity: 24902786	25	39	streptozotocin	Chemical	D013311
Entity: 24902786	48	65	memory impairment	Disease	D008569
Relation: 24902786	CID	0	12	D013739	48	65	D008569	false
Relation: 24902786	CID	25	39	D013311	48	65	D008569	true

Sentence: AIM: To study the effects of testosterone on streptozotocin (STZ) induced memory impairment in male rats.
Entity: 24902786	29	41	testosterone	Chemical	D013739
Entity: 24902786	45	59	streptozotocin	Chemical	D013311
Entity: 24902786	61	64	STZ	Chemical	D013311
Entity: 24902786	74	91	memory impairment	Disease	D008569
Relation: 24902786	CID	29	41	D013739	74	91	D008569	false
Relation: 24902786	CID	45	59	D013311	74	91	D008569	true
Relation: 24902786	CID	61	64	D013311	74	91	D008569	true

Sentence: Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration induced memory impairment.
Entity: 24902786	18	27	flutamide	Chemical	D005485
Entity: 24902786	29	38	letrozole	Chemical	C067431
Entity: 24902786	42	51	tamoxifen	Chemical	D013629
Entity: 24902786	66	85	impaired the memory	Disease	D008569
Entity: 24902786	135	147	testosterone	Chemical	D013739
Entity: 24902786	173	176	STZ	Chemical	D013311
Entity: 24902786	201	218	memory impairment	Disease	D008569
Relation: 24902786	CID	18	27	D005485	66	85	D008569	true
Relation: 24902786	CID	18	27	D005485	201	218	D008569	true
Relation: 24902786	CID	29	38	C067431	66	85	D008569	true
Relation: 24902786	CID	29	38	C067431	201	218	D008569	true
Relation: 24902786	CID	42	51	D013629	66	85	D008569	true
Relation: 24902786	CID	42	51	D013629	201	218	D008569	true
Relation: 24902786	CID	135	147	D013739	66	85	D008569	false
Relation: 24902786	CID	135	147	D013739	201	218	D008569	false
Relation: 24902786	CID	173	176	D013311	66	85	D008569	true
Relation: 24902786	CID	173	176	D013311	201	218	D008569	true

Sentence: Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine induced seizures.
Entity: 24911645	61	80	garcinielliptone FC	Chemical	C573355
Entity: 24911645	84	95	pilocarpine	Chemical	D010862
Entity: 24911645	104	112	seizures	Disease	D012640
Relation: 24911645	CID	61	80	C573355	104	112	D012640	false
Relation: 24911645	CID	84	95	D010862	104	112	D012640	true

Sentence: The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.
Entity: 24911645	40	43	GFC	Chemical	C573355
Entity: 24911645	86	93	seizure	Disease	D012640
Entity: 24911645	167	177	amino acid	Chemical	D000596
Entity: 24911645	179	198	r-aminobutyric acid	Chemical	D005680
Entity: 24911645	200	204	GABA	Chemical	D005680
Entity: 24911645	207	216	glutamine	Chemical	D018698
Entity: 24911645	218	227	aspartate	Chemical	D001224
Entity: 24911645	232	243	glutathione	Chemical	D005978
Entity: 24911645	329	337	seizures	Disease	D012640
Relation: 24911645	CID	40	43	C573355	86	93	D012640	false
Relation: 24911645	CID	40	43	C573355	329	337	D012640	false
Relation: 24911645	CID	167	177	D000596	86	93	D012640	false
Relation: 24911645	CID	167	177	D000596	329	337	D012640	false
Relation: 24911645	CID	179	198	D005680	86	93	D012640	false
Relation: 24911645	CID	179	198	D005680	329	337	D012640	false
Relation: 24911645	CID	200	204	D005680	86	93	D012640	false
Relation: 24911645	CID	200	204	D005680	329	337	D012640	false
Relation: 24911645	CID	207	216	D018698	86	93	D012640	false
Relation: 24911645	CID	207	216	D018698	329	337	D012640	false
Relation: 24911645	CID	218	227	D001224	86	93	D012640	false
Relation: 24911645	CID	218	227	D001224	329	337	D012640	false
Relation: 24911645	CID	232	243	D005978	86	93	D012640	false
Relation: 24911645	CID	232	243	D005978	329	337	D012640	false

Sentence: GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.
Entity: 24911645	0	3	GFC	Chemical	C573355
Entity: 24911645	43	50	seizure	Disease	D012640
Relation: 24911645	CID	0	3	C573355	43	50	D012640	false

Sentence: The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.
Entity: 24911645	26	29	GFC	Chemical	C573355
Entity: 24911645	108	119	pilocarpine	Chemical	D010862
Entity: 24911645	128	146	status epilepticus	Disease	D013226
Entity: 24911645	196	203	seizure	Disease	D012640
Relation: 24911645	CID	26	29	C573355	128	146	D013226	false
Relation: 24911645	CID	26	29	C573355	196	203	D012640	false
Relation: 24911645	CID	108	119	D010862	128	146	D013226	true
Relation: 24911645	CID	108	119	D010862	196	203	D012640	true

Sentence: Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
Entity: 24927617	0	14	Rhabdomyolysis	Disease	D012206
Entity: 24927617	20	46	hepatitis C virus infected	Disease	D006526
Entity: 24927617	68	78	telaprevir	Chemical	C486464
Entity: 24927617	83	94	simvastatin	Chemical	D019821
Relation: 24927617	CID	68	78	C486464	0	14	D012206	true
Relation: 24927617	CID	68	78	C486464	20	46	D006526	false
Relation: 24927617	CID	83	94	D019821	0	14	D012206	true
Relation: 24927617	CID	83	94	D019821	20	46	D006526	false

Sentence: A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.
Entity: 24927617	33	60	hepatitis C virus infection	Disease	D006526
Entity: 24927617	90	99	ribavirin	Chemical	D012254
Entity: 24927617	101	121	pegylated interferon	Chemical	C417083
Entity: 24927617	126	136	telaprevir	Chemical	C486464
Relation: 24927617	CID	90	99	D012254	33	60	D006526	false
Relation: 24927617	CID	101	121	C417083	33	60	D006526	false
Relation: 24927617	CID	126	136	C486464	33	60	D006526	false

Sentence: At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.
Entity: 24927617	13	24	simvastatin	Chemical	D019821
Entity: 24927617	75	83	toxicity	Disease	D064420
Relation: 24927617	CID	13	24	D019821	75	83	D064420	false

Sentence: Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.
Entity: 24927617	0	11	Simvastatin	Chemical	D019821
Entity: 24927617	72	78	statin	Chemical	D019821
Entity: 24927617	87	102	muscle toxicity	Disease	D009135
Entity: 24927617	142	148	statin	Chemical	D019821
Relation: 24927617	CID	0	11	D019821	87	102	D009135	true
Relation: 24927617	CID	72	78	D019821	87	102	D009135	true
Relation: 24927617	CID	142	148	D019821	87	102	D009135	true

Sentence: Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Entity: 24928523	15	25	bortezomib	Chemical	C400082
Entity: 24928523	27	38	thalidomide	Chemical	D013792
Entity: 24928523	44	57	dexamethasone	Chemical	D003907
Entity: 24928523	150	166	multiple myeloma	Disease	D009101
Relation: 24928523	CID	15	25	C400082	150	166	D009101	false
Relation: 24928523	CID	27	38	D013792	150	166	D009101	false
Relation: 24928523	CID	44	57	D003907	150	166	D009101	false

Sentence: In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.
Entity: 24928523	93	103	bortezomib	Chemical	C400082
Entity: 24928523	105	116	thalidomide	Chemical	D013792
Entity: 24928523	122	135	dexamethasone	Chemical	D003907
Entity: 24928523	212	214	MM	Disease	D009101
Relation: 24928523	CID	93	103	C400082	212	214	D009101	false
Relation: 24928523	CID	105	116	D013792	212	214	D009101	false
Relation: 24928523	CID	122	135	D003907	212	214	D009101	false

Sentence: Conversion to sirolimus ameliorates cyclosporine induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.
Entity: 24971338	14	23	sirolimus	Chemical	D020123
Entity: 24971338	36	48	cyclosporine	Chemical	D016572
Entity: 24971338	57	68	nephropathy	Disease	D007674
Relation: 24971338	CID	14	23	D020123	57	68	D007674	false
Relation: 24971338	CID	36	48	D016572	57	68	D007674	true

Sentence: Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.
Entity: 24971338	29	42	cyclosporin A	Chemical	D016572
Entity: 24971338	44	47	CsA	Chemical	D016572
Entity: 24971338	52	61	sirolimus	Chemical	D020123
Entity: 24971338	63	66	SRL	Chemical	D020123
Entity: 24971338	140	143	CsA	Chemical	D016572
Entity: 24971338	152	163	nephropathy	Disease	D007674
Relation: 24971338	CID	29	42	D016572	152	163	D007674	true
Relation: 24971338	CID	44	47	D016572	152	163	D007674	true
Relation: 24971338	CID	52	61	D020123	152	163	D007674	false
Relation: 24971338	CID	63	66	D020123	152	163	D007674	false
Relation: 24971338	CID	140	143	D016572	152	163	D007674	true

Sentence: Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.
Entity: 24971338	0	13	Renal lesions	Disease	D007674
Entity: 24971338	31	42	hematoxylin	Chemical	D006416
Entity: 24971338	47	52	eosin	Chemical	D004801
Relation: 24971338	CID	31	42	D006416	0	13	D007674	false
Relation: 24971338	CID	47	52	D004801	0	13	D007674	false

Sentence: SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.
Entity: 24971338	0	3	SRL	Chemical	D020123
Entity: 24971338	27	38	proteinuria	Disease	D011507
Entity: 24971338	91	107	renal impairment	Disease	D007674
Relation: 24971338	CID	0	3	D020123	27	38	D011507	true
Relation: 24971338	CID	0	3	D020123	91	107	D007674	false

Sentence: Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.
Entity: 24971338	6	9	CsA	Chemical	D016572
Entity: 24971338	52	66	kidney lesions	Disease	D007674
Relation: 24971338	CID	6	9	D016572	52	66	D007674	true

Sentence: Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.
Entity: 24971338	10	13	CsA	Chemical	D016572
Entity: 24971338	34	46	renal damage	Disease	D007674
Relation: 24971338	CID	10	13	D016572	34	46	D007674	true

Sentence: Kinin B2 receptor deletion and blockage ameliorates cisplatin induced acute renal injury.
Entity: 24975837	52	61	cisplatin	Chemical	D002945
Entity: 24975837	70	88	acute renal injury	Disease	D058186
Relation: 24975837	CID	52	61	D002945	70	88	D058186	true

Sentence: Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).
Entity: 24975837	0	9	Cisplatin	Chemical	D002945
Entity: 24975837	91	110	acute kidney injury	Disease	D058186
Entity: 24975837	188	198	creatinine	Chemical	D003404
Entity: 24975837	203	207	urea	Chemical	D014508
Entity: 24975837	222	244	acute tubular necrosis	Disease	D007683
Relation: 24975837	CID	0	9	D002945	91	110	D058186	true
Relation: 24975837	CID	0	9	D002945	222	244	D007683	true
Relation: 24975837	CID	188	198	D003404	91	110	D058186	false
Relation: 24975837	CID	188	198	D003404	222	244	D007683	false
Relation: 24975837	CID	203	207	D014508	91	110	D058186	false
Relation: 24975837	CID	203	207	D014508	222	244	D007683	false

Sentence: To examine the role of the kinin B2 receptor in cisplatin induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.
Entity: 24975837	48	57	cisplatin	Chemical	D002945
Entity: 24975837	66	85	acute kidney injury	Disease	D058186
Entity: 24975837	140	149	cisplatin	Chemical	D002945
Relation: 24975837	CID	48	57	D002945	66	85	D058186	true
Relation: 24975837	CID	140	149	D002945	66	85	D058186	true

Sentence: Thus, our data suggest that the kinin B2 receptor is involved in cisplatin induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.
Entity: 24975837	65	74	cisplatin	Chemical	D002945
Entity: 24975837	83	102	acute kidney injury	Disease	D058186
Entity: 24975837	120	128	necrotic	Disease	D009336
Relation: 24975837	CID	65	74	D002945	83	102	D058186	true
Relation: 24975837	CID	65	74	D002945	120	128	D009336	false

Sentence: Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
Entity: 24999722	23	45	fluocinolone acetonide	Chemical	D005446
Entity: 24999722	80	108	birdshot retinochoroidopathy	Disease	C537630
Relation: 24999722	CID	23	45	D005446	80	108	C537630	false

Sentence: PURPOSE: To report the treatment outcomes of the fluocinolone acetonide intravitreal implant (0.59 mg) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy.
Entity: 24999722	49	71	fluocinolone acetonide	Chemical	D005446
Entity: 24999722	120	148	birdshot retinochoroidopathy	Disease	C537630
Relation: 24999722	CID	49	71	D005446	120	148	C537630	false

Sentence: CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy.
Entity: 24999722	34	56	fluocinolone acetonide	Chemical	D005446
Entity: 24999722	92	104	inflammation	Disease	D007249
Entity: 24999722	148	176	birdshot retinochoroidopathy	Disease	C537630
Relation: 24999722	CID	34	56	D005446	92	104	D007249	false
Relation: 24999722	CID	34	56	D005446	148	176	C537630	false

Sentence: Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.
Entity: 25006369	30	40	rocuronium	Chemical	C061870
Entity: 25006369	53	66	fasciculation	Disease	D005207
Entity: 25006369	71	78	myalgia	Disease	D063806
Entity: 25006369	89	104	succinylcholine	Chemical	D013390
Relation: 25006369	CID	30	40	C061870	53	66	D005207	false
Relation: 25006369	CID	30	40	C061870	71	78	D063806	false
Relation: 25006369	CID	89	104	D013390	53	66	D005207	true
Relation: 25006369	CID	89	104	D013390	71	78	D063806	true

Sentence: BACKGROUND: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculation and myalgia.
Entity: 25006369	12	27	Succinylcholine	Chemical	D013390
Entity: 25006369	82	102	muscle fasciculation	Disease	D005207
Entity: 25006369	107	114	myalgia	Disease	D063806
Relation: 25006369	CID	12	27	D013390	82	102	D005207	true
Relation: 25006369	CID	12	27	D013390	107	114	D063806	true

Sentence: The current study identified the optimal dose of rocuronium to prevent succinylcholine induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.
Entity: 25006369	49	59	rocuronium	Chemical	C061870
Entity: 25006369	71	86	succinylcholine	Chemical	D013390
Entity: 25006369	95	108	fasciculation	Disease	D005207
Entity: 25006369	113	120	myalgia	Disease	D063806
Entity: 25006369	152	162	rocuronium	Chemical	C061870
Entity: 25006369	197	212	succinylcholine	Chemical	D013390
Relation: 25006369	CID	49	59	C061870	95	108	D005207	false
Relation: 25006369	CID	49	59	C061870	113	120	D063806	false
Relation: 25006369	CID	71	86	D013390	95	108	D005207	true
Relation: 25006369	CID	71	86	D013390	113	120	D063806	true
Relation: 25006369	CID	152	162	C061870	95	108	D005207	false
Relation: 25006369	CID	152	162	C061870	113	120	D063806	false
Relation: 25006369	CID	197	212	D013390	95	108	D005207	true
Relation: 25006369	CID	197	212	D013390	113	120	D063806	true

Sentence: All patients received succinylcholine 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while myalgia was assessed at 24 hours after surgery.
Entity: 25006369	22	37	succinylcholine	Chemical	D013390
Entity: 25006369	136	150	fasciculations	Disease	D005207
Entity: 25006369	158	165	myalgia	Disease	D063806
Relation: 25006369	CID	22	37	D013390	136	150	D005207	true
Relation: 25006369	CID	22	37	D013390	158	165	D063806	true

Sentence: RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium (P < 0.001).
Entity: 25006369	47	67	muscle fasciculation	Disease	D005207
Entity: 25006369	143	153	rocuronium	Chemical	C061870
Relation: 25006369	CID	143	153	C061870	47	67	D005207	false

Sentence: Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0.072).
Entity: 25006369	9	16	myalgia	Disease	D063806
Entity: 25006369	94	104	rocuronium	Chemical	C061870
Relation: 25006369	CID	94	104	C061870	9	16	D063806	false

Sentence: Absence of PKC-alpha attenuates lithium induced nephrogenic diabetes insipidus.
Entity: 25006961	32	39	lithium	Chemical	D008094
Entity: 25006961	48	78	nephrogenic diabetes insipidus	Disease	D018500
Relation: 25006961	CID	32	39	D008094	48	78	D018500	true

Sentence: Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients.
Entity: 25006961	0	7	Lithium	Chemical	D008094
Entity: 25006961	45	75	nephrogenic diabetes insipidus	Disease	D018500
Entity: 25006961	77	80	NDI	Disease	D018500
Relation: 25006961	CID	0	7	D008094	45	75	D018500	true
Relation: 25006961	CID	0	7	D008094	77	80	D018500	true

Sentence: Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium induced polyuria.
Entity: 25006961	115	122	lithium	Chemical	D008094
Entity: 25006961	131	139	polyuria	Disease	D011141
Relation: 25006961	CID	115	122	D008094	131	139	D011141	true

Sentence: Is Dysguesia Going to be a Rare or a Common Side-effect of Amlodipine.
Entity: 25031906	3	12	Dysguesia	Disease	D004408
Entity: 25031906	59	69	Amlodipine	Chemical	D017311
Relation: 25031906	CID	59	69	D017311	3	12	D004408	true

Sentence: A very rare side-effect of amlodipine is dysguesia.
Entity: 25031906	27	37	amlodipine	Chemical	D017311
Entity: 25031906	41	50	dysguesia	Disease	D004408
Relation: 25031906	CID	27	37	D017311	41	50	D004408	true

Sentence: We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.
Entity: 25031906	47	59	hypertension	Disease	D006973
Entity: 25031906	83	93	amlodipine	Chemical	D017311
Entity: 25031906	104	127	loss of taste sensation	Disease	D012678
Relation: 25031906	CID	83	93	D017311	47	59	D006973	false
Relation: 25031906	CID	83	93	D017311	104	127	D012678	false

Sentence: We conclude that amlodipine can cause dysguesia.
Entity: 25031906	17	27	amlodipine	Chemical	D017311
Entity: 25031906	38	47	dysguesia	Disease	D004408
Relation: 25031906	CID	17	27	D017311	38	47	D004408	true

Sentence: Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.
Entity: 25041770	0	14	Rhabdomyolysis	Disease	D012206
Entity: 25041770	35	46	simvastatin	Chemical	D019821
Entity: 25041770	71	85	clarithromycin	Chemical	D017291
Relation: 25041770	CID	35	46	D019821	0	14	D012206	true
Relation: 25041770	CID	71	85	D017291	0	14	D012206	true

Sentence: This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin.
Entity: 25041770	39	53	rhabdomyolysis	Disease	D012206
Entity: 25041770	101	115	clarithromycin	Chemical	D017291
Relation: 25041770	CID	101	115	D017291	39	53	D012206	true

Sentence: Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.
Entity: 25054547	49	54	apnea	Disease	D001049
Entity: 25054547	60	73	suxamethonium	Chemical	D013390
Relation: 25054547	CID	60	73	D013390	49	54	D001049	true

Sentence: Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.
Entity: 25054547	0	32	Butyrylcholinesterase deficiency	Disease	C537417
Entity: 25054547	63	68	apnea	Disease	D001049
Entity: 25054547	104	117	suxamethonium	Chemical	D013390
Entity: 25054547	121	131	mivacurium	Chemical	C049430
Relation: 25054547	CID	104	117	D013390	0	32	C537417	true
Relation: 25054547	CID	104	117	D013390	63	68	D001049	true
Relation: 25054547	CID	121	131	C049430	0	32	C537417	true
Relation: 25054547	CID	121	131	C049430	63	68	D001049	true

Sentence: Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo: a manageable issue.
Entity: 25071004	8	14	anemia	Disease	D000740
Entity: 25071004	47	57	artesunate	Chemical	C039726
Relation: 25071004	CID	47	57	C039726	8	14	D000740	false

Sentence: Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria.
Entity: 25071004	17	33	hemolytic anemia	Disease	D000743
Entity: 25071004	86	96	artesunate	Chemical	C039726
Entity: 25071004	198	205	malaria	Disease	D008288
Relation: 25071004	CID	86	96	C039726	17	33	D000743	true
Relation: 25071004	CID	86	96	C039726	198	205	D008288	false

Sentence: A total of 350 patients (215 [61.4%] < 5 years of age and 135 [38.6%] > 5 years of age) were followed-up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo.
Entity: 25071004	137	147	artesunate	Chemical	C039726
Entity: 25071004	159	166	malaria	Disease	D008288
Relation: 25071004	CID	137	147	C039726	159	166	D008288	false

Sentence: Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol induced acute myocardial injury in rats.
Entity: 25080425	91	98	betaine	Chemical	D001622
Entity: 25080425	110	123	isoproterenol	Chemical	D007545
Entity: 25080425	138	155	myocardial injury	Disease	D009202
Relation: 25080425	CID	91	98	D001622	138	155	D009202	false
Relation: 25080425	CID	110	123	D007545	138	155	D009202	false

Sentence: The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.
Entity: 25080425	78	85	betaine	Chemical	D001622
Entity: 25080425	95	114	myocardial ischemia	Disease	D017202
Relation: 25080425	CID	78	85	D001622	95	114	D017202	false

Sentence: Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.
Entity: 25080425	6	32	myocardial ischemic injury	Disease	D017202
Entity: 25080425	82	95	isoproterenol	Chemical	D007545
Relation: 25080425	CID	82	95	D007545	6	32	D017202	true

Sentence: Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.
Entity: 25080425	23	30	betaine	Chemical	D001622
Entity: 25080425	140	162	ventricular remodeling	Disease	D020257
Relation: 25080425	CID	23	30	D001622	140	162	D020257	false

Sentence: The protective role of betaine on myocardial damage was further confirmed by histopathological examination.
Entity: 25080425	23	30	betaine	Chemical	D001622
Entity: 25080425	34	51	myocardial damage	Disease	D009202
Relation: 25080425	CID	23	30	D001622	34	51	D009202	false

Sentence: Quetiapine induced neutropenia in a bipolar patient with hepatocellular carcinoma.
Entity: 25084821	0	10	Quetiapine	Chemical	C069541
Entity: 25084821	19	30	neutropenia	Disease	D009503
Entity: 25084821	36	43	bipolar	Disease	D001714
Entity: 25084821	57	81	hepatocellular carcinoma	Disease	D006528
Relation: 25084821	CID	0	10	C069541	19	30	D009503	true
Relation: 25084821	CID	0	10	C069541	36	43	D001714	false
Relation: 25084821	CID	0	10	C069541	57	81	D006528	false

Sentence: OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.
Entity: 25084821	11	21	Quetiapine	Chemical	C069541
Entity: 25084821	68	77	clozapine	Chemical	D003024
Entity: 25084821	117	133	blood dyscrasias	Disease	D006402
Entity: 25084821	146	157	neutropenia	Disease	D009503
Relation: 25084821	CID	11	21	C069541	117	133	D006402	false
Relation: 25084821	CID	11	21	C069541	146	157	D009503	true
Relation: 25084821	CID	68	77	D003024	117	133	D006402	false
Relation: 25084821	CID	68	77	D003024	146	157	D009503	false

Sentence: A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.
Entity: 25084821	25	49	hepatocellular carcinoma	Disease	D006528
Entity: 25084821	65	76	neutropenia	Disease	D009503
Entity: 25084821	98	108	quetiapine	Chemical	C069541
Relation: 25084821	CID	98	108	C069541	25	49	D006528	false
Relation: 25084821	CID	98	108	C069541	65	76	D009503	true

Sentence: She developed leucopenia after being treated with quetiapine.
Entity: 25084821	14	24	leucopenia	Disease	D007970
Entity: 25084821	50	60	quetiapine	Chemical	C069541
Relation: 25084821	CID	50	60	C069541	14	24	D007970	true

Sentence: CONCLUSIONS: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.
Entity: 25084821	22	33	neutropenia	Disease	D009503
Entity: 25084821	65	75	quetiapine	Chemical	C069541
Relation: 25084821	CID	65	75	C069541	22	33	D009503	true

Sentence: Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle.
Entity: 25096313	31	41	neuropathy	Disease	D009422
Entity: 25096313	48	55	steroid	Chemical	D013256
Relation: 25096313	CID	48	55	D013256	31	41	D009422	false

Sentence: BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman.
Entity: 25096313	97	107	neuropathy	Disease	D009422
Entity: 25096313	138	145	steroid	Chemical	D013256
Entity: 25096313	191	212	lateral epicondylitis	Disease	D013716
Relation: 25096313	CID	138	145	D013256	97	107	D009422	false
Relation: 25096313	CID	138	145	D013256	191	212	D013716	false

Sentence: MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before.
Entity: 25096313	80	91	paresthesia	Disease	D010292
Entity: 25096313	128	139	paresthesia	Disease	D010292
Entity: 25096313	161	168	steroid	Chemical	D013256
Relation: 25096313	CID	161	168	D013256	80	91	D010292	true
Relation: 25096313	CID	161	168	D013256	128	139	D010292	true

Sentence: Curcumin prevents maleate induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.
Entity: 25119790	0	8	Curcumin	Chemical	D003474
Entity: 25119790	18	25	maleate	Chemical	C030272
Entity: 25119790	34	48	nephrotoxicity	Disease	D007674
Entity: 25119790	119	125	oxygen	Chemical	D010100
Relation: 25119790	CID	0	8	D003474	34	48	D007674	false
Relation: 25119790	CID	18	25	C030272	34	48	D007674	true
Relation: 25119790	CID	119	125	D010100	34	48	D007674	false

Sentence: The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.
Entity: 25119790	59	67	curcumin	Chemical	D003474
Entity: 25119790	107	119	renal injury	Disease	D007674
Entity: 25119790	131	138	maleate	Chemical	C030272
Relation: 25119790	CID	59	67	D003474	107	119	D007674	false
Relation: 25119790	CID	131	138	C030272	107	119	D007674	true

Sentence: Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.
Entity: 25119790	8	19	proteinuria	Disease	D011507
Entity: 25119790	79	86	maleate	Chemical	C030272
Relation: 25119790	CID	79	86	C030272	8	19	D011507	true

Sentence: Maleate induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h.
Entity: 25119790	0	7	Maleate	Chemical	C030272
Entity: 25119790	16	28	renal injury	Disease	D007674
Entity: 25119790	123	130	glucose	Chemical	D005947
Entity: 25119790	132	138	sodium	Chemical	D012964
Entity: 25119790	246	259	kidney injury	Disease	D007674
Entity: 25119790	343	351	necrosis	Disease	D009336
Relation: 25119790	CID	0	7	C030272	16	28	D007674	true
Relation: 25119790	CID	0	7	C030272	246	259	D007674	true
Relation: 25119790	CID	0	7	C030272	343	351	D009336	true
Relation: 25119790	CID	123	130	D005947	16	28	D007674	false
Relation: 25119790	CID	123	130	D005947	246	259	D007674	false
Relation: 25119790	CID	123	130	D005947	343	351	D009336	false
Relation: 25119790	CID	132	138	D012964	16	28	D007674	false
Relation: 25119790	CID	132	138	D012964	246	259	D007674	false
Relation: 25119790	CID	132	138	D012964	343	351	D009336	false

Sentence: It is concluded that curcumin is able to attenuate in vivo maleate induced nephropathy and in vitro cell damage.
Entity: 25119790	21	29	curcumin	Chemical	D003474
Entity: 25119790	59	66	maleate	Chemical	C030272
Entity: 25119790	75	86	nephropathy	Disease	D007674
Relation: 25119790	CID	21	29	D003474	75	86	D007674	false
Relation: 25119790	CID	59	66	C030272	75	86	D007674	true

Sentence: Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.
Entity: 25907210	19	26	tumours	Disease	D009369
Entity: 25907210	70	85	organophosphate	Chemical	D010755
Entity: 25907210	98	106	diazinon	Chemical	D003976
Relation: 25907210	CID	70	85	D010755	19	26	D009369	false
Relation: 25907210	CID	98	106	D003976	19	26	D009369	false

Sentence: OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.
Entity: 25907210	11	19	Diazinon	Chemical	D003976
Entity: 25907210	30	45	organophosphate	Chemical	D010755
Entity: 25907210	116	127	lung cancer	Disease	D008175
Entity: 25907210	227	235	diazinon	Chemical	D003976
Entity: 25907210	247	253	cancer	Disease	D009369
Relation: 25907210	CID	11	19	D003976	116	127	D008175	true
Relation: 25907210	CID	11	19	D003976	247	253	D009369	false
Relation: 25907210	CID	30	45	D010755	116	127	D008175	false
Relation: 25907210	CID	30	45	D010755	247	253	D009369	false
Relation: 25907210	CID	227	235	D003976	116	127	D008175	true
Relation: 25907210	CID	227	235	D003976	247	253	D009369	false

Sentence: We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS.
Entity: 25907210	16	24	diazinon	Chemical	D003976
Entity: 25907210	38	44	cancer	Disease	D009369
Entity: 25907210	85	91	tumour	Disease	D009369
Relation: 25907210	CID	16	24	D003976	38	44	D009369	false
Relation: 25907210	CID	16	24	D003976	85	91	D009369	false

Sentence: METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa).
Entity: 25907210	81	89	diazinon	Chemical	D003976
Entity: 25907210	146	152	cancer	Disease	D009369
Relation: 25907210	CID	81	89	D003976	146	152	D009369	false

Sentence: RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08).
Entity: 25907210	30	41	lung cancer	Disease	D008175
Entity: 25907210	164	172	diazinon	Chemical	D003976
Relation: 25907210	CID	164	172	D003976	30	41	D008175	true

Sentence: CONCLUSIONS: Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk.
Entity: 25907210	39	47	diazinon	Chemical	D003976
Entity: 25907210	100	111	lung cancer	Disease	D008175
Relation: 25907210	CID	39	47	D003976	100	111	D008175	true

Sentence: Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.
Entity: 25951420	16	21	Ozone	Chemical	D010126
Entity: 25951420	52	71	Parkinson's Disease	Disease	D010300
Relation: 25951420	CID	16	21	D010126	52	71	D010300	true

Sentence: OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.
Entity: 25951420	48	53	ozone	Chemical	D010126
Entity: 25951420	63	81	particulate matter	Chemical	D052638
Entity: 25951420	87	106	Parkinson's disease	Disease	D010300
Relation: 25951420	CID	48	53	D010126	87	106	D010300	true
Relation: 25951420	CID	63	81	D052638	87	106	D010300	true

Sentence: RESULTS: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.
Entity: 25951420	46	65	Parkinson's disease	Disease	D010300
Entity: 25951420	71	76	ozone	Chemical	D010126
Entity: 25951420	128	146	particulate matter	Chemical	D052638
Relation: 25951420	CID	71	76	D010126	46	65	D010300	true
Relation: 25951420	CID	128	146	D052638	46	65	D010300	true

Sentence: Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.
Entity: 25986755	78	96	glomerulosclerosis	Disease	D005921
Entity: 25986755	136	144	caffeine	Chemical	D002110
Relation: 25986755	CID	136	144	D002110	78	96	D005921	false

Sentence: UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.
Entity: 25986755	59	67	caffeine	Chemical	D002110
Entity: 25986755	96	127	intrauterine growth retardation	Disease	D005317
Entity: 25986755	129	133	IUGR	Disease	D005317
Relation: 25986755	CID	59	67	D002110	96	127	D005317	true
Relation: 25986755	CID	59	67	D002110	129	133	D005317	true

Sentence: The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.
Entity: 25986755	81	99	glomerulosclerosis	Disease	D005921
Entity: 25986755	111	132	interstitial fibrosis	Disease	D005355
Entity: 25986755	174	184	creatinine	Chemical	D003404
Relation: 25986755	CID	174	184	D003404	81	99	D005921	false
Relation: 25986755	CID	174	184	D003404	111	132	D005355	false

Sentence: 1,3-Butadiene, CML and the t(9:22) translocation: A reality check.
Entity: 26002693	0	13	1,3-Butadiene	Chemical	C031763
Entity: 26002693	15	18	CML	Disease	D015464
Relation: 26002693	CID	0	13	C031763	15	18	D015464	false

Sentence: UNASSIGNED: Epidemiological studies of 1,3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML).
Entity: 26002693	39	52	1,3-butadiene	Chemical	C031763
Entity: 26002693	111	135	chronic myeloid leukemia	Disease	D015464
Entity: 26002693	137	140	CML	Disease	D015464
Relation: 26002693	CID	39	52	C031763	111	135	D015464	false
Relation: 26002693	CID	39	52	C031763	137	140	D015464	false

Sentence: Cancer incidence and metolachlor use in the Agricultural Health Study: An update.
Entity: 26033014	0	6	Cancer	Disease	D009369
Entity: 26033014	21	32	metolachlor	Chemical	C051786
Relation: 26033014	CID	21	32	C051786	0	6	D009369	false

Sentence: We evaluated cancer incidence through 2010/2011 (NC/IA) for 49,616 applicators, 53% of whom reported ever using metolachlor.
Entity: 26033014	13	19	cancer	Disease	D009369
Entity: 26033014	112	123	metolachlor	Chemical	C051786
Relation: 26033014	CID	112	123	C051786	13	19	D009369	false

Sentence: We used Poisson regression to evaluate relations between two metrics of metolachlor use (lifetime days, intensity-weighted lifetime days) and cancer incidence.
Entity: 26033014	72	83	metolachlor	Chemical	C051786
Entity: 26033014	142	148	cancer	Disease	D009369
Relation: 26033014	CID	72	83	C051786	142	148	D009369	false

Sentence: We saw no association between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific cancers.
Entity: 26033014	30	41	metolachlor	Chemical	C051786
Entity: 26033014	67	74	cancers	Disease	D009369
Entity: 26033014	136	143	cancers	Disease	D009369
Relation: 26033014	CID	30	41	C051786	67	74	D009369	false
Relation: 26033014	CID	30	41	C051786	136	143	D009369	false

Sentence: An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update.
Entity: 26033014	35	46	lung cancer	Disease	D008175
Entity: 26033014	70	81	metolachlor	Chemical	C051786
Relation: 26033014	CID	70	81	C051786	35	46	D008175	false

Sentence: This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.
Entity: 26033014	42	53	metolachlor	Chemical	C051786
Entity: 26033014	58	70	liver cancer	Disease	D008113
Entity: 26033014	154	169	liver neoplasms	Disease	D008113
Relation: 26033014	CID	42	53	C051786	58	70	D008113	true
Relation: 26033014	CID	42	53	C051786	154	169	D008113	true

Sentence: There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to cancer.
Entity: 26115410	94	97	iAs	Chemical	D001152
Entity: 26115410	184	190	cancer	Disease	D009369
Relation: 26115410	CID	94	97	D001152	184	190	D009369	true

Sentence: OBJECTIVES: This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early-life iAs exposure.
Entity: 26115410	106	112	cancer	Disease	D009369
Entity: 26115410	173	176	iAs	Chemical	D001152
Relation: 26115410	CID	173	176	D001152	106	112	D009369	true

Sentence: DISCUSSION: Epigenetic reprogramming that imparts functional changes in gene expression, the development of cancer stem cells, and immunomodulation are plausible underlying mechanisms by which early-life iAs exposure elicits latent carcinogenic effects.
Entity: 26115410	108	114	cancer	Disease	D009369
Entity: 26115410	204	207	iAs	Chemical	D001152
Relation: 26115410	CID	204	207	D001152	108	114	D009369	true

Sentence: Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.
Entity: 44072	27	37	arrhythmia	Disease	D001145
Entity: 44072	53	58	BaCl2	Chemical	C024986
Entity: 44072	65	75	chloroform	Chemical	D002725
Entity: 44072	76	86	adrenaline	Chemical	D004837
Entity: 44072	93	107	strophantine G	Chemical	D010042
Entity: 44072	117	126	aconitine	Chemical	D000157
Relation: 44072	CID	53	58	C024986	27	37	D001145	true
Relation: 44072	CID	65	75	D002725	27	37	D001145	true
Relation: 44072	CID	76	86	D004837	27	37	D001145	true
Relation: 44072	CID	93	107	D010042	27	37	D001145	true
Relation: 44072	CID	117	126	D000157	27	37	D001145	true

Sentence: Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.
Entity: 753803	0	8	Myopathy	Disease	D009135
Entity: 753803	24	33	vitamin E	Chemical	D014810
Entity: 753803	38	46	myopathy	Disease	D009135
Relation: 753803	CID	24	33	D014810	0	8	D009135	false
Relation: 753803	CID	24	33	D014810	38	46	D009135	false

Sentence: The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E.
Entity: 753803	20	32	myodystrophy	Disease	D009136
Entity: 753803	75	84	vitamin E	Chemical	D014810
Relation: 753803	CID	75	84	D014810	20	32	D009136	true

Sentence: The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.
Entity: 753803	73	82	myopathic	Disease	D009135
Entity: 753803	113	121	steroids	Chemical	D013256
Entity: 753803	214	222	Dianabol	Chemical	D008696
Entity: 753803	224	228	CIBA	Chemical	-1
Entity: 753803	261	270	myopathic	Disease	D009135
Entity: 753803	294	303	vitamin E	Chemical	D014810
Relation: 753803	CID	113	121	D013256	73	82	D009135	false
Relation: 753803	CID	113	121	D013256	261	270	D009135	false
Relation: 753803	CID	214	222	D008696	73	82	D009135	false
Relation: 753803	CID	214	222	D008696	261	270	D009135	false
Relation: 753803	CID	224	228	-1	73	82	D009135	false
Relation: 753803	CID	224	228	-1	261	270	D009135	false
Relation: 753803	CID	294	303	D014810	73	82	D009135	false
Relation: 753803	CID	294	303	D014810	261	270	D009135	false

Sentence: The baby showed warfarin induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).
Entity: 920167	16	24	warfarin	Chemical	D014859
Entity: 920167	33	44	embryopathy	Disease	D005315
Entity: 920167	50	66	nasal hypoplasia	Disease	-1
Entity: 920167	71	89	stippled epiphyses	Disease	D002806
Entity: 920167	91	116	chondrodysplasia punctata	Disease	D002806
Relation: 920167	CID	16	24	D014859	33	44	D005315	false
Relation: 920167	CID	16	24	D014859	50	66	-1	false
Relation: 920167	CID	16	24	D014859	71	89	D002806	true
Relation: 920167	CID	16	24	D014859	91	116	D002806	true

Sentence: Isradipine treatment for hypertension in general practice in Hong Kong.
Entity: 1451544	0	10	Isradipine	Chemical	D017275
Entity: 1451544	25	37	hypertension	Disease	D006973
Relation: 1451544	CID	0	10	D017275	25	37	D006973	false

Sentence: A 6-week open study of the introduction of isradipine treatment was conducted in general practice in Hong Kong. 303 Chinese patients with mild to moderate hypertension entered the study.
Entity: 1451544	43	53	isradipine	Chemical	D017275
Entity: 1451544	155	167	hypertension	Disease	D006973
Relation: 1451544	CID	43	53	D017275	155	167	D006973	false

Sentence: The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.
Entity: 1451544	27	35	headache	Disease	D006261
Entity: 1451544	37	46	dizziness	Disease	D004244
Entity: 1451544	48	59	palpitation	Disease	-1
Entity: 1451544	64	72	flushing	Disease	D005483
Entity: 1451544	142	152	isradipine	Chemical	D017275
Relation: 1451544	CID	142	152	D017275	27	35	D006261	true
Relation: 1451544	CID	142	152	D017275	37	46	D004244	true
Relation: 1451544	CID	142	152	D017275	48	59	-1	false
Relation: 1451544	CID	142	152	D017275	64	72	D005483	true

Sentence: Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics.
Entity: 2782734	102	112	salbutamol	Chemical	D000420
Entity: 2782734	116	126	asthmatics	Disease	D001249
Relation: 2782734	CID	102	112	D000420	116	126	D001249	false

Sentence: High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.
Entity: 2782734	22	32	salbutamol	Chemical	D000420
Entity: 2782734	102	108	asthma	Disease	D001249
Relation: 2782734	CID	22	32	D000420	102	108	D001249	false

Sentence: Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design.
Entity: 2782734	7	16	asthmatic	Disease	D001249
Entity: 2782734	179	189	salbutamol	Chemical	D000420
Entity: 2782734	238	248	salbutamol	Chemical	D000420
Relation: 2782734	CID	179	189	D000420	7	16	D001249	false
Relation: 2782734	CID	238	248	D000420	7	16	D001249	false

Sentence: At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).
Entity: 2782734	127	133	tremor	Disease	D014202
Entity: 2782734	150	151	K	Chemical	D011188
Entity: 2782734	153	156	Glu	Chemical	D005947
Relation: 2782734	CID	150	151	D011188	127	133	D014202	false
Relation: 2782734	CID	153	156	D005947	127	133	D014202	false

Sentence: Increased anxiogenic effects of caffeine in panic disorders.
Entity: 2983630	32	40	caffeine	Chemical	D002110
Entity: 2983630	44	59	panic disorders	Disease	D016584
Relation: 2983630	CID	32	40	D002110	44	59	D016584	false

Sentence: The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.
Entity: 2983630	38	46	caffeine	Chemical	D002110
Entity: 2983630	135	172	3-methoxy-4-hydroxyphenethyleneglycol	Chemical	D008734
Entity: 2983630	174	178	MHPG	Chemical	D008734
Entity: 2983630	184	192	cortisol	Chemical	D006854
Entity: 2983630	277	288	agoraphobia	Disease	D000379
Entity: 2983630	294	307	panic attacks	Disease	D016584
Entity: 2983630	311	325	panic disorder	Disease	D016584
Relation: 2983630	CID	38	46	D002110	277	288	D000379	false
Relation: 2983630	CID	38	46	D002110	294	307	D016584	false
Relation: 2983630	CID	38	46	D002110	311	325	D016584	false
Relation: 2983630	CID	135	172	D008734	277	288	D000379	false
Relation: 2983630	CID	135	172	D008734	294	307	D016584	false
Relation: 2983630	CID	135	172	D008734	311	325	D016584	false
Relation: 2983630	CID	174	178	D008734	277	288	D000379	false
Relation: 2983630	CID	174	178	D008734	294	307	D016584	false
Relation: 2983630	CID	174	178	D008734	311	325	D016584	false
Relation: 2983630	CID	184	192	D006854	277	288	D000379	false
Relation: 2983630	CID	184	192	D006854	294	307	D016584	false
Relation: 2983630	CID	184	192	D006854	311	325	D016584	false

Sentence: Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.
Entity: 2983630	0	8	Caffeine	Chemical	D002110
Entity: 2983630	67	74	anxiety	Disease	D001008
Entity: 2983630	95	101	nausea	Disease	D009325
Entity: 2983630	103	115	palpitations	Disease	-1
Entity: 2983630	117	129	restlessness	Disease	D011595
Entity: 2983630	135	142	tremors	Disease	D014202
Relation: 2983630	CID	0	8	D002110	67	74	D001008	true
Relation: 2983630	CID	0	8	D002110	95	101	D009325	true
Relation: 2983630	CID	0	8	D002110	103	115	-1	false
Relation: 2983630	CID	0	8	D002110	117	129	D011595	false
Relation: 2983630	CID	0	8	D002110	135	142	D014202	true

Sentence: Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks.
Entity: 2983630	76	84	caffeine	Chemical	D002110
Entity: 2983630	126	139	panic attacks	Disease	D016584
Relation: 2983630	CID	76	84	D002110	126	139	D016584	false

Sentence: Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.
Entity: 2983630	8	16	caffeine	Chemical	D002110
Entity: 2983630	23	32	adenosine	Chemical	D000241
Entity: 2983630	86	100	panic disorder	Disease	D016584
Entity: 2983630	119	152	abnormalities in neuronal systems	Disease	D009421
Entity: 2983630	163	172	adenosine	Chemical	D000241
Relation: 2983630	CID	8	16	D002110	86	100	D016584	false
Relation: 2983630	CID	8	16	D002110	119	152	D009421	false
Relation: 2983630	CID	23	32	D000241	86	100	D016584	false
Relation: 2983630	CID	23	32	D000241	119	152	D009421	false
Relation: 2983630	CID	163	172	D000241	86	100	D016584	false
Relation: 2983630	CID	163	172	D000241	119	152	D009421	false

Sentence: In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05).
Entity: 3711722	14	20	cobalt	Chemical	D003035
Entity: 3711722	21	35	cardiomyopathy	Disease	D009202
Relation: 3711722	CID	14	20	D003035	21	35	D009202	true

Sentence: In six dogs with doxorubicin induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05).
Entity: 3711722	17	28	doxorubicin	Chemical	D004317
Entity: 3711722	37	50	heart failure	Disease	D006333
Relation: 3711722	CID	17	28	D004317	37	50	D006333	true

Sentence: Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.
Entity: 6728873	71	85	clonic seizure	Disease	D012640
Entity: 6728873	177	185	caffeine	Chemical	D002110
Relation: 6728873	CID	177	185	D002110	71	85	D012640	true

Sentence: Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.
Entity: 7248895	9	38	carcinoma of the renal pelvis	Disease	D010386
Entity: 7248895	49	65	cyclophosphamide	Chemical	D003520
Relation: 7248895	CID	49	65	D003520	9	38	D010386	false

Sentence: A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.
Entity: 7248895	31	52	hydroureteronephrosis	Disease	D006869
Entity: 7248895	106	115	hematuria	Disease	D006417
Entity: 7248895	156	172	cyclophosphamide	Chemical	D003520
Entity: 7248895	177	196	cerebral vasculitis	Disease	D020293
Relation: 7248895	CID	156	172	D003520	31	52	D006869	false
Relation: 7248895	CID	156	172	D003520	106	115	D006417	true
Relation: 7248895	CID	156	172	D003520	177	196	D020293	false

Sentence: Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.
Entity: 7248895	24	40	cyclophosphamide	Chemical	D003520
Entity: 7248895	50	61	hemorrhagic	Disease	D006470
Entity: 7248895	62	70	cystitis	Disease	D003556
Entity: 7248895	139	148	carcinoma	Disease	D002277
Entity: 7248895	226	256	carcinoma of the urinary tract	Disease	D014571
Relation: 7248895	CID	24	40	D003520	50	61	D006470	false
Relation: 7248895	CID	24	40	D003520	62	70	D003556	false
Relation: 7248895	CID	24	40	D003520	139	148	D002277	true
Relation: 7248895	CID	24	40	D003520	226	256	D014571	false

Sentence: The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment.
Entity: 7248895	30	59	carcinoma of the renal pelvis	Disease	D010386
Entity: 7248895	89	105	cyclophosphamide	Chemical	D003520
Relation: 7248895	CID	89	105	D003520	30	59	D010386	false

Sentence: It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease.
Entity: 7248895	16	36	urinary tract cancer	Disease	D014571
Entity: 7248895	66	82	cyclophosphamide	Chemical	D003520
Relation: 7248895	CID	66	82	D003520	16	36	D014571	false

Sentence: The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.
Entity: 7248895	23	28	tumor	Disease	D009369
Entity: 7248895	46	67	hydroureteronephrosis	Disease	D006869
Entity: 7248895	161	177	cyclophosphamide	Chemical	D003520
Relation: 7248895	CID	161	177	D003520	23	28	D009369	false
Relation: 7248895	CID	161	177	D003520	46	67	D006869	false

Sentence: A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.
Entity: 11423811	38	48	dobutamine	Chemical	D004280
Entity: 11423811	115	122	cocaine	Chemical	D003042
Entity: 11423811	134	144	chest pain	Disease	D002637
Relation: 11423811	CID	38	48	D004280	134	144	D002637	false
Relation: 11423811	CID	115	122	D003042	134	144	D002637	true

Sentence: STUDY OBJECTIVE: Chest pain in the setting of cocaine use poses a diagnostic dilemma.
Entity: 11423811	17	27	Chest pain	Disease	D002637
Entity: 11423811	46	53	cocaine	Chemical	D003042
Relation: 11423811	CID	46	53	D003042	17	27	D002637	true

Sentence: Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia.
Entity: 11423811	0	10	Dobutamine	Chemical	D004280
Entity: 11423811	105	113	ischemia	Disease	D007511
Relation: 11423811	CID	0	10	D004280	105	113	D007511	false

Sentence: Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain.
Entity: 11423811	63	73	dobutamine	Chemical	D004280
Entity: 11423811	92	99	cocaine	Chemical	D003042
Entity: 11423811	198	205	cocaine	Chemical	D003042
Entity: 11423811	217	227	chest pain	Disease	D002637
Relation: 11423811	CID	63	73	D004280	217	227	D002637	false
Relation: 11423811	CID	92	99	D003042	217	227	D002637	true
Relation: 11423811	CID	198	205	D003042	217	227	D002637	true

Sentence: Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level.
Entity: 11423811	48	55	cocaine	Chemical	D003042
Entity: 11423811	95	105	chest pain	Disease	D002637
Relation: 11423811	CID	48	55	D003042	95	105	D002637	true

Sentence: Patients exhibiting signs of continuing cocaine toxicity were excluded from the study.
Entity: 11423811	40	47	cocaine	Chemical	D003042
Entity: 11423811	48	56	toxicity	Disease	D064420
Relation: 11423811	CID	40	47	D003042	48	56	D064420	false

Sentence: Amiodarone induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.
Entity: 12678199	0	10	Amiodarone	Chemical	D000638
Entity: 12678199	19	37	torsade de pointes	Disease	D016171
Relation: 12678199	CID	0	10	D000638	19	37	D016171	true

Sentence: The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.
Entity: 12678199	67	85	torsade de pointes	Disease	D016171
Entity: 12678199	87	90	TdP	Disease	D016171
Entity: 12678199	113	123	amiodarone	Chemical	D000638
Relation: 12678199	CID	113	123	D000638	67	85	D016171	true
Relation: 12678199	CID	113	123	D000638	87	90	D016171	true

Sentence: Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.
Entity: 12678199	43	46	TdP	Disease	D016171
Entity: 12678199	114	125	hypokalemia	Disease	D007008
Entity: 12678199	130	137	digoxin	Chemical	D004077
Relation: 12678199	CID	130	137	D004077	43	46	D016171	false
Relation: 12678199	CID	130	137	D004077	114	125	D007008	false

Sentence: The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of amiodarone therapy resulted in amiodarone induced proarrhythmia.
Entity: 12678199	115	125	amiodarone	Chemical	D000638
Entity: 12678199	146	156	amiodarone	Chemical	D000638
Entity: 12678199	165	178	proarrhythmia	Disease	-1
Relation: 12678199	CID	115	125	D000638	165	178	-1	false
Relation: 12678199	CID	146	156	D000638	165	178	-1	false

Sentence: Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
Entity: 15696449	0	25	Acute renal insufficiency	Disease	D058186
Entity: 15696449	42	51	melphalan	Chemical	D008558
Entity: 15696449	69	97	primary systemic amyloidosis	Disease	C531616
Relation: 15696449	CID	42	51	D008558	0	25	D058186	true
Relation: 15696449	CID	42	51	D008558	69	97	C531616	false

Sentence: The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning.
Entity: 15696449	42	67	acute renal insufficiency	Disease	D058186
Entity: 15696449	86	95	melphalan	Chemical	D008558
Relation: 15696449	CID	86	95	D008558	42	67	D058186	true

Sentence: Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.
Entity: 15696449	0	25	Acute renal insufficiency	Disease	D058186
Entity: 15696449	27	30	ARI	Disease	D058186
Entity: 15696449	48	57	melphalan	Chemical	D008558
Entity: 15696449	134	144	creatinine	Chemical	D003404
Relation: 15696449	CID	48	57	D008558	0	25	D058186	true
Relation: 15696449	CID	48	57	D008558	27	30	D058186	true
Relation: 15696449	CID	134	144	D003404	0	25	D058186	false
Relation: 15696449	CID	134	144	D003404	27	30	D058186	false

Sentence: RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan.
Entity: 15696449	37	40	ARI	Disease	D058186
Entity: 15696449	92	101	melphalan	Chemical	D008558
Relation: 15696449	CID	92	101	D008558	37	40	D058186	true

Sentence: Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03).
Entity: 15696449	17	20	ARI	Disease	D058186
Entity: 15696449	37	46	melphalan	Chemical	D008558
Relation: 15696449	CID	37	46	D008558	17	20	D058186	true

Sentence: CONCLUSION: The timing of renal injury strongly suggests melphalan as the causative agent.
Entity: 15696449	26	38	renal injury	Disease	D058186
Entity: 15696449	57	66	melphalan	Chemical	D008558
Relation: 15696449	CID	57	66	D008558	26	38	D058186	true

Sentence: Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.
Entity: 15696449	8	22	tubular injury	Disease	-1
Entity: 15696449	49	61	renal injury	Disease	D058186
Entity: 15696449	65	74	melphalan	Chemical	D008558
Relation: 15696449	CID	65	74	D008558	8	22	-1	false
Relation: 15696449	CID	65	74	D008558	49	61	D058186	true

Sentence: Impaired fear recognition in regular recreational cocaine users.
Entity: 17554526	0	25	Impaired fear recognition	Disease	D001925
Entity: 17554526	50	57	cocaine	Chemical	D003042
Relation: 17554526	CID	50	57	D003042	0	25	D001925	true

Sentence: The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired.
Entity: 17554526	14	41	deficit in fear recognition	Disease	D001925
Entity: 17554526	125	132	cocaine	Chemical	D003042
Entity: 17554526	137	144	ecstasy	Chemical	D018817
Relation: 17554526	CID	125	132	D003042	14	41	D001925	true
Relation: 17554526	CID	137	144	D018817	14	41	D001925	false

Sentence: Corneal ulcers associated with aerosolized crack cocaine use.
Entity: 17721298	0	14	Corneal ulcers	Disease	D003320
Entity: 17721298	43	56	crack cocaine	Chemical	D016578
Relation: 17721298	CID	43	56	D016578	0	14	D003320	true

Sentence: RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed.
Entity: 17721298	28	42	corneal ulcers	Disease	D003320
Entity: 17721298	59	72	crack cocaine	Chemical	D016578
Relation: 17721298	CID	59	72	D016578	28	42	D003320	true

Sentence: CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers.
Entity: 17721298	25	38	crack cocaine	Chemical	D016578
Entity: 17721298	85	99	corneal ulcers	Disease	D003320
Relation: 17721298	CID	25	38	D016578	85	99	D003320	true

Sentence: Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
Entity: 18341442	0	13	Levetiracetam	Chemical	C026098
Entity: 18341442	31	44	phenobarbital	Chemical	D010634
Entity: 18341442	78	97	idiopathic epilepsy	Disease	C562694
Relation: 18341442	CID	0	13	C026098	78	97	C562694	false
Relation: 18341442	CID	31	44	D010634	78	97	C562694	false

Sentence: OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.
Entity: 18341442	74	87	levetiracetam	Chemical	C026098
Entity: 18341442	118	131	phenobarbital	Chemical	D010634
Entity: 18341442	183	202	idiopathic epilepsy	Disease	C562694
Relation: 18341442	CID	74	87	C026098	183	202	C562694	false
Relation: 18341442	CID	118	131	D010634	183	202	C562694	false

Sentence: ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.
Entity: 18341442	35	54	idiopathic epilepsy	Disease	C562694
Entity: 18341442	87	100	phenobarbital	Chemical	D010634
Entity: 18341442	160	173	phenobarbital	Chemical	D010634
Relation: 18341442	CID	87	100	D010634	35	54	C562694	false
Relation: 18341442	CID	160	173	D010634	35	54	C562694	false

Sentence: Seizure frequencies before and after initiation of levetiracetam treatment were compared, and adverse effects were recorded.
Entity: 18341442	0	7	Seizure	Disease	D012640
Entity: 18341442	51	64	levetiracetam	Chemical	C026098
Relation: 18341442	CID	51	64	C026098	0	7	D012640	false

Sentence: Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).
Entity: 18341442	7	14	seizure	Disease	D012640
Entity: 18341442	49	62	levetiracetam	Chemical	C026098
Entity: 18341442	68	76	seizures	Disease	D012640
Entity: 18341442	118	125	seizure	Disease	D012640
Entity: 18341442	156	169	levetiracetam	Chemical	C026098
Entity: 18341442	186	194	seizures	Disease	D012640
Entity: 18341442	256	269	levetiracetam	Chemical	C026098
Entity: 18341442	298	305	seizure	Disease	D012640
Relation: 18341442	CID	49	62	C026098	7	14	D012640	false
Relation: 18341442	CID	49	62	C026098	68	76	D012640	false
Relation: 18341442	CID	49	62	C026098	118	125	D012640	false
Relation: 18341442	CID	49	62	C026098	186	194	D012640	false
Relation: 18341442	CID	49	62	C026098	298	305	D012640	false
Relation: 18341442	CID	156	169	C026098	7	14	D012640	false
Relation: 18341442	CID	156	169	C026098	68	76	D012640	false
Relation: 18341442	CID	156	169	C026098	118	125	D012640	false
Relation: 18341442	CID	156	169	C026098	186	194	D012640	false
Relation: 18341442	CID	156	169	C026098	298	305	D012640	false
Relation: 18341442	CID	256	269	C026098	7	14	D012640	false
Relation: 18341442	CID	256	269	C026098	68	76	D012640	false
Relation: 18341442	CID	256	269	C026098	118	125	D012640	false
Relation: 18341442	CID	256	269	C026098	186	194	D012640	false
Relation: 18341442	CID	256	269	C026098	298	305	D012640	false

Sentence: Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.
Entity: 19681452	10	22	haemorrhagic	Disease	D002543
Entity: 19681452	23	33	infarction	Disease	D020520
Entity: 19681452	63	70	cocaine	Chemical	D003042
Entity: 19681452	75	82	alcohol	Chemical	D000431
Relation: 19681452	CID	63	70	D003042	10	22	D002543	false
Relation: 19681452	CID	63	70	D003042	23	33	D020520	false
Relation: 19681452	CID	75	82	D000431	10	22	D002543	false
Relation: 19681452	CID	75	82	D000431	23	33	D020520	false

Sentence: Cocaine is a risk factor for both ischemic and haemorrhagic stroke.
Entity: 19681452	0	7	Cocaine	Chemical	D003042
Entity: 19681452	34	42	ischemic	Disease	D002544
Entity: 19681452	47	59	haemorrhagic	Disease	D020521
Relation: 19681452	CID	0	7	D003042	34	42	D002544	false
Relation: 19681452	CID	0	7	D003042	47	59	D020521	false

Sentence: We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.
Entity: 19681452	56	87	ischemia of the globus pallidus	Disease	D002545
Entity: 19681452	104	111	alcohol	Chemical	D000431
Entity: 19681452	127	134	cocaine	Chemical	D003042
Relation: 19681452	CID	104	111	D000431	56	87	D002545	false
Relation: 19681452	CID	127	134	D003042	56	87	D002545	true

Sentence: Drug-related globus pallidus infarctions are most often associated with heroin.
Entity: 19681452	13	40	globus pallidus infarctions	Disease	D020520
Entity: 19681452	72	78	heroin	Chemical	D003932
Relation: 19681452	CID	72	78	D003932	13	40	D020520	true

Sentence: Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.
Entity: 19681452	10	32	basal ganglia infarcts	Disease	D020520
Entity: 19681452	50	57	cocaine	Chemical	D003042
Entity: 19681452	78	84	heroin	Chemical	D003932
Relation: 19681452	CID	50	57	D003042	10	32	D020520	false
Relation: 19681452	CID	78	84	D003932	10	32	D020520	true

Sentence: Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.
Entity: 20009434	0	19	Acute renal failure	Disease	D058186
Entity: 20009434	36	48	methotrexate	Chemical	D008727
Relation: 20009434	CID	36	48	D008727	0	19	D058186	true

Sentence: High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.
Entity: 20009434	10	22	methotrexate	Chemical	D008727
Entity: 20009434	27	30	MTX	Chemical	D008727
Entity: 20009434	62	78	Burkitt lymphoma	Disease	D002051
Entity: 20009434	94	101	hepatic	Disease	D056486
Entity: 20009434	106	111	renal	Disease	D007674
Relation: 20009434	CID	10	22	D008727	62	78	D002051	false
Relation: 20009434	CID	10	22	D008727	94	101	D056486	false
Relation: 20009434	CID	10	22	D008727	106	111	D007674	false
Relation: 20009434	CID	27	30	D008727	62	78	D002051	false
Relation: 20009434	CID	27	30	D008727	94	101	D056486	false
Relation: 20009434	CID	27	30	D008727	106	111	D007674	false

Sentence: We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.
Entity: 20009434	20	39	acute renal failure	Disease	D058186
Entity: 20009434	49	52	MTX	Chemical	D008727
Entity: 20009434	194	209	biliary atresia	Disease	D001656
Relation: 20009434	CID	49	52	D008727	20	39	D058186	true
Relation: 20009434	CID	49	52	D008727	194	209	D001656	false

Sentence: Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.
Entity: 20009434	14	17	MTX	Chemical	D008727
Entity: 20009434	33	52	acute renal failure	Disease	D058186
Relation: 20009434	CID	14	17	D008727	33	52	D058186	true

Sentence: RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).
Entity: 20431083	38	41	ICH	Disease	D002543
Entity: 20431083	51	53	IS	Disease	D002544
Entity: 20431083	54	57	TIA	Disease	D002546
Entity: 20431083	59	61	MB	Disease	-1
Entity: 20431083	84	87	ICH	Disease	D002543
Entity: 20431083	91	93	IS	Disease	D002544
Entity: 20431083	94	97	TIA	Disease	D002546
Entity: 20431083	288	296	warfarin	Chemical	D014859
Relation: 20431083	CID	288	296	D014859	38	41	D002543	true
Relation: 20431083	CID	288	296	D014859	51	53	D002544	false
Relation: 20431083	CID	288	296	D014859	54	57	D002546	false
Relation: 20431083	CID	288	296	D014859	59	61	-1	false
Relation: 20431083	CID	288	296	D014859	84	87	D002543	true
Relation: 20431083	CID	288	296	D014859	91	93	D002544	false
Relation: 20431083	CID	288	296	D014859	94	97	D002546	false

Sentence: There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).
Entity: 20431083	28	30	MB	Disease	-1
Entity: 20431083	34	42	warfarin	Chemical	D014859
Entity: 20431083	66	69	ICH	Disease	D002543
Entity: 20431083	118	126	warfarin	Chemical	D014859
Entity: 20431083	138	140	IS	Disease	D002544
Entity: 20431083	141	144	TIA	Disease	D002546
Relation: 20431083	CID	34	42	D014859	28	30	-1	false
Relation: 20431083	CID	34	42	D014859	66	69	D002543	true
Relation: 20431083	CID	34	42	D014859	138	140	D002544	false
Relation: 20431083	CID	34	42	D014859	141	144	D002546	false
Relation: 20431083	CID	118	126	D014859	28	30	-1	false
Relation: 20431083	CID	118	126	D014859	66	69	D002543	true
Relation: 20431083	CID	118	126	D014859	138	140	D002544	false
Relation: 20431083	CID	118	126	D014859	141	144	D002546	false

Sentence: Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
Entity: 20595935	0	9	Verapamil	Chemical	D014700
Entity: 20595935	30	48	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	0	9	D014700	30	48	D006966	false

Sentence: AIM: Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia, but with conflicting results.
Entity: 20595935	5	14	Verapamil	Chemical	D014700
Entity: 20595935	100	118	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	5	14	D014700	100	118	D006966	false

Sentence: Here, we aimed to re-investigate the diagnostic value of verapamil in a population who were all screened for macroprolactinemia.
Entity: 20595935	57	66	verapamil	Chemical	D014700
Entity: 20595935	109	127	macroprolactinemia	Disease	D015175
Relation: 20595935	CID	57	66	D014700	109	127	D015175	false

Sentence: Prolactin responses to verapamil in 65 female patients (age: 29.9 +/- 8.1 years) with hyperprolactinemia were tested in a descriptive, matched case-control study.
Entity: 20595935	23	32	verapamil	Chemical	D014700
Entity: 20595935	86	104	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	23	32	D014700	86	104	D006966	false

Sentence: RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone induced hyperprolactinemia (N. 7, PRL: 3%).
Entity: 20595935	9	18	Verapamil	Chemical	D014700
Entity: 20595935	93	110	macroprolactinoma	Disease	D015175
Entity: 20595935	128	145	microprolactinoma	Disease	D015175
Entity: 20595935	165	183	macroprolactinemia	Disease	D015175
Entity: 20595935	215	233	pseudoprolactinoma	Disease	-1
Entity: 20595935	257	268	risperidone	Chemical	D018967
Entity: 20595935	277	295	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	9	18	D014700	93	110	D015175	false
Relation: 20595935	CID	9	18	D014700	128	145	D015175	false
Relation: 20595935	CID	9	18	D014700	165	183	D015175	false
Relation: 20595935	CID	9	18	D014700	215	233	-1	false
Relation: 20595935	CID	9	18	D014700	277	295	D006966	false
Relation: 20595935	CID	257	268	D018967	93	110	D015175	false
Relation: 20595935	CID	257	268	D018967	128	145	D015175	false
Relation: 20595935	CID	257	268	D018967	165	183	D015175	false
Relation: 20595935	CID	257	268	D018967	215	233	-1	false
Relation: 20595935	CID	257	268	D018967	277	295	D006966	true

Sentence: ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone induced hyperprolactinemia, respectively.
Entity: 20595935	53	62	verapamil	Chemical	D014700
Entity: 20595935	234	252	pseudoprolactinoma	Disease	-1
Entity: 20595935	256	267	risperidone	Chemical	D018967
Entity: 20595935	276	294	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	53	62	D014700	234	252	-1	false
Relation: 20595935	CID	53	62	D014700	276	294	D006966	false
Relation: 20595935	CID	256	267	D018967	234	252	-1	false
Relation: 20595935	CID	256	267	D018967	276	294	D006966	true

Sentence: CONCLUSION: Verapamil responsiveness is not a reliable finding for the differential diagnosis of hyperprolactinemia.
Entity: 20595935	12	21	Verapamil	Chemical	D014700
Entity: 20595935	97	115	hyperprolactinemia	Disease	D006966
Relation: 20595935	CID	12	21	D014700	97	115	D006966	false

Sentence: The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.
Entity: 35781	14	23	clonidine	Chemical	D003000
Entity: 35781	25	36	naphazoline	Chemical	D009278
Entity: 35781	41	55	xylometazoline	Chemical	C009695
Entity: 35781	80	88	morphine	Chemical	D009020
Entity: 35781	90	97	codeine	Chemical	D003061
Entity: 35781	99	107	fentanyl	Chemical	D005283
Entity: 35781	112	123	pentazocine	Chemical	D010423
Entity: 35781	132	142	cataleptic	Disease	D002375
Entity: 35781	153	161	morphine	Chemical	D009020
Entity: 35781	163	169	codine	Chemical	D003061
Entity: 35781	174	182	fentanyl	Chemical	D005283
Relation: 35781	CID	14	23	D003000	132	142	D002375	true
Relation: 35781	CID	25	36	D009278	132	142	D002375	true
Relation: 35781	CID	41	55	C009695	132	142	D002375	true
Relation: 35781	CID	80	88	D009020	132	142	D002375	true
Relation: 35781	CID	90	97	D003061	132	142	D002375	true
Relation: 35781	CID	99	107	D005283	132	142	D002375	true
Relation: 35781	CID	112	123	D010423	132	142	D002375	false
Relation: 35781	CID	153	161	D009020	132	142	D002375	true
Relation: 35781	CID	163	169	D003061	132	142	D002375	true
Relation: 35781	CID	174	182	D005283	132	142	D002375	true

Sentence: It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.
Entity: 35781	50	52	NA	Chemical	D009638
Entity: 35781	147	156	catalepsy	Disease	D002375
Entity: 35781	168	176	morphine	Chemical	D009020
Entity: 35781	181	189	fentanyl	Chemical	D005283
Relation: 35781	CID	50	52	D009638	147	156	D002375	false
Relation: 35781	CID	168	176	D009020	147	156	D002375	true
Relation: 35781	CID	181	189	D005283	147	156	D002375	true

Sentence: Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.
Entity: 35781	0	7	Codeine	Chemical	D003061
Entity: 35781	8	17	catalepsy	Disease	D002375
Entity: 35781	35	44	clonidine	Chemical	D003000
Entity: 35781	62	73	naphazoline	Chemical	D009278
Entity: 35781	78	92	xylometazoline	Chemical	C009695
Relation: 35781	CID	0	7	D003061	8	17	D002375	true
Relation: 35781	CID	35	44	D003000	8	17	D002375	true
Relation: 35781	CID	62	73	D009278	8	17	D002375	true
Relation: 35781	CID	78	92	C009695	8	17	D002375	true

Sentence: Modification by propranolol of cardiovascular effects of induced hypoglycaemia.
Entity: 48835	16	27	propranolol	Chemical	D011433
Entity: 48835	65	78	hypoglycaemia	Disease	D007003
Relation: 48835	CID	16	27	D011433	65	78	D007003	false

Sentence: Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy.
Entity: 89511	28	47	endometrial disease	Disease	D014591
Entity: 89511	79	88	oestrogen	Chemical	D004967
Relation: 89511	CID	79	88	D004967	28	47	D014591	false

Sentence: The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy.
Entity: 89511	57	76	endometrial disease	Disease	D014591
Entity: 89511	115	124	oestrogen	Chemical	D004967
Relation: 89511	CID	115	124	D004967	57	76	D014591	false

Sentence: Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.
Entity: 89511	7	18	hyperplasia	Disease	D006965
Entity: 89511	49	58	oestrogen	Chemical	D004967
Entity: 89511	75	86	progestagen	Chemical	D011372
Relation: 89511	CID	49	58	D004967	7	18	D006965	true
Relation: 89511	CID	75	86	D011372	7	18	D006965	false

Sentence: Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.
Entity: 89511	31	45	norethisterone	Chemical	D009640
Entity: 89511	105	116	hyperplasia	Disease	D006965
Entity: 89511	150	161	hyperplasia	Disease	D006965
Entity: 89511	174	195	endometrial carcinoma	Disease	D016889
Entity: 89511	290	299	oestrogen	Chemical	D004967
Entity: 89511	352	363	hyperplasia	Disease	D006965
Entity: 89511	369	379	malignancy	Disease	D009369
Relation: 89511	CID	31	45	D009640	105	116	D006965	false
Relation: 89511	CID	31	45	D009640	150	161	D006965	false
Relation: 89511	CID	31	45	D009640	174	195	D016889	false
Relation: 89511	CID	31	45	D009640	352	363	D006965	false
Relation: 89511	CID	31	45	D009640	369	379	D009369	false
Relation: 89511	CID	290	299	D004967	105	116	D006965	true
Relation: 89511	CID	290	299	D004967	150	161	D006965	true
Relation: 89511	CID	290	299	D004967	174	195	D016889	false
Relation: 89511	CID	290	299	D004967	352	363	D006965	true
Relation: 89511	CID	290	299	D004967	369	379	D009369	false

Sentence: Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.
Entity: 146391	0	21	Pure red cell aplasia	Disease	D012010
Entity: 146391	23	39	toxic dermatitis	Disease	D003875
Entity: 146391	44	59	lymphadenopathy	Disease	D008206
Entity: 146391	80	97	diphenylhydantoin	Chemical	D010672
Relation: 146391	CID	80	97	D010672	0	21	D012010	true
Relation: 146391	CID	80	97	D010672	23	39	D003875	true
Relation: 146391	CID	80	97	D010672	44	59	D008206	true

Sentence: A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.
Entity: 146391	17	34	diphenylhydantoin	Chemical	D010672
Entity: 146391	71	80	skin rash	Disease	D005076
Entity: 146391	82	97	lymphadenopathy	Disease	D008206
Entity: 146391	102	123	pure red cell aplasia	Disease	D012010
Relation: 146391	CID	17	34	D010672	71	80	D005076	false
Relation: 146391	CID	17	34	D010672	82	97	D008206	true
Relation: 146391	CID	17	34	D010672	102	123	D012010	true

Sentence: Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.
Entity: 146391	0	9	Skin rash	Disease	D005076
Entity: 146391	42	59	diphenylhydantoin	Chemical	D010672
Entity: 146391	97	112	lymphadenopathy	Disease	D008206
Relation: 146391	CID	42	59	D010672	0	9	D005076	false
Relation: 146391	CID	42	59	D010672	97	112	D008206	true

Sentence: Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients.
Entity: 146391	0	21	Pure red cell aplasia	Disease	D012010
Entity: 146391	38	55	diphenylhydantoin	Chemical	D010672
Relation: 146391	CID	38	55	D010672	0	21	D012010	true

Sentence: Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.
Entity: 256433	20	30	tobramycin	Chemical	D014031
Entity: 256433	45	58	carbenicillin	Chemical	D002228
Entity: 256433	63	73	infections	Disease	D007239
Entity: 256433	77	83	cancer	Disease	D009369
Relation: 256433	CID	20	30	D014031	63	73	D007239	false
Relation: 256433	CID	20	30	D014031	77	83	D009369	false
Relation: 256433	CID	45	58	D002228	63	73	D007239	false
Relation: 256433	CID	45	58	D002228	77	83	D009369	false

Sentence: To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.
Entity: 256433	35	46	neutropenia	Disease	D009503
Entity: 256433	48	58	tobramycin	Chemical	D014031
Entity: 256433	123	136	carbenicillin	Chemical	D002228
Relation: 256433	CID	48	58	D014031	35	46	D009503	false
Relation: 256433	CID	123	136	D002228	35	46	D009503	false

Sentence: Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%.
Entity: 256433	6	14	azotemia	Disease	D053099
Entity: 256433	22	32	creatinine	Chemical	D003404
Relation: 256433	CID	22	32	D003404	6	14	D053099	false

Sentence: Azotemia was not related to duration of therapy or serum tobramycin concentration.
Entity: 256433	0	8	Azotemia	Disease	D053099
Entity: 256433	57	67	tobramycin	Chemical	D014031
Relation: 256433	CID	57	67	D014031	0	8	D053099	true

Sentence: Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.
Entity: 448423	10	33	subarachnoid hemorrhage	Disease	D013345
Entity: 448423	50	67	aminocaproic acid	Chemical	D000614
Entity: 448423	80	109	acute renal artery thrombosis	Disease	D007674
Relation: 448423	CID	50	67	D000614	10	33	D013345	false
Relation: 448423	CID	50	67	D000614	80	109	D007674	false

Sentence: Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).
Entity: 448423	0	25	Epsilon aminocaproic acid	Chemical	D015119
Entity: 448423	27	31	EACA	Chemical	D015119
Entity: 448423	86	109	subarachnoid hemorrhage	Disease	D013345
Entity: 448423	111	114	SAH	Disease	D013345
Relation: 448423	CID	0	25	D015119	86	109	D013345	true
Relation: 448423	CID	0	25	D015119	111	114	D013345	true
Relation: 448423	CID	27	31	D015119	86	109	D013345	true
Relation: 448423	CID	27	31	D015119	111	114	D013345	true

Sentence: Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.
Entity: 448423	94	104	thrombotic	Disease	D013927
Entity: 448423	122	126	EACA	Chemical	D015119
Relation: 448423	CID	122	126	D015119	94	104	D013927	true

Sentence: These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.
Entity: 448423	61	93	intracranial vascular thrombosis	Disease	D020767
Entity: 448423	111	114	SAH	Disease	D013345
Entity: 448423	148	155	thrombi	Disease	D013927
Entity: 448423	209	213	EACA	Chemical	D015119
Entity: 448423	224	248	thromboembolic phenomena	Disease	D013923
Relation: 448423	CID	209	213	D015119	61	93	D020767	true
Relation: 448423	CID	209	213	D015119	111	114	D013345	true
Relation: 448423	CID	209	213	D015119	148	155	D013927	true
Relation: 448423	CID	209	213	D015119	224	248	D013923	false

Sentence: Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies." This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery.
Entity: 448423	27	34	thrombi	Disease	D013927
Entity: 448423	95	99	EACA	Chemical	D015119
Entity: 448423	155	162	thrombi	Disease	D013927
Entity: 448423	180	218	disseminated intravascular coagulation	Disease	D004211
Entity: 448423	229	255	consumption coagulopathies	Disease	D004211
Entity: 448423	289	299	infarction	Disease	D007238
Entity: 448423	321	356	thrombosis of a normal renal artery	Disease	D007674
Relation: 448423	CID	95	99	D015119	27	34	D013927	true
Relation: 448423	CID	95	99	D015119	155	162	D013927	true
Relation: 448423	CID	95	99	D015119	180	218	D004211	false
Relation: 448423	CID	95	99	D015119	229	255	D004211	false
Relation: 448423	CID	95	99	D015119	289	299	D007238	false
Relation: 448423	CID	95	99	D015119	321	356	D007674	true

Sentence: This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.
Entity: 448423	30	34	EACA	Chemical	D015119
Entity: 448423	61	64	SAH	Disease	D013345
Entity: 448423	114	117	SAH	Disease	D013345
Relation: 448423	CID	30	34	D015119	61	64	D013345	true
Relation: 448423	CID	30	34	D015119	114	117	D013345	true

Sentence: We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.
Entity: 573555	37	49	hypoglycemia	Disease	D007003
Entity: 573555	51	69	hyperbilirubinemia	Disease	D006932
Entity: 573555	71	83	polycythemia	Disease	D011086
Entity: 573555	85	99	neonatal apnea	Disease	D001049
Entity: 573555	105	116	bradycardia	Disease	D001919
Entity: 573555	188	199	propranolol	Chemical	D011433
Relation: 573555	CID	188	199	D011433	37	49	D007003	false
Relation: 573555	CID	188	199	D011433	51	69	D006932	false
Relation: 573555	CID	188	199	D011433	71	83	D011086	false
Relation: 573555	CID	188	199	D011433	85	99	D001049	false
Relation: 573555	CID	188	199	D011433	105	116	D001919	false

Sentence: Use of propranolol in the treatment of idiopathic orthostatic hypotension.
Entity: 611664	7	18	propranolol	Chemical	D011433
Entity: 611664	39	73	idiopathic orthostatic hypotension	Disease	C544351
Relation: 611664	CID	7	18	D011433	39	73	C544351	false

Sentence: They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.
Entity: 611664	43	57	catecholamines	Chemical	D002395
Entity: 611664	139	155	hypersensitivity	Disease	D004342
Entity: 611664	190	204	norepinephrine	Chemical	D009638
Relation: 611664	CID	43	57	D002395	139	155	D004342	false
Relation: 611664	CID	190	204	D009638	139	155	D004342	false

Sentence: In 1 patient, marked hypertension was induced by propranolol and the drug had to be withdrawn.
Entity: 611664	21	33	hypertension	Disease	D006973
Entity: 611664	49	60	propranolol	Chemical	D011433
Relation: 611664	CID	49	60	D011433	21	33	D006973	true

Sentence: Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting corticosteroid suspensions in combination with other drugs: I.
Entity: 733189	10	55	retinal artery and choriocapillaris occlusion	Disease	D015356
Entity: 733189	95	109	corticosteroid	Chemical	D000305
Relation: 733189	CID	95	109	D000305	10	55	D015356	false

Sentence: Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.
Entity: 733189	39	85	retinal artery and choriocapillaris occlusions	Disease	D015356
Entity: 733189	91	100	blindness	Disease	D001766
Entity: 733189	152	178	methylprednisolone acetate	Chemical	C000873
Entity: 733189	199	208	lidocaine	Chemical	D008012
Entity: 733189	210	221	epinephrine	Chemical	D004837
Entity: 733189	226	236	penicillin	Chemical	D010406
Relation: 733189	CID	152	178	C000873	39	85	D015356	true
Relation: 733189	CID	152	178	C000873	91	100	D001766	false
Relation: 733189	CID	199	208	D008012	39	85	D015356	false
Relation: 733189	CID	199	208	D008012	91	100	D001766	false
Relation: 733189	CID	210	221	D004837	39	85	D015356	false
Relation: 733189	CID	210	221	D004837	91	100	D001766	false
Relation: 733189	CID	226	236	D010406	39	85	D015356	false
Relation: 733189	CID	226	236	D010406	91	100	D001766	false

Sentence: Cephalothin induced immune hemolytic anemia.
Entity: 816141	0	11	Cephalothin	Chemical	D002512
Entity: 816141	27	43	hemolytic anemia	Disease	D000743
Relation: 816141	CID	0	11	D002512	27	43	D000743	true

Sentence: A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.
Entity: 816141	15	28	renal disease	Disease	D007674
Entity: 816141	55	71	hemolytic anemia	Disease	D000743
Entity: 816141	88	99	cephalothin	Chemical	D002512
Relation: 816141	CID	88	99	D002512	15	28	D007674	false
Relation: 816141	CID	88	99	D002512	55	71	D000743	true

Sentence: Kaliuretic effect of L-dopa treatment in parkinsonian patients.
Entity: 851038	21	27	L-dopa	Chemical	D007980
Entity: 851038	41	53	parkinsonian	Disease	D010300
Relation: 851038	CID	21	27	D007980	41	53	D010300	false

Sentence: Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.
Entity: 851038	0	11	Hypokalemia	Disease	D007008
Entity: 851038	52	58	L-dopa	Chemical	D007980
Entity: 851038	67	79	parkinsonian	Disease	D010300
Relation: 851038	CID	52	58	D007980	0	11	D007008	true
Relation: 851038	CID	52	58	D007980	67	79	D010300	false

Sentence: The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.
Entity: 851038	17	23	L-dopa	Chemical	D007980
Entity: 851038	50	59	potassium	Chemical	D011188
Entity: 851038	91	102	hypokalemia	Disease	D007008
Entity: 851038	225	234	potassium	Chemical	D011188
Entity: 851038	239	245	sodium	Chemical	D012964
Entity: 851038	278	287	potassium	Chemical	D011188
Entity: 851038	289	295	sodium	Chemical	D012964
Entity: 851038	300	311	aldosterone	Chemical	D000450
Relation: 851038	CID	17	23	D007980	91	102	D007008	true
Relation: 851038	CID	50	59	D011188	91	102	D007008	false
Relation: 851038	CID	225	234	D011188	91	102	D007008	false
Relation: 851038	CID	239	245	D012964	91	102	D007008	false
Relation: 851038	CID	278	287	D011188	91	102	D007008	false
Relation: 851038	CID	289	295	D012964	91	102	D007008	false
Relation: 851038	CID	300	311	D000450	91	102	D007008	false

Sentence: Phenytoin encephalopathy as probable idiosyncratic reaction: case report.
Entity: 891494	0	9	Phenytoin	Chemical	D010672
Entity: 891494	10	24	encephalopathy	Disease	D001927
Relation: 891494	CID	0	9	D010672	10	24	D001927	true

Sentence: A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.
Entity: 891494	10	19	phenytoin	Chemical	D010672
Entity: 891494	21	24	DPH	Chemical	D010672
Entity: 891494	26	40	encephalopathy	Disease	D001927
Entity: 891494	57	65	seizures	Disease	D012640
Relation: 891494	CID	10	19	D010672	26	40	D001927	true
Relation: 891494	CID	10	19	D010672	57	65	D012640	false
Relation: 891494	CID	21	24	D010672	26	40	D001927	true
Relation: 891494	CID	21	24	D010672	57	65	D012640	false

Sentence: In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.
Entity: 891494	34	37	DPH	Chemical	D010672
Entity: 891494	96	100	rash	Disease	D005076
Entity: 891494	108	111	DPH	Chemical	D010672
Entity: 891494	170	173	DPH	Chemical	D010672
Relation: 891494	CID	34	37	D010672	96	100	D005076	false
Relation: 891494	CID	108	111	D010672	96	100	D005076	false
Relation: 891494	CID	170	173	D010672	96	100	D005076	false

Sentence: Effects of exercise on the severity of isoproterenol induced myocardial infarction.
Entity: 895432	39	52	isoproterenol	Chemical	D007545
Entity: 895432	61	82	myocardial infarction	Disease	D009203
Relation: 895432	CID	39	52	D007545	61	82	D009203	true

Sentence: The effect of exercise on the severity of isoproterenol induced myocardial infarction was studied in male rats.
Entity: 895432	42	55	isoproterenol	Chemical	D007545
Entity: 895432	64	85	myocardial infarction	Disease	D009203
Relation: 895432	CID	42	55	D007545	64	85	D009203	true

Sentence: Effect of D-Glucarates on basic antibiotic induced renal damage in rats.
Entity: 931801	10	22	D-Glucarates	Chemical	D005937
Entity: 931801	51	63	renal damage	Disease	D007674
Relation: 931801	CID	10	22	D005937	51	63	D007674	false

Sentence: Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.
Entity: 931801	0	10	Dehydrated	Disease	D003681
Entity: 931801	34	53	acute renal failure	Disease	D058186
Entity: 931801	84	98	aminoglycoside	Chemical	D000617
Relation: 931801	CID	84	98	D000617	0	10	D003681	false
Relation: 931801	CID	84	98	D000617	34	53	D058186	true

Sentence: Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.
Entity: 931801	23	66	2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone	Chemical	C038936
Entity: 931801	90	103	renal failure	Disease	D051437
Entity: 931801	115	124	kanamycin	Chemical	D007612
Relation: 931801	CID	23	66	C038936	90	103	D051437	false
Relation: 931801	CID	115	124	D007612	90	103	D051437	false

Sentence: D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis.
Entity: 931801	0	12	D-Glucarates	Chemical	D005937
Entity: 931801	36	48	renal damage	Disease	D007674
Entity: 931801	99	113	aminoglycoside	Chemical	D000617
Relation: 931801	CID	0	12	D005937	36	48	D007674	false
Relation: 931801	CID	99	113	D000617	36	48	D007674	false

Sentence: With a D-glucarate of a fixed size of dose, approximately the same degree of protection was obtained against renal damages induced by different basic antibiotics despite large disparities in administration doses of different antibiotics.
Entity: 931801	7	18	D-glucarate	Chemical	D005937
Entity: 931801	109	122	renal damages	Disease	D007674
Relation: 931801	CID	7	18	D005937	109	122	D007674	false

Sentence: D-Glucarates had the ability to prevent renal damage but not to cure it.
Entity: 931801	0	12	D-Glucarates	Chemical	D005937
Entity: 931801	40	52	renal damage	Disease	D007674
Relation: 931801	CID	0	12	D005937	40	52	D007674	false

Sentence: Rats excreted acidic urine when they were spared from renal lesions by monosaccharides.
Entity: 931801	54	67	renal lesions	Disease	D007674
Entity: 931801	71	86	monosaccharides	Chemical	D009005
Relation: 931801	CID	71	86	D009005	54	67	D007674	false

Sentence: Paraplegia following intrathecal methotrexate: report of a case and review of the literature.
Entity: 946593	0	10	Paraplegia	Disease	D010264
Entity: 946593	33	45	methotrexate	Chemical	D008727
Relation: 946593	CID	33	45	D008727	0	10	D010264	true

Sentence: A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed.
Entity: 946593	24	34	paraplegia	Disease	D010264
Entity: 946593	77	89	methotrexate	Chemical	D008727
Relation: 946593	CID	77	89	D008727	24	34	D010264	true

Sentence: The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.
Entity: 946593	143	174	central nervous system leukemia	Disease	D002493
Entity: 946593	241	253	methothexate	Chemical	D008727
Entity: 946593	345	357	methotrexate	Chemical	D008727
Entity: 946593	450	460	neurotoxic	Disease	D020258
Entity: 946593	501	513	methotrexate	Chemical	D008727
Entity: 946593	556	568	methotrexate	Chemical	D008727
Relation: 946593	CID	241	253	D008727	143	174	D002493	false
Relation: 946593	CID	241	253	D008727	450	460	D020258	false
Relation: 946593	CID	345	357	D008727	143	174	D002493	false
Relation: 946593	CID	345	357	D008727	450	460	D020258	false
Relation: 946593	CID	501	513	D008727	143	174	D002493	false
Relation: 946593	CID	501	513	D008727	450	460	D020258	false
Relation: 946593	CID	556	568	D008727	143	174	D002493	false
Relation: 946593	CID	556	568	D008727	450	460	D020258	false

Sentence: The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.
Entity: 946593	12	24	methotrexate	Chemical	D008727
Entity: 946593	45	62	folate deficiency	Disease	C536409
Entity: 946593	123	135	methotrexate	Chemical	D008727
Entity: 946593	136	144	toxicity	Disease	D064420
Relation: 946593	CID	12	24	D008727	45	62	C536409	false
Relation: 946593	CID	12	24	D008727	136	144	D064420	false
Relation: 946593	CID	123	135	D008727	45	62	C536409	false
Relation: 946593	CID	123	135	D008727	136	144	D064420	false

Sentence: The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.
Entity: 946593	17	30	neurotoxicity	Disease	D020258
Entity: 946593	74	86	methotrexate	Chemical	D008727
Entity: 946593	106	137	central nervous system leukemia	Disease	D002493
Relation: 946593	CID	74	86	D008727	17	30	D020258	false
Relation: 946593	CID	74	86	D008727	106	137	D002493	false

Sentence: This response was significantly reduced by the intravenous (i.v.) injection of guanethidine (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c. carbachol (1 mug).
Entity: 978847	79	91	guanethidine	Chemical	D006145
Entity: 978847	100	113	hexamethonium	Chemical	D018738
Entity: 978847	125	137	phentolamine	Chemical	D010646
Entity: 978847	182	201	desmethylimipramine	Chemical	D003891
Entity: 978847	218	229	propranolol	Chemical	D011433
Entity: 978847	270	299	enlargement of pulse pressure	Disease	D006973
Entity: 978847	308	319	tachycardia	Disease	D013610
Entity: 978847	335	344	carbachol	Chemical	D002217
Relation: 978847	CID	79	91	D006145	270	299	D006973	false
Relation: 978847	CID	79	91	D006145	308	319	D013610	false
Relation: 978847	CID	100	113	D018738	270	299	D006973	false
Relation: 978847	CID	100	113	D018738	308	319	D013610	false
Relation: 978847	CID	125	137	D010646	270	299	D006973	false
Relation: 978847	CID	125	137	D010646	308	319	D013610	false
Relation: 978847	CID	182	201	D003891	270	299	D006973	true
Relation: 978847	CID	182	201	D003891	308	319	D013610	false
Relation: 978847	CID	218	229	D011433	270	299	D006973	false
Relation: 978847	CID	218	229	D011433	308	319	D013610	false
Relation: 978847	CID	335	344	D002217	270	299	D006973	true
Relation: 978847	CID	335	344	D002217	308	319	D013610	true

Sentence: Hyperglycemic effect of amino compounds structurally related to caproate in rats.
Entity: 1117341	0	13	Hyperglycemic	Disease	D006943
Entity: 1117341	24	29	amino	Chemical	D015119
Entity: 1117341	64	72	caproate	Chemical	C037652
Relation: 1117341	CID	24	29	D015119	0	13	D006943	true
Relation: 1117341	CID	64	72	C037652	0	13	D006943	false

Sentence: The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.
Entity: 1117341	72	77	amino	Chemical	D015119
Entity: 1117341	93	101	caproate	Chemical	C037652
Entity: 1117341	114	127	hyperglycemia	Disease	D006943
Entity: 1117341	141	148	glucose	Chemical	D005947
Entity: 1117341	184	194	glucosuria	Disease	D006030
Relation: 1117341	CID	72	77	D015119	114	127	D006943	true
Relation: 1117341	CID	72	77	D015119	184	194	D006030	false
Relation: 1117341	CID	93	101	C037652	114	127	D006943	false
Relation: 1117341	CID	93	101	C037652	184	194	D006030	false
Relation: 1117341	CID	141	148	D005947	114	127	D006943	false
Relation: 1117341	CID	141	148	D005947	184	194	D006030	false

Sentence: Fatty liver induced by tetracycline in the rat.
Entity: 1158089	0	11	Fatty liver	Disease	D005234
Entity: 1158089	23	35	tetracycline	Chemical	D013752
Relation: 1158089	CID	23	35	D013752	0	11	D005234	true

Sentence: Dose-response relationships, biochemical mechanisms, and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro.
Entity: 1158089	93	104	fatty liver	Disease	D005234
Entity: 1158089	116	128	tetracycline	Chemical	D013752
Relation: 1158089	CID	116	128	D013752	93	104	D005234	true

Sentence: With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.
Entity: 1158089	27	37	oleic acid	Chemical	D019301
Entity: 1158089	137	149	tetracycline	Chemical	D013752
Entity: 1158089	175	187	triglyceride	Chemical	D014280
Entity: 1158089	205	215	depression	Disease	D003866
Entity: 1158089	229	241	triglyceride	Chemical	D014280
Relation: 1158089	CID	27	37	D019301	205	215	D003866	false
Relation: 1158089	CID	137	149	D013752	205	215	D003866	false
Relation: 1158089	CID	175	187	D014280	205	215	D003866	false
Relation: 1158089	CID	229	241	D014280	205	215	D003866	false

Sentence: However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.
Entity: 1158089	110	122	tetracycline	Chemical	D013752
Entity: 1158089	126	136	depression	Disease	D003866
Entity: 1158089	150	162	triglyceride	Chemical	D014280
Relation: 1158089	CID	110	122	D013752	126	136	D003866	false
Relation: 1158089	CID	150	162	D014280	126	136	D003866	false

Sentence: Fatal myeloencephalopathy due to intrathecal vincristine administration.
Entity: 1280054	6	25	myeloencephalopathy	Disease	D001927
Entity: 1280054	45	56	vincristine	Chemical	D014750
Relation: 1280054	CID	45	56	D014750	6	25	D001927	true

Sentence: Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.
Entity: 1280054	0	11	Vincristine	Chemical	D014750
Entity: 1280054	65	74	leukaemia	Disease	D007938
Entity: 1280054	86	115	sensory and motor dysfunction	Disease	D007049
Entity: 1280054	128	142	encephalopathy	Disease	D001927
Relation: 1280054	CID	0	11	D014750	65	74	D007938	false
Relation: 1280054	CID	0	11	D014750	86	115	D007049	true
Relation: 1280054	CID	0	11	D014750	128	142	D001927	true

Sentence: After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.
Entity: 1280707	22	33	bupivacaine	Chemical	D002045
Entity: 1280707	61	72	bupivacaine	Chemical	D002045
Entity: 1280707	141	151	arrhythmic	Disease	D001145
Entity: 1280707	189	201	progesterone	Chemical	D011374
Entity: 1280707	202	205	HCl	Chemical	D006851
Relation: 1280707	CID	22	33	D002045	141	151	D001145	true
Relation: 1280707	CID	61	72	D002045	141	151	D001145	true
Relation: 1280707	CID	189	201	D011374	141	151	D001145	true
Relation: 1280707	CID	202	205	D006851	141	151	D001145	false

Sentence: Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
Entity: 1289188	0	19	Acute renal failure	Disease	D058186
Entity: 1289188	49	64	desferrioxamine	Chemical	D003676
Relation: 1289188	CID	49	64	D003676	0	19	D058186	false

Sentence: A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.
Entity: 1289188	37	48	thalassemia	Disease	D013789
Entity: 1289188	81	96	desferrioxamine	Chemical	D003676
Entity: 1289188	98	101	DFX	Chemical	D003676
Relation: 1289188	CID	81	96	D003676	37	48	D013789	false
Relation: 1289188	CID	98	101	D003676	37	48	D013789	false

Sentence: Neuroleptic-associated hyperprolactinemia.
Entity: 1359137	0	11	Neuroleptic	Chemical	D014150
Entity: 1359137	23	41	hyperprolactinemia	Disease	D006966
Relation: 1359137	CID	0	11	D014150	23	41	D006966	true

Sentence: Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.
Entity: 1359137	40	58	hyperprolactinemia	Disease	D006966
Entity: 1359137	63	73	amenorrhea	Disease	D000568
Entity: 1359137	74	88	oligomenorrhea	Disease	D009839
Entity: 1359137	111	134	neuroleptic medications	Chemical	D014150
Entity: 1359137	153	166	bromocriptine	Chemical	D001971
Relation: 1359137	CID	111	134	D014150	40	58	D006966	true
Relation: 1359137	CID	111	134	D014150	63	73	D000568	true
Relation: 1359137	CID	111	134	D014150	74	88	D009839	true
Relation: 1359137	CID	153	166	D001971	40	58	D006966	false
Relation: 1359137	CID	153	166	D001971	63	73	D000568	false
Relation: 1359137	CID	153	166	D001971	74	88	D009839	false

Sentence: One woman, however, developed worsened psychiatric symptoms while taking bromocriptine, and it was discontinued.
Entity: 1359137	39	59	psychiatric symptoms	Disease	D011618
Entity: 1359137	73	86	bromocriptine	Chemical	D001971
Relation: 1359137	CID	73	86	D001971	39	59	D011618	true

Sentence: Ethacrynic acid induced convulsions and brain neurotransmitters in mice.
Entity: 1360900	0	15	Ethacrynic acid	Chemical	D004976
Entity: 1360900	24	35	convulsions	Disease	D012640
Relation: 1360900	CID	0	15	D004976	24	35	D012640	true

Sentence: Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.
Entity: 1360900	37	52	ethacrynic acid	Chemical	D004976
Entity: 1360900	58	68	convulsive	Disease	D012640
Entity: 1360900	134	153	5-hydroxytryptamine	Chemical	D012701
Entity: 1360900	155	159	5-HT	Chemical	D012701
Entity: 1360900	193	216	gamma-aminobutyric acid	Chemical	D005680
Entity: 1360900	221	234	acetylcholine	Chemical	D000109
Relation: 1360900	CID	37	52	D004976	58	68	D012640	true
Relation: 1360900	CID	134	153	D012701	58	68	D012640	false
Relation: 1360900	CID	155	159	D012701	58	68	D012640	false
Relation: 1360900	CID	193	216	D005680	58	68	D012640	false
Relation: 1360900	CID	221	234	D000109	58	68	D012640	false

Sentence: Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.
Entity: 1395192	10	31	myocardial infarction	Disease	D009203
Entity: 1395192	66	79	bromocriptine	Chemical	D001971
Relation: 1395192	CID	66	79	D001971	10	31	D009203	true

Sentence: Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium.
Entity: 1395192	0	13	Bromocriptine	Chemical	D001971
Entity: 1395192	70	91	myocardial infarction	Disease	D009203
Relation: 1395192	CID	0	13	D001971	70	91	D009203	true

Sentence: Asterixis induced by carbamazepine therapy.
Entity: 1420650	0	9	Asterixis	Disease	D020820
Entity: 1420650	21	34	carbamazepine	Chemical	D002220
Relation: 1420650	CID	21	34	D002220	0	9	D020820	false

Sentence: In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.
Entity: 1420650	108	117	asterixis	Disease	D020820
Entity: 1420650	149	162	carbamazepine	Chemical	D002220
Entity: 1420650	164	167	CBZ	Chemical	D002220
Relation: 1420650	CID	149	162	D002220	108	117	D020820	false
Relation: 1420650	CID	164	167	D002220	108	117	D020820	false

Sentence: Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
Entity: 1423336	24	35	hypotensive	Disease	D007022
Entity: 1423336	46	54	levodopa	Chemical	D007980
Entity: 1423336	58	70	parkinsonian	Disease	D010300
Relation: 1423336	CID	46	54	D007980	24	35	D007022	true
Relation: 1423336	CID	46	54	D007980	58	70	D010300	false

Sentence: Blood pressure effects of i.v. levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa.
Entity: 1423336	31	39	levodopa	Chemical	D007980
Entity: 1423336	57	69	parkinsonian	Disease	D010300
Entity: 1423336	120	128	levodopa	Chemical	D007980
Relation: 1423336	CID	31	39	D007980	57	69	D010300	false
Relation: 1423336	CID	120	128	D007980	57	69	D010300	false

Sentence: The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.
Entity: 1423336	21	32	hypotensive	Disease	D007022
Entity: 1423336	43	51	levodopa	Chemical	D007980
Relation: 1423336	CID	43	51	D007980	21	32	D007022	true

Sentence: Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.
Entity: 1423336	0	13	Phenylalanine	Chemical	D010649
Entity: 1423336	31	41	amino acid	Chemical	D000596
Entity: 1423336	64	72	levodopa	Chemical	D007980
Entity: 1423336	131	142	hypotensive	Disease	D007022
Entity: 1423336	175	183	levodopa	Chemical	D007980
Relation: 1423336	CID	0	13	D010649	131	142	D007022	false
Relation: 1423336	CID	31	41	D000596	131	142	D007022	false
Relation: 1423336	CID	64	72	D007980	131	142	D007022	true
Relation: 1423336	CID	175	183	D007980	131	142	D007022	true

Sentence: We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients.
Entity: 1423336	17	25	levodopa	Chemical	D007980
Entity: 1423336	40	51	hypotensive	Disease	D007022
Relation: 1423336	CID	17	25	D007980	40	51	D007022	true

Sentence: Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine.
Entity: 1424076	0	59	Syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
Entity: 1424076	77	88	vincristine	Chemical	D014750
Relation: 1424076	CID	77	88	D014750	0	59	D007177	true

Sentence: A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.
Entity: 1424076	36	52	multiple myeloma	Disease	D009101
Entity: 1424076	113	124	vincristine	Chemical	D014750
Entity: 1424076	129	140	doxorubicin	Chemical	D004317
Entity: 1424076	160	173	dexamethasone	Chemical	D003907
Relation: 1424076	CID	113	124	D014750	36	52	D009101	false
Relation: 1424076	CID	129	140	D004317	36	52	D009101	false
Relation: 1424076	CID	160	173	D003907	36	52	D009101	false

Sentence: Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion.
Entity: 1424076	24	83	syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
Entity: 1424076	113	124	vincristine	Chemical	D014750
Relation: 1424076	CID	113	124	D014750	24	83	D007177	true

Sentence: In patients with atrial fibrillation digoxin is beneficial for ventricular rate control.
Entity: 1449452	17	36	atrial fibrillation	Disease	D001281
Entity: 1449452	37	44	digoxin	Chemical	D004077
Relation: 1449452	CID	37	44	D004077	17	36	D001281	false

Sentence: Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias.
Entity: 1449452	6	13	digoxin	Chemical	D004077
Entity: 1449452	115	126	arrhythmias	Disease	D001145
Relation: 1449452	CID	6	13	D004077	115	126	D001145	true

Sentence: Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI).
Entity: 1449452	114	121	digoxin	Chemical	D004077
Entity: 1449452	151	172	myocardial infarction	Disease	D009203
Entity: 1449452	174	176	MI	Disease	D009203
Relation: 1449452	CID	114	121	D004077	151	172	D009203	false
Relation: 1449452	CID	114	121	D004077	174	176	D009203	false

Sentence: Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.
Entity: 1522360	14	23	hemolysis	Disease	D006461
Entity: 1522360	28	47	acute renal failure	Disease	D058186
Entity: 1522360	71	79	rifampin	Chemical	D012293
Relation: 1522360	CID	71	79	D012293	14	23	D006461	true
Relation: 1522360	CID	71	79	D012293	28	47	D058186	true

Sentence: Renal failure is a rare complication associated with the use of rifampin.
Entity: 1522360	0	13	Renal failure	Disease	D051437
Entity: 1522360	64	72	rifampin	Chemical	D012293
Relation: 1522360	CID	64	72	D012293	0	13	D051437	false

Sentence: Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.
Entity: 1522360	14	23	hemolysis	Disease	D006461
Entity: 1522360	35	54	acute renal failure	Disease	D058186
Entity: 1522360	65	73	rifampin	Chemical	D012293
Relation: 1522360	CID	65	73	D012293	14	23	D006461	true
Relation: 1522360	CID	65	73	D012293	35	54	D058186	true

Sentence: Zidovudine induced hepatitis.
Entity: 1556529	0	10	Zidovudine	Chemical	D015215
Entity: 1556529	19	28	hepatitis	Disease	D056486
Relation: 1556529	CID	0	10	D015215	19	28	D056486	true

Sentence: A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.
Entity: 1556529	16	25	hepatitis	Disease	D056486
Entity: 1556529	37	47	zidovudine	Chemical	D015215
Entity: 1556529	78	82	AIDS	Disease	D000163
Relation: 1556529	CID	37	47	D015215	16	25	D056486	true
Relation: 1556529	CID	37	47	D015215	78	82	D000163	false

Sentence: Thoracic hematomyelia secondary to coumadin anticoagulant therapy: a case report.
Entity: 1563460	0	21	Thoracic hematomyelia	Disease	D020758
Entity: 1563460	35	43	coumadin	Chemical	D014859
Relation: 1563460	CID	35	43	D014859	0	21	D020758	true

Sentence: Mania associated with fluoxetine treatment in adolescents.
Entity: 1564030	0	5	Mania	Disease	D001714
Entity: 1564030	22	32	fluoxetine	Chemical	D005473
Relation: 1564030	CID	22	32	D005473	0	5	D001714	true

Sentence: Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.
Entity: 1564030	0	10	Fluoxetine	Chemical	D005473
Entity: 1564030	24	33	serotonin	Chemical	D012701
Entity: 1564030	117	127	depression	Disease	D003866
Relation: 1564030	CID	0	10	D005473	117	127	D003866	false
Relation: 1564030	CID	24	33	D012701	117	127	D003866	false

Sentence: Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania.
Entity: 1564030	45	55	fluoxetine	Chemical	D005473
Entity: 1564030	84	89	mania	Disease	D001714
Relation: 1564030	CID	45	55	D005473	84	89	D001714	true

Sentence: The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.
Entity: 1564030	18	27	depressed	Disease	D003866
Entity: 1564030	75	80	mania	Disease	D001714
Entity: 1564030	109	119	fluoxetine	Chemical	D005473
Relation: 1564030	CID	109	119	D005473	18	27	D003866	false
Relation: 1564030	CID	109	119	D005473	75	80	D001714	true

Sentence: Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.
Entity: 1564030	45	50	mania	Disease	D001714
Entity: 1564030	54	63	hypomania	Disease	D001714
Entity: 1564030	71	81	fluoxetine	Chemical	D005473
Entity: 1564030	141	181	attention-deficit hyperactivity disorder	Disease	D001289
Entity: 1564030	215	225	depression	Disease	D003866
Entity: 1564030	231	240	psychotic	Disease	D011618
Entity: 1564030	271	289	affective disorder	Disease	D019964
Entity: 1564030	302	318	bipolar disorder	Disease	D001714
Entity: 1564030	339	355	bipolar disorder	Disease	D001714
Relation: 1564030	CID	71	81	D005473	45	50	D001714	true
Relation: 1564030	CID	71	81	D005473	54	63	D001714	true
Relation: 1564030	CID	71	81	D005473	141	181	D001289	false
Relation: 1564030	CID	71	81	D005473	215	225	D003866	false
Relation: 1564030	CID	71	81	D005473	231	240	D011618	false
Relation: 1564030	CID	71	81	D005473	271	289	D019964	false
Relation: 1564030	CID	71	81	D005473	302	318	D001714	true
Relation: 1564030	CID	71	81	D005473	339	355	D001714	true

Sentence: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
Entity: 1615846	0	11	Gemfibrozil	Chemical	D015248
Entity: 1615846	12	22	lovastatin	Chemical	D008148
Entity: 1615846	43	64	hyperlipoproteinemias	Disease	D006951
Relation: 1615846	CID	0	11	D015248	43	64	D006951	false
Relation: 1615846	CID	12	22	D008148	43	64	D006951	false

Sentence: The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).
Entity: 1615846	140	151	gemfibrozil	Chemical	D015248
Entity: 1615846	152	162	lovastatin	Chemical	D008148
Entity: 1615846	207	221	hyperlipidemia	Disease	D006949
Entity: 1615846	239	271	atherosclerotic vascular disease	Disease	D002340
Relation: 1615846	CID	140	151	D015248	207	221	D006949	false
Relation: 1615846	CID	140	151	D015248	239	271	D002340	false
Relation: 1615846	CID	152	162	D008148	207	221	D006949	false
Relation: 1615846	CID	152	162	D008148	239	271	D002340	false

Sentence: Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.
Entity: 1655018	0	24	Hepatocellular carcinoma	Disease	D006528
Entity: 1655018	28	44	Fanconi's anemia	Disease	D005199
Entity: 1655018	58	66	androgen	Chemical	D000728
Entity: 1655018	71	85	corticosteroid	Chemical	D000305
Relation: 1655018	CID	58	66	D000728	0	24	D006528	true
Relation: 1655018	CID	58	66	D000728	28	44	D005199	false
Relation: 1655018	CID	71	85	D000305	0	24	D006528	true
Relation: 1655018	CID	71	85	D000305	28	44	D005199	false

Sentence: The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, corticosteroids and transfusions.
Entity: 1655018	65	81	Fanconi's anemia	Disease	D005199
Entity: 1655018	115	124	androgens	Chemical	D000728
Entity: 1655018	126	141	corticosteroids	Chemical	D000305
Relation: 1655018	CID	115	124	D000728	65	81	D005199	false
Relation: 1655018	CID	126	141	D000305	65	81	D005199	false

Sentence: The trimethaphan induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion.
Entity: 1735570	4	16	trimethaphan	Chemical	D014294
Entity: 1735570	25	36	hypotension	Disease	D007022
Entity: 1735570	70	81	bradycardia	Disease	D001919
Entity: 1735570	135	146	tachycardia	Disease	D013610
Relation: 1735570	CID	4	16	D014294	25	36	D007022	true
Relation: 1735570	CID	4	16	D014294	70	81	D001919	false
Relation: 1735570	CID	4	16	D014294	135	146	D013610	true

Sentence: Damage of substantia nigra pars reticulata during pilocarpine induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.
Entity: 1756784	0	42	Damage of substantia nigra pars reticulata	Disease	D001930
Entity: 1756784	50	61	pilocarpine	Chemical	D010862
Entity: 1756784	70	88	status epilepticus	Disease	D013226
Relation: 1756784	CID	50	61	D010862	0	42	D001930	true
Relation: 1756784	CID	50	61	D010862	70	88	D013226	true

Sentence: In this study, status epilepticus was induced by systemic injection of pilocarpine in rats.
Entity: 1756784	15	33	status epilepticus	Disease	D013226
Entity: 1756784	71	82	pilocarpine	Chemical	D010862
Relation: 1756784	CID	71	82	D010862	15	33	D013226	true

Sentence: Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR.
Entity: 1756784	58	65	calcium	Chemical	D002118
Entity: 1756784	113	128	neuronal damage	Disease	D009422
Relation: 1756784	CID	58	65	D002118	113	128	D009422	false

Sentence: Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.
Entity: 1760851	8	22	cardiotoxicity	Disease	D066126
Entity: 1760851	26	37	doxorubicin	Chemical	D004317
Entity: 1760851	59	92	N-(2-hydroxypropyl)methacrylamide	Chemical	C032976
Relation: 1760851	CID	26	37	D004317	8	22	D066126	true
Relation: 1760851	CID	59	92	C032976	8	22	D066126	false

Sentence: A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.
Entity: 1760851	51	59	toxicity	Disease	D064420
Entity: 1760851	73	87	cardiotoxicity	Disease	D066126
Entity: 1760851	99	110	doxorubicin	Chemical	D004317
Entity: 1760851	112	115	DOX	Chemical	D004317
Entity: 1760851	167	200	N-(2-hydroxypropyl)methacrylamide	Chemical	C032976
Entity: 1760851	202	206	HPMA	Chemical	C032976
Relation: 1760851	CID	99	110	D004317	51	59	D064420	false
Relation: 1760851	CID	99	110	D004317	73	87	D066126	true
Relation: 1760851	CID	112	115	D004317	51	59	D064420	false
Relation: 1760851	CID	112	115	D004317	73	87	D066126	true
Relation: 1760851	CID	167	200	C032976	51	59	D064420	false
Relation: 1760851	CID	167	200	C032976	73	87	D066126	false
Relation: 1760851	CID	202	206	C032976	51	59	D064420	false
Relation: 1760851	CID	202	206	C032976	73	87	D066126	false

Sentence: Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX induced cardiotoxicity.
Entity: 1760851	51	65	cardiotoxicity	Disease	D066126
Entity: 1760851	122	125	DOX	Chemical	D004317
Entity: 1760851	144	148	HPMA	Chemical	C032976
Entity: 1760851	168	171	DOX	Chemical	D004317
Entity: 1760851	280	283	DOX	Chemical	D004317
Entity: 1760851	292	306	cardiotoxicity	Disease	D066126
Relation: 1760851	CID	122	125	D004317	51	65	D066126	true
Relation: 1760851	CID	122	125	D004317	292	306	D066126	true
Relation: 1760851	CID	144	148	C032976	51	65	D066126	false
Relation: 1760851	CID	144	148	C032976	292	306	D066126	false
Relation: 1760851	CID	168	171	D004317	51	65	D066126	true
Relation: 1760851	CID	168	171	D004317	292	306	D066126	true
Relation: 1760851	CID	280	283	D004317	51	65	D066126	true
Relation: 1760851	CID	280	283	D004317	292	306	D066126	true

Sentence: Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course.
Entity: 1779253	15	24	capsaicin	Chemical	D002211
Entity: 1779253	36	59	post-herpetic neuralgia	Disease	D051474
Relation: 1779253	CID	15	24	D002211	36	59	D051474	false

Sentence: In order to evaluate the efficacy, time-course of action and predictors of response to topical capsaicin, 39 patients with chronic post-herpetic neuralgia (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.
Entity: 1779253	95	104	capsaicin	Chemical	D002211
Entity: 1779253	131	154	post-herpetic neuralgia	Disease	D051474
Entity: 1779253	156	159	PHN	Disease	D051474
Entity: 1779253	214	223	capsaicin	Chemical	D002211
Relation: 1779253	CID	95	104	D002211	131	154	D051474	false
Relation: 1779253	CID	95	104	D002211	156	159	D051474	false
Relation: 1779253	CID	214	223	D002211	131	154	D051474	false
Relation: 1779253	CID	214	223	D002211	156	159	D051474	false

Sentence: Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable capsaicin induced burning sensations (4) or mastitis (1); 15 (38.5%) reported no benefit.
Entity: 1779253	144	153	capsaicin	Chemical	D002211
Entity: 1779253	188	196	mastitis	Disease	D008413
Relation: 1779253	CID	144	153	D002211	188	196	D008413	true

Sentence: Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia.
Entity: 1837756	0	9	Serotonin	Chemical	D012701
Entity: 1837756	31	39	paranoia	Disease	D010259
Relation: 1837756	CID	0	9	D012701	31	39	D010259	false

Sentence: Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.
Entity: 1837756	14	22	paranoid	Disease	D010259
Entity: 1837756	45	54	serotonin	Chemical	D012701
Entity: 1837756	75	85	fluoxetine	Chemical	D005473
Entity: 1837756	90	103	amitriptyline	Chemical	D000639
Relation: 1837756	CID	45	54	D012701	14	22	D010259	false
Relation: 1837756	CID	75	85	D005473	14	22	D010259	true
Relation: 1837756	CID	90	103	D000639	14	22	D010259	true

Sentence: Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.
Entity: 1837756	12	32	depressive disorders	Disease	D003866
Entity: 1837756	98	107	psychosis	Disease	D011605
Entity: 1837756	168	177	psychosis	Disease	D011605
Entity: 1837756	219	227	paranoid	Disease	D010259
Entity: 1837756	258	267	serotonin	Chemical	D012701
Relation: 1837756	CID	258	267	D012701	12	32	D003866	false
Relation: 1837756	CID	258	267	D012701	98	107	D011605	false
Relation: 1837756	CID	258	267	D012701	168	177	D011605	false
Relation: 1837756	CID	258	267	D012701	219	227	D010259	false

Sentence: Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated dopamine release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon.
Entity: 1837756	46	54	paranoia	Disease	D010259
Entity: 1837756	124	132	dopamine	Chemical	D004298
Relation: 1837756	CID	124	132	D004298	46	54	D010259	false

Sentence: Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.
Entity: 1858969	14	26	encephalitis	Disease	D004660
Entity: 1858969	47	54	loiasis	Disease	D008118
Entity: 1858969	60	78	diethylcarbamazine	Chemical	D004049
Relation: 1858969	CID	60	78	D004049	14	26	D004660	true
Relation: 1858969	CID	60	78	D004049	47	54	D008118	false

Sentence: Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.
Entity: 1858969	14	26	encephalitis	Disease	D004660
Entity: 1858969	52	70	diethylcarbamazine	Chemical	D004049
Entity: 1858969	72	75	DEC	Chemical	D004049
Entity: 1858969	126	136	filariasis	Disease	D005368
Relation: 1858969	CID	52	70	D004049	14	26	D004660	true
Relation: 1858969	CID	52	70	D004049	126	136	D005368	false
Relation: 1858969	CID	72	75	D004049	14	26	D004660	true
Relation: 1858969	CID	72	75	D004049	126	136	D005368	false

Sentence: Delirium in an elderly woman possibly associated with administration of misoprostol.
Entity: 1905439	0	8	Delirium	Disease	D003693
Entity: 1905439	72	83	misoprostol	Chemical	D016595
Relation: 1905439	CID	72	83	D016595	0	8	D003693	true

Sentence: Misoprostol has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and headache.
Entity: 1905439	0	11	Misoprostol	Chemical	D016595
Entity: 1905439	119	127	headache	Disease	D006261
Relation: 1905439	CID	0	11	D016595	119	127	D006261	false

Sentence: Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.
Entity: 1905439	4	12	delirium	Disease	D003693
Entity: 1905439	42	53	misoprostol	Chemical	D016595
Relation: 1905439	CID	42	53	D016595	4	12	D003693	true

Sentence: There was no change in hepatic tissue total glutathione following intestinal ischemia-reperfusion injury.
Entity: 1943082	44	55	glutathione	Chemical	D005978
Entity: 1943082	77	85	ischemia	Disease	D007511
Entity: 1943082	86	104	reperfusion injury	Disease	D015427
Relation: 1943082	CID	44	55	D005978	77	85	D007511	false
Relation: 1943082	CID	44	55	D005978	86	104	D015427	false

Sentence: Acute renal failure due to rifampicin.
Entity: 2083961	0	19	Acute renal failure	Disease	D058186
Entity: 2083961	27	37	rifampicin	Chemical	D012293
Relation: 2083961	CID	27	37	D012293	0	19	D058186	true

Sentence: Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.
Entity: 2131034	7	21	polyneuropathy	Disease	D011115
Entity: 2131034	55	63	thiotepa	Chemical	D013852
Relation: 2131034	CID	55	63	D013852	7	21	D011115	true

Sentence: Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.
Entity: 2131034	28	47	neurologic toxicity	Disease	D020258
Entity: 2131034	133	141	thiotepa	Chemical	D013852
Entity: 2131034	143	147	TSPA	Chemical	D013852
Relation: 2131034	CID	133	141	D013852	28	47	D020258	true
Relation: 2131034	CID	143	147	D013852	28	47	D020258	true

Sentence: Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.
Entity: 2131034	0	21	Neurologic toxicities	Disease	D020258
Entity: 2131034	50	62	methotrexate	Chemical	D008727
Entity: 2131034	67	87	cytosine arabinoside	Chemical	D003561
Entity: 2131034	95	99	TSPA	Chemical	D013852
Relation: 2131034	CID	50	62	D008727	0	21	D020258	true
Relation: 2131034	CID	67	87	D003561	0	21	D020258	true
Relation: 2131034	CID	95	99	D013852	0	21	D020258	true

Sentence: In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.
Entity: 2131034	26	30	TSPA	Chemical	D013852
Entity: 2131034	74	77	MTX	Chemical	D008727
Entity: 2131034	79	84	ara-C	Chemical	D003561
Entity: 2131034	121	134	neurotoxicity	Disease	D020258
Relation: 2131034	CID	26	30	D013852	121	134	D020258	true
Relation: 2131034	CID	74	77	D008727	121	134	D020258	true
Relation: 2131034	CID	79	84	D003561	121	134	D020258	true

Sentence: Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug induced tachycardia was abolished.
Entity: 2173761	53	64	hypotension	Disease	D007022
Entity: 2173761	76	86	cromakalim	Chemical	D019806
Entity: 2173761	91	100	pinacidil	Chemical	D020110
Entity: 2173761	137	141	beta	Chemical	D000319
Entity: 2173761	157	167	muscarinic	Chemical	D018727
Entity: 2173761	204	215	tachycardia	Disease	D013610
Relation: 2173761	CID	76	86	D019806	53	64	D007022	true
Relation: 2173761	CID	76	86	D019806	204	215	D013610	true
Relation: 2173761	CID	91	100	D020110	53	64	D007022	true
Relation: 2173761	CID	91	100	D020110	204	215	D013610	true
Relation: 2173761	CID	137	141	D000319	53	64	D007022	false
Relation: 2173761	CID	137	141	D000319	204	215	D013610	false
Relation: 2173761	CID	157	167	D018727	53	64	D007022	false
Relation: 2173761	CID	157	167	D018727	204	215	D013610	false

Sentence: Mefenamic acid induced neutropenia and renal failure in elderly females with hypothyroidism.
Entity: 2217015	0	14	Mefenamic acid	Chemical	D008528
Entity: 2217015	23	34	neutropenia	Disease	D009503
Entity: 2217015	39	52	renal failure	Disease	D051437
Entity: 2217015	77	91	hypothyroidism	Disease	D007037
Relation: 2217015	CID	0	14	D008528	23	34	D009503	true
Relation: 2217015	CID	0	14	D008528	39	52	D051437	true
Relation: 2217015	CID	0	14	D008528	77	91	D007037	false

Sentence: We report mefenamic acid induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.
Entity: 2217015	10	24	mefenamic acid	Chemical	D008528
Entity: 2217015	46	59	renal failure	Disease	D051437
Entity: 2217015	71	82	neutropenia	Disease	D009503
Relation: 2217015	CID	10	24	D008528	46	59	D051437	true
Relation: 2217015	CID	10	24	D008528	71	82	D009503	true

Sentence: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.
Entity: 2239937	12	25	hypercalcemia	Disease	D006934
Entity: 2239937	54	71	calcium carbonate	Chemical	D002119
Relation: 2239937	CID	54	71	D002119	12	25	D006934	true

Sentence: Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder.
Entity: 2239937	46	59	hypercalcemic	Disease	D006934
Entity: 2239937	79	96	calcium carbonate	Chemical	D002119
Entity: 2239937	116	125	phosphate	Chemical	D010710
Relation: 2239937	CID	79	96	D002119	46	59	D006934	true
Relation: 2239937	CID	116	125	D010710	46	59	D006934	false

Sentence: In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.
Entity: 2239937	69	82	hypercalcemia	Disease	D006934
Entity: 2239937	118	125	calcium	Chemical	D002118
Entity: 2239937	302	315	renal disease	Disease	D007674
Relation: 2239937	CID	118	125	D002118	69	82	D006934	false
Relation: 2239937	CID	118	125	D002118	302	315	D007674	false

Sentence: In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006).
Entity: 2239937	28	41	hypercalcemic	Disease	D006934
Entity: 2239937	61	68	calcium	Chemical	D002118
Entity: 2239937	135	148	hypercalcemic	Disease	D006934
Entity: 2239937	200	207	calcium	Chemical	D002118
Relation: 2239937	CID	61	68	D002118	28	41	D006934	false
Relation: 2239937	CID	61	68	D002118	135	148	D006934	false
Relation: 2239937	CID	200	207	D002118	28	41	D006934	false
Relation: 2239937	CID	200	207	D002118	135	148	D006934	false

Sentence: Methyldopa induced hemolytic anemia in a 15 year old presenting as near-syncope.
Entity: 2320485	0	10	Methyldopa	Chemical	D008750
Entity: 2320485	19	35	hemolytic anemia	Disease	D000743
Entity: 2320485	72	79	syncope	Disease	D013575
Relation: 2320485	CID	0	10	D008750	19	35	D000743	true
Relation: 2320485	CID	0	10	D008750	72	79	D013575	false

Sentence: Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug.
Entity: 2320485	0	10	Methyldopa	Chemical	D008750
Entity: 2320485	21	48	autoimmune hemolytic anemia	Disease	D000744
Relation: 2320485	CID	0	10	D008750	21	48	D000744	false

Sentence: We report a case of methyldopa induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.
Entity: 2320485	20	30	methyldopa	Chemical	D008750
Entity: 2320485	39	55	hemolytic anemia	Disease	D000743
Entity: 2320485	98	118	emergency department	Disease	D004630
Entity: 2320485	129	136	syncope	Disease	D013575
Relation: 2320485	CID	20	30	D008750	39	55	D000743	true
Relation: 2320485	CID	20	30	D008750	98	118	D004630	false
Relation: 2320485	CID	20	30	D008750	129	136	D013575	false

Sentence: The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation.
Entity: 2320485	42	52	methyldopa	Chemical	D008750
Entity: 2320485	62	68	trauma	Disease	D014947
Relation: 2320485	CID	42	52	D008750	62	68	D014947	false

Sentence: The long-term safety of danazol in women with hereditary angioedema.
Entity: 2358093	24	31	danazol	Chemical	D003613
Entity: 2358093	46	67	hereditary angioedema	Disease	D054179
Relation: 2358093	CID	24	31	D003613	46	67	D054179	false

Sentence: We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer.
Entity: 2358093	50	57	danazol	Chemical	D003613
Entity: 2358093	128	149	hereditary angioedema	Disease	D054179
Entity: 2358093	163	170	danazol	Chemical	D003613
Relation: 2358093	CID	50	57	D003613	128	149	D054179	false
Relation: 2358093	CID	163	170	D003613	128	149	D054179	false

Sentence: Patient tolerance study of topical chlorhexidine diphosphanilate: a new topical agent for burns.
Entity: 2383364	35	64	chlorhexidine diphosphanilate	Chemical	C048279
Entity: 2383364	90	95	burns	Disease	D002056
Relation: 2383364	CID	35	64	C048279	90	95	D002056	false

Sentence: Chlorhexidine phosphanilate (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application.
Entity: 2383364	0	27	Chlorhexidine phosphanilate	Chemical	C048279
Entity: 2383364	29	32	CHP	Chemical	C048279
Entity: 2383364	109	113	burn	Disease	D002056
Relation: 2383364	CID	0	27	C048279	109	113	D002056	false
Relation: 2383364	CID	29	32	C048279	109	113	D002056	false

Sentence: One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds.
Entity: 2383364	4	8	burn	Disease	D002056
Entity: 2383364	54	57	CHP	Chemical	C048279
Entity: 2383364	138	158	silver sulphadiazine	Chemical	D012837
Entity: 2383364	160	164	AgSD	Chemical	D012837
Entity: 2383364	237	241	burn	Disease	D002056
Relation: 2383364	CID	54	57	C048279	4	8	D002056	false
Relation: 2383364	CID	54	57	C048279	237	241	D002056	false
Relation: 2383364	CID	138	158	D012837	4	8	D002056	false
Relation: 2383364	CID	138	158	D012837	237	241	D002056	false
Relation: 2383364	CID	160	164	D012837	4	8	D002056	false
Relation: 2383364	CID	160	164	D012837	237	241	D002056	false

Sentence: There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale.
Entity: 2383364	40	43	CHP	Chemical	C048279
Entity: 2383364	83	87	pain	Disease	D010146
Relation: 2383364	CID	40	43	C048279	83	87	D010146	true

Sentence: The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.
Entity: 2383364	18	21	CHP	Chemical	C048279
Entity: 2383364	43	47	AgSD	Chemical	D012837
Entity: 2383364	51	55	pain	Disease	D010146
Entity: 2383364	127	131	AgSD	Chemical	D012837
Relation: 2383364	CID	18	21	C048279	51	55	D010146	true
Relation: 2383364	CID	43	47	D012837	51	55	D010146	false
Relation: 2383364	CID	127	131	D012837	51	55	D010146	false

Sentence: Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
Entity: 2400986	15	28	neurotoxicity	Disease	D020258
Entity: 2400986	42	50	busulfan	Chemical	D002066
Relation: 2400986	CID	42	50	D002066	15	28	D020258	false

Sentence: Busulfan is known to be neurotoxic in animals and humans, but its acute neurotoxicity remains poorly characterized in children.
Entity: 2400986	0	8	Busulfan	Chemical	D002066
Entity: 2400986	24	34	neurotoxic	Disease	D020258
Entity: 2400986	72	85	neurotoxicity	Disease	D020258
Relation: 2400986	CID	0	8	D002066	24	34	D020258	false
Relation: 2400986	CID	0	8	D002066	72	85	D020258	false

Sentence: We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.
Entity: 2400986	97	105	busulfan	Chemical	D002066
Entity: 2400986	186	192	tumors	Disease	D009369
Entity: 2400986	194	206	brain tumors	Disease	D001932
Relation: 2400986	CID	97	105	D002066	186	192	D009369	false
Relation: 2400986	CID	97	105	D002066	194	206	D001932	false

Sentence: Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing.
Entity: 2400986	82	90	seizures	Disease	D012640
Entity: 2400986	116	124	busulfan	Chemical	D002066
Relation: 2400986	CID	116	124	D002066	82	90	D012640	true

Sentence: When the total busulfan dose was taken into account, there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02).
Entity: 2400986	15	23	busulfan	Chemical	D002066
Entity: 2400986	100	113	neurotoxicity	Disease	D020258
Relation: 2400986	CID	15	23	D002066	100	113	D020258	false

Sentence: Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of clonazepam; none had any neurological symptoms.
Entity: 2400986	45	53	busulfan	Chemical	D002066
Entity: 2400986	98	108	clonazepam	Chemical	D002998
Entity: 2400986	123	144	neurological symptoms	Disease	D009461
Relation: 2400986	CID	45	53	D002066	123	144	D009461	false
Relation: 2400986	CID	98	108	D002998	123	144	D009461	false

Sentence: Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.
Entity: 2400986	0	8	Busulfan	Chemical	D002066
Entity: 2400986	139	169	central nervous system disease	Disease	D002493
Entity: 2400986	186	194	busulfan	Chemical	D002066
Entity: 2400986	200	210	clonazepam	Chemical	D002998
Entity: 2400986	211	219	busulfan	Chemical	D002066
Relation: 2400986	CID	0	8	D002066	139	169	D002493	false
Relation: 2400986	CID	186	194	D002066	139	169	D002493	false
Relation: 2400986	CID	200	210	D002998	139	169	D002493	false
Relation: 2400986	CID	211	219	D002066	139	169	D002493	false

Sentence: This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.
Entity: 2400986	22	30	busulfan	Chemical	D002066
Entity: 2400986	31	44	neurotoxicity	Disease	D020258
Entity: 2400986	104	114	clonazepam	Chemical	D002998
Relation: 2400986	CID	22	30	D002066	31	44	D020258	false
Relation: 2400986	CID	104	114	D002998	31	44	D020258	false

Sentence: A busulfan dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased neurotoxicity, close to neurotoxicity incidence observed in adults.
Entity: 2400986	2	10	busulfan	Chemical	D002066
Entity: 2400986	133	146	neurotoxicity	Disease	D020258
Entity: 2400986	157	170	neurotoxicity	Disease	D020258
Relation: 2400986	CID	2	10	D002066	133	146	D020258	false
Relation: 2400986	CID	2	10	D002066	157	170	D020258	false

Sentence: Histamine antagonists and d-tubocurarine induced hypotension in cardiac surgical patients.
Entity: 2429800	0	9	Histamine	Chemical	D006632
Entity: 2429800	26	40	d-tubocurarine	Chemical	D014403
Entity: 2429800	49	60	hypotension	Disease	D007022
Relation: 2429800	CID	0	9	D006632	49	60	D007022	false
Relation: 2429800	CID	26	40	D014403	49	60	D007022	true

Sentence: Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.
Entity: 2453942	0	7	Lindane	Chemical	D001556
Entity: 2453942	9	36	gamma-hexachlorocyclohexane	Chemical	D001556
Entity: 2453942	82	92	neurotoxic	Disease	D020258
Relation: 2453942	CID	0	7	D001556	82	92	D020258	false
Relation: 2453942	CID	9	36	D001556	82	92	D020258	false

Sentence: We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.
Entity: 2453942	25	32	lindane	Chemical	D001556
Entity: 2453942	121	125	GABA	Chemical	D005680
Entity: 2453942	127	135	dopamine	Chemical	D004298
Entity: 2453942	189	197	seizures	Disease	D012640
Relation: 2453942	CID	25	32	D001556	189	197	D012640	true
Relation: 2453942	CID	121	125	D005680	189	197	D012640	false
Relation: 2453942	CID	127	135	D004298	189	197	D012640	false

Sentence: All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration.
Entity: 2453942	27	38	convulsions	Disease	D012640
Entity: 2453942	65	72	lindane	Chemical	D001556
Relation: 2453942	CID	65	72	D001556	27	38	D012640	true

Sentence: Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.
Entity: 2484903	13	29	propylthiouracil	Chemical	D011441
Entity: 2484903	47	56	hepatitis	Disease	D056486
Entity: 2484903	76	87	methimazole	Chemical	D008713
Entity: 2484903	99	122	hepatocellular necrosis	Disease	D047508
Entity: 2484903	139	155	propylthiouracil	Chemical	D011441
Entity: 2484903	167	186	lupus-like syndrome	Disease	D008180
Relation: 2484903	CID	13	29	D011441	47	56	D056486	true
Relation: 2484903	CID	13	29	D011441	99	122	D047508	false
Relation: 2484903	CID	13	29	D011441	167	186	D008180	true
Relation: 2484903	CID	76	87	D008713	47	56	D056486	false
Relation: 2484903	CID	76	87	D008713	99	122	D047508	true
Relation: 2484903	CID	76	87	D008713	167	186	D008180	false
Relation: 2484903	CID	139	155	D011441	47	56	D056486	true
Relation: 2484903	CID	139	155	D011441	99	122	D047508	false
Relation: 2484903	CID	139	155	D011441	167	186	D008180	true

Sentence: Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.
Entity: 2553470	26	32	MK-801	Chemical	D016291
Entity: 2553470	40	47	lithium	Chemical	D008094
Entity: 2553470	48	59	pilocarpine	Chemical	D010862
Entity: 2553470	69	87	status epilepticus	Disease	D013226
Relation: 2553470	CID	26	32	D016291	69	87	D013226	false
Relation: 2553470	CID	40	47	D008094	69	87	D013226	true
Relation: 2553470	CID	48	59	D010862	69	87	D013226	true

Sentence: MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.
Entity: 2553470	0	6	MK-801	Chemical	D016291
Entity: 2553470	25	45	N-methyl-D-aspartate	Chemical	D016202
Entity: 2553470	47	51	NMDA	Chemical	D016202
Entity: 2553470	130	137	seizure	Disease	D012640
Entity: 2553470	166	173	lithium	Chemical	D008094
Entity: 2553470	178	189	pilocarpine	Chemical	D010862
Entity: 2553470	227	238	pilocarpine	Chemical	D010862
Relation: 2553470	CID	0	6	D016291	130	137	D012640	false
Relation: 2553470	CID	25	45	D016202	130	137	D012640	false
Relation: 2553470	CID	47	51	D016202	130	137	D012640	false
Relation: 2553470	CID	166	173	D008094	130	137	D012640	false
Relation: 2553470	CID	178	189	D010862	130	137	D012640	false
Relation: 2553470	CID	227	238	D010862	130	137	D012640	false

Sentence: First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.
Entity: 2553470	25	31	MK-801	Chemical	D016291
Entity: 2553470	104	111	lithium	Chemical	D008094
Entity: 2553470	112	123	pilocarpine	Chemical	D010862
Entity: 2553470	161	172	pilocarpine	Chemical	D010862
Entity: 2553470	237	245	seizures	Disease	D012640
Relation: 2553470	CID	25	31	D016291	237	245	D012640	false
Relation: 2553470	CID	104	111	D008094	237	245	D012640	false
Relation: 2553470	CID	112	123	D010862	237	245	D012640	false
Relation: 2553470	CID	161	172	D010862	237	245	D012640	false

Sentence: Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.
Entity: 2553470	37	43	MK-801	Chemical	D016291
Entity: 2553470	51	58	lithium	Chemical	D008094
Entity: 2553470	59	70	pilocarpine	Chemical	D010862
Entity: 2553470	116	123	seizure	Disease	D012640
Relation: 2553470	CID	37	43	D016291	116	123	D012640	false
Relation: 2553470	CID	51	58	D008094	116	123	D012640	false
Relation: 2553470	CID	59	70	D010862	116	123	D012640	false

Sentence: Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.
Entity: 2553470	47	55	seizures	Disease	D012640
Entity: 2553470	67	74	lithium	Chemical	D008094
Entity: 2553470	79	90	pilocarpine	Chemical	D010862
Entity: 2553470	137	148	pilocarpine	Chemical	D010862
Entity: 2553470	192	210	status epilepticus	Disease	D013226
Entity: 2553470	242	250	seizures	Disease	D012640
Relation: 2553470	CID	67	74	D008094	47	55	D012640	false
Relation: 2553470	CID	67	74	D008094	192	210	D013226	true
Relation: 2553470	CID	67	74	D008094	242	250	D012640	false
Relation: 2553470	CID	79	90	D010862	47	55	D012640	false
Relation: 2553470	CID	79	90	D010862	192	210	D013226	true
Relation: 2553470	CID	79	90	D010862	242	250	D012640	false
Relation: 2553470	CID	137	148	D010862	47	55	D012640	false
Relation: 2553470	CID	137	148	D010862	192	210	D013226	true
Relation: 2553470	CID	137	148	D010862	242	250	D012640	false

Sentence: Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.
Entity: 2553470	18	24	MK-801	Chemical	D016291
Entity: 2553470	44	55	pilocarpine	Chemical	D010862
Entity: 2553470	70	88	status epilepticus	Disease	D013226
Entity: 2553470	134	141	seizure	Disease	D012640
Relation: 2553470	CID	18	24	D016291	70	88	D013226	false
Relation: 2553470	CID	18	24	D016291	134	141	D012640	false
Relation: 2553470	CID	44	55	D010862	70	88	D013226	true
Relation: 2553470	CID	44	55	D010862	134	141	D012640	false

Sentence: These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.
Entity: 2553470	41	45	NMDA	Chemical	D016202
Entity: 2553470	83	101	status epilepticus	Disease	D013226
Entity: 2553470	106	118	brain damage	Disease	D001930
Entity: 2553470	126	133	lithium	Chemical	D008094
Entity: 2553470	134	145	pilocarpine	Chemical	D010862
Relation: 2553470	CID	41	45	D016202	83	101	D013226	false
Relation: 2553470	CID	41	45	D016202	106	118	D001930	false
Relation: 2553470	CID	126	133	D008094	83	101	D013226	true
Relation: 2553470	CID	126	133	D008094	106	118	D001930	false
Relation: 2553470	CID	134	145	D010862	83	101	D013226	true
Relation: 2553470	CID	134	145	D010862	106	118	D001930	false

Sentence: Nifedipine induced bradycardia in a patient with autonomic neuropathy.
Entity: 2614930	0	10	Nifedipine	Chemical	D009543
Entity: 2614930	19	30	bradycardia	Disease	D001919
Entity: 2614930	49	69	autonomic neuropathy	Disease	D009422
Relation: 2614930	CID	0	10	D009543	19	30	D001919	true
Relation: 2614930	CID	0	10	D009543	49	69	D009422	false

Sentence: He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when nifedipine (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min.
Entity: 2614930	21	35	atrial flutter	Disease	D001282
Entity: 2614930	104	114	nifedipine	Chemical	D009543
Relation: 2614930	CID	104	114	D009543	21	35	D001282	false

Sentence: This is inconsistent with the well-established finding that nifedipine induces tachycardia in normally innervated hearts.
Entity: 2614930	60	70	nifedipine	Chemical	D009543
Entity: 2614930	79	90	tachycardia	Disease	D013610
Relation: 2614930	CID	60	70	D009543	79	90	D013610	true

Sentence: Haloperidol failed to prevent amphetamine induced seizures, but did lower the mortality rate at most doses tested.
Entity: 2625524	0	11	Haloperidol	Chemical	D006220
Entity: 2625524	30	41	amphetamine	Chemical	D000661
Entity: 2625524	50	58	seizures	Disease	D012640
Relation: 2625524	CID	0	11	D006220	50	58	D012640	false
Relation: 2625524	CID	30	41	D000661	50	58	D012640	true

Sentence: Haloperidol decreased the incidence of cocaine induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.
Entity: 2625524	0	11	Haloperidol	Chemical	D006220
Entity: 2625524	39	46	cocaine	Chemical	D003042
Entity: 2625524	55	63	seizures	Disease	D012640
Relation: 2625524	CID	0	11	D006220	55	63	D012640	false
Relation: 2625524	CID	39	46	D003042	55	63	D012640	true

Sentence: These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.
Entity: 2625524	53	61	dopamine	Chemical	D004298
Entity: 2625524	70	81	haloperidol	Chemical	D006220
Entity: 2625524	111	122	amphetamine	Chemical	D000661
Entity: 2625524	166	174	seizures	Disease	D012640
Relation: 2625524	CID	53	61	D004298	166	174	D012640	false
Relation: 2625524	CID	70	81	D006220	166	174	D012640	false
Relation: 2625524	CID	111	122	D000661	166	174	D012640	true

Sentence: Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.
Entity: 2650911	29	37	estrogen	Chemical	D004967
Entity: 2650911	65	84	diethylstilbesterol	Chemical	D004054
Entity: 2650911	101	117	renal carcinomas	Disease	D002292
Relation: 2650911	CID	29	37	D004967	101	117	D002292	false
Relation: 2650911	CID	65	84	D004054	101	117	D002292	true

Sentence: Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters.
Entity: 2650911	0	8	Estrogen	Chemical	D004967
Entity: 2650911	99	118	diethylstilbesterol	Chemical	D004054
Entity: 2650911	127	143	renal carcinomas	Disease	D002292
Relation: 2650911	CID	0	8	D004967	127	143	D002292	false
Relation: 2650911	CID	99	118	D004054	127	143	D002292	true

Sentence: Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.
Entity: 2650911	62	71	estradiol	Chemical	D004958
Entity: 2650911	111	116	tumor	Disease	D009369
Entity: 2650911	206	212	silver	Chemical	D012834
Relation: 2650911	CID	62	71	D004958	111	116	D009369	false
Relation: 2650911	CID	206	212	D012834	111	116	D009369	false

Sentence: Bradycardia due to biperiden.
Entity: 2710809	0	11	Bradycardia	Disease	D001919
Entity: 2710809	19	28	biperiden	Chemical	D001712
Relation: 2710809	CID	19	28	D001712	0	11	D001919	true

Sentence: In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.
Entity: 2710809	54	66	postzosteric	Disease	D006562
Entity: 2710809	67	87	trigeminal neuralgia	Disease	D014277
Entity: 2710809	122	139	biperiden lactate	Chemical	C036432
Entity: 2710809	213	224	bradycardia	Disease	D001919
Entity: 2710809	226	236	dysarthria	Disease	D004401
Entity: 2710809	242	251	dysphagia	Disease	D003680
Relation: 2710809	CID	122	139	C036432	54	66	D006562	false
Relation: 2710809	CID	122	139	C036432	67	87	D014277	false
Relation: 2710809	CID	122	139	C036432	213	224	D001919	false
Relation: 2710809	CID	122	139	C036432	226	236	D004401	false
Relation: 2710809	CID	122	139	C036432	242	251	D003680	false

Sentence: Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.
Entity: 2718706	11	22	hypotension	Disease	D007022
Entity: 2718706	34	43	labetalol	Chemical	D007741
Entity: 2718706	49	58	halothane	Chemical	D006221
Entity: 2718706	60	69	enflurane	Chemical	D004737
Entity: 2718706	73	83	isoflurane	Chemical	D007530
Relation: 2718706	CID	34	43	D007741	11	22	D007022	true
Relation: 2718706	CID	49	58	D006221	11	22	D007022	true
Relation: 2718706	CID	60	69	D004737	11	22	D007022	true
Relation: 2718706	CID	73	83	D007530	11	22	D007022	true

Sentence: The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.
Entity: 2718706	25	34	labetalol	Chemical	D007741
Entity: 2718706	87	98	hypotensive	Disease	D007022
Entity: 2718706	150	159	halothane	Chemical	D006221
Entity: 2718706	161	170	enflurane	Chemical	D004737
Entity: 2718706	174	184	isoflurane	Chemical	D007530
Relation: 2718706	CID	25	34	D007741	87	98	D007022	true
Relation: 2718706	CID	150	159	D006221	87	98	D007022	true
Relation: 2718706	CID	161	170	D004737	87	98	D007022	true
Relation: 2718706	CID	174	184	D007530	87	98	D007022	true

Sentence: The mean H concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%.
Entity: 2718706	9	10	H	Chemical	D006221
Entity: 2718706	32	43	hypotension	Disease	D007022
Entity: 2718706	98	99	E	Chemical	D004737
Entity: 2718706	145	146	I	Chemical	D007530
Relation: 2718706	CID	9	10	D006221	32	43	D007022	true
Relation: 2718706	CID	98	99	D004737	32	43	D007022	true
Relation: 2718706	CID	145	146	D007530	32	43	D007022	true

Sentence: During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.
Entity: 2718706	7	18	hypotension	Disease	D007022
Entity: 2718706	30	40	creatinine	Chemical	D003404
Entity: 2718706	111	122	hypotension	Disease	D007022
Entity: 2718706	205	215	isoflurane	Chemical	D007530
Relation: 2718706	CID	30	40	D003404	7	18	D007022	false
Relation: 2718706	CID	30	40	D003404	111	122	D007022	false
Relation: 2718706	CID	205	215	D007530	7	18	D007022	true
Relation: 2718706	CID	205	215	D007530	111	122	D007022	true

Sentence: Convulsion following intravenous fluorescein angiography.
Entity: 2765447	0	10	Convulsion	Disease	D012640
Entity: 2765447	33	44	fluorescein	Chemical	D019793
Relation: 2765447	CID	33	44	D019793	0	10	D012640	false

Sentence: Tonic-clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.
Entity: 2765447	0	21	Tonic-clonic seizures	Disease	D004830
Entity: 2765447	43	54	fluorescein	Chemical	D019793
Relation: 2765447	CID	43	54	D019793	0	21	D004830	true

Sentence: ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against seizures induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration.
Entity: 2767010	0	8	ACC-9653	Chemical	C043114
Entity: 2767010	13	29	phenytoin sodium	Chemical	C043114
Entity: 2767010	78	86	seizures	Disease	D012640
Relation: 2767010	CID	0	8	C043114	78	86	D012640	false
Relation: 2767010	CID	13	29	C043114	78	86	D012640	false

Sentence: ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain induced ventricular tachycardia in anesthetized dogs.
Entity: 2767010	0	8	ACC-9653	Chemical	C043114
Entity: 2767010	13	29	phenytoin sodium	Chemical	C043114
Entity: 2767010	75	82	ouabain	Chemical	D010042
Entity: 2767010	91	114	ventricular tachycardia	Disease	D017180
Relation: 2767010	CID	0	8	C043114	91	114	D017180	false
Relation: 2767010	CID	13	29	C043114	91	114	D017180	false
Relation: 2767010	CID	75	82	D010042	91	114	D017180	true

Sentence: The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively.
Entity: 2767010	19	27	ACC-9653	Chemical	C043114
Entity: 2767010	31	47	phenytoin sodium	Chemical	C043114
Entity: 2767010	73	83	arrhythmia	Disease	D001145
Relation: 2767010	CID	19	27	C043114	73	83	D001145	false
Relation: 2767010	CID	31	47	C043114	73	83	D001145	false

Sentence: Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin induced arrhythmias in guinea pig right atria.
Entity: 2767010	5	21	phenytoin sodium	Chemical	C043114
Entity: 2767010	73	87	strophanthidin	Chemical	D013327
Entity: 2767010	96	107	arrhythmias	Disease	D001145
Relation: 2767010	CID	5	21	C043114	96	107	D001145	false
Relation: 2767010	CID	73	87	D013327	96	107	D001145	true

Sentence: Acute toxicity studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v., i.m., and i.p. routes of administration.
Entity: 2767010	6	14	toxicity	Disease	D064420
Entity: 2767010	26	34	ACC-9653	Chemical	C043114
Entity: 2767010	39	55	phenytoin sodium	Chemical	C043114
Relation: 2767010	CID	26	34	C043114	6	14	D064420	false
Relation: 2767010	CID	39	55	C043114	6	14	D064420	false

Sentence: Phenytoin induced fatal hepatic injury.
Entity: 2818777	0	9	Phenytoin	Chemical	D010672
Entity: 2818777	24	38	hepatic injury	Disease	D056486
Relation: 2818777	CID	0	9	D010672	24	38	D056486	false

Sentence: A 61 year old female developed fatal hepatic failure after phenytoin administration.
Entity: 2818777	37	52	hepatic failure	Disease	D017093
Entity: 2818777	59	68	phenytoin	Chemical	D010672
Relation: 2818777	CID	59	68	D010672	37	52	D017093	true

Sentence: Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.
Entity: 2904523	12	22	adrenaline	Chemical	D004837
Entity: 2904523	23	35	hypertension	Disease	D006973
Entity: 2904523	85	95	adrenaline	Chemical	D004837
Relation: 2904523	CID	12	22	D004837	23	35	D006973	true
Relation: 2904523	CID	85	95	D004837	23	35	D006973	true

Sentence: Effect of alkylxanthines on gentamicin induced acute renal failure in the rat.
Entity: 2907577	10	24	alkylxanthines	Chemical	-1
Entity: 2907577	28	38	gentamicin	Chemical	D005839
Entity: 2907577	47	66	acute renal failure	Disease	D058186
Relation: 2907577	CID	10	24	-1	47	66	D058186	false
Relation: 2907577	CID	28	38	D005839	47	66	D058186	true

Sentence: Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).
Entity: 2907577	0	9	Adenosine	Chemical	D000241
Entity: 2907577	74	83	ischaemic	Disease	D007511
Entity: 2907577	88	99	nephrotoxic	Disease	D007674
Entity: 2907577	110	129	acute renal failure	Disease	D058186
Entity: 2907577	131	134	ARF	Disease	D058186
Relation: 2907577	CID	0	9	D000241	74	83	D007511	false
Relation: 2907577	CID	0	9	D000241	88	99	D007674	false
Relation: 2907577	CID	0	9	D000241	110	129	D058186	false
Relation: 2907577	CID	0	9	D000241	131	134	D058186	false

Sentence: In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).
Entity: 2907577	43	57	alkylxanthines	Chemical	-1
Entity: 2907577	86	95	adenosine	Chemical	D000241
Entity: 2907577	108	128	8-phenyltheophylline	Chemical	C028322
Entity: 2907577	130	142	theophylline	Chemical	D013806
Entity: 2907577	147	159	enprofylline	Chemical	C034347
Entity: 2907577	194	213	acute renal failure	Disease	D058186
Entity: 2907577	242	252	gentamicin	Chemical	D005839
Relation: 2907577	CID	43	57	-1	194	213	D058186	false
Relation: 2907577	CID	86	95	D000241	194	213	D058186	false
Relation: 2907577	CID	108	128	C028322	194	213	D058186	false
Relation: 2907577	CID	130	142	D013806	194	213	D058186	false
Relation: 2907577	CID	147	159	C034347	194	213	D058186	false
Relation: 2907577	CID	242	252	D005839	194	213	D058186	true

Sentence: Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.
Entity: 2907577	51	55	urea	Chemical	D014508
Entity: 2907577	60	70	creatinine	Chemical	D003404
Entity: 2907577	124	144	p-aminohippuric acid	Chemical	D010130
Entity: 2907577	186	194	necrosis	Disease	D009336
Relation: 2907577	CID	51	55	D014508	186	194	D009336	false
Relation: 2907577	CID	60	70	D003404	186	194	D009336	false
Relation: 2907577	CID	124	144	D010130	186	194	D009336	false

Sentence: A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin, a commonly used drug in the treatment of severe cystic acne.
Entity: 2931989	78	90	isotretinoin	Chemical	D015474
Entity: 2931989	147	151	acne	Disease	D000152
Relation: 2931989	CID	78	90	D015474	147	151	D000152	false

Sentence: Procaterol and terbutaline in bronchial asthma.
Entity: 2933998	0	10	Procaterol	Chemical	D017265
Entity: 2933998	15	26	terbutaline	Chemical	D013726
Entity: 2933998	30	46	bronchial asthma	Disease	D001249
Relation: 2933998	CID	0	10	D017265	30	46	D001249	false
Relation: 2933998	CID	15	26	D013726	30	46	D001249	false

Sentence: Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma.
Entity: 2933998	0	10	Procaterol	Chemical	D017265
Entity: 2933998	134	150	bronchial asthma	Disease	D001249
Relation: 2933998	CID	0	10	D017265	134	150	D001249	false

Sentence: Both anti-asthmatic and tremorgenic effects of procaterol were dose-related.
Entity: 2933998	10	19	asthmatic	Disease	D001249
Entity: 2933998	24	35	tremorgenic	Disease	D014202
Entity: 2933998	47	57	procaterol	Chemical	D017265
Relation: 2933998	CID	47	57	D017265	10	19	D001249	false
Relation: 2933998	CID	47	57	D017265	24	35	D014202	true

Sentence: Subacute effects of propranolol and B 24/76 on isoproterenol induced rat heart hypertrophy in correlation with blood pressure.
Entity: 2974281	20	31	propranolol	Chemical	D011433
Entity: 2974281	47	60	isoproterenol	Chemical	D007545
Entity: 2974281	73	90	heart hypertrophy	Disease	D006332
Relation: 2974281	CID	20	31	D011433	73	90	D006332	false
Relation: 2974281	CID	47	60	D007545	73	90	D006332	true

Sentence: The studies were performed using an experimental model of isoproterenol induced heart hypertrophy in rats.
Entity: 2974281	58	71	isoproterenol	Chemical	D007545
Entity: 2974281	80	97	heart hypertrophy	Disease	D006332
Relation: 2974281	CID	58	71	D007545	80	97	D006332	true

Sentence: It was possible to suppress the increased ornithine decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass.
Entity: 2974281	42	51	ornithine	Chemical	D009952
Entity: 2974281	102	122	hypertrophied hearts	Disease	D006332
Relation: 2974281	CID	42	51	D009952	102	122	D006332	false

Sentence: Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart.
Entity: 2974281	8	19	propranolol	Chemical	D011433
Entity: 2974281	109	122	hypertrophied	Disease	D006984
Relation: 2974281	CID	8	19	D011433	109	122	D006984	false

Sentence: Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.
Entity: 3074291	28	46	oxitropium bromide	Chemical	C017590
Entity: 3074291	67	79	theophylline	Chemical	D013806
Entity: 3074291	93	99	asthma	Disease	D001249
Relation: 3074291	CID	28	46	C017590	93	99	D001249	false
Relation: 3074291	CID	67	79	D013806	93	99	D001249	false

Sentence: The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study.
Entity: 3074291	50	68	oxitropium bromide	Chemical	C017590
Entity: 3074291	92	104	theophylline	Chemical	D013806
Entity: 3074291	132	138	asthma	Disease	D001249
Relation: 3074291	CID	50	68	C017590	132	138	D001249	false
Relation: 3074291	CID	92	104	D013806	132	138	D001249	false

Sentence: No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.
Entity: 3074291	36	46	oxitropium	Chemical	C017590
Entity: 3074291	88	94	nausea	Disease	D009325
Entity: 3074291	96	104	vomiting	Disease	D014839
Entity: 3074291	109	116	tremors	Disease	D014202
Entity: 3074291	123	135	theophylline	Chemical	D013806
Relation: 3074291	CID	36	46	C017590	88	94	D009325	false
Relation: 3074291	CID	36	46	C017590	96	104	D014839	false
Relation: 3074291	CID	36	46	C017590	109	116	D014202	false
Relation: 3074291	CID	123	135	D013806	88	94	D009325	true
Relation: 3074291	CID	123	135	D013806	96	104	D014839	true
Relation: 3074291	CID	123	135	D013806	109	116	D014202	true

Sentence: Penicillin anaphylaxis.
Entity: 3083835	0	10	Penicillin	Chemical	D010406
Entity: 3083835	11	22	anaphylaxis	Disease	D000707
Relation: 3083835	CID	0	10	D010406	11	22	D000707	true

Sentence: A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.
Entity: 3083835	15	25	penicillin	Chemical	D010406
Entity: 3083835	26	37	anaphylaxis	Disease	D000707
Entity: 3083835	153	164	anaphylaxis	Disease	D000707
Relation: 3083835	CID	15	25	D010406	26	37	D000707	true
Relation: 3083835	CID	15	25	D010406	153	164	D000707	true

Sentence: Reversible valproic acid induced dementia: a case report.
Entity: 3084231	11	24	valproic acid	Chemical	D014635
Entity: 3084231	33	41	dementia	Disease	D003704
Relation: 3084231	CID	11	24	D014635	33	41	D003704	true

Sentence: Reversible valproic acid induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.
Entity: 3084231	11	24	valproic acid	Chemical	D014635
Entity: 3084231	33	41	dementia	Disease	D003704
Entity: 3084231	83	91	epilepsy	Disease	D004827
Relation: 3084231	CID	11	24	D014635	33	41	D003704	true
Relation: 3084231	CID	11	24	D014635	83	91	D004827	false

Sentence: Reversal of scopolamine induced amnesia of passive avoidance by pre- and post-training naloxone.
Entity: 3088653	12	23	scopolamine	Chemical	D012601
Entity: 3088653	32	39	amnesia	Disease	D000647
Entity: 3088653	87	95	naloxone	Chemical	D009270
Relation: 3088653	CID	12	23	D012601	32	39	D000647	true
Relation: 3088653	CID	87	95	D009270	32	39	D000647	false

Sentence: In a series of five experiments, the modulating role of naloxone on a scopolamine induced retention deficit in a passive avoidance paradigm was investigated in mice.
Entity: 3088653	56	64	naloxone	Chemical	D009270
Entity: 3088653	70	81	scopolamine	Chemical	D012601
Entity: 3088653	90	107	retention deficit	Disease	D008569
Relation: 3088653	CID	56	64	D009270	90	107	D008569	false
Relation: 3088653	CID	70	81	D012601	90	107	D008569	false

Sentence: Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.
Entity: 3088653	0	11	Scopolamine	Chemical	D012601
Entity: 3088653	21	39	methyl scopolamine	Chemical	D019832
Entity: 3088653	68	75	amnesia	Disease	D000647
Relation: 3088653	CID	0	11	D012601	68	75	D000647	true
Relation: 3088653	CID	21	39	D019832	68	75	D000647	false

Sentence: Naloxone (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg/kg.
Entity: 3088653	0	8	Naloxone	Chemical	D009270
Entity: 3088653	77	94	retention deficit	Disease	D008569
Relation: 3088653	CID	0	8	D009270	77	94	D008569	false

Sentence: Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine induced amnesia.
Entity: 3088653	32	40	naloxone	Chemical	D009270
Entity: 3088653	102	113	scopolamine	Chemical	D012601
Entity: 3088653	122	129	amnesia	Disease	D000647
Relation: 3088653	CID	32	40	D009270	122	129	D000647	false
Relation: 3088653	CID	102	113	D012601	122	129	D000647	true

Sentence: Electron microscopic investigations of the cyclophosphamide induced lesions of the urinary bladder of the rat and their prevention by mesna.
Entity: 3109094	43	59	cyclophosphamide	Chemical	D003520
Entity: 3109094	68	98	lesions of the urinary bladder	Disease	D001745
Entity: 3109094	134	139	mesna	Chemical	D015080
Relation: 3109094	CID	43	59	D003520	68	98	D001745	true
Relation: 3109094	CID	134	139	D015080	68	98	D001745	false

Sentence: Fully developed cyclophosphamide induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.
Entity: 3109094	16	32	cyclophosphamide	Chemical	D003520
Entity: 3109094	41	49	cystitis	Disease	D003556
Entity: 3109094	134	139	edema	Disease	D004487
Entity: 3109094	198	206	necroses	Disease	D009336
Relation: 3109094	CID	16	32	D003520	41	49	D003556	false
Relation: 3109094	CID	16	32	D003520	134	139	D004487	false
Relation: 3109094	CID	16	32	D003520	198	206	D009336	false

Sentence: Increase in intragastric pressure during suxamethonium induced muscle fasciculations in children: inhibition by alfentanil.
Entity: 3125850	41	54	suxamethonium	Chemical	D013390
Entity: 3125850	63	84	muscle fasciculations	Disease	D005207
Entity: 3125850	112	122	alfentanil	Chemical	D015760
Relation: 3125850	CID	41	54	D013390	63	84	D005207	true
Relation: 3125850	CID	112	122	D015760	63	84	D005207	false

Sentence: The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.
Entity: 3125850	31	52	muscle fasciculations	Disease	D005207
Entity: 3125850	63	76	suxamethonium	Chemical	D013390
Entity: 3125850	131	141	alfentanil	Chemical	D015760
Relation: 3125850	CID	63	76	D013390	31	52	D005207	true
Relation: 3125850	CID	131	141	D015760	31	52	D005207	false

Sentence: The intragastric pressure during muscle fasciculations was significantly higher in the control group (16 +/- 0.7 (SEM) cm H2O) than in the alfentanil group (7.7 +/- 1.5 (SEM) cm H2O).
Entity: 3125850	33	54	muscle fasciculations	Disease	D005207
Entity: 3125850	122	125	H2O	Chemical	D014867
Entity: 3125850	139	149	alfentanil	Chemical	D015760
Entity: 3125850	178	181	H2O	Chemical	D014867
Relation: 3125850	CID	122	125	D014867	33	54	D005207	false
Relation: 3125850	CID	139	149	D015760	33	54	D005207	false
Relation: 3125850	CID	178	181	D014867	33	54	D005207	false

Sentence: It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children.
Entity: 3125850	74	95	muscle fasciculations	Disease	D005207
Entity: 3125850	106	119	suxamethonium	Chemical	D013390
Relation: 3125850	CID	106	119	D013390	74	95	D005207	true

Sentence: Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.
Entity: 3155884	57	68	cardiotoxic	Disease	D066126
Entity: 3155884	79	92	isoproterenol	Chemical	D007545
Entity: 3155884	96	110	streptozotocin	Chemical	D013311
Entity: 3155884	111	119	diabetic	Disease	D003920
Relation: 3155884	CID	79	92	D007545	57	68	D066126	false
Relation: 3155884	CID	79	92	D007545	111	119	D003920	false
Relation: 3155884	CID	96	110	D013311	57	68	D066126	false
Relation: 3155884	CID	96	110	D013311	111	119	D003920	true

Sentence: A morphometric study of isoproterenol induced myocardial fibrosis.
Entity: 3155884	24	37	isoproterenol	Chemical	D007545
Entity: 3155884	57	65	fibrosis	Disease	D005355
Relation: 3155884	CID	24	37	D007545	57	65	D005355	true

Sentence: The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.
Entity: 3155884	83	97	streptozotocin	Chemical	D013311
Entity: 3155884	98	106	diabetes	Disease	D003920
Entity: 3155884	119	130	cardiotoxic	Disease	D066126
Entity: 3155884	155	168	isoproterenol	Chemical	D007545
Entity: 3155884	170	173	ISO	Chemical	D007545
Relation: 3155884	CID	83	97	D013311	98	106	D003920	true
Relation: 3155884	CID	83	97	D013311	119	130	D066126	false
Relation: 3155884	CID	155	168	D007545	98	106	D003920	false
Relation: 3155884	CID	155	168	D007545	119	130	D066126	false
Relation: 3155884	CID	170	173	D007545	98	106	D003920	false
Relation: 3155884	CID	170	173	D007545	119	130	D066126	false

Sentence: Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.
Entity: 3155884	62	65	ISO	Chemical	D007545
Entity: 3155884	100	103	ISO	Chemical	D007545
Entity: 3155884	112	120	fibrosis	Disease	D005355
Entity: 3155884	274	281	glucose	Chemical	D005947
Relation: 3155884	CID	62	65	D007545	112	120	D005355	true
Relation: 3155884	CID	100	103	D007545	112	120	D005355	true
Relation: 3155884	CID	274	281	D005947	112	120	D005355	false

Sentence: The myocardial content of catecholamines was estimated in these 8 day diabetic rats.
Entity: 3155884	26	40	catecholamines	Chemical	D002395
Entity: 3155884	70	78	diabetic	Disease	D003920
Relation: 3155884	CID	26	40	D002395	70	78	D003920	false

Sentence: The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.
Entity: 3155884	74	88	streptozotocin	Chemical	D013311
Entity: 3155884	110	113	ISO	Chemical	D007545
Entity: 3155884	182	195	catecholamine	Chemical	D002395
Entity: 3155884	211	219	diabetic	Disease	D003920
Relation: 3155884	CID	74	88	D013311	211	219	D003920	true
Relation: 3155884	CID	110	113	D007545	211	219	D003920	false
Relation: 3155884	CID	182	195	D002395	211	219	D003920	false

Sentence: Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats.
Entity: 3191389	65	73	seizures	Disease	D012640
Entity: 3191389	86	97	pilocarpine	Chemical	D010862
Relation: 3191389	CID	86	97	D010862	65	73	D012640	true

Sentence: The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.
Entity: 3191389	35	46	pilocarpine	Chemical	D010862
Entity: 3191389	63	71	seizures	Disease	D012640
Entity: 3191389	76	94	status epilepticus	Disease	D013226
Relation: 3191389	CID	35	46	D010862	63	71	D012640	true
Relation: 3191389	CID	35	46	D010862	76	94	D013226	true

Sentence: The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.
Entity: 3191389	101	118	sodium salicylate	Chemical	D012980
Entity: 3191389	120	134	phenylbutazone	Chemical	D010653
Entity: 3191389	136	148	indomethacin	Chemical	D007213
Entity: 3191389	150	159	ibuprofen	Chemical	D007052
Entity: 3191389	164	178	mefenamic acid	Chemical	D008528
Entity: 3191389	183	191	seizures	Disease	D012640
Entity: 3191389	204	215	pilocarpine	Chemical	D010862
Relation: 3191389	CID	101	118	D012980	183	191	D012640	true
Relation: 3191389	CID	120	134	D010653	183	191	D012640	true
Relation: 3191389	CID	136	148	D007213	183	191	D012640	false
Relation: 3191389	CID	150	159	D007052	183	191	D012640	false
Relation: 3191389	CID	164	178	D008528	183	191	D012640	false
Relation: 3191389	CID	204	215	D010862	183	191	D012640	true

Sentence: Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.
Entity: 3191389	0	12	Indomethacin	Chemical	D007213
Entity: 3191389	30	39	ibuprofen	Chemical	D007052
Entity: 3191389	74	82	seizures	Disease	D012640
Entity: 3191389	95	106	pilocarpine	Chemical	D010862
Relation: 3191389	CID	0	12	D007213	74	82	D012640	false
Relation: 3191389	CID	30	39	D007052	74	82	D012640	false
Relation: 3191389	CID	95	106	D010862	74	82	D012640	true

Sentence: Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.
Entity: 3191389	0	14	Mefenamic acid	Chemical	D008528
Entity: 3191389	44	52	seizures	Disease	D012640
Entity: 3191389	77	84	seizure	Disease	D012640
Entity: 3191389	93	105	brain damage	Disease	D001930
Entity: 3191389	117	128	pilocarpine	Chemical	D010862
Relation: 3191389	CID	0	14	D008528	44	52	D012640	false
Relation: 3191389	CID	0	14	D008528	77	84	D012640	false
Relation: 3191389	CID	0	14	D008528	93	105	D001930	false
Relation: 3191389	CID	117	128	D010862	44	52	D012640	true
Relation: 3191389	CID	117	128	D010862	77	84	D012640	true
Relation: 3191389	CID	117	128	D010862	93	105	D001930	false

Sentence: Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
Entity: 3289726	0	28	Acute neurologic dysfunction	Disease	D009422
Entity: 3289726	45	54	etoposide	Chemical	D005047
Entity: 3289726	67	83	malignant glioma	Disease	D005910
Relation: 3289726	CID	45	54	D005047	0	28	D009422	false
Relation: 3289726	CID	45	54	D005047	67	83	D005910	false

Sentence: Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.
Entity: 3289726	0	9	Etoposide	Chemical	D005047
Entity: 3289726	11	20	VP-16-213	Chemical	D005047
Entity: 3289726	67	73	tumors	Disease	D009369
Entity: 3289726	78	102	hematologic malignancies	Disease	D019337
Relation: 3289726	CID	0	9	D005047	67	73	D009369	false
Relation: 3289726	CID	0	9	D005047	78	102	D019337	false
Relation: 3289726	CID	11	20	D005047	67	73	D009369	false
Relation: 3289726	CID	11	20	D005047	78	102	D019337	false

Sentence: Progressive bile duct injury after thiabendazole administration.
Entity: 3297909	12	28	bile duct injury	Disease	D001649
Entity: 3297909	35	48	thiabendazole	Chemical	D013827
Relation: 3297909	CID	35	48	D013827	12	28	D001649	false

Sentence: A 27-yr-old man developed jaundice 2 wk after exposure to thiabendazole.
Entity: 3297909	26	34	jaundice	Disease	D007565
Entity: 3297909	58	71	thiabendazole	Chemical	D013827
Relation: 3297909	CID	58	71	D013827	26	34	D007565	false

Sentence: Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.
Entity: 3323259	44	51	calcium	Chemical	D002118
Entity: 3323259	75	97	cardiovascular disease	Disease	D002318
Entity: 3323259	138	169	calcium channel blocking agents	Chemical	D002121
Entity: 3323259	200	223	cardiovascular diseases	Disease	D002318
Relation: 3323259	CID	44	51	D002118	75	97	D002318	false
Relation: 3323259	CID	44	51	D002118	200	223	D002318	false
Relation: 3323259	CID	138	169	D002121	75	97	D002318	false
Relation: 3323259	CID	138	169	D002121	200	223	D002318	false

Sentence: As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.
Entity: 3323259	13	28	dihydropyridine	Chemical	C038806
Entity: 3323259	69	79	nifedipine	Chemical	D009543
Entity: 3323259	89	95	angina	Disease	D000787
Entity: 3323259	100	112	hypertension	Disease	D006973
Relation: 3323259	CID	13	28	C038806	89	95	D000787	false
Relation: 3323259	CID	13	28	C038806	100	112	D006973	false
Relation: 3323259	CID	69	79	D009543	89	95	D000787	false
Relation: 3323259	CID	69	79	D009543	100	112	D006973	false

Sentence: Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.
Entity: 3323259	41	53	nitrendipine	Chemical	D009568
Entity: 3323259	58	69	nisoldipine	Chemical	D015737
Entity: 3323259	175	187	hypertension	Disease	D006973
Relation: 3323259	CID	41	53	D009568	175	187	D006973	false
Relation: 3323259	CID	58	69	D015737	175	187	D006973	false

Sentence: The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina.
Entity: 3323259	40	51	nisoldipine	Chemical	D015737
Entity: 3323259	107	113	angina	Disease	D000787
Relation: 3323259	CID	40	51	D015737	107	113	D000787	false

Sentence: Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.
Entity: 3323259	46	56	nimodipine	Chemical	D009553
Entity: 3323259	96	119	subarachnoid hemorrhage	Disease	D013345
Entity: 3323259	121	138	migraine headache	Disease	D008881
Entity: 3323259	140	148	dementia	Disease	D003704
Entity: 3323259	154	160	stroke	Disease	D020521
Relation: 3323259	CID	46	56	D009553	96	119	D013345	false
Relation: 3323259	CID	46	56	D009553	121	138	D008881	false
Relation: 3323259	CID	46	56	D009553	140	148	D003704	false
Relation: 3323259	CID	46	56	D009553	154	160	D020521	false

Sentence: The enhancement of aminonucleoside nephrosis by the co-administration of protamine.
Entity: 3323599	19	34	aminonucleoside	Chemical	D011692
Entity: 3323599	35	44	nephrosis	Disease	D009401
Relation: 3323599	CID	19	34	D011692	35	44	D009401	false

Sentence: An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).
Entity: 3323599	25	61	focal segmental glomerular sclerosis	Disease	D005923
Entity: 3323599	63	67	FSGS	Disease	D005923
Entity: 3323599	125	150	puromycin-aminonucleoside	Chemical	D011692
Entity: 3323599	152	156	AMNS	Chemical	D011692
Entity: 3323599	162	179	protamine sulfate	Chemical	D011479
Entity: 3323599	181	183	PS	Chemical	D011479
Relation: 3323599	CID	125	150	D011692	25	61	D005923	true
Relation: 3323599	CID	125	150	D011692	63	67	D005923	true
Relation: 3323599	CID	152	156	D011692	25	61	D005923	true
Relation: 3323599	CID	152	156	D011692	63	67	D005923	true
Relation: 3323599	CID	162	179	D011479	25	61	D005923	false
Relation: 3323599	CID	162	179	D011479	63	67	D005923	false
Relation: 3323599	CID	181	183	D011479	25	61	D005923	false
Relation: 3323599	CID	181	183	D011479	63	67	D005923	false

Sentence: Theophylline neurotoxicity in pregnant rats.
Entity: 3339945	0	12	Theophylline	Chemical	D013806
Entity: 3339945	13	26	neurotoxicity	Disease	D020258
Relation: 3339945	CID	0	12	D013806	13	26	D020258	false

Sentence: The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy.
Entity: 3339945	63	76	neurotoxicity	Disease	D020258
Entity: 3339945	80	92	theophylline	Chemical	D013806
Relation: 3339945	CID	80	92	D013806	63	76	D020258	false

Sentence: Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively.
Entity: 3339945	117	130	aminophylline	Chemical	D000628
Entity: 3339945	154	162	seizures	Disease	D012640
Relation: 3339945	CID	117	130	D000628	154	162	D012640	true

Sentence: Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.
Entity: 3375885	0	12	Hyperkalemia	Disease	D006947
Entity: 3375885	24	36	indomethacin	Chemical	D007213
Entity: 3375885	41	49	naproxen	Chemical	D009288
Entity: 3375885	66	81	fludrocortisone	Chemical	D005438
Relation: 3375885	CID	24	36	D007213	0	12	D006947	true
Relation: 3375885	CID	41	49	D009288	0	12	D006947	true
Relation: 3375885	CID	66	81	D005438	0	12	D006947	false

Sentence: We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.
Entity: 3375885	40	60	rheumatoid arthritis	Disease	D001172
Entity: 3375885	78	92	mefenamic acid	Chemical	D008528
Entity: 3375885	93	104	nephropathy	Disease	D007674
Entity: 3375885	113	125	hyperkalemia	Disease	D006947
Entity: 3375885	144	161	hypoaldosteronism	Disease	D006994
Entity: 3375885	182	194	indomethacin	Chemical	D007213
Entity: 3375885	199	207	naproxen	Chemical	D009288
Relation: 3375885	CID	78	92	D008528	40	60	D001172	false
Relation: 3375885	CID	78	92	D008528	93	104	D007674	true
Relation: 3375885	CID	78	92	D008528	113	125	D006947	false
Relation: 3375885	CID	78	92	D008528	144	161	D006994	false
Relation: 3375885	CID	182	194	D007213	40	60	D001172	false
Relation: 3375885	CID	182	194	D007213	93	104	D007674	false
Relation: 3375885	CID	182	194	D007213	113	125	D006947	true
Relation: 3375885	CID	182	194	D007213	144	161	D006994	true
Relation: 3375885	CID	199	207	D009288	40	60	D001172	false
Relation: 3375885	CID	199	207	D009288	93	104	D007674	false
Relation: 3375885	CID	199	207	D009288	113	125	D006947	true
Relation: 3375885	CID	199	207	D009288	144	161	D006994	true

Sentence: It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.
Entity: 3375885	30	43	renal disease	Disease	D007674
Entity: 3375885	72	102	type IV renal tubular acidosis	Disease	D006994
Entity: 3375885	108	121	prostaglandin	Chemical	D011453
Relation: 3375885	CID	108	121	D011453	30	43	D007674	false
Relation: 3375885	CID	108	121	D011453	72	102	D006994	false

Sentence: Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
Entity: 3383127	0	11	Hypotension	Disease	D007022
Entity: 3383127	34	48	cardiotoxicity	Disease	D066126
Entity: 3383127	77	86	cisplatin	Chemical	D002945
Entity: 3383127	91	105	5-fluorouracil	Chemical	D005472
Relation: 3383127	CID	77	86	D002945	0	11	D007022	true
Relation: 3383127	CID	77	86	D002945	34	48	D066126	false
Relation: 3383127	CID	91	105	D005472	0	11	D007022	true
Relation: 3383127	CID	91	105	D005472	34	48	D066126	false

Sentence: Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).
Entity: 3383127	28	39	hypotension	Disease	D007022
Entity: 3383127	83	103	colorectal carcinoma	Disease	D015179
Entity: 3383127	129	138	cisplatin	Chemical	D002945
Entity: 3383127	140	144	CDDP	Chemical	D002945
Entity: 3383127	150	164	5-fluorouracil	Chemical	D005472
Entity: 3383127	166	170	5-FU	Chemical	D005472
Relation: 3383127	CID	129	138	D002945	28	39	D007022	true
Relation: 3383127	CID	129	138	D002945	83	103	D015179	false
Relation: 3383127	CID	140	144	D002945	28	39	D007022	true
Relation: 3383127	CID	140	144	D002945	83	103	D015179	false
Relation: 3383127	CID	150	164	D005472	28	39	D007022	true
Relation: 3383127	CID	150	164	D005472	83	103	D015179	false
Relation: 3383127	CID	166	170	D005472	28	39	D007022	true
Relation: 3383127	CID	166	170	D005472	83	103	D015179	false

Sentence: Fatal aplastic anemia in a patient treated with carbamazepine.
Entity: 3409843	6	21	aplastic anemia	Disease	D000741
Entity: 3409843	48	61	carbamazepine	Chemical	D002220
Relation: 3409843	CID	48	61	D002220	6	21	D000741	true

Sentence: A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.
Entity: 3409843	16	31	aplastic anemia	Disease	D000741
Entity: 3409843	39	52	carbamazepine	Chemical	D002220
Entity: 3409843	69	78	epileptic	Disease	D004827
Relation: 3409843	CID	39	52	D002220	16	31	D000741	true
Relation: 3409843	CID	39	52	D002220	69	78	D004827	false

Sentence: Despite concerns of fatal bone marrow toxicity due to carbamazepine, this is only the fourth documented and published report.
Entity: 3409843	26	46	bone marrow toxicity	Disease	D001855
Entity: 3409843	54	67	carbamazepine	Chemical	D002220
Relation: 3409843	CID	54	67	D002220	26	46	D001855	false

Sentence: Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine induced hypotension and bradycardia.
Entity: 3423103	72	81	clonidine	Chemical	D003000
Entity: 3423103	90	101	hypotension	Disease	D007022
Entity: 3423103	106	117	bradycardia	Disease	D001919
Relation: 3423103	CID	72	81	D003000	90	101	D007022	true
Relation: 3423103	CID	72	81	D003000	106	117	D001919	true

Sentence: The clonidine induced hypotension was antagonized by prior spinal transection, but not bilateral vagotomy.
Entity: 3423103	4	13	clonidine	Chemical	D003000
Entity: 3423103	22	33	hypotension	Disease	D007022
Relation: 3423103	CID	4	13	D003000	22	33	D007022	true

Sentence: On the other hand, the clonidine induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection.
Entity: 3423103	23	32	clonidine	Chemical	D003000
Entity: 3423103	41	52	bradycardia	Disease	D001919
Relation: 3423103	CID	23	32	D003000	41	52	D001919	true

Sentence: Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats.
Entity: 3423103	49	53	5-HT	Chemical	D012701
Entity: 3423103	104	127	5,7-dihydroxytryptamine	Chemical	D015116
Entity: 3423103	179	191	bradycardiac	Disease	D001919
Entity: 3423103	205	214	clonidine	Chemical	D003000
Relation: 3423103	CID	49	53	D012701	179	191	D001919	false
Relation: 3423103	CID	104	127	D015116	179	191	D001919	false
Relation: 3423103	CID	205	214	D003000	179	191	D001919	true

Sentence: The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine induced hypotension and bradycardia.
Entity: 3423103	88	97	clonidine	Chemical	D003000
Entity: 3423103	106	117	hypotension	Disease	D007022
Entity: 3423103	122	133	bradycardia	Disease	D001919
Relation: 3423103	CID	88	97	D003000	106	117	D007022	true
Relation: 3423103	CID	88	97	D003000	122	133	D001919	true

Sentence: Hypertension in neuroblastoma induced by imipramine.
Entity: 3439580	0	12	Hypertension	Disease	D006973
Entity: 3439580	16	29	neuroblastoma	Disease	D009447
Entity: 3439580	41	51	imipramine	Chemical	D007099
Relation: 3439580	CID	41	51	D007099	0	12	D006973	true
Relation: 3439580	CID	41	51	D007099	16	29	D009447	false

Sentence: We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.
Entity: 3439580	35	47	hypertension	Disease	D006973
Entity: 3439580	99	112	neuroblastoma	Disease	D009447
Entity: 3439580	127	137	Imipramine	Chemical	D007099
Entity: 3439580	151	168	behavior disorder	Disease	D002653
Relation: 3439580	CID	127	137	D007099	35	47	D006973	true
Relation: 3439580	CID	127	137	D007099	99	112	D009447	false
Relation: 3439580	CID	127	137	D007099	151	168	D002653	false

Sentence: Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension.
Entity: 3439580	105	115	Imipramine	Chemical	D007099
Entity: 3439580	228	240	hypertension	Disease	D006973
Relation: 3439580	CID	105	115	D007099	228	240	D006973	true

Sentence: Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.
Entity: 3475563	38	54	oral candidiasis	Disease	D002180
Entity: 3475563	58	68	hoarseness	Disease	D006685
Entity: 3475563	74	101	beclomethasone dipropionate	Chemical	D001507
Relation: 3475563	CID	74	101	D001507	38	54	D002180	true
Relation: 3475563	CID	74	101	D001507	58	68	D006685	true

Sentence: Of 158 asthmatic patients who were placed on inhaled beclomethasone, 15 (9.5%) developed either hoarseness (8), oral thrush (6), or both (1).
Entity: 3475563	7	16	asthmatic	Disease	D001249
Entity: 3475563	53	67	beclomethasone	Chemical	D001507
Entity: 3475563	96	106	hoarseness	Disease	D006685
Entity: 3475563	117	123	thrush	Disease	D002180
Relation: 3475563	CID	53	67	D001507	7	16	D001249	false
Relation: 3475563	CID	53	67	D001507	96	106	D006685	true
Relation: 3475563	CID	53	67	D001507	117	123	D002180	true

Sentence: We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged.
Entity: 3475563	54	68	beclomethasone	Chemical	D001507
Entity: 3475563	163	173	hoarseness	Disease	D006685
Relation: 3475563	CID	54	68	D001507	163	173	D006685	true

Sentence: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
Entity: 3533179	0	16	Cyclophosphamide	Chemical	D003520
Entity: 3533179	17	31	cardiotoxicity	Disease	D066126
Relation: 3533179	CID	0	16	D003520	17	31	D066126	false

Sentence: At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described.
Entity: 3533179	23	26	CYA	Chemical	D003520
Entity: 3533179	36	50	cardiotoxicity	Disease	D066126
Entity: 3533179	118	132	cardiotoxicity	Disease	D066126
Relation: 3533179	CID	23	26	D003520	36	50	D066126	false
Relation: 3533179	CID	23	26	D003520	118	132	D066126	false

Sentence: Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.
Entity: 3533179	29	37	toxicity	Disease	D064420
Entity: 3533179	134	137	CYA	Chemical	D003520
Entity: 3533179	220	223	CYA	Chemical	D003520
Entity: 3533179	224	238	cardiotoxicity	Disease	D066126
Relation: 3533179	CID	134	137	D003520	29	37	D064420	false
Relation: 3533179	CID	134	137	D003520	224	238	D066126	false
Relation: 3533179	CID	220	223	D003520	29	37	D064420	false
Relation: 3533179	CID	220	223	D003520	224	238	D066126	false

Sentence: Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.
Entity: 3533179	36	39	CYA	Chemical	D003520
Entity: 3533179	140	155	aplastic anemia	Disease	D000741
Entity: 3533179	157	181	Wiskott-Aldrich syndrome	Disease	D014923
Entity: 3533179	186	227	severe combined immunodeficiency syndrome	Disease	D016511
Relation: 3533179	CID	36	39	D003520	140	155	D000741	false
Relation: 3533179	CID	36	39	D003520	157	181	D014923	false
Relation: 3533179	CID	36	39	D003520	186	227	D016511	false

Sentence: Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA.
Entity: 3533179	69	72	CYA	Chemical	D003520
Entity: 3533179	73	87	cardiotoxicity	Disease	D066126
Entity: 3533179	133	136	CYA	Chemical	D003520
Relation: 3533179	CID	69	72	D003520	73	87	D066126	false
Relation: 3533179	CID	133	136	D003520	73	87	D066126	false

Sentence: Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025).
Entity: 3533179	0	14	Cardiotoxicity	Disease	D066126
Entity: 3533179	49	52	CYA	Chemical	D003520
Relation: 3533179	CID	49	52	D003520	0	14	D066126	false

Sentence: We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
Entity: 3533179	21	24	CYA	Chemical	D003520
Entity: 3533179	25	39	cardiotoxicity	Disease	D066126
Entity: 3533179	56	59	CYA	Chemical	D003520
Entity: 3533179	126	141	aplastic anemia	Disease	D000741
Entity: 3533179	146	164	immunodeficiencies	Disease	D007153
Entity: 3533179	223	226	CYA	Chemical	D003520
Entity: 3533179	287	301	cardiotoxicity	Disease	D066126
Entity: 3533179	322	325	CYA	Chemical	D003520
Relation: 3533179	CID	21	24	D003520	25	39	D066126	false
Relation: 3533179	CID	21	24	D003520	126	141	D000741	false
Relation: 3533179	CID	21	24	D003520	146	164	D007153	false
Relation: 3533179	CID	21	24	D003520	287	301	D066126	false
Relation: 3533179	CID	56	59	D003520	25	39	D066126	false
Relation: 3533179	CID	56	59	D003520	126	141	D000741	false
Relation: 3533179	CID	56	59	D003520	146	164	D007153	false
Relation: 3533179	CID	56	59	D003520	287	301	D066126	false
Relation: 3533179	CID	223	226	D003520	25	39	D066126	false
Relation: 3533179	CID	223	226	D003520	126	141	D000741	false
Relation: 3533179	CID	223	226	D003520	146	164	D007153	false
Relation: 3533179	CID	223	226	D003520	287	301	D066126	false
Relation: 3533179	CID	322	325	D003520	25	39	D066126	false
Relation: 3533179	CID	322	325	D003520	126	141	D000741	false
Relation: 3533179	CID	322	325	D003520	146	164	D007153	false
Relation: 3533179	CID	322	325	D003520	287	301	D066126	false

Sentence: Studies of risk factors for aminoglycoside nephrotoxicity.
Entity: 3538855	28	42	aminoglycoside	Chemical	D000617
Entity: 3538855	43	57	nephrotoxicity	Disease	D007674
Relation: 3538855	CID	28	42	D000617	43	57	D007674	true

Sentence: The epidemiology of aminoglycoside induced nephrotoxicity is not fully understood.
Entity: 3538855	20	34	aminoglycoside	Chemical	D000617
Entity: 3538855	43	57	nephrotoxicity	Disease	D007674
Relation: 3538855	CID	20	34	D000617	43	57	D007674	true

Sentence: Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients, but rarely, if ever, cause glomerular or tubular dysfunction.
Entity: 3538855	58	73	aminoglycosides	Chemical	D000617
Entity: 3538855	149	182	glomerular or tubular dysfunction	Disease	D007674
Relation: 3538855	CID	58	73	D000617	149	182	D007674	true

Sentence: Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%.
Entity: 3538855	19	34	aminoglycosides	Chemical	D000617
Entity: 3538855	108	127	acute renal failure	Disease	D058186
Relation: 3538855	CID	19	34	D000617	108	127	D058186	false

Sentence: Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.
Entity: 3538855	77	91	aminoglycoside	Chemical	D000617
Entity: 3538855	100	113	liver disease	Disease	D008107
Entity: 3538855	152	162	creatinine	Chemical	D003404
Entity: 3538855	228	242	nephrotoxicity	Disease	D007674
Relation: 3538855	CID	77	91	D000617	100	113	D008107	false
Relation: 3538855	CID	77	91	D000617	228	242	D007674	true
Relation: 3538855	CID	152	162	D003404	100	113	D008107	false
Relation: 3538855	CID	152	162	D003404	228	242	D007674	false

Sentence: Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.
Entity: 3685052	0	9	Flurothyl	Chemical	D005481
Entity: 3685052	10	17	seizure	Disease	D012640
Entity: 3685052	83	103	monosodium glutamate	Chemical	D012970
Entity: 3685052	105	108	MSG	Chemical	D012970
Entity: 3685052	152	161	flurothyl	Chemical	D005481
Entity: 3685052	162	169	seizure	Disease	D012640
Relation: 3685052	CID	0	9	D005481	10	17	D012640	false
Relation: 3685052	CID	0	9	D005481	162	169	D012640	false
Relation: 3685052	CID	83	103	D012970	10	17	D012640	false
Relation: 3685052	CID	83	103	D012970	162	169	D012640	false
Relation: 3685052	CID	105	108	D012970	10	17	D012640	false
Relation: 3685052	CID	105	108	D012970	162	169	D012640	false
Relation: 3685052	CID	152	161	D005481	10	17	D012640	false
Relation: 3685052	CID	152	161	D005481	162	169	D012640	false

Sentence: Monosodium glutamate (MSG) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits.
Entity: 3685052	0	20	Monosodium glutamate	Chemical	D012970
Entity: 3685052	22	25	MSG	Chemical	D012970
Entity: 3685052	71	82	convulsions	Disease	D012640
Relation: 3685052	CID	0	20	D012970	71	82	D012640	false
Relation: 3685052	CID	22	25	D012970	71	82	D012640	false

Sentence: These studies were undertaken to determine if neonatal administration of MSG produced permanent alterations in seizure susceptibility, since previous investigations were inconclusive.
Entity: 3685052	73	76	MSG	Chemical	D012970
Entity: 3685052	111	118	seizure	Disease	D012640
Relation: 3685052	CID	73	76	D012970	111	118	D012640	false

Sentence: A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).
Entity: 3685052	2	11	flurothyl	Chemical	D005481
Entity: 3685052	12	17	ether	Chemical	D004986
Entity: 3685052	18	25	seizure	Disease	D012640
Entity: 3685052	67	74	seizure	Disease	D012640
Entity: 3685052	141	144	MSG	Chemical	D012970
Relation: 3685052	CID	2	11	D005481	18	25	D012640	false
Relation: 3685052	CID	2	11	D005481	67	74	D012640	false
Relation: 3685052	CID	12	17	D004986	18	25	D012640	false
Relation: 3685052	CID	12	17	D004986	67	74	D012640	false
Relation: 3685052	CID	141	144	D012970	18	25	D012640	false
Relation: 3685052	CID	141	144	D012970	67	74	D012640	false

Sentence: MSG treatment resulted in significant reductions in whole brain weight but did not alter seizure threshold.
Entity: 3685052	0	3	MSG	Chemical	D012970
Entity: 3685052	89	96	seizure	Disease	D012640
Relation: 3685052	CID	0	3	D012970	89	96	D012640	false

Sentence: A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice.
Entity: 3685052	2	10	naloxone	Chemical	D009270
Entity: 3685052	68	75	seizure	Disease	D012640
Entity: 3685052	108	111	MSG	Chemical	D012970
Relation: 3685052	CID	2	10	D009270	68	75	D012640	false
Relation: 3685052	CID	108	111	D012970	68	75	D012640	false

Sentence: Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.
Entity: 3685052	0	9	Flurothyl	Chemical	D005481
Entity: 3685052	10	15	ether	Chemical	D004986
Entity: 3685052	25	36	hypothermia	Disease	D007035
Entity: 3685052	79	88	flurothyl	Chemical	D005481
Entity: 3685052	128	139	hypothermia	Disease	D007035
Entity: 3685052	143	150	seizure	Disease	D012640
Relation: 3685052	CID	0	9	D005481	25	36	D007035	true
Relation: 3685052	CID	0	9	D005481	128	139	D007035	true
Relation: 3685052	CID	0	9	D005481	143	150	D012640	false
Relation: 3685052	CID	10	15	D004986	25	36	D007035	false
Relation: 3685052	CID	10	15	D004986	128	139	D007035	false
Relation: 3685052	CID	10	15	D004986	143	150	D012640	false
Relation: 3685052	CID	79	88	D005481	25	36	D007035	true
Relation: 3685052	CID	79	88	D005481	128	139	D007035	true
Relation: 3685052	CID	79	88	D005481	143	150	D012640	false

Sentence: Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
Entity: 3708328	18	26	seizures	Disease	D012640
Entity: 3708328	39	50	pilocarpine	Chemical	D010862
Entity: 3708328	83	92	isoniazid	Chemical	D007538
Entity: 3708328	96	112	gamma-vinyl-GABA	Chemical	D020888
Relation: 3708328	CID	39	50	D010862	18	26	D012640	true
Relation: 3708328	CID	83	92	D007538	18	26	D012640	false
Relation: 3708328	CID	96	112	D020888	18	26	D012640	false

Sentence: Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.
Entity: 3708328	0	11	Pilocarpine	Chemical	D010862
Entity: 3708328	91	113	temporal lobe epilepsy	Disease	D004833
Entity: 3708328	189	199	convulsive	Disease	D012640
Entity: 3708328	273	281	seizures	Disease	D012640
Relation: 3708328	CID	0	11	D010862	91	113	D004833	false
Relation: 3708328	CID	0	11	D010862	189	199	D012640	true
Relation: 3708328	CID	0	11	D010862	273	281	D012640	true

Sentence: In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.
Entity: 3708328	70	93	gamma-aminobutyric acid	Chemical	D005680
Entity: 3708328	95	99	GABA	Chemical	D005680
Entity: 3708328	161	169	seizures	Disease	D012640
Entity: 3708328	182	193	pilocarpine	Chemical	D010862
Relation: 3708328	CID	70	93	D005680	161	169	D012640	false
Relation: 3708328	CID	95	99	D005680	161	169	D012640	false
Relation: 3708328	CID	182	193	D010862	161	169	D012640	true

Sentence: In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.
Entity: 3708328	46	55	isoniazid	Chemical	D007538
Entity: 3708328	105	109	GABA	Chemical	D005680
Entity: 3708328	131	146	L-glutamic acid	Chemical	D018698
Entity: 3708328	248	259	pilocarpine	Chemical	D010862
Entity: 3708328	312	320	seizures	Disease	D012640
Entity: 3708328	325	343	status epilepticus	Disease	D013226
Relation: 3708328	CID	46	55	D007538	312	320	D012640	false
Relation: 3708328	CID	46	55	D007538	325	343	D013226	false
Relation: 3708328	CID	105	109	D005680	312	320	D012640	false
Relation: 3708328	CID	105	109	D005680	325	343	D013226	false
Relation: 3708328	CID	131	146	D018698	312	320	D012640	false
Relation: 3708328	CID	131	146	D018698	325	343	D013226	false
Relation: 3708328	CID	248	259	D010862	312	320	D012640	true
Relation: 3708328	CID	248	259	D010862	325	343	D013226	false

Sentence: Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine induced convulsions.
Entity: 3708328	101	112	pilocarpine	Chemical	D010862
Entity: 3708328	121	132	convulsions	Disease	D012640
Relation: 3708328	CID	101	112	D010862	121	132	D012640	true

Sentence: Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg.
Entity: 3708328	84	91	seizure	Disease	D012640
Entity: 3708328	240	251	pilocarpine	Chemical	D010862
Relation: 3708328	CID	240	251	D010862	84	91	D012640	true

Sentence: Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.
Entity: 3708328	38	47	isoniazid	Chemical	D007538
Entity: 3708328	64	72	seizures	Disease	D012640
Entity: 3708328	85	96	pilocarpine	Chemical	D010862
Relation: 3708328	CID	38	47	D007538	64	72	D012640	false
Relation: 3708328	CID	85	96	D010862	64	72	D012640	true

Sentence: Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.
Entity: 3708328	44	48	GABA	Chemical	D005680
Entity: 3708328	63	79	gamma-vinyl-GABA	Chemical	D020888
Entity: 3708328	81	109	D,L-4-amino-hex-5-enoic acid	Chemical	D020888
Entity: 3708328	212	220	seizures	Disease	D012640
Entity: 3708328	233	244	pilocarpine	Chemical	D010862
Relation: 3708328	CID	44	48	D005680	212	220	D012640	false
Relation: 3708328	CID	63	79	D020888	212	220	D012640	false
Relation: 3708328	CID	81	109	D020888	212	220	D012640	false
Relation: 3708328	CID	233	244	D010862	212	220	D012640	true

Sentence: Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.
Entity: 3708328	19	35	gamma-vinyl-GABA	Chemical	D020888
Entity: 3708328	127	138	convulsions	Disease	D012640
Entity: 3708328	151	162	pilocarpine	Chemical	D010862
Relation: 3708328	CID	19	35	D020888	127	138	D012640	false
Relation: 3708328	CID	151	162	D010862	127	138	D012640	true

Sentence: Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion.
Entity: 3746148	26	49	coronary artery disease	Disease	D003324
Entity: 3746148	101	113	dipyridamole	Chemical	D004176
Relation: 3746148	CID	101	113	D004176	26	49	D003324	false

Sentence: Electrocardiographic changes after dipyridamole infusion (0.568 mg/kg/4 min) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique.
Entity: 3746148	35	47	dipyridamole	Chemical	D004176
Entity: 3746148	110	133	coronary artery disease	Disease	D003324
Relation: 3746148	CID	35	47	D004176	110	133	D003324	false

Sentence: After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.
Entity: 3746148	6	18	dipyridamole	Chemical	D004176
Entity: 3746148	20	28	ischemic	Disease	D007511
Entity: 3746148	40	50	depression	Disease	D003866
Entity: 3746148	100	102	MI	Disease	D009203
Entity: 3746148	121	127	ANT-MI	Disease	D056988
Entity: 3746148	146	152	INF-MI	Disease	D056989
Relation: 3746148	CID	6	18	D004176	20	28	D007511	false
Relation: 3746148	CID	6	18	D004176	40	50	D003866	false
Relation: 3746148	CID	6	18	D004176	100	102	D009203	false
Relation: 3746148	CID	6	18	D004176	121	127	D056988	false
Relation: 3746148	CID	6	18	D004176	146	152	D056989	false

Sentence: The data suggest that the dipyridamole induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow.
Entity: 3746148	26	38	dipyridamole	Chemical	D004176
Entity: 3746148	47	66	myocardial ischemia	Disease	D017202
Relation: 3746148	CID	26	38	D004176	47	66	D017202	true

Sentence: Bradycardia after high-dose intravenous methylprednisolone therapy.
Entity: 3798047	0	11	Bradycardia	Disease	D001919
Entity: 3798047	40	58	methylprednisolone	Chemical	D008775
Relation: 3798047	CID	40	58	D008775	0	11	D001919	true

Sentence: In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.
Entity: 3798047	31	51	rheumatoid arthritis	Disease	D001172
Entity: 3798047	87	105	methylprednisolone	Chemical	D008775
Entity: 3798047	107	109	MP	Chemical	D008775
Relation: 3798047	CID	87	105	D008775	31	51	D001172	false
Relation: 3798047	CID	107	109	D008775	31	51	D001172	false

Sentence: Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.
Entity: 3812624	13	31	downbeat nystagmus	Disease	D009759
Entity: 3812624	36	47	oscillopsia	Disease	D015835
Entity: 3812624	64	77	carbamazepine	Chemical	D002220
Relation: 3812624	CID	64	77	D002220	13	31	D009759	false
Relation: 3812624	CID	64	77	D002220	36	47	D015835	true

Sentence: We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy.
Entity: 3812624	62	80	downbeat nystagmus	Disease	D009759
Entity: 3812624	92	105	carbamazepine	Chemical	D002220
Relation: 3812624	CID	92	105	D002220	62	80	D009759	false

Sentence: The nystagmus of both patients resolved after reduction of the serum carbamazepine levels.
Entity: 3812624	4	13	nystagmus	Disease	D009759
Entity: 3812624	69	82	carbamazepine	Chemical	D002220
Relation: 3812624	CID	69	82	D002220	4	13	D009759	false

Sentence: Improvement by denopamine (TA-064) of pentobarbital induced cardiac failure in the dog heart-lung preparation.
Entity: 3831029	15	25	denopamine	Chemical	C037293
Entity: 3831029	27	33	TA-064	Chemical	C037293
Entity: 3831029	38	51	pentobarbital	Chemical	D010424
Entity: 3831029	60	75	cardiac failure	Disease	D006333
Relation: 3831029	CID	15	25	C037293	60	75	D006333	false
Relation: 3831029	CID	27	33	C037293	60	75	D006333	false
Relation: 3831029	CID	38	51	D010424	60	75	D006333	true

Sentence: The efficacy of denopamine, an orally active beta 1-adrenoceptor agonist, in improving cardiac failure was assessed in dog heart-lung preparations.
Entity: 3831029	16	26	denopamine	Chemical	C037293
Entity: 3831029	87	102	cardiac failure	Disease	D006333
Relation: 3831029	CID	16	26	C037293	87	102	D006333	false

Sentence: No arrhythmias were induced by these doses of denopamine.
Entity: 3831029	3	14	arrhythmias	Disease	D001145
Entity: 3831029	46	56	denopamine	Chemical	C037293
Relation: 3831029	CID	46	56	C037293	3	14	D001145	false

Sentence: Clonazepam monotherapy for epilepsy in childhood.
Entity: 3832950	0	10	Clonazepam	Chemical	D002998
Entity: 3832950	27	35	epilepsy	Disease	D004827
Relation: 3832950	CID	0	10	D002998	27	35	D004827	false

Sentence: Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.
Entity: 3832950	69	77	epilepsy	Disease	D004827
Entity: 3832950	83	99	infantile spasms	Disease	D013036
Entity: 3832950	118	128	clonazepam	Chemical	D002998
Relation: 3832950	CID	118	128	D002998	69	77	D004827	false
Relation: 3832950	CID	118	128	D002998	83	99	D013036	false

Sentence: A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.
Entity: 3833372	135	150	timolol maleate	Chemical	D013999
Entity: 3833372	164	183	hydrochlorothiazide	Chemical	D006852
Entity: 3833372	227	239	hypertensive	Disease	D006973
Relation: 3833372	CID	135	150	D013999	227	239	D006973	false
Relation: 3833372	CID	164	183	D006852	227	239	D006973	false

Sentence: Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.
Entity: 3864191	0	10	Salicylate	Chemical	D012459
Entity: 3864191	11	22	nephropathy	Disease	D007674
Entity: 3864191	58	72	prostaglandins	Chemical	D011453
Relation: 3864191	CID	0	10	D012459	11	22	D007674	false
Relation: 3864191	CID	58	72	D011453	11	22	D007674	false

Sentence: We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat.
Entity: 3864191	34	48	prostaglandins	Chemical	D011453
Entity: 3864191	81	92	nephropathy	Disease	D007674
Relation: 3864191	CID	34	48	D011453	81	92	D007674	false

Sentence: The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.
Entity: 3864191	43	61	hyperbilirubinemia	Disease	D006932
Entity: 3864191	84	94	glucuronyl	Chemical	-1
Entity: 3864191	126	135	bilirubin	Chemical	D001663
Relation: 3864191	CID	84	94	-1	43	61	D006932	false
Relation: 3864191	CID	126	135	D001663	43	61	D006932	false

Sentence: The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).
Entity: 3864191	21	34	prostaglandin	Chemical	D011453
Entity: 3864191	77	89	renal damage	Disease	D007674
Entity: 3864191	93	100	aspirin	Chemical	D001241
Entity: 3864191	181	190	hematuria	Disease	D006417
Entity: 3864191	227	237	creatinine	Chemical	D003404
Entity: 3864191	371	378	aspirin	Chemical	D001241
Relation: 3864191	CID	21	34	D011453	77	89	D007674	false
Relation: 3864191	CID	21	34	D011453	181	190	D006417	false
Relation: 3864191	CID	93	100	D001241	77	89	D007674	true
Relation: 3864191	CID	93	100	D001241	181	190	D006417	false
Relation: 3864191	CID	227	237	D003404	77	89	D007674	false
Relation: 3864191	CID	227	237	D003404	181	190	D006417	false
Relation: 3864191	CID	371	378	D001241	77	89	D007674	true
Relation: 3864191	CID	371	378	D001241	181	190	D006417	false

Sentence: Prophylactic lidocaine in the early phase of suspected myocardial infarction.
Entity: 3895875	13	22	lidocaine	Chemical	D008012
Entity: 3895875	55	76	myocardial infarction	Disease	D009203
Relation: 3895875	CID	13	22	D008012	55	76	D009203	false

Sentence: Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo.
Entity: 3895875	41	62	myocardial infarction	Disease	D009203
Entity: 3895875	151	160	lidocaine	Chemical	D008012
Relation: 3895875	CID	151	160	D008012	41	62	D009203	false

Sentence: Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).
Entity: 3895875	0	9	Lidocaine	Chemical	D008012
Entity: 3895875	110	133	ventricular tachycardia	Disease	D017180
Entity: 3895875	217	228	arrhythmias	Disease	D001145
Entity: 3895875	283	292	lidocaine	Chemical	D008012
Relation: 3895875	CID	0	9	D008012	110	133	D017180	false
Relation: 3895875	CID	0	9	D008012	217	228	D001145	false
Relation: 3895875	CID	283	292	D008012	110	133	D017180	false
Relation: 3895875	CID	283	292	D008012	217	228	D001145	false

Sentence: The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.
Entity: 3895875	19	28	lidocaine	Chemical	D008012
Entity: 3895875	90	111	myocardial infarction	Disease	D009203
Entity: 3895875	174	184	infarction	Disease	D007238
Relation: 3895875	CID	19	28	D008012	90	111	D009203	false
Relation: 3895875	CID	19	28	D008012	174	184	D007238	false

Sentence: During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine.
Entity: 3895875	118	127	lidocaine	Chemical	D008012
Entity: 3895875	135	146	hypotension	Disease	D007022
Entity: 3895875	198	207	lidocaine	Chemical	D008012
Entity: 3895875	237	245	asystole	Disease	D006323
Entity: 3895875	269	278	lidocaine	Chemical	D008012
Relation: 3895875	CID	118	127	D008012	135	146	D007022	true
Relation: 3895875	CID	118	127	D008012	237	245	D006323	false
Relation: 3895875	CID	198	207	D008012	135	146	D007022	true
Relation: 3895875	CID	198	207	D008012	237	245	D006323	false
Relation: 3895875	CID	269	278	D008012	135	146	D007022	true
Relation: 3895875	CID	269	278	D008012	237	245	D006323	false

Sentence: Evidence for a cholinergic role in haloperidol induced catalepsy.
Entity: 3925479	35	46	haloperidol	Chemical	D006220
Entity: 3925479	55	64	catalepsy	Disease	D002375
Relation: 3925479	CID	35	46	D006220	55	64	D002375	true

Sentence: Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic induced catalepsy.
Entity: 3925479	93	102	catalepsy	Disease	D002375
Entity: 3925479	176	187	neuroleptic	Chemical	D014150
Entity: 3925479	196	205	catalepsy	Disease	D002375
Relation: 3925479	CID	176	187	D014150	93	102	D002375	false
Relation: 3925479	CID	176	187	D014150	196	205	D002375	false

Sentence: Large doses of the cholinomimetic, pilocarpine, could induce catalepsy when peripheral cholinergic receptors were blocked.
Entity: 3925479	35	46	pilocarpine	Chemical	D010862
Entity: 3925479	61	70	catalepsy	Disease	D002375
Relation: 3925479	CID	35	46	D010862	61	70	D002375	true

Sentence: Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.
Entity: 3925479	13	24	pilocarpine	Chemical	D010862
Entity: 3925479	64	73	catalepsy	Disease	D002375
Entity: 3925479	120	131	haloperidol	Chemical	D006220
Relation: 3925479	CID	13	24	D010862	64	73	D002375	true
Relation: 3925479	CID	120	131	D006220	64	73	D002375	true

Sentence: A muscarinic receptor blocker, atropine, disrupted haloperidol induced catalepsy.
Entity: 3925479	31	39	atropine	Chemical	D001285
Entity: 3925479	51	62	haloperidol	Chemical	D006220
Entity: 3925479	71	80	catalepsy	Disease	D002375
Relation: 3925479	CID	31	39	D001285	71	80	D002375	false
Relation: 3925479	CID	51	62	D006220	71	80	D002375	true

Sentence: Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.
Entity: 3925479	29	42	acetylcholine	Chemical	D000109
Entity: 3925479	64	77	hemicholinium	Chemical	D006426
Entity: 3925479	93	102	catalepsy	Disease	D002375
Entity: 3925479	130	141	haloperidol	Chemical	D006220
Relation: 3925479	CID	29	42	D000109	93	102	D002375	false
Relation: 3925479	CID	64	77	D006426	93	102	D002375	false
Relation: 3925479	CID	130	141	D006220	93	102	D002375	true

Sentence: These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.
Entity: 3925479	47	56	catalepsy	Disease	D002375
Entity: 3925479	77	89	neuroleptics	Chemical	D014150
Entity: 3925479	98	109	haloperidol	Chemical	D006220
Relation: 3925479	CID	77	89	D014150	47	56	D002375	false
Relation: 3925479	CID	98	109	D006220	47	56	D002375	true

Sentence: Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.
Entity: 3975902	0	26	Cardiovascular dysfunction	Disease	D002318
Entity: 3975902	31	47	hypersensitivity	Disease	D004342
Entity: 3975902	51	71	sodium pentobarbital	Chemical	D010424
Entity: 3975902	91	106	barium chloride	Chemical	C024986
Relation: 3975902	CID	51	71	D010424	0	26	D002318	false
Relation: 3975902	CID	51	71	D010424	31	47	D004342	false
Relation: 3975902	CID	91	106	C024986	0	26	D002318	false
Relation: 3975902	CID	91	106	C024986	31	47	D004342	false

Sentence: Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.
Entity: 3975902	0	6	Barium	Chemical	D001464
Entity: 3975902	78	90	hypertension	Disease	D006973
Entity: 3975902	125	131	barium	Chemical	D001464
Relation: 3975902	CID	0	6	D001464	78	90	D006973	false
Relation: 3975902	CID	125	131	D001464	78	90	D006973	false

Sentence: Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium induced disturbances within the cardiovascular system.
Entity: 3975902	130	136	barium	Chemical	D001464
Entity: 3975902	145	190	disturbances within the cardiovascular system	Disease	D002318
Relation: 3975902	CID	130	136	D001464	145	190	D002318	false

Sentence: The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.
Entity: 3975902	35	41	barium	Chemical	D001464
Entity: 3975902	68	84	hypersensitivity	Disease	D004342
Entity: 3975902	117	137	sodium pentobarbital	Chemical	D010424
Relation: 3975902	CID	35	41	D001464	68	84	D004342	false
Relation: 3975902	CID	117	137	D010424	68	84	D004342	false

Sentence: Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.
Entity: 3975902	92	114	metabolic disturbances	Disease	D008659
Entity: 3975902	124	140	hypersensitivity	Disease	D004342
Entity: 3975902	173	193	sodium pentobarbital	Chemical	D010424
Entity: 3975902	244	268	cardiomyopathic disorder	Disease	D009202
Entity: 3975902	288	294	barium	Chemical	D001464
Relation: 3975902	CID	173	193	D010424	92	114	D008659	false
Relation: 3975902	CID	173	193	D010424	124	140	D004342	false
Relation: 3975902	CID	173	193	D010424	244	268	D009202	false
Relation: 3975902	CID	288	294	D001464	92	114	D008659	false
Relation: 3975902	CID	288	294	D001464	124	140	D004342	false
Relation: 3975902	CID	288	294	D001464	244	268	D009202	false

Sentence: Propranolol antagonism of phenylpropanolamine induced hypertension.
Entity: 3987172	0	11	Propranolol	Chemical	D011433
Entity: 3987172	26	45	phenylpropanolamine	Chemical	D010665
Entity: 3987172	54	66	hypertension	Disease	D006973
Relation: 3987172	CID	0	11	D011433	54	66	D006973	false
Relation: 3987172	CID	26	45	D010665	54	66	D006973	true

Sentence: Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.
Entity: 3987172	0	19	Phenylpropanolamine	Chemical	D010665
Entity: 3987172	21	24	PPA	Chemical	D010665
Entity: 3987172	26	34	overdose	Disease	D062787
Entity: 3987172	52	64	hypertension	Disease	D006973
Entity: 3987172	66	90	intracerebral hemorrhage	Disease	D002543
Relation: 3987172	CID	0	19	D010665	26	34	D062787	false
Relation: 3987172	CID	0	19	D010665	52	64	D006973	true
Relation: 3987172	CID	0	19	D010665	66	90	D002543	false
Relation: 3987172	CID	21	24	D010665	26	34	D062787	false
Relation: 3987172	CID	21	24	D010665	52	64	D006973	true
Relation: 3987172	CID	21	24	D010665	66	90	D002543	false

Sentence: We studied the efficacy and safety of propranolol in the treatment of PPA induced hypertension.
Entity: 3987172	38	49	propranolol	Chemical	D011433
Entity: 3987172	70	73	PPA	Chemical	D010665
Entity: 3987172	82	94	hypertension	Disease	D006973
Relation: 3987172	CID	38	49	D011433	82	94	D006973	false
Relation: 3987172	CID	70	73	D010665	82	94	D006973	true

Sentence: Left ventricular function (assessed by echocardiography) showed that PPA increased the stroke volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min).
Entity: 3987172	69	72	PPA	Chemical	D010665
Entity: 3987172	87	93	stroke	Disease	D020521
Relation: 3987172	CID	69	72	D010665	87	93	D020521	false

Sentence: Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.
Entity: 3990093	23	43	glomerular sclerosis	Disease	D007674
Entity: 3990093	57	72	aminonucleoside	Chemical	D011692
Entity: 3990093	73	82	nephrosis	Disease	D009401
Relation: 3990093	CID	57	72	D011692	23	43	D007674	false
Relation: 3990093	CID	57	72	D011692	73	82	D009401	false

Sentence: The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.
Entity: 3990093	34	55	mesangial dysfunction	Disease	D007674
Entity: 3990093	75	95	glomerular sclerosis	Disease	D007674
Entity: 3990093	115	140	puromycin aminonucleoside	Chemical	D011692
Entity: 3990093	142	145	PAN	Chemical	D011692
Relation: 3990093	CID	115	140	D011692	34	55	D007674	false
Relation: 3990093	CID	115	140	D011692	75	95	D007674	false
Relation: 3990093	CID	142	145	D011692	34	55	D007674	false
Relation: 3990093	CID	142	145	D011692	75	95	D007674	false

Sentence: After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously.
Entity: 3990093	18	21	PAN	Chemical	D011692
Entity: 3990093	41	52	proteinuric	Disease	D011507
Entity: 3990093	110	116	carbon	Chemical	D002244
Relation: 3990093	CID	18	21	D011692	41	52	D011507	true
Relation: 3990093	CID	110	116	D002244	41	52	D011507	false

Sentence: At 5 months glomerular sclerosis was found in 7.6 +/- 3.4% of the glomeruli of PAN rats; glomeruli of the controls were normal.
Entity: 3990093	12	32	glomerular sclerosis	Disease	D007674
Entity: 3990093	79	82	PAN	Chemical	D011692
Relation: 3990093	CID	79	82	D011692	12	32	D007674	false

Sentence: Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.
Entity: 3990093	78	81	PAN	Chemical	D011692
Entity: 3990093	258	267	sclerosis	Disease	D012598
Relation: 3990093	CID	78	81	D011692	258	267	D012598	false

Sentence: Relationship between nicotine induced seizures and hippocampal nicotinic receptors.
Entity: 4010471	21	29	nicotine	Chemical	D009538
Entity: 4010471	38	46	seizures	Disease	D012640
Relation: 4010471	CID	21	29	D009538	38	46	D012640	true

Sentence: Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.
Entity: 4010471	92	100	nicotine	Chemical	D009538
Entity: 4010471	109	117	seizures	Disease	D012640
Relation: 4010471	CID	92	100	D009538	109	117	D012640	true

Sentence: Mice sensitive to the convulsant effects of nicotine had greater alpha-bungarotoxin binding in the hippocampus than seizure insensitive mice.
Entity: 4010471	44	52	nicotine	Chemical	D009538
Entity: 4010471	116	123	seizure	Disease	D012640
Relation: 4010471	CID	44	52	D009538	116	123	D012640	true

Sentence: The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.
Entity: 4010471	23	30	seizure	Disease	D012640
Entity: 4010471	100	114	dithiothreitol	Chemical	D004229
Relation: 4010471	CID	100	114	D004229	23	30	D012640	false

Sentence: The role of p-aminophenol in acetaminophen induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.
Entity: 4082192	12	25	p-aminophenol	Chemical	C026729
Entity: 4082192	29	42	acetaminophen	Chemical	D000082
Entity: 4082192	51	65	nephrotoxicity	Disease	D007674
Entity: 4082192	77	105	bis(p-nitrophenyl) phosphate	Chemical	C002887
Entity: 4082192	109	122	acetaminophen	Chemical	D000082
Entity: 4082192	127	140	p-aminophenol	Chemical	C026729
Entity: 4082192	141	155	nephrotoxicity	Disease	D007674
Relation: 4082192	CID	12	25	C026729	51	65	D007674	false
Relation: 4082192	CID	12	25	C026729	141	155	D007674	false
Relation: 4082192	CID	29	42	D000082	51	65	D007674	false
Relation: 4082192	CID	29	42	D000082	141	155	D007674	false
Relation: 4082192	CID	77	105	C002887	51	65	D007674	false
Relation: 4082192	CID	77	105	C002887	141	155	D007674	false
Relation: 4082192	CID	109	122	D000082	51	65	D007674	false
Relation: 4082192	CID	109	122	D000082	141	155	D007674	false
Relation: 4082192	CID	127	140	C026729	51	65	D007674	false
Relation: 4082192	CID	127	140	C026729	141	155	D007674	false

Sentence: Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.
Entity: 4082192	0	13	Acetaminophen	Chemical	D000082
Entity: 4082192	15	19	APAP	Chemical	D000082
Entity: 4082192	39	55	tubular necrosis	Disease	D007683
Relation: 4082192	CID	0	13	D000082	39	55	D007683	true
Relation: 4082192	CID	15	19	D000082	39	55	D007683	true

Sentence: The purpose of this study was to determine if PAP formation is a requisite step in APAP induced nephrotoxicity.
Entity: 4082192	46	49	PAP	Chemical	C026729
Entity: 4082192	83	87	APAP	Chemical	D000082
Entity: 4082192	96	110	nephrotoxicity	Disease	D007674
Relation: 4082192	CID	46	49	C026729	96	110	D007674	false
Relation: 4082192	CID	83	87	D000082	96	110	D007674	false

Sentence: Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.
Entity: 4082192	25	53	bis(p-nitrophenyl) phosphate	Chemical	C002887
Entity: 4082192	55	59	BNPP	Chemical	C002887
Entity: 4082192	91	95	APAP	Chemical	D000082
Entity: 4082192	100	103	PAP	Chemical	C026729
Entity: 4082192	104	118	nephrotoxicity	Disease	D007674
Relation: 4082192	CID	25	53	C002887	104	118	D007674	false
Relation: 4082192	CID	55	59	C002887	104	118	D007674	false
Relation: 4082192	CID	91	95	D000082	104	118	D007674	false
Relation: 4082192	CID	100	103	C026729	104	118	D007674	false

Sentence: Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.
Entity: 4082192	29	33	BNPP	Chemical	C002887
Entity: 4082192	43	47	APAP	Chemical	D000082
Entity: 4082192	51	54	PAP	Chemical	C026729
Entity: 4082192	102	106	APAP	Chemical	D000082
Entity: 4082192	119	133	nephrotoxicity	Disease	D007674
Entity: 4082192	142	145	PAP	Chemical	C026729
Entity: 4082192	146	160	nephrotoxicity	Disease	D007674
Relation: 4082192	CID	29	33	C002887	119	133	D007674	false
Relation: 4082192	CID	29	33	C002887	146	160	D007674	false
Relation: 4082192	CID	43	47	D000082	119	133	D007674	false
Relation: 4082192	CID	43	47	D000082	146	160	D007674	false
Relation: 4082192	CID	51	54	C026729	119	133	D007674	false
Relation: 4082192	CID	51	54	C026729	146	160	D007674	false
Relation: 4082192	CID	102	106	D000082	119	133	D007674	false
Relation: 4082192	CID	102	106	D000082	146	160	D007674	false
Relation: 4082192	CID	142	145	C026729	119	133	D007674	false
Relation: 4082192	CID	142	145	C026729	146	160	D007674	false

Sentence: Therefore, the BNPP induced reduction in APAP induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.
Entity: 4082192	15	19	BNPP	Chemical	C002887
Entity: 4082192	41	45	APAP	Chemical	D000082
Entity: 4082192	54	68	nephrotoxicity	Disease	D007674
Entity: 4082192	104	108	APAP	Chemical	D000082
Relation: 4082192	CID	15	19	C002887	54	68	D007674	false
Relation: 4082192	CID	41	45	D000082	54	68	D007674	false
Relation: 4082192	CID	104	108	D000082	54	68	D007674	false

Sentence: Morphine induced seizures in newborn infants.
Entity: 4082466	0	8	Morphine	Chemical	D009020
Entity: 4082466	17	25	seizures	Disease	D012640
Relation: 4082466	CID	0	8	D009020	17	25	D012640	true

Sentence: Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.
Entity: 4082466	39	47	seizures	Disease	D012640
Entity: 4082466	81	97	morphine sulfate	Chemical	D009020
Relation: 4082466	CID	81	97	D009020	39	47	D012640	true

Sentence: They received morphine in doses of 32 micrograms/kg/hr and 40 micrograms/kg/hr larger than a group of 10 neonates who received 6-24 micrograms/kg/hr and had no seizures.
Entity: 4082466	14	22	morphine	Chemical	D009020
Entity: 4082466	160	168	seizures	Disease	D012640
Relation: 4082466	CID	14	22	D009020	160	168	D012640	true

Sentence: Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.
Entity: 4082466	24	32	seizures	Disease	D012640
Entity: 4082466	56	67	convulsions	Disease	D012640
Entity: 4082466	107	115	morphine	Chemical	D009020
Relation: 4082466	CID	107	115	D009020	24	32	D012640	true
Relation: 4082466	CID	107	115	D009020	56	67	D012640	true

Sentence: Effect of vincristine sulfate on Pseudomonas infections in monkeys.
Entity: 4631913	10	29	vincristine sulfate	Chemical	D014750
Entity: 4631913	33	55	Pseudomonas infections	Disease	D011552
Relation: 4631913	CID	10	29	D014750	33	55	D011552	true

Sentence: Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days.
Entity: 4631913	61	80	vincristine sulfate	Chemical	D014750
Entity: 4631913	97	107	leukopenia	Disease	D007970
Relation: 4631913	CID	61	80	D014750	97	107	D007970	true

Sentence: Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died.
Entity: 4631913	109	128	vincristine sulfate	Chemical	D014750
Entity: 4631913	165	174	infection	Disease	D007239
Relation: 4631913	CID	109	128	D014750	165	174	D007239	false

Sentence: Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.
Entity: 6106951	9	12	FZP	Chemical	D005479
Entity: 6106951	13	21	toxocity	Disease	D064420
Entity: 6106951	49	59	salivation	Disease	D012798
Entity: 6106951	102	116	muscle tremors	Disease	D014202
Entity: 6106951	121	132	convulsions	Disease	D012640
Relation: 6106951	CID	9	12	D005479	13	21	D064420	false
Relation: 6106951	CID	9	12	D005479	49	59	D012798	false
Relation: 6106951	CID	9	12	D005479	102	116	D014202	false
Relation: 6106951	CID	9	12	D005479	121	132	D012640	true

Sentence: As a function of dose, FZP first protected against convulsions and death.
Entity: 6106951	23	26	FZP	Chemical	D005479
Entity: 6106951	51	62	convulsions	Disease	D012640
Relation: 6106951	CID	23	26	D005479	51	62	D012640	true

Sentence: These doses of FZP were lower than those that would alone cause convulsions.
Entity: 6106951	15	18	FZP	Chemical	D005479
Entity: 6106951	64	75	convulsions	Disease	D012640
Relation: 6106951	CID	15	18	D005479	64	75	D012640	true

Sentence: We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol induced tachycardia in two experiments involving nine normal subjects.
Entity: 6299641	49	57	atenolol	Chemical	D001262
Entity: 6299641	83	94	propranolol	Chemical	D011433
Entity: 6299641	145	158	isoproterenol	Chemical	D007545
Entity: 6299641	167	178	tachycardia	Disease	D013610
Relation: 6299641	CID	49	57	D001262	167	178	D013610	false
Relation: 6299641	CID	83	94	D011433	167	178	D013610	false
Relation: 6299641	CID	145	158	D007545	167	178	D013610	true

Sentence: The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).
Entity: 6299641	15	28	isoproterenol	Chemical	D007545
Entity: 6299641	29	40	tachycardia	Disease	D013610
Entity: 6299641	74	82	atropine	Chemical	D001285
Relation: 6299641	CID	15	28	D007545	29	40	D013610	true
Relation: 6299641	CID	74	82	D001285	29	40	D013610	false

Sentence: Early infections in kidney, heart, and liver transplant recipients on cyclosporine.
Entity: 6310832	6	16	infections	Disease	D007239
Entity: 6310832	70	82	cyclosporine	Chemical	D016572
Relation: 6310832	CID	70	82	D016572	6	16	D007239	true

Sentence: The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.
Entity: 6310832	15	18	Aza	Chemical	D001379
Entity: 6310832	45	55	infections	Disease	D007239
Entity: 6310832	93	103	infections	Disease	D007239
Entity: 6310832	143	155	cyclosporine	Chemical	D016572
Relation: 6310832	CID	15	18	D001379	45	55	D007239	true
Relation: 6310832	CID	15	18	D001379	93	103	D007239	true
Relation: 6310832	CID	143	155	D016572	45	55	D007239	true
Relation: 6310832	CID	143	155	D016572	93	103	D007239	true

Sentence: Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.
Entity: 6310832	34	44	infections	Disease	D007239
Entity: 6310832	50	62	cyclosporine	Chemical	D016572
Entity: 6310832	88	98	infections	Disease	D007239
Entity: 6310832	108	111	Aza	Chemical	D001379
Relation: 6310832	CID	50	62	D016572	34	44	D007239	true
Relation: 6310832	CID	50	62	D016572	88	98	D007239	true
Relation: 6310832	CID	108	111	D001379	34	44	D007239	true
Relation: 6310832	CID	108	111	D001379	88	98	D007239	true

Sentence: There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.
Entity: 6310832	64	76	cyclosporine	Chemical	D016572
Entity: 6310832	80	83	Aza	Chemical	D001379
Entity: 6310832	89	98	infection	Disease	D007239
Relation: 6310832	CID	64	76	D016572	89	98	D007239	true
Relation: 6310832	CID	80	83	D001379	89	98	D007239	true

Sentence: Renal patients on cyclosporine had the fewest bacteremias.
Entity: 6310832	18	30	cyclosporine	Chemical	D016572
Entity: 6310832	46	57	bacteremias	Disease	D016470
Relation: 6310832	CID	18	30	D016572	46	57	D016470	false

Sentence: Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).
Entity: 6310832	10	20	infections	Disease	D007239
Entity: 6310832	41	53	cyclosporine	Chemical	D016572
Entity: 6310832	85	88	Aza	Chemical	D001379
Relation: 6310832	CID	41	53	D016572	10	20	D007239	true
Relation: 6310832	CID	85	88	D001379	10	20	D007239	true

Sentence: Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.
Entity: 6310832	0	3	Aza	Chemical	D001379
Entity: 6310832	36	61	staphylococcal infections	Disease	D013203
Entity: 6310832	129	146	fungal infections	Disease	D009181
Relation: 6310832	CID	0	3	D001379	36	61	D013203	false
Relation: 6310832	CID	0	3	D001379	129	146	D009181	false

Sentence: Of the cyclosporine patients, 15% had symptoms related to CMV infection.
Entity: 6310832	7	19	cyclosporine	Chemical	D016572
Entity: 6310832	58	71	CMV infection	Disease	D003586
Relation: 6310832	CID	7	19	D016572	58	71	D003586	false

Sentence: Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied.
Entity: 6310832	25	53	Epstein Barr Virus infection	Disease	D020031
Entity: 6310832	77	89	cyclosporine	Chemical	D016572
Relation: 6310832	CID	77	89	D016572	25	53	D020031	false

Sentence: Structure-activity and dose-effect relationships of the antagonism of picrotoxin induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.
Entity: 6316193	70	80	picrotoxin	Chemical	D010852
Entity: 6316193	89	97	seizures	Disease	D012640
Entity: 6316193	101	116	cholecystokinin	Chemical	D002766
Entity: 6316193	145	160	cholecystokinin	Chemical	D002766
Relation: 6316193	CID	70	80	D010852	89	97	D012640	true
Relation: 6316193	CID	101	116	D002766	89	97	D012640	false
Relation: 6316193	CID	145	160	D002766	89	97	D012640	false

Sentence: Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.
Entity: 6316193	34	61	cholecystokinin octapeptide	Chemical	D012844
Entity: 6316193	78	83	CCK-8	Chemical	D012844
Entity: 6316193	105	132	cholecystokinin octapeptide	Chemical	D012844
Entity: 6316193	134	139	CCK-8	Chemical	D012844
Entity: 6316193	168	176	seizures	Disease	D012640
Entity: 6316193	188	198	picrotoxin	Chemical	D010852
Relation: 6316193	CID	34	61	D012844	168	176	D012640	false
Relation: 6316193	CID	78	83	D012844	168	176	D012640	false
Relation: 6316193	CID	105	132	D012844	168	176	D012640	false
Relation: 6316193	CID	134	139	D012844	168	176	D012640	false
Relation: 6316193	CID	188	198	D010852	168	176	D012640	true

Sentence: The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin induced seizures and mortality.
Entity: 6316193	141	149	diazepam	Chemical	D003975
Entity: 6316193	169	179	picrotoxin	Chemical	D010852
Entity: 6316193	188	196	seizures	Disease	D012640
Relation: 6316193	CID	141	149	D003975	188	196	D012640	false
Relation: 6316193	CID	169	179	D010852	188	196	D012640	true

Sentence: Vasopressin as a possible contributor to hypertension.
Entity: 6321816	0	11	Vasopressin	Chemical	D014667
Entity: 6321816	41	53	hypertension	Disease	D006973
Relation: 6321816	CID	0	11	D014667	41	53	D006973	false

Sentence: The role of vasopressin as a pressor agent to the hypertensive process was examined.
Entity: 6321816	12	23	vasopressin	Chemical	D014667
Entity: 6321816	50	62	hypertensive	Disease	D006973
Relation: 6321816	CID	12	23	D014667	50	62	D006973	false

Sentence: Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.
Entity: 6321816	0	11	Vasopressin	Chemical	D014667
Entity: 6321816	54	58	DOCA	Chemical	D003900
Entity: 6321816	64	76	hypertension	Disease	D006973
Entity: 6321816	153	160	lithium	Chemical	D008094
Entity: 6321816	169	187	diabetes insipidus	Disease	D003919
Entity: 6321816	194	198	DOCA	Chemical	D003900
Relation: 6321816	CID	0	11	D014667	64	76	D006973	false
Relation: 6321816	CID	0	11	D014667	169	187	D003919	false
Relation: 6321816	CID	54	58	D003900	64	76	D006973	true
Relation: 6321816	CID	54	58	D003900	169	187	D003919	false
Relation: 6321816	CID	153	160	D008094	64	76	D006973	false
Relation: 6321816	CID	153	160	D008094	169	187	D003919	true
Relation: 6321816	CID	194	198	D003900	64	76	D006973	true
Relation: 6321816	CID	194	198	D003900	169	187	D003919	false

Sentence: Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension.
Entity: 6321816	35	46	vasopressin	Chemical	D014667
Entity: 6321816	107	119	hypertension	Disease	D006973
Entity: 6321816	215	227	hypertension	Disease	D006973
Relation: 6321816	CID	35	46	D014667	107	119	D006973	false
Relation: 6321816	CID	35	46	D014667	215	227	D006973	false

Sentence: Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension.
Entity: 6321816	23	34	vasopressin	Chemical	D014667
Entity: 6321816	126	138	hypertension	Disease	D006973
Relation: 6321816	CID	23	34	D014667	126	138	D006973	false

Sentence: Toxic hepatitis induced by disulfiram in a non-alcoholic.
Entity: 6453500	0	15	Toxic hepatitis	Disease	D056486
Entity: 6453500	27	37	disulfiram	Chemical	D004221
Relation: 6453500	CID	27	37	D004221	0	15	D056486	true

Sentence: Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.
Entity: 6517710	0	17	Atrial thrombosis	Disease	D003328
Entity: 6517710	62	86	quinacrine hydrochloride	Chemical	D011796
Relation: 6517710	CID	62	86	D011796	0	17	D003328	true

Sentence: Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis.
Entity: 6517710	26	50	quinacrine hydrochloride	Chemical	D011796
Entity: 6517710	102	119	atrial thrombosis	Disease	D003328
Relation: 6517710	CID	26	50	D011796	102	119	D003328	true

Sentence: Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.
Entity: 6517710	38	62	quinacrine hydrochloride	Chemical	D011796
Entity: 6517710	77	91	sodium nitrite	Chemical	D012977
Entity: 6517710	123	133	thrombosis	Disease	D013927
Entity: 6517710	222	239	atrial thrombosis	Disease	D003328
Relation: 6517710	CID	38	62	D011796	123	133	D013927	false
Relation: 6517710	CID	38	62	D011796	222	239	D003328	true
Relation: 6517710	CID	77	91	D012977	123	133	D013927	false
Relation: 6517710	CID	77	91	D012977	222	239	D003328	false

Sentence: Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.
Entity: 6529939	0	24	Alternating sinus rhythm	Disease	D001146
Entity: 6529939	42	58	sinoatrial block	Disease	D012848
Entity: 6529939	70	81	propranolol	Chemical	D011433
Relation: 6529939	CID	70	81	D011433	0	24	D001146	true
Relation: 6529939	CID	70	81	D011433	42	58	D012848	true

Sentence: Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.
Entity: 6529939	0	24	Alternating sinus rhythm	Disease	D001146
Entity: 6529939	42	64	sinoatrial (S-A) block	Disease	D012848
Entity: 6529939	122	128	angina	Disease	D000787
Entity: 6529939	140	151	propranolol	Chemical	D011433
Relation: 6529939	CID	140	151	D011433	0	24	D001146	true
Relation: 6529939	CID	140	151	D011433	42	64	D012848	true
Relation: 6529939	CID	140	151	D011433	122	128	D000787	false

Sentence: The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen.
Entity: 6529939	55	66	propranolol	Chemical	D011433
Entity: 6529939	105	114	S-A block	Disease	D012848
Relation: 6529939	CID	55	66	D011433	105	114	D012848	true

Sentence: Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.
Entity: 6585590	18	32	cardiotoxicity	Disease	D066126
Entity: 6585590	38	52	nephrotoxicity	Disease	D007674
Entity: 6585590	56	67	doxorubicin	Chemical	D004317
Entity: 6585590	85	97	immunocytoma	Disease	-1
Relation: 6585590	CID	56	67	D004317	18	32	D066126	false
Relation: 6585590	CID	56	67	D004317	38	52	D007674	false
Relation: 6585590	CID	56	67	D004317	85	97	-1	false

Sentence: Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.
Entity: 6585590	20	34	cardiotoxicity	Disease	D066126
Entity: 6585590	40	54	nephrotoxicity	Disease	D007674
Entity: 6585590	66	77	doxorubicin	Chemical	D004317
Entity: 6585590	156	168	immunocytoma	Disease	-1
Relation: 6585590	CID	66	77	D004317	20	34	D066126	false
Relation: 6585590	CID	66	77	D004317	40	54	D007674	false
Relation: 6585590	CID	66	77	D004317	156	168	-1	false

Sentence: Animals with a tumor (diameter, 15.8 +/- 3.3 mm) were treated with iv injections of doxorubicin on 5 consecutive days, followed by 1 weekly injection for 7 weeks (dose range, 0.015-4.0 mg/kg body wt).
Entity: 6585590	15	20	tumor	Disease	D009369
Entity: 6585590	84	95	doxorubicin	Chemical	D004317
Relation: 6585590	CID	84	95	D004317	15	20	D009369	false

Sentence: Tumor regression was observed with 0.5 mg doxorubicin/kg.
Entity: 6585590	0	5	Tumor	Disease	D009369
Entity: 6585590	42	53	doxorubicin	Chemical	D004317
Relation: 6585590	CID	42	53	D004317	0	5	D009369	false

Sentence: Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.
Entity: 6585590	30	35	tumor	Disease	D009369
Entity: 6585590	60	71	doxorubicin	Chemical	D004317
Relation: 6585590	CID	60	71	D004317	30	35	D009369	false

Sentence: Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1.0 mg doxorubicin/kg.
Entity: 6585590	23	37	cardiotoxicity	Disease	D066126
Entity: 6585590	96	107	doxorubicin	Chemical	D004317
Relation: 6585590	CID	96	107	D004317	23	37	D066126	false

Sentence: Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.
Entity: 6585590	30	42	renal damage	Disease	D007674
Entity: 6585590	75	86	doxorubicin	Chemical	D004317
Entity: 6585590	109	120	albuminuria	Disease	D000419
Relation: 6585590	CID	75	86	D004317	30	42	D007674	false
Relation: 6585590	CID	75	86	D004317	109	120	D000419	true

Sentence: Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.
Entity: 6615679	15	26	bradycardia	Disease	D001919
Entity: 6615679	31	42	hypotension	Disease	D007022
Entity: 6615679	59	66	timolol	Chemical	D013999
Entity: 6615679	71	82	pilocarpine	Chemical	D010862
Relation: 6615679	CID	59	66	D013999	15	26	D001919	true
Relation: 6615679	CID	59	66	D013999	31	42	D007022	true
Relation: 6615679	CID	71	82	D010862	15	26	D001919	true
Relation: 6615679	CID	71	82	D010862	31	42	D007022	true

Sentence: A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.
Entity: 6615679	57	76	pilocarpine nitrate	Chemical	D010862
Entity: 6615679	81	96	timolol maleate	Chemical	D013999
Entity: 6615679	120	131	bradycardia	Disease	D001919
Entity: 6615679	143	154	hypotensive	Disease	D007022
Entity: 6615679	162	171	halothane	Chemical	D006221
Relation: 6615679	CID	57	76	D010862	120	131	D001919	true
Relation: 6615679	CID	57	76	D010862	143	154	D007022	true
Relation: 6615679	CID	81	96	D013999	120	131	D001919	true
Relation: 6615679	CID	81	96	D013999	143	154	D007022	true
Relation: 6615679	CID	162	171	D006221	120	131	D001919	false
Relation: 6615679	CID	162	171	D006221	143	154	D007022	false

Sentence: It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.
Entity: 6615679	64	73	halothane	Chemical	D006221
Entity: 6615679	101	112	bradycardia	Disease	D001919
Entity: 6615679	117	128	hypotension	Disease	D007022
Relation: 6615679	CID	64	73	D006221	101	112	D001919	false
Relation: 6615679	CID	64	73	D006221	117	128	D007022	false

Sentence: Succinylcholine apnoea: attempted reversal with anticholinesterases.
Entity: 6627074	0	15	Succinylcholine	Chemical	D013390
Entity: 6627074	16	22	apnoea	Disease	D001049
Relation: 6627074	CID	0	15	D013390	16	22	D001049	true

Sentence: Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase.
Entity: 6627074	76	98	neuromuscular blockade	Disease	D020879
Entity: 6627074	131	146	succinylcholine	Chemical	D013390
Relation: 6627074	CID	131	146	D013390	76	98	D020879	false

Sentence: Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).
Entity: 6673474	76	96	sodium nitroprusside	Chemical	D009599
Entity: 6673474	98	101	SNP	Chemical	D009599
Entity: 6673474	107	118	trimetaphan	Chemical	D014294
Entity: 6673474	120	123	TMP	Chemical	D014294
Entity: 6673474	136	147	hypotension	Disease	D007022
Relation: 6673474	CID	76	96	D009599	136	147	D007022	true
Relation: 6673474	CID	98	101	D009599	136	147	D007022	true
Relation: 6673474	CID	107	118	D014294	136	147	D007022	true
Relation: 6673474	CID	120	123	D014294	136	147	D007022	true

Sentence: Regarding the effects of drug induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.
Entity: 6673474	38	49	hypotension	Disease	D007022
Entity: 6673474	153	166	nitroprusside	Chemical	D009599
Entity: 6673474	167	178	hypotension	Disease	D007022
Entity: 6673474	250	261	trimetaphan	Chemical	D014294
Entity: 6673474	262	273	hypotension	Disease	D007022
Relation: 6673474	CID	153	166	D009599	38	49	D007022	true
Relation: 6673474	CID	153	166	D009599	167	178	D007022	true
Relation: 6673474	CID	153	166	D009599	262	273	D007022	true
Relation: 6673474	CID	250	261	D014294	38	49	D007022	true
Relation: 6673474	CID	250	261	D014294	167	178	D007022	true
Relation: 6673474	CID	250	261	D014294	262	273	D007022	true

Sentence: Cardiac work was significantly reduced during SNP hypotension.
Entity: 6673474	46	49	SNP	Chemical	D009599
Entity: 6673474	50	61	hypotension	Disease	D007022
Relation: 6673474	CID	46	49	D009599	50	61	D007022	true

Sentence: The hyperactivity induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.
Entity: 6687006	4	17	hyperactivity	Disease	D006948
Entity: 6687006	29	42	D-amphetamine	Chemical	D003913
Entity: 6687006	86	90	DSP4	Chemical	C012102
Relation: 6687006	CID	29	42	D003913	4	17	D006948	true
Relation: 6687006	CID	86	90	C012102	4	17	D006948	false

Sentence: However, the increased rearings and the amphetamine induced stereotypies were not blocked by pretreatment with DSP4.
Entity: 6687006	40	51	amphetamine	Chemical	D000661
Entity: 6687006	60	72	stereotypies	Disease	D019956
Entity: 6687006	111	115	DSP4	Chemical	C012102
Relation: 6687006	CID	40	51	D000661	60	72	D019956	false
Relation: 6687006	CID	111	115	C012102	60	72	D019956	false

Sentence: The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.
Entity: 6687006	17	28	amphetamine	Chemical	D000661
Entity: 6687006	29	42	hyperactivity	Disease	D006948
Entity: 6687006	54	58	DSP4	Chemical	C012102
Entity: 6687006	96	109	noradrenaline	Chemical	D009638
Entity: 6687006	133	144	desipramine	Chemical	D003891
Entity: 6687006	165	175	neurotoxic	Disease	D020258
Entity: 6687006	186	190	DSP4	Chemical	C012102
Relation: 6687006	CID	17	28	D000661	29	42	D006948	false
Relation: 6687006	CID	17	28	D000661	165	175	D020258	false
Relation: 6687006	CID	54	58	C012102	29	42	D006948	false
Relation: 6687006	CID	54	58	C012102	165	175	D020258	false
Relation: 6687006	CID	96	109	D009638	29	42	D006948	false
Relation: 6687006	CID	96	109	D009638	165	175	D020258	false
Relation: 6687006	CID	133	144	D003891	29	42	D006948	false
Relation: 6687006	CID	133	144	D003891	165	175	D020258	false
Relation: 6687006	CID	186	190	C012102	29	42	D006948	false
Relation: 6687006	CID	186	190	C012102	165	175	D020258	false

Sentence: Accelerated junctional rhythms during oral verapamil therapy.
Entity: 6695685	0	30	Accelerated junctional rhythms	Disease	D001145
Entity: 6695685	43	52	verapamil	Chemical	D014700
Relation: 6695685	CID	43	52	D014700	0	30	D001145	true

Sentence: This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil.
Entity: 6695685	76	106	accelerated junctional rhythms	Disease	D001145
Entity: 6695685	137	146	verapamil	Chemical	D014700
Relation: 6695685	CID	137	146	D014700	76	106	D001145	true

Sentence: Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Entity: 6806735	13	27	ovarian cancer	Disease	D010051
Entity: 6806735	50	62	cis-platinum	Chemical	D002945
Entity: 6806735	64	74	adriamycin	Chemical	D004317
Entity: 6806735	76	92	cyclophosphamide	Chemical	D003520
Entity: 6806735	97	115	hexamethylmelamine	Chemical	D006585
Relation: 6806735	CID	50	62	D002945	13	27	D010051	false
Relation: 6806735	CID	64	74	D004317	13	27	D010051	false
Relation: 6806735	CID	76	92	D003520	13	27	D010051	false
Relation: 6806735	CID	97	115	D006585	13	27	D010051	false

Sentence: During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.
Entity: 6806735	46	60	ovarian cancer	Disease	D010051
Entity: 6806735	96	107	cisplatinum	Chemical	D002945
Entity: 6806735	109	113	CPDD	Chemical	C034868
Entity: 6806735	126	136	adriamycin	Chemical	D004317
Entity: 6806735	148	164	cyclophosphamide	Chemical	D003520
Entity: 6806735	191	209	hexamethylmelamine	Chemical	D006585
Entity: 6806735	211	214	HMM	Chemical	D006585
Relation: 6806735	CID	96	107	D002945	46	60	D010051	false
Relation: 6806735	CID	109	113	C034868	46	60	D010051	false
Relation: 6806735	CID	126	136	D004317	46	60	D010051	false
Relation: 6806735	CID	148	164	D003520	46	60	D010051	false
Relation: 6806735	CID	191	209	D006585	46	60	D010051	false
Relation: 6806735	CID	211	214	D006585	46	60	D010051	false

Sentence: HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients.
Entity: 6806735	0	3	HMM	Chemical	D006585
Entity: 6806735	4	29	gastrointestinal toxicity	Disease	D005767
Relation: 6806735	CID	0	3	D006585	4	29	D005767	false

Sentence: Propylthiouracil induced hepatic damage.
Entity: 6893265	0	16	Propylthiouracil	Chemical	D011441
Entity: 6893265	25	39	hepatic damage	Disease	D056486
Relation: 6893265	CID	0	16	D011441	25	39	D056486	true

Sentence: Two cases of propylthiouracil induced liver damage have been observed.
Entity: 6893265	13	29	propylthiouracil	Chemical	D011441
Entity: 6893265	38	50	liver damage	Disease	D056486
Relation: 6893265	CID	13	29	D011441	38	50	D056486	true

Sentence: Studies on the bradycardia induced by bepridil.
Entity: 6985297	15	26	bradycardia	Disease	D001919
Entity: 6985297	38	46	bepridil	Chemical	D015764
Relation: 6985297	CID	38	46	D015764	15	26	D001919	true

Sentence: Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.
Entity: 6985297	0	8	Bepridil	Chemical	D015764
Entity: 6985297	64	79	anginal attacks	Disease	D000787
Entity: 6985297	100	111	bradycardia	Disease	D001919
Entity: 6985297	136	148	tachycardial	Disease	D013610
Relation: 6985297	CID	0	8	D015764	64	79	D000787	false
Relation: 6985297	CID	0	8	D015764	100	111	D001919	true
Relation: 6985297	CID	0	8	D015764	136	148	D013610	false

Sentence: Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.
Entity: 6985498	0	9	Hepatitis	Disease	D056486
Entity: 6985498	14	36	renal tubular acidosis	Disease	D000141
Entity: 6985498	59	73	methoxyflurane	Chemical	D008733
Relation: 6985498	CID	59	73	D008733	0	9	D056486	true
Relation: 6985498	CID	59	73	D008733	14	36	D000141	true

Sentence: A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.
Entity: 6985498	31	50	acute cholecystitis	Disease	D041881
Entity: 6985498	57	71	methoxyflurane	Chemical	D008733
Entity: 6985498	111	141	hepatic insufficiency syndrome	Disease	D048550
Entity: 6985498	146	168	renal tubular acidosis	Disease	D000141
Relation: 6985498	CID	57	71	D008733	31	50	D041881	false
Relation: 6985498	CID	57	71	D008733	111	141	D048550	false
Relation: 6985498	CID	57	71	D008733	146	168	D000141	true

Sentence: Pituitary response to luteinizing hormone-releasing hormone during haloperidol induced hyperprolactinemia.
Entity: 7018927	67	78	haloperidol	Chemical	D006220
Entity: 7018927	87	105	hyperprolactinemia	Disease	D006966
Relation: 7018927	CID	67	78	D006220	87	105	D006966	true

Sentence: Antirifampicin antibodies in acute rifampicin-associated renal failure. 5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.
Entity: 7121659	35	45	rifampicin	Chemical	D012293
Entity: 7121659	57	70	renal failure	Disease	D051437
Entity: 7121659	88	107	acute renal failure	Disease	D058186
Entity: 7121659	116	128	thrombopenia	Disease	D013921
Entity: 7121659	133	142	hemolysis	Disease	D006461
Entity: 7121659	177	187	rifampicin	Chemical	D012293
Relation: 7121659	CID	35	45	D012293	57	70	D051437	false
Relation: 7121659	CID	35	45	D012293	88	107	D058186	false
Relation: 7121659	CID	35	45	D012293	116	128	D013921	true
Relation: 7121659	CID	35	45	D012293	133	142	D006461	true
Relation: 7121659	CID	177	187	D012293	57	70	D051437	false
Relation: 7121659	CID	177	187	D012293	88	107	D058186	false
Relation: 7121659	CID	177	187	D012293	116	128	D013921	true
Relation: 7121659	CID	177	187	D012293	133	142	D006461	true

Sentence: Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.
Entity: 7147232	26	37	hypotension	Disease	D007022
Entity: 7147232	49	71	adenosine triphosphate	Chemical	D000255
Entity: 7147232	76	96	sodium nitroprusside	Chemical	D009599
Relation: 7147232	CID	49	71	D000255	26	37	D007022	true
Relation: 7147232	CID	76	96	D009599	26	37	D007022	true

Sentence: Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.
Entity: 7147232	0	22	Adenosine triphosphate	Chemical	D000255
Entity: 7147232	24	27	ATP	Chemical	D000255
Entity: 7147232	33	53	sodium nitroprusside	Chemical	D009599
Entity: 7147232	55	58	SNP	Chemical	D009599
Entity: 7147232	111	122	hypotension	Disease	D007022
Relation: 7147232	CID	0	22	D000255	111	122	D007022	true
Relation: 7147232	CID	24	27	D000255	111	122	D007022	true
Relation: 7147232	CID	33	53	D009599	111	122	D007022	true
Relation: 7147232	CID	55	58	D009599	111	122	D007022	true

Sentence: Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.
Entity: 7147232	0	11	Hypotension	Disease	D007022
Entity: 7147232	23	26	ATP	Chemical	D000255
Entity: 7147232	334	340	oxygen	Chemical	D010100
Entity: 7147232	465	468	ATP	Chemical	D000255
Relation: 7147232	CID	23	26	D000255	0	11	D007022	true
Relation: 7147232	CID	334	340	D010100	0	11	D007022	false
Relation: 7147232	CID	465	468	D000255	0	11	D007022	true

Sentence: During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased.
Entity: 7147232	7	18	hypotension	Disease	D007022
Entity: 7147232	31	34	SNP	Chemical	D009599
Entity: 7147232	324	330	oxygen	Chemical	D010100
Relation: 7147232	CID	31	34	D009599	7	18	D007022	true
Relation: 7147232	CID	324	330	D010100	7	18	D007022	false

Sentence: The Dimer-X group had a higher incidence of nausea and dizziness.
Entity: 7173007	4	11	Dimer-X	Chemical	C025504
Entity: 7173007	44	50	nausea	Disease	D009325
Entity: 7173007	55	64	dizziness	Disease	D004244
Relation: 7173007	CID	4	11	C025504	44	50	D009325	true
Relation: 7173007	CID	4	11	C025504	55	64	D004244	true

Sentence: The Endografine group had a higher incidence of abdominal pain.
Entity: 7173007	4	15	Endografine	Chemical	C006753
Entity: 7173007	48	62	abdominal pain	Disease	D015746
Relation: 7173007	CID	4	15	C006753	48	62	D015746	true

Sentence: Post-suxamethonium pains in Nigerian surgical patients.
Entity: 7176945	5	18	suxamethonium	Chemical	D013390
Entity: 7176945	19	24	pains	Disease	D010146
Relation: 7176945	CID	5	18	D013390	19	24	D010146	true

Sentence: Contrary to an earlier report by Coxon, scoline pain occurs in African negroes.
Entity: 7176945	40	47	scoline	Chemical	D013390
Entity: 7176945	48	52	pain	Disease	D010146
Relation: 7176945	CID	40	47	D013390	48	52	D010146	true

Sentence: About 62% of the out-patients developed scoline pain as compared with about 26% among the in-patients.
Entity: 7176945	40	47	scoline	Chemical	D013390
Entity: 7176945	48	52	pain	Disease	D010146
Relation: 7176945	CID	40	47	D013390	48	52	D010146	true

Sentence: The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.
Entity: 7176945	24	38	fasciculations	Disease	D005207
Entity: 7176945	62	72	Fazadinium	Chemical	C084773
Entity: 7176945	110	117	scoline	Chemical	D013390
Entity: 7176945	118	122	pain	Disease	D010146
Relation: 7176945	CID	62	72	C084773	24	38	D005207	false
Relation: 7176945	CID	62	72	C084773	118	122	D010146	false
Relation: 7176945	CID	110	117	D013390	24	38	D005207	true
Relation: 7176945	CID	110	117	D013390	118	122	D010146	true

Sentence: Medial changes in arterial spasm induced by L-norepinephrine.
Entity: 7315949	27	32	spasm	Disease	D013035
Entity: 7315949	44	60	L-norepinephrine	Chemical	D009638
Relation: 7315949	CID	44	60	D009638	27	32	D013035	true

Sentence: In the media of the saphenous artery and its distal branch, vasoconstriction induced by L-norepinephrine produced many cell-to-cell hernias within 15 minutes.
Entity: 7315949	88	104	L-norepinephrine	Chemical	D009638
Entity: 7315949	132	139	hernias	Disease	D006547
Relation: 7315949	CID	88	104	D009638	132	139	D006547	false

Sentence: Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.
Entity: 7369302	58	65	quinine	Chemical	D011803
Entity: 7369302	66	75	amblyopia	Disease	D000550
Relation: 7369302	CID	58	65	D011803	66	75	D000550	true

Sentence: Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.
Entity: 7369302	6	15	blindness	Disease	D001766
Entity: 7369302	33	48	tonic pupillary	Disease	D015845
Entity: 7369302	175	190	quinine sulfate	Chemical	D011803
Entity: 7369302	195	205	leg cramps	Disease	D009120
Relation: 7369302	CID	175	190	D011803	6	15	D001766	true
Relation: 7369302	CID	175	190	D011803	33	48	D015845	true
Relation: 7369302	CID	175	190	D011803	195	205	D009120	false

Sentence: Suxamethonium induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.
Entity: 7378868	0	13	Suxamethonium	Chemical	D013390
Entity: 7378868	22	35	jaw stiffness	Disease	D014313
Entity: 7378868	40	47	myalgia	Disease	D063806
Relation: 7378868	CID	0	13	D013390	22	35	D014313	true
Relation: 7378868	CID	0	13	D013390	40	47	D063806	true

Sentence: Indomethacin induced hyperkalemia in three patients with gouty arthritis.
Entity: 7411769	0	12	Indomethacin	Chemical	D007213
Entity: 7411769	21	33	hyperkalemia	Disease	D006947
Entity: 7411769	57	72	gouty arthritis	Disease	D015210
Relation: 7411769	CID	0	12	D007213	21	33	D006947	true
Relation: 7411769	CID	0	12	D007213	57	72	D015210	false

Sentence: We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.
Entity: 7411769	60	72	hyperkalemia	Disease	D006947
Entity: 7411769	77	96	renal insufficiency	Disease	D051437
Entity: 7411769	132	147	gouty arthritis	Disease	D015210
Entity: 7411769	153	165	indomethacin	Chemical	D007213
Relation: 7411769	CID	153	165	D007213	60	72	D006947	true
Relation: 7411769	CID	153	165	D007213	77	96	D051437	true
Relation: 7411769	CID	153	165	D007213	132	147	D015210	false

Sentence: This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism.
Entity: 7411769	51	64	prostaglandin	Chemical	D011453
Entity: 7411769	90	121	hyporeninemic hypoaidosteronism	Disease	D006994
Relation: 7411769	CID	51	64	D011453	90	121	D006994	false

Sentence: Levodopa induced dyskinesias are improved by fluoxetine.
Entity: 7477981	0	8	Levodopa	Chemical	D007980
Entity: 7477981	17	28	dyskinesias	Disease	D004409
Entity: 7477981	45	55	fluoxetine	Chemical	D005473
Relation: 7477981	CID	0	8	D007980	17	28	D004409	false
Relation: 7477981	CID	45	55	D005473	17	28	D004409	true

Sentence: We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days.
Entity: 7477981	29	45	motor disability	Disease	D009069
Entity: 7477981	50	61	dyskinesias	Disease	D004409
Entity: 7477981	71	79	levodopa	Chemical	D007980
Entity: 7477981	105	124	Parkinson's disease	Disease	D010300
Entity: 7477981	165	173	dopamine	Chemical	D004298
Entity: 7477981	183	194	apomorphine	Chemical	D001058
Entity: 7477981	235	245	fluoxetine	Chemical	D005473
Relation: 7477981	CID	71	79	D007980	29	45	D009069	false
Relation: 7477981	CID	71	79	D007980	50	61	D004409	false
Relation: 7477981	CID	71	79	D007980	105	124	D010300	false
Relation: 7477981	CID	165	173	D004298	29	45	D009069	false
Relation: 7477981	CID	165	173	D004298	50	61	D004409	false
Relation: 7477981	CID	165	173	D004298	105	124	D010300	false
Relation: 7477981	CID	183	194	D001058	29	45	D009069	false
Relation: 7477981	CID	183	194	D001058	50	61	D004409	true
Relation: 7477981	CID	183	194	D001058	105	124	D010300	false
Relation: 7477981	CID	235	245	D005473	29	45	D009069	false
Relation: 7477981	CID	235	245	D005473	50	61	D004409	true
Relation: 7477981	CID	235	245	D005473	105	124	D010300	false

Sentence: After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine induced dyskinesias without modification of parkinsonian motor disability.
Entity: 7477981	6	16	fluoxetine	Chemical	D005473
Entity: 7477981	82	93	apomorphine	Chemical	D001058
Entity: 7477981	102	113	dyskinesias	Disease	D004409
Entity: 7477981	138	150	parkinsonian	Disease	D010300
Entity: 7477981	151	167	motor disability	Disease	D009069
Relation: 7477981	CID	6	16	D005473	102	113	D004409	true
Relation: 7477981	CID	6	16	D005473	138	150	D010300	false
Relation: 7477981	CID	6	16	D005473	151	167	D009069	false
Relation: 7477981	CID	82	93	D001058	102	113	D004409	true
Relation: 7477981	CID	82	93	D001058	138	150	D010300	false
Relation: 7477981	CID	82	93	D001058	151	167	D009069	false

Sentence: A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.
Entity: 7479194	44	73	trimethoprim-sulfamethoxazole	Chemical	D015662
Entity: 7479194	75	87	trimethoprim	Chemical	D014295
Entity: 7479194	93	103	cephalexin	Chemical	D002506
Entity: 7479194	125	138	drug toxicity	Disease	D064420
Relation: 7479194	CID	44	73	D015662	125	138	D064420	false
Relation: 7479194	CID	75	87	D014295	125	138	D064420	false
Relation: 7479194	CID	93	103	D002506	125	138	D064420	false

Sentence: We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.
Entity: 7479194	93	122	trimethoprim-sulfamethoxazole	Chemical	D015662
Entity: 7479194	124	131	TMP-SMZ	Chemical	D015662
Entity: 7479194	153	165	trimethoprim	Chemical	D014295
Entity: 7479194	196	206	cephalexin	Chemical	D002506
Entity: 7479194	240	279	liver, blood, skin, and renal disorders	Disease	D008107|D006402|D012871|D007674	liver disorders|blood disorders|skin disorders|renal disorders
Relation: 7479194	CID	93	122	D015662	240	279	D008107|D006402|D012871|D007674	liver disorders|blood disorders|skin disorders|renal disorders	false
Relation: 7479194	CID	124	131	D015662	240	279	D008107|D006402|D012871|D007674	liver disorders|blood disorders|skin disorders|renal disorders	false
Relation: 7479194	CID	153	165	D014295	240	279	D008107|D006402|D012871|D007674	liver disorders|blood disorders|skin disorders|renal disorders	false
Relation: 7479194	CID	196	206	D002506	240	279	D008107|D006402|D012871|D007674	liver disorders|blood disorders|skin disorders|renal disorders	false

Sentence: The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).
Entity: 7479194	44	57	liver disease	Disease	D008107
Entity: 7479194	93	100	TMP-SMZ	Chemical	D015662
Entity: 7479194	136	148	trimethoprim	Chemical	D014295
Relation: 7479194	CID	93	100	D015662	44	57	D008107	true
Relation: 7479194	CID	136	148	D014295	44	57	D008107	true

Sentence: Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.
Entity: 7479194	75	82	TMP-SMZ	Chemical	D015662
Entity: 7479194	98	117	erythema multiforme	Disease	D004892
Entity: 7479194	122	146	Stevens-Johnson syndrome	Disease	D013262
Entity: 7479194	169	176	TMP-SMZ	Chemical	D015662
Relation: 7479194	CID	75	82	D015662	98	117	D004892	false
Relation: 7479194	CID	75	82	D015662	122	146	D013262	true
Relation: 7479194	CID	169	176	D015662	98	117	D004892	false
Relation: 7479194	CID	169	176	D015662	122	146	D013262	true

Sentence: The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin.
Entity: 7479194	16	42	toxic epidermal necrolysis	Disease	D013262
Entity: 7479194	74	84	cephalexin	Chemical	D002506
Relation: 7479194	CID	74	84	D002506	16	42	D013262	true

Sentence: Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.
Entity: 7492040	19	28	lidocaine	Chemical	D008012
Entity: 7492040	46	53	cocaine	Chemical	D003042
Entity: 7492040	65	86	myocardial infarction	Disease	D009203
Relation: 7492040	CID	19	28	D008012	65	86	D009203	false
Relation: 7492040	CID	46	53	D003042	65	86	D009203	true

Sentence: STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine induced myocardial infarction (MI).
Entity: 7492040	43	52	lidocaine	Chemical	D008012
Entity: 7492040	71	78	cocaine	Chemical	D003042
Entity: 7492040	87	108	myocardial infarction	Disease	D009203
Entity: 7492040	110	112	MI	Disease	D009203
Relation: 7492040	CID	43	52	D008012	87	108	D009203	false
Relation: 7492040	CID	43	52	D008012	110	112	D009203	false
Relation: 7492040	CID	71	78	D003042	87	108	D009203	true
Relation: 7492040	CID	71	78	D003042	110	112	D009203	true

Sentence: PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department.
Entity: 7492040	28	35	cocaine	Chemical	D003042
Entity: 7492040	47	49	MI	Disease	D009203
Entity: 7492040	63	72	lidocaine	Chemical	D008012
Relation: 7492040	CID	28	35	D003042	47	49	D009203	true
Relation: 7492040	CID	63	72	D008012	47	49	D009203	false

Sentence: RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).
Entity: 7492040	37	46	lidocaine	Chemical	D008012
Entity: 7492040	65	72	cocaine	Chemical	D003042
Entity: 7492040	84	86	MI	Disease	D009203
Entity: 7492040	115	132	bradydysrhythmias	Disease	D001919
Entity: 7492040	134	157	ventricular tachycardia	Disease	D017180
Entity: 7492040	162	186	ventricular fibrillation	Disease	D014693
Entity: 7492040	203	211	seizures	Disease	D012640
Entity: 7492040	236	245	lidocaine	Chemical	D008012
Relation: 7492040	CID	37	46	D008012	84	86	D009203	false
Relation: 7492040	CID	37	46	D008012	115	132	D001919	false
Relation: 7492040	CID	37	46	D008012	134	157	D017180	false
Relation: 7492040	CID	37	46	D008012	162	186	D014693	false
Relation: 7492040	CID	37	46	D008012	203	211	D012640	false
Relation: 7492040	CID	65	72	D003042	84	86	D009203	true
Relation: 7492040	CID	65	72	D003042	115	132	D001919	false
Relation: 7492040	CID	65	72	D003042	134	157	D017180	false
Relation: 7492040	CID	65	72	D003042	162	186	D014693	false
Relation: 7492040	CID	65	72	D003042	203	211	D012640	false
Relation: 7492040	CID	236	245	D008012	84	86	D009203	false
Relation: 7492040	CID	236	245	D008012	115	132	D001919	false
Relation: 7492040	CID	236	245	D008012	134	157	D017180	false
Relation: 7492040	CID	236	245	D008012	162	186	D014693	false
Relation: 7492040	CID	236	245	D008012	203	211	D012640	false

Sentence: Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.
Entity: 7644931	0	10	Paclitaxel	Chemical	D017239
Entity: 7644931	12	17	Taxol	Chemical	D017239
Entity: 7644931	101	112	carboplatin	Chemical	D016190
Entity: 7644931	161	187	non-small cell lung cancer	Disease	D002289
Relation: 7644931	CID	0	10	D017239	161	187	D002289	false
Relation: 7644931	CID	12	17	D017239	161	187	D002289	false
Relation: 7644931	CID	101	112	D016190	161	187	D002289	false

Sentence: Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels.
Entity: 7644931	0	10	Toxicities	Disease	D064420
Entity: 7644931	73	83	paclitaxel	Chemical	D017239
Relation: 7644931	CID	73	83	D017239	0	10	D064420	false

Sentence: The dose-dependent effect of misoprostol on indomethacin induced renal dysfunction in well compensated cirrhosis.
Entity: 7661171	29	40	misoprostol	Chemical	D016595
Entity: 7661171	44	56	indomethacin	Chemical	D007213
Entity: 7661171	65	82	renal dysfunction	Disease	D007674
Entity: 7661171	103	112	cirrhosis	Disease	D005355
Relation: 7661171	CID	29	40	D016595	65	82	D007674	false
Relation: 7661171	CID	29	40	D016595	103	112	D005355	false
Relation: 7661171	CID	44	56	D007213	65	82	D007674	true
Relation: 7661171	CID	44	56	D007213	103	112	D005355	false

Sentence: Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin induced renal dysfunction in well compensated cirrhotic patients.
Entity: 7661171	0	11	Misoprostol	Chemical	D016595
Entity: 7661171	70	82	indomethacin	Chemical	D007213
Entity: 7661171	91	108	renal dysfunction	Disease	D007674
Entity: 7661171	129	138	cirrhotic	Disease	D005355
Relation: 7661171	CID	0	11	D016595	91	108	D007674	false
Relation: 7661171	CID	0	11	D016595	129	138	D005355	false
Relation: 7661171	CID	70	82	D007213	91	108	D007674	true
Relation: 7661171	CID	70	82	D007213	129	138	D005355	false

Sentence: Parameters of renal hemodynamics and tubular sodium and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol.
Entity: 7661171	45	51	sodium	Chemical	D012964
Entity: 7661171	132	141	cirrhotic	Disease	D005355
Entity: 7661171	200	212	indomethacin	Chemical	D007213
Entity: 7661171	234	245	misoprostol	Chemical	D016595
Relation: 7661171	CID	45	51	D012964	132	141	D005355	false
Relation: 7661171	CID	200	212	D007213	132	141	D005355	false
Relation: 7661171	CID	234	245	D016595	132	141	D005355	false

Sentence: Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.
Entity: 7671401	36	48	angio-oedema	Disease	D000799
Entity: 7671401	83	122	angiotensin-converting enzyme inhibitor	Chemical	D000806
Relation: 7671401	CID	83	122	D000806	36	48	D000799	true

Sentence: Angiotensin-converting enzyme (ACE) inhibitors, used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively.
Entity: 7671401	0	46	Angiotensin-converting enzyme (ACE) inhibitors	Chemical	D000806
Entity: 7671401	62	74	hypertension	Disease	D006973
Entity: 7671401	79	103	congestive heart failure	Disease	D006333
Relation: 7671401	CID	0	46	D000806	62	74	D006973	false
Relation: 7671401	CID	0	46	D000806	79	103	D006333	false

Sentence: Soon after the introduction of ACE inhibitors, acute bouts of angio-oedema were reported in association with the use of these drugs.
Entity: 7671401	31	45	ACE inhibitors	Chemical	D000806
Entity: 7671401	62	74	angio-oedema	Disease	D000799
Relation: 7671401	CID	31	45	D000806	62	74	D000799	true

Sentence: Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.
Entity: 7727612	0	9	Myoclonus	Disease	D009207
Entity: 7727612	26	35	lorazepam	Chemical	D008140
Relation: 7727612	CID	26	35	D008140	0	9	D009207	true

Sentence: Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam.
Entity: 7727612	64	73	myoclonus	Disease	D009207
Entity: 7727612	118	127	lorazepam	Chemical	D008140
Relation: 7727612	CID	118	127	D008140	64	73	D009207	true

Sentence: Three patients had acute viral myocarditis, one had a carbamazepine induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.
Entity: 7739955	31	42	myocarditis	Disease	D009205
Entity: 7739955	54	67	carbamazepine	Chemical	D002220
Entity: 7739955	82	94	eosinophilic	Disease	D004802
Entity: 7739955	95	106	myocarditis	Disease	D009205
Entity: 7739955	161	178	cardiogenic shock	Disease	D012770
Relation: 7739955	CID	54	67	D002220	31	42	D009205	true
Relation: 7739955	CID	54	67	D002220	82	94	D004802	true
Relation: 7739955	CID	54	67	D002220	95	106	D009205	true
Relation: 7739955	CID	54	67	D002220	161	178	D012770	false

Sentence: Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
Entity: 7931490	23	34	granisetron	Chemical	D017829
Entity: 7931490	48	67	5-hydroxytryptamine	Chemical	D012701
Entity: 7931490	112	118	nausea	Disease	D009325
Entity: 7931490	123	131	vomiting	Disease	D014839
Entity: 7931490	153	162	cisplatin	Chemical	D002945
Relation: 7931490	CID	23	34	D017829	112	118	D009325	false
Relation: 7931490	CID	23	34	D017829	123	131	D014839	false
Relation: 7931490	CID	48	67	D012701	112	118	D009325	false
Relation: 7931490	CID	48	67	D012701	123	131	D014839	false
Relation: 7931490	CID	153	162	D002945	112	118	D009325	true
Relation: 7931490	CID	153	162	D002945	123	131	D014839	true

Sentence: PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin induced nausea and vomiting.
Entity: 7931490	88	99	granisetron	Chemical	D017829
Entity: 7931490	101	107	Kytril	Chemical	D017829
Entity: 7931490	234	243	cisplatin	Chemical	D002945
Entity: 7931490	252	258	nausea	Disease	D009325
Entity: 7931490	263	271	vomiting	Disease	D014839
Relation: 7931490	CID	88	99	D017829	252	258	D009325	false
Relation: 7931490	CID	88	99	D017829	263	271	D014839	false
Relation: 7931490	CID	101	107	D017829	252	258	D009325	false
Relation: 7931490	CID	101	107	D017829	263	271	D014839	false
Relation: 7931490	CID	234	243	D002945	252	258	D009325	true
Relation: 7931490	CID	234	243	D002945	263	271	D014839	true

Sentence: RESULTS: After granisetron doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two vomiting or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no vomiting or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.
Entity: 7931490	15	26	granisetron	Chemical	D017829
Entity: 7931490	98	106	vomiting	Disease	D014839
Entity: 7931490	249	257	vomiting	Disease	D014839
Relation: 7931490	CID	15	26	D017829	98	106	D014839	false
Relation: 7931490	CID	15	26	D017829	249	257	D014839	false

Sentence: CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.
Entity: 7931490	59	70	granisetron	Chemical	D017829
Entity: 7931490	100	108	vomiting	Disease	D014839
Entity: 7931490	148	157	cisplatin	Chemical	D002945
Entity: 7931490	211	219	vomiting	Disease	D014839
Relation: 7931490	CID	59	70	D017829	100	108	D014839	false
Relation: 7931490	CID	59	70	D017829	211	219	D014839	false
Relation: 7931490	CID	148	157	D002945	100	108	D014839	true
Relation: 7931490	CID	148	157	D002945	211	219	D014839	true

Sentence: OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.
Entity: 7949506	73	82	clonidine	Chemical	D003000
Entity: 7949506	87	96	verapamil	Chemical	D014700
Entity: 7949506	110	137	atrioventricular (AV) block	Disease	D054537
Entity: 7949506	166	177	hypotension	Disease	D007022
Relation: 7949506	CID	73	82	D003000	110	137	D054537	true
Relation: 7949506	CID	73	82	D003000	166	177	D007022	true
Relation: 7949506	CID	87	96	D014700	110	137	D054537	true
Relation: 7949506	CID	87	96	D014700	166	177	D007022	true

Sentence: CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.
Entity: 7949506	41	59	hyperaldosteronism	Disease	D006929
Entity: 7949506	77	86	verapamil	Chemical	D014700
Entity: 7949506	100	114	spironolactone	Chemical	D013148
Relation: 7949506	CID	77	86	D014700	41	59	D006929	false
Relation: 7949506	CID	100	114	D013148	41	59	D006929	false

Sentence: After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.
Entity: 7949506	40	49	clonidine	Chemical	D003000
Entity: 7949506	88	96	AV block	Disease	D054537
Entity: 7949506	108	119	hypotension	Disease	D007022
Relation: 7949506	CID	40	49	D003000	88	96	D054537	true
Relation: 7949506	CID	40	49	D003000	108	119	D007022	true

Sentence: After the addition of clonidine 0.15 mg bid she developed complete AV block, which resolved after all therapy was stopped.
Entity: 7949506	22	31	clonidine	Chemical	D003000
Entity: 7949506	67	75	AV block	Disease	D054537
Relation: 7949506	CID	22	31	D003000	67	75	D054537	true

Sentence: S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o.
Entity: 7967231	0	5	S-312	Chemical	C059447
Entity: 7967231	7	14	S-312-d	Chemical	C059447
Entity: 7967231	24	31	S-312-l	Chemical	-1
Entity: 7967231	40	47	calcium	Chemical	D002118
Entity: 7967231	106	134	audiogenic tonic convulsions	Disease	D020195
Entity: 7967231	268	279	flunarizine	Chemical	D005444
Relation: 7967231	CID	0	5	C059447	106	134	D020195	false
Relation: 7967231	CID	7	14	C059447	106	134	D020195	false
Relation: 7967231	CID	24	31	-1	106	134	D020195	false
Relation: 7967231	CID	40	47	D002118	106	134	D020195	false
Relation: 7967231	CID	268	279	D005444	106	134	D020195	false

Sentence: Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.
Entity: 7967231	44	51	S-312-d	Chemical	C059447
Entity: 7967231	101	112	convulsions	Disease	D012640
Entity: 7967231	124	142	pentylenetetrazole	Chemical	D010433
Entity: 7967231	163	172	bemegride	Chemical	D001534
Entity: 7967231	219	230	convulsions	Disease	D012640
Entity: 7967231	242	262	N-methyl-D-aspartate	Chemical	D016202
Entity: 7967231	264	274	picrotoxin	Chemical	D010852
Relation: 7967231	CID	44	51	C059447	101	112	D012640	false
Relation: 7967231	CID	44	51	C059447	219	230	D012640	false
Relation: 7967231	CID	124	142	D010433	101	112	D012640	true
Relation: 7967231	CID	124	142	D010433	219	230	D012640	true
Relation: 7967231	CID	163	172	D001534	101	112	D012640	true
Relation: 7967231	CID	163	172	D001534	219	230	D012640	true
Relation: 7967231	CID	242	262	D016202	101	112	D012640	false
Relation: 7967231	CID	242	262	D016202	219	230	D012640	false
Relation: 7967231	CID	264	274	D010852	101	112	D012640	true
Relation: 7967231	CID	264	274	D010852	219	230	D012640	true

Sentence: Transmural myocardial infarction with sumatriptan.
Entity: 8096565	11	32	myocardial infarction	Disease	D009203
Entity: 8096565	38	49	sumatriptan	Chemical	D018170
Relation: 8096565	CID	38	49	D018170	11	32	D009203	true

Sentence: We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.
Entity: 8096565	46	67	myocardial infarction	Disease	D009203
Entity: 8096565	92	103	sumatriptan	Chemical	D018170
Entity: 8096565	128	144	cluster headache	Disease	D003027
Relation: 8096565	CID	92	103	D018170	46	67	D009203	true
Relation: 8096565	CID	92	103	D018170	128	144	D003027	false

Sentence: Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.
Entity: 8135424	0	10	Flumazenil	Chemical	D005442
Entity: 8135424	19	27	seizures	Disease	D012640
Entity: 8135424	47	54	cocaine	Chemical	D003042
Entity: 8135424	55	63	diazepam	Chemical	D003975
Relation: 8135424	CID	0	10	D005442	19	27	D012640	true
Relation: 8135424	CID	47	54	D003042	19	27	D012640	true
Relation: 8135424	CID	55	63	D003975	19	27	D012640	true

Sentence: STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.
Entity: 8135424	40	54	benzodiazepine	Chemical	D001569
Entity: 8135424	66	76	flumazenil	Chemical	D005442
Entity: 8135424	88	96	seizures	Disease	D012640
Entity: 8135424	106	113	cocaine	Chemical	D003042
Entity: 8135424	114	128	benzodiazepine	Chemical	D001569
Relation: 8135424	CID	40	54	D001569	88	96	D012640	false
Relation: 8135424	CID	66	76	D005442	88	96	D012640	true
Relation: 8135424	CID	106	113	D003042	88	96	D012640	true
Relation: 8135424	CID	114	128	D001569	88	96	D012640	false

Sentence: Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.
Entity: 8160791	64	74	gentamicin	Chemical	D005839
Entity: 8160791	84	95	nephropathy	Disease	D007674
Relation: 8160791	CID	64	74	D005839	84	95	D007674	true

Sentence: Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.
Entity: 8160791	106	116	gentamicin	Chemical	D005839
Entity: 8160791	118	120	GM	Chemical	D005839
Entity: 8160791	131	142	nephropathy	Disease	D007674
Relation: 8160791	CID	106	116	D005839	131	142	D007674	true
Relation: 8160791	CID	118	120	D005839	131	142	D007674	true

Sentence: Administration of GM at 40 mg/kg sc for 13 days to rats induced a significant reduction in renal blood flow (RBF) and inulin clearance (CIn) as well as marked tubular damage.
Entity: 8160791	18	20	GM	Chemical	D005839
Entity: 8160791	159	173	tubular damage	Disease	D007674
Relation: 8160791	CID	18	20	D005839	159	173	D007674	true

Sentence: A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.
Entity: 8160791	35	71	guanosine 3',5'-cyclic monophosphate	Chemical	D006152
Entity: 8160791	73	77	cGMP	Chemical	D006152
Entity: 8160791	188	190	GM	Chemical	D005839
Entity: 8160791	200	211	nephropathy	Disease	D007674
Relation: 8160791	CID	35	71	D006152	200	211	D007674	false
Relation: 8160791	CID	73	77	D006152	200	211	D007674	false
Relation: 8160791	CID	188	190	D005839	200	211	D007674	true

Sentence: In contrast, DMTU significantly reduced the tubular damage and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances.
Entity: 8160791	13	17	DMTU	Chemical	C038983
Entity: 8160791	44	58	tubular damage	Disease	D007674
Relation: 8160791	CID	13	17	C038983	44	58	D007674	false

Sentence: Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats.
Entity: 8188982	34	37	AVP	Chemical	D001127
Entity: 8188982	80	92	hypertensive	Disease	D006973
Relation: 8188982	CID	34	37	D001127	80	92	D006973	true

Sentence: The purpose of the present study was to compare influence of central arginine vasopressin (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously hypertensive (SHR) rats.
Entity: 8188982	69	89	arginine vasopressin	Chemical	D001127
Entity: 8188982	91	94	AVP	Chemical	D001127
Entity: 8188982	240	252	hypertensive	Disease	D006973
Relation: 8188982	CID	69	89	D001127	240	252	D006973	true
Relation: 8188982	CID	91	94	D001127	240	252	D006973	true

Sentence: Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe) induced hypertension and sodium nitroprusside (SN) induced hypotension.
Entity: 8188982	200	213	phenylephrine	Chemical	D010656
Entity: 8188982	215	218	Phe	Chemical	D010656
Entity: 8188982	228	240	hypertension	Disease	D006973
Entity: 8188982	245	265	sodium nitroprusside	Chemical	D009599
Entity: 8188982	267	269	SN	Chemical	D009599
Entity: 8188982	279	290	hypotension	Disease	D007022
Relation: 8188982	CID	200	213	D010656	228	240	D006973	true
Relation: 8188982	CID	200	213	D010656	279	290	D007022	false
Relation: 8188982	CID	215	218	D010656	228	240	D006973	true
Relation: 8188982	CID	215	218	D010656	279	290	D007022	false
Relation: 8188982	CID	245	265	D009599	228	240	D006973	false
Relation: 8188982	CID	245	265	D009599	279	290	D007022	true
Relation: 8188982	CID	267	269	D009599	228	240	D006973	false
Relation: 8188982	CID	267	269	D009599	279	290	D007022	true

Sentence: CCB was reduced in WKY and SHR after LV administration of AVP during SN induced hypotension.
Entity: 8188982	58	61	AVP	Chemical	D001127
Entity: 8188982	69	71	SN	Chemical	D009599
Entity: 8188982	80	91	hypotension	Disease	D007022
Relation: 8188982	CID	58	61	D001127	80	91	D007022	false
Relation: 8188982	CID	69	71	D009599	80	91	D007022	true

Sentence: Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.
Entity: 8308951	22	30	warfarin	Chemical	D014859
Entity: 8308951	61	85	intracerebral hemorrhage	Disease	D002543
Relation: 8308951	CID	22	30	D014859	61	85	D002543	true

Sentence: A case of intercerebral hematoma due to warfarin induced coagulopathy is presented.
Entity: 8308951	24	32	hematoma	Disease	D006406
Entity: 8308951	40	48	warfarin	Chemical	D014859
Entity: 8308951	57	69	coagulopathy	Disease	D001778
Relation: 8308951	CID	40	48	D014859	24	32	D006406	false
Relation: 8308951	CID	40	48	D014859	57	69	D001778	false

Sentence: Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.
Entity: 8308951	27	35	warfarin	Chemical	D014859
Entity: 8308951	44	56	coagulopathy	Disease	D001778
Relation: 8308951	CID	27	35	D014859	44	56	D001778	false

Sentence: Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).
Entity: 8312343	37	62	idiopathic cardiomyopathy	Disease	D002311
Entity: 8312343	70	94	congenital heart disease	Disease	D006331
Entity: 8312343	160	187	hypertrophic cardiomyopathy	Disease	D002312
Entity: 8312343	194	216	valvular heart disease	Disease	D006349
Entity: 8312343	227	238	doxorubicin	Chemical	D004317
Entity: 8312343	239	253	cardiomyopathy	Disease	D009202
Relation: 8312343	CID	227	238	D004317	37	62	D002311	false
Relation: 8312343	CID	227	238	D004317	70	94	D006331	false
Relation: 8312343	CID	227	238	D004317	160	187	D002312	false
Relation: 8312343	CID	227	238	D004317	194	216	D006349	false
Relation: 8312343	CID	227	238	D004317	239	253	D009202	true

Sentence: Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients.
Entity: 8312343	0	26	Cytomegalovirus infections	Disease	D003586
Entity: 8312343	58	69	ganciclovir	Chemical	D015774
Relation: 8312343	CID	58	69	D015774	0	26	D003586	false

Sentence: Delirium during fluoxetine treatment.
Entity: 8312983	0	8	Delirium	Disease	D003693
Entity: 8312983	16	26	fluoxetine	Chemical	D005473
Relation: 8312983	CID	16	26	D005473	0	8	D003693	true

Sentence: In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties.
Entity: 8312983	45	55	citalopram	Chemical	D015283
Entity: 8312983	126	136	somnolence	Disease	D006970
Entity: 8312983	141	162	movement difficulties	Disease	D020820
Relation: 8312983	CID	45	55	D015283	126	136	D006970	false
Relation: 8312983	CID	45	55	D015283	141	162	D020820	false

Sentence: Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.
Entity: 8318674	0	15	Pulmonary edema	Disease	D011654
Entity: 8318674	20	25	shock	Disease	D012769
Entity: 8318674	42	53	aracytine-C	Chemical	D003561
Entity: 8318674	58	66	lymphoma	Disease	D008223
Relation: 8318674	CID	42	53	D003561	0	15	D011654	true
Relation: 8318674	CID	42	53	D003561	20	25	D012769	true
Relation: 8318674	CID	42	53	D003561	58	66	D008223	false

Sentence: Four out of 23 consecutive patients treated with high-dose Ara-C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion.
Entity: 8318674	59	64	Ara-C	Chemical	D003561
Entity: 8318674	69	78	lymphomas	Disease	D008223
Relation: 8318674	CID	59	64	D003561	69	78	D008223	false

Sentence: Protective effect of clentiazem against epinephrine induced cardiac injury in rats.
Entity: 8392553	21	31	clentiazem	Chemical	C056595
Entity: 8392553	40	51	epinephrine	Chemical	D004837
Entity: 8392553	60	74	cardiac injury	Disease	D006331
Relation: 8392553	CID	21	31	C056595	60	74	D006331	false
Relation: 8392553	CID	40	51	D004837	60	74	D006331	false

Sentence: We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine induced cardiomyopathy in rats.
Entity: 8392553	31	41	clentiazem	Chemical	C056595
Entity: 8392553	45	64	1,5-benzothiazepine	Chemical	C106746
Entity: 8392553	65	72	calcium	Chemical	D002118
Entity: 8392553	88	99	epinephrine	Chemical	D004837
Entity: 8392553	108	122	cardiomyopathy	Disease	D009202
Relation: 8392553	CID	31	41	C056595	108	122	D009202	false
Relation: 8392553	CID	45	64	C106746	108	122	D009202	false
Relation: 8392553	CID	65	72	D002118	108	122	D009202	false
Relation: 8392553	CID	88	99	D004837	108	122	D009202	true

Sentence: With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.
Entity: 8392553	20	31	epinephrine	Chemical	D004837
Entity: 8392553	87	103	ischemic lesions	Disease	D007511
Entity: 8392553	108	116	fibrosis	Disease	D005355
Relation: 8392553	CID	20	31	D004837	87	103	D007511	false
Relation: 8392553	CID	20	31	D004837	108	116	D005355	false

Sentence: Treatment with clentiazem prevented epinephrine induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.
Entity: 8392553	15	25	clentiazem	Chemical	C056595
Entity: 8392553	36	47	epinephrine	Chemical	D004837
Entity: 8392553	104	120	ischemic lesions	Disease	D007511
Entity: 8392553	125	133	fibrosis	Disease	D005355
Relation: 8392553	CID	15	25	C056595	104	120	D007511	false
Relation: 8392553	CID	15	25	C056595	125	133	D005355	false
Relation: 8392553	CID	36	47	D004837	104	120	D007511	false
Relation: 8392553	CID	36	47	D004837	125	133	D005355	false

Sentence: Cocaine induced myocardial ischemia.
Entity: 8511251	0	7	Cocaine	Chemical	D003042
Entity: 8511251	16	35	myocardial ischemia	Disease	D017202
Relation: 8511251	CID	0	7	D003042	16	35	D017202	true

Sentence: We report a case of myocardial ischemia induced by cocaine.
Entity: 8511251	20	39	myocardial ischemia	Disease	D017202
Entity: 8511251	51	58	cocaine	Chemical	D003042
Relation: 8511251	CID	51	58	D003042	20	39	D017202	true

Sentence: Doxorubicin induced cardiotoxicity monitored by ECG in freely moving mice.
Entity: 8603459	0	11	Doxorubicin	Chemical	D004317
Entity: 8603459	20	34	cardiotoxicity	Disease	D066126
Relation: 8603459	CID	0	11	D004317	20	34	D066126	true

Sentence: In laboratory animals, histology is most commonly used to study doxorubicin induced cardiotoxicity.
Entity: 8603459	64	75	doxorubicin	Chemical	D004317
Entity: 8603459	84	98	cardiotoxicity	Disease	D066126
Relation: 8603459	CID	64	75	D004317	84	98	D066126	true

Sentence: After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were hypertrophic.
Entity: 8603459	30	41	doxorubicin	Chemical	D004317
Entity: 8603459	91	103	hypertrophic	Disease	D006984
Relation: 8603459	CID	30	41	D004317	91	103	D006984	false

Sentence: As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus 2 weeks of observation).
Entity: 8603459	30	38	toxicity	Disease	D064420
Entity: 8603459	103	111	ICRF-187	Chemical	D064730
Entity: 8603459	168	176	toxicity	Disease	D064420
Entity: 8603459	204	215	doxorubicin	Chemical	D004317
Relation: 8603459	CID	103	111	D064730	30	38	D064420	false
Relation: 8603459	CID	103	111	D064730	168	176	D064420	false
Relation: 8603459	CID	204	215	D004317	30	38	D064420	false
Relation: 8603459	CID	204	215	D004317	168	176	D064420	false

Sentence: Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.
Entity: 8659767	6	17	bupivacaine	Chemical	D002045
Entity: 8659767	22	33	epinephrine	Chemical	D004837
Entity: 8659767	55	67	dysrhythmias	Disease	D001145
Entity: 8659767	81	92	bupivacaine	Chemical	D002045
Entity: 8659767	164	175	epinephrine	Chemical	D004837
Relation: 8659767	CID	6	17	D002045	55	67	D001145	false
Relation: 8659767	CID	22	33	D004837	55	67	D001145	false
Relation: 8659767	CID	81	92	D002045	55	67	D001145	false
Relation: 8659767	CID	164	175	D004837	55	67	D001145	false

Sentence: We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.
Entity: 8659767	30	41	bupivacaine	Chemical	D002045
Entity: 8659767	104	115	epinephrine	Chemical	D004837
Entity: 8659767	173	194	myocardial infarction	Disease	D009203
Relation: 8659767	CID	30	41	D002045	173	194	D009203	false
Relation: 8659767	CID	104	115	D004837	173	194	D009203	false

Sentence: One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.
Entity: 8659767	27	48	myocardial infarction	Disease	D009203
Entity: 8659767	65	74	halothane	Chemical	D006221
Entity: 8659767	126	137	epinephrine	Chemical	D004837
Entity: 8659767	144	146	VT	Disease	D017180
Relation: 8659767	CID	65	74	D006221	27	48	D009203	false
Relation: 8659767	CID	65	74	D006221	144	146	D017180	false
Relation: 8659767	CID	126	137	D004837	27	48	D009203	false
Relation: 8659767	CID	126	137	D004837	144	146	D017180	true

Sentence: Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.
Entity: 8659767	0	11	Bupivacaine	Chemical	D002045
Entity: 8659767	24	35	epinephrine	Chemical	D004837
Entity: 8659767	88	90	VT	Disease	D017180
Entity: 8659767	145	157	dysrhythmias	Disease	D001145
Relation: 8659767	CID	0	11	D002045	88	90	D017180	false
Relation: 8659767	CID	0	11	D002045	145	157	D001145	false
Relation: 8659767	CID	24	35	D004837	88	90	D017180	true
Relation: 8659767	CID	24	35	D004837	145	157	D001145	false

Sentence: Milk-alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism.
Entity: 8667442	0	20	Milk-alkali syndrome	Disease	D006934
Entity: 8667442	32	42	1,25(OH)2D	Chemical	D002117
Entity: 8667442	61	79	hypoparathyroidism	Disease	D007011
Relation: 8667442	CID	32	42	D002117	0	20	D006934	true
Relation: 8667442	CID	32	42	D002117	61	79	D007011	false

Sentence: Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.
Entity: 8667442	0	20	Milk-alkali syndrome	Disease	D006934
Entity: 8667442	89	109	peptic ulcer disease	Disease	D010437
Entity: 8667442	132	139	calcium	Chemical	D002118
Entity: 8667442	144	150	alkali	Chemical	D000468
Relation: 8667442	CID	132	139	D002118	0	20	D006934	true
Relation: 8667442	CID	132	139	D002118	89	109	D010437	false
Relation: 8667442	CID	144	150	D000468	0	20	D006934	true
Relation: 8667442	CID	144	150	D000468	89	109	D010437	false

Sentence: Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.
Entity: 8667442	22	27	ulcer	Disease	D014456
Entity: 8667442	51	61	omeprazole	Chemical	D009853
Entity: 8667442	67	77	sucralfate	Chemical	D013392
Entity: 8667442	97	117	milk-alkali syndrome	Disease	D006934
Entity: 8667442	168	181	hypercalcemia	Disease	D006934
Entity: 8667442	183	192	alkalosis	Disease	D000471
Entity: 8667442	198	214	renal impairment	Disease	D051437
Relation: 8667442	CID	51	61	D009853	22	27	D014456	false
Relation: 8667442	CID	51	61	D009853	97	117	D006934	false
Relation: 8667442	CID	51	61	D009853	168	181	D006934	false
Relation: 8667442	CID	51	61	D009853	183	192	D000471	false
Relation: 8667442	CID	51	61	D009853	198	214	D051437	false
Relation: 8667442	CID	67	77	D013392	22	27	D014456	false
Relation: 8667442	CID	67	77	D013392	97	117	D006934	false
Relation: 8667442	CID	67	77	D013392	168	181	D006934	false
Relation: 8667442	CID	67	77	D013392	183	192	D000471	false
Relation: 8667442	CID	67	77	D013392	198	214	D051437	false

Sentence: This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.
Entity: 8667442	37	55	hypoparathyroidism	Disease	D007011
Entity: 8667442	77	94	calcium carbonate	Chemical	D002119
Entity: 8667442	99	109	calcitriol	Chemical	D002117
Entity: 8667442	158	178	milk-alkali syndrome	Disease	D006934
Relation: 8667442	CID	77	94	D002119	37	55	D007011	false
Relation: 8667442	CID	77	94	D002119	158	178	D006934	true
Relation: 8667442	CID	99	109	D002117	37	55	D007011	false
Relation: 8667442	CID	99	109	D002117	158	178	D006934	true

Sentence: Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders.
Entity: 8748050	0	14	Encephalopathy	Disease	D001927
Entity: 8748050	22	35	amitriptyline	Chemical	D000639
Entity: 8748050	49	79	neuroleptic malignant syndrome	Disease	D009459
Entity: 8748050	84	102	serotonin syndrome	Disease	D020230
Relation: 8748050	CID	22	35	D000639	0	14	D001927	true
Relation: 8748050	CID	22	35	D000639	49	79	D009459	false
Relation: 8748050	CID	22	35	D000639	84	102	D020230	false

Sentence: This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.
Entity: 8748050	32	46	encephalopathy	Disease	D001927
Entity: 8748050	74	87	amitriptyline	Chemical	D000639
Entity: 8748050	119	138	unipolar depression	Disease	D003866
Relation: 8748050	CID	74	87	D000639	32	46	D001927	true
Relation: 8748050	CID	74	87	D000639	119	138	D003866	false

Sentence: Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen induced tumor.
Entity: 8755612	22	27	tumor	Disease	D009369
Entity: 8755612	39	50	hemorrhagic	Disease	D006470
Entity: 8755612	68	76	estrogen	Chemical	D004967
Entity: 8755612	85	90	tumor	Disease	D009369
Relation: 8755612	CID	68	76	D004967	22	27	D009369	false
Relation: 8755612	CID	68	76	D004967	39	50	D006470	false
Relation: 8755612	CID	68	76	D004967	85	90	D009369	false

Sentence: Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic pituitary tumors.
Entity: 8755612	26	34	estrogen	Chemical	D004967
Entity: 8755612	90	101	hemorrhagic	Disease	D006470
Entity: 8755612	102	118	pituitary tumors	Disease	D010911
Relation: 8755612	CID	26	34	D004967	90	101	D006470	false
Relation: 8755612	CID	26	34	D004967	102	118	D010911	false

Sentence: Ten weeks of diethylstilbestrol (DES) treatment caused female F344 rat pituitaries to grow to an average of 109.2 +/- 6.3 mg (mean +/- SE) versus 11.3 +/- 1.4 mg for untreated rats, and to become highly hemorrhagic.
Entity: 8755612	13	31	diethylstilbestrol	Chemical	D004054
Entity: 8755612	33	36	DES	Chemical	D004054
Entity: 8755612	203	214	hemorrhagic	Disease	D006470
Relation: 8755612	CID	13	31	D004054	203	214	D006470	false
Relation: 8755612	CID	33	36	D004054	203	214	D006470	false

Sentence: However, while DES induced pituitary growth exhibited quantitative, additive inheritance, the hemorrhagic phenotype exhibited recessive, epistatic inheritance.
Entity: 8755612	15	18	DES	Chemical	D004054
Entity: 8755612	94	105	hemorrhagic	Disease	D006470
Relation: 8755612	CID	15	18	D004054	94	105	D006470	false

Sentence: Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation.
Entity: 8808730	33	45	nitric oxide	Chemical	D009569
Entity: 8808730	102	120	bladder irritation	Disease	D001745
Relation: 8808730	CID	33	45	D009569	102	120	D001745	false

Sentence: Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat.
Entity: 8808730	93	105	nitric oxide	Chemical	D009569
Entity: 8808730	169	200	irritation of the urinary tract	Disease	D014570
Relation: 8808730	CID	93	105	D009569	169	200	D014570	false

Sentence: Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.
Entity: 8808730	9	17	cystitis	Disease	D003556
Entity: 8808730	33	49	cyclophosphamide	Chemical	D003520
Entity: 8808730	51	54	CYP	Chemical	D003520
Entity: 8808730	80	88	acrolein	Chemical	D000171
Relation: 8808730	CID	33	49	D003520	9	17	D003556	true
Relation: 8808730	CID	51	54	D003520	9	17	D003556	true
Relation: 8808730	CID	80	88	D000171	9	17	D003556	false

Sentence: Effects of a new calcium antagonist, CD-832, on isoproterenol induced myocardial ischemia in dogs with partial coronary stenosis.
Entity: 8819482	17	24	calcium	Chemical	D002118
Entity: 8819482	37	43	CD-832	Chemical	C082828
Entity: 8819482	48	61	isoproterenol	Chemical	D007545
Entity: 8819482	70	89	myocardial ischemia	Disease	D017202
Entity: 8819482	111	128	coronary stenosis	Disease	D023921
Relation: 8819482	CID	17	24	D002118	70	89	D017202	false
Relation: 8819482	CID	17	24	D002118	111	128	D023921	false
Relation: 8819482	CID	37	43	C082828	70	89	D017202	false
Relation: 8819482	CID	37	43	C082828	111	128	D023921	false
Relation: 8819482	CID	48	61	D007545	70	89	D017202	true
Relation: 8819482	CID	48	61	D007545	111	128	D023921	false

Sentence: Effects of CD-832 on isoproterenol (ISO) induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.
Entity: 8819482	11	17	CD-832	Chemical	C082828
Entity: 8819482	21	34	isoproterenol	Chemical	D007545
Entity: 8819482	36	39	ISO	Chemical	D007545
Entity: 8819482	49	68	myocardial ischemia	Disease	D017202
Entity: 8819482	103	120	coronary stenosis	Disease	D023921
Entity: 8819482	202	212	nifedipine	Chemical	D009543
Entity: 8819482	216	225	diltiazem	Chemical	D004110
Relation: 8819482	CID	11	17	C082828	49	68	D017202	false
Relation: 8819482	CID	11	17	C082828	103	120	D023921	false
Relation: 8819482	CID	21	34	D007545	49	68	D017202	true
Relation: 8819482	CID	21	34	D007545	103	120	D023921	false
Relation: 8819482	CID	36	39	D007545	49	68	D017202	true
Relation: 8819482	CID	36	39	D007545	103	120	D023921	false
Relation: 8819482	CID	202	212	D009543	49	68	D017202	false
Relation: 8819482	CID	202	212	D009543	103	120	D023921	false
Relation: 8819482	CID	216	225	D004110	49	68	D017202	false
Relation: 8819482	CID	216	225	D004110	103	120	D023921	false

Sentence: In the presence of coronary artery stenosis, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram.
Entity: 8819482	19	43	coronary artery stenosis	Disease	D023921
Entity: 8819482	76	79	ISO	Chemical	D007545
Relation: 8819482	CID	76	79	D007545	19	43	D023921	false

Sentence: After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.
Entity: 8819482	18	21	ISO	Chemical	D007545
Entity: 8819482	36	44	stenosis	Disease	D003251
Entity: 8819482	85	91	CD-832	Chemical	C082828
Entity: 8819482	129	139	nifedipine	Chemical	D009543
Entity: 8819482	178	187	diltiazem	Chemical	D004110
Entity: 8819482	283	286	ISO	Chemical	D007545
Relation: 8819482	CID	18	21	D007545	36	44	D003251	false
Relation: 8819482	CID	85	91	C082828	36	44	D003251	false
Relation: 8819482	CID	129	139	D009543	36	44	D003251	false
Relation: 8819482	CID	178	187	D004110	36	44	D003251	false
Relation: 8819482	CID	283	286	D007545	36	44	D003251	false

Sentence: In contrast to nifedipine, CD-832 (10 micrograms/kg/min) prevented the decrease in percentage segmental shortening from 32 +/- 12% to 115 +/- 26% of the control value (P < .01) and ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- 1.3 mV (P < .01) at 3 min after ISO infusion with stenosis.
Entity: 8819482	15	25	nifedipine	Chemical	D009543
Entity: 8819482	27	33	CD-832	Chemical	C082828
Entity: 8819482	265	268	ISO	Chemical	D007545
Entity: 8819482	283	291	stenosis	Disease	D003251
Relation: 8819482	CID	15	25	D009543	283	291	D003251	false
Relation: 8819482	CID	27	33	C082828	283	291	D003251	false
Relation: 8819482	CID	265	268	D007545	283	291	D003251	false

Sentence: Diltiazem (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P < .05) and ST-segment elevation from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 min after ISO infusion with stenosis.
Entity: 8819482	0	9	Diltiazem	Chemical	D004110
Entity: 8819482	245	248	ISO	Chemical	D007545
Entity: 8819482	263	271	stenosis	Disease	D003251
Relation: 8819482	CID	0	9	D004110	263	271	D003251	false
Relation: 8819482	CID	245	248	D007545	263	271	D003251	false

Sentence: The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.
Entity: 8825380	72	97	puromycin aminonucleoside	Chemical	D011692
Entity: 8825380	98	109	nephropathy	Disease	D007674
Relation: 8825380	CID	72	97	D011692	98	109	D007674	true

Sentence: We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.
Entity: 8825380	108	133	puromycin aminonucleoside	Chemical	D011692
Entity: 8825380	135	138	PAN	Chemical	D011692
Entity: 8825380	140	151	nephropathy	Disease	D007674
Entity: 8825380	178	196	glomerular disease	Disease	D007674
Relation: 8825380	CID	108	133	D011692	140	151	D007674	true
Relation: 8825380	CID	108	133	D011692	178	196	D007674	true
Relation: 8825380	CID	135	138	D011692	140	151	D007674	true
Relation: 8825380	CID	135	138	D011692	178	196	D007674	true

Sentence: Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.
Entity: 8825380	104	118	growth failure	Disease	D006130
Entity: 8825380	140	143	PAN	Chemical	D011692
Entity: 8825380	144	155	nephropathy	Disease	D007674
Relation: 8825380	CID	140	143	D011692	104	118	D006130	false
Relation: 8825380	CID	140	143	D011692	144	155	D007674	true

Sentence: The glomerulopathy was induced by seven serial injections of PAN over 12 wk.
Entity: 8825380	4	18	glomerulopathy	Disease	D007674
Entity: 8825380	61	64	PAN	Chemical	D011692
Relation: 8825380	CID	61	64	D011692	4	18	D007674	true

Sentence: Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy.
Entity: 8825380	82	85	PAN	Chemical	D011692
Entity: 8825380	86	97	nephropathy	Disease	D007674
Relation: 8825380	CID	82	85	D011692	86	97	D007674	true

Sentence: After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 +/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05.
Entity: 8825380	146	149	PAN	Chemical	D011692
Entity: 8825380	150	161	nephropathy	Disease	D007674
Relation: 8825380	CID	146	149	D011692	150	161	D007674	true

Sentence: The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.
Entity: 8825380	56	78	glomerular hypertrophy	Disease	D007674
Entity: 8825380	102	120	glomerulosclerosis	Disease	D005921
Entity: 8825380	122	147	tubulointerstitial injury	Disease	-1
Entity: 8825380	167	182	malondialdehyde	Chemical	D008315
Relation: 8825380	CID	167	182	D008315	56	78	D007674	false
Relation: 8825380	CID	167	182	D008315	102	120	D005921	false
Relation: 8825380	CID	167	182	D008315	122	147	-1	false

Sentence: In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.
Entity: 8825380	13	16	PAN	Chemical	D011692
Entity: 8825380	17	28	nephropathy	Disease	D007674
Relation: 8825380	CID	13	16	D011692	17	28	D007674	true

Sentence: In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors.
Entity: 8825380	110	121	proteinuria	Disease	D011507
Entity: 8825380	167	182	malondialdehyde	Chemical	D008315
Entity: 8825380	209	234	tubulointerstitial damage	Disease	D007674
Relation: 8825380	CID	167	182	D008315	110	121	D011507	false
Relation: 8825380	CID	167	182	D008315	209	234	D007674	false

Sentence: Nefiracetam (DM-9384) reverses apomorphine induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.
Entity: 8829135	0	11	Nefiracetam	Chemical	C058876
Entity: 8829135	13	20	DM-9384	Chemical	C058876
Entity: 8829135	31	42	apomorphine	Chemical	D001058
Entity: 8829135	51	58	amnesia	Disease	D000647
Relation: 8829135	CID	0	11	C058876	51	58	D000647	false
Relation: 8829135	CID	13	20	C058876	51	58	D000647	false
Relation: 8829135	CID	31	42	D001058	51	58	D000647	true

Sentence: Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine induced learning and post-training consolidation deficits.
Entity: 8829135	0	11	Nefiracetam	Chemical	C058876
Entity: 8829135	23	34	pyrrolidone	Chemical	D011760
Entity: 8829135	63	74	scopolamine	Chemical	D012601
Entity: 8829135	83	132	learning and post-training consolidation deficits	Disease	D007859
Relation: 8829135	CID	0	11	C058876	83	132	D007859	false
Relation: 8829135	CID	23	34	D011760	83	132	D007859	false
Relation: 8829135	CID	63	74	D012601	83	132	D007859	true

Sentence: Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.
Entity: 8829135	11	22	apomorphine	Chemical	D001058
Entity: 8829135	160	171	nefiracetam	Chemical	C058876
Entity: 8829135	185	192	amnesia	Disease	D000647
Relation: 8829135	CID	11	22	D001058	185	192	D000647	true
Relation: 8829135	CID	160	171	C058876	185	192	D000647	false

Sentence: However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.
Entity: 8829135	27	38	nefiracetam	Chemical	C058876
Entity: 8829135	79	86	amnesia	Disease	D000647
Entity: 8829135	98	109	apomorphine	Chemical	D001058
Relation: 8829135	CID	27	38	C058876	79	86	D000647	false
Relation: 8829135	CID	98	109	D001058	79	86	D000647	true

Sentence: Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the hypercapnic ventilatory response in humans.
Entity: 8957205	6	19	corticotropin	Chemical	D000324
Entity: 8957205	42	53	thyrotropin	Chemical	D013972
Entity: 8957205	85	96	hypercapnic	Disease	D006935
Relation: 8957205	CID	6	19	D000324	85	96	D006935	false
Relation: 8957205	CID	42	53	D013972	85	96	D006935	false

Sentence: Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.
Entity: 8985298	0	10	Lamivudine	Chemical	D019259
Entity: 8985298	39	50	hepatitis B	Disease	D006509
Entity: 8985298	72	99	hepatitis B surface antigen	Chemical	D006514
Relation: 8985298	CID	0	10	D019259	39	50	D006509	false
Relation: 8985298	CID	72	99	D006514	39	50	D006509	true

Sentence: Lamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo.
Entity: 8985298	0	10	Lamivudine	Chemical	D019259
Entity: 8985298	22	44	2',3'-dideoxy cytosine	Chemical	D019259
Entity: 8985298	92	103	hepatitis B	Disease	D006509
Relation: 8985298	CID	0	10	D019259	92	103	D006509	false
Relation: 8985298	CID	22	44	D019259	92	103	D006509	false

Sentence: All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo).
Entity: 8985298	26	36	lamivudine	Chemical	D019259
Entity: 8985298	55	66	hepatitis B	Disease	D006509
Relation: 8985298	CID	26	36	D019259	55	66	D006509	false

Sentence: Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Entity: 8996419	34	56	venous thromboembolism	Disease	D054556
Entity: 8996419	81	100	oral contraceptives	Chemical	D003276
Relation: 8996419	CID	81	100	D003276	34	56	D054556	true

Sentence: BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.
Entity: 8996419	88	110	venous thromboembolism	Disease	D054556
Entity: 8996419	112	115	VTE	Disease	D054556
Entity: 8996419	146	165	oral contraceptives	Chemical	D003276
Entity: 8996419	167	170	OCs	Chemical	D003276
Entity: 8996419	204	216	progestagens	Chemical	D011374
Entity: 8996419	217	226	gestodene	Chemical	C033273
Entity: 8996419	230	241	desogestrel	Chemical	D017135
Entity: 8996419	259	262	OCs	Chemical	D003276
Entity: 8996419	292	304	progestagens	Chemical	D011374
Relation: 8996419	CID	146	165	D003276	88	110	D054556	true
Relation: 8996419	CID	146	165	D003276	112	115	D054556	true
Relation: 8996419	CID	167	170	D003276	88	110	D054556	true
Relation: 8996419	CID	167	170	D003276	112	115	D054556	true
Relation: 8996419	CID	204	216	D011374	88	110	D054556	false
Relation: 8996419	CID	204	216	D011374	112	115	D054556	false
Relation: 8996419	CID	217	226	C033273	88	110	D054556	false
Relation: 8996419	CID	217	226	C033273	112	115	D054556	false
Relation: 8996419	CID	230	241	D017135	88	110	D054556	false
Relation: 8996419	CID	230	241	D017135	112	115	D054556	false
Relation: 8996419	CID	259	262	D003276	88	110	D054556	true
Relation: 8996419	CID	259	262	D003276	112	115	D054556	true
Relation: 8996419	CID	292	304	D011374	88	110	D054556	false
Relation: 8996419	CID	292	304	D011374	112	115	D054556	false

Sentence: The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.
Entity: 8996419	71	74	VTE	Disease	D054556
Entity: 8996419	79	81	OC	Chemical	D003276
Relation: 8996419	CID	79	81	D003276	71	74	D054556	true

Sentence: We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.
Entity: 8996419	62	65	VTE	Disease	D054556
Entity: 8996419	87	89	OC	Chemical	D003276
Entity: 8996419	168	171	VTE	Disease	D054556
Entity: 8996419	214	216	OC	Chemical	D003276
Relation: 8996419	CID	87	89	D003276	62	65	D054556	true
Relation: 8996419	CID	87	89	D003276	168	171	D054556	true
Relation: 8996419	CID	214	216	D003276	62	65	D054556	true
Relation: 8996419	CID	214	216	D003276	168	171	D054556	true

Sentence: FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.
Entity: 8996419	50	53	VTE	Disease	D054556
Entity: 8996419	81	92	progestagen	Chemical	D011372
Entity: 8996419	98	101	OCs	Chemical	D003276
Relation: 8996419	CID	81	92	D011372	50	53	D054556	false
Relation: 8996419	CID	98	101	D003276	50	53	D054556	true

Sentence: Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.
Entity: 8996419	19	22	VTE	Disease	D054556
Entity: 8996419	55	58	OCs	Chemical	D003276
Entity: 8996419	80	100	deep-vein thrombosis	Disease	D020246
Entity: 8996419	118	128	thrombosis	Disease	D013927
Entity: 8996419	142	159	venous thrombosis	Disease	D020246
Relation: 8996419	CID	55	58	D003276	19	22	D054556	true
Relation: 8996419	CID	55	58	D003276	80	100	D020246	false
Relation: 8996419	CID	55	58	D003276	118	128	D013927	false
Relation: 8996419	CID	55	58	D003276	142	159	D020246	false

Sentence: The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.
Entity: 8996419	18	21	VTE	Disease	D054556
Entity: 8996419	78	80	OC	Chemical	D003276
Entity: 8996419	117	120	OCs	Chemical	D003276
Relation: 8996419	CID	78	80	D003276	18	21	D054556	true
Relation: 8996419	CID	117	120	D003276	18	21	D054556	true

Sentence: After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75).
Entity: 8996419	44	47	VTE	Disease	D054556
Entity: 8996419	107	110	OCs	Chemical	D003276
Relation: 8996419	CID	107	110	D003276	44	47	D054556	true

Sentence: Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs.
Entity: 8996419	68	71	VTE	Disease	D054556
Entity: 8996419	128	131	OCs	Chemical	D003276
Relation: 8996419	CID	128	131	D003276	68	71	D054556	true

Sentence: Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.
Entity: 8996419	32	44	progestagens	Chemical	D011374
Entity: 8996419	58	61	VTE	Disease	D054556
Entity: 8996419	85	96	desogestrel	Chemical	D017135
Entity: 8996419	107	124	ethinyloestradiol	Chemical	D004997
Entity: 8996419	142	151	gestodene	Chemical	C033273
Entity: 8996419	155	166	desogestrel	Chemical	D017135
Entity: 8996419	177	194	ethinyloestradiol	Chemical	D004997
Relation: 8996419	CID	32	44	D011374	58	61	D054556	false
Relation: 8996419	CID	85	96	D017135	58	61	D054556	false
Relation: 8996419	CID	107	124	D004997	58	61	D054556	false
Relation: 8996419	CID	142	151	C033273	58	61	D054556	false
Relation: 8996419	CID	155	166	D017135	58	61	D054556	false
Relation: 8996419	CID	177	194	D004997	58	61	D054556	false

Sentence: With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.
Entity: 8996419	27	30	OCs	Chemical	D003276
Entity: 8996419	69	72	VTE	Disease	D054556
Entity: 8996419	100	111	desogestrel	Chemical	D017135
Entity: 8996419	122	139	ethinyloestradiol	Chemical	D004997
Entity: 8996419	192	204	progestagens	Chemical	D011374
Relation: 8996419	CID	27	30	D003276	69	72	D054556	true
Relation: 8996419	CID	100	111	D017135	69	72	D054556	false
Relation: 8996419	CID	122	139	D004997	69	72	D054556	false
Relation: 8996419	CID	192	204	D011374	69	72	D054556	false

Sentence: MK-801 augments pilocarpine induced electrographic seizure but protects against brain damage in rats. 1.
Entity: 9061777	0	6	MK-801	Chemical	D016291
Entity: 9061777	16	27	pilocarpine	Chemical	D010862
Entity: 9061777	51	58	seizure	Disease	D012640
Entity: 9061777	80	92	brain damage	Disease	D001930
Relation: 9061777	CID	0	6	D016291	51	58	D012640	true
Relation: 9061777	CID	0	6	D016291	80	92	D001930	false
Relation: 9061777	CID	16	27	D010862	51	58	D012640	true
Relation: 9061777	CID	16	27	D010862	80	92	D001930	false

Sentence: The authors examined the anticonvulsant effects of MK-801 on the pilocarpine induced seizure model.
Entity: 9061777	51	57	MK-801	Chemical	D016291
Entity: 9061777	65	76	pilocarpine	Chemical	D010862
Entity: 9061777	85	92	seizure	Disease	D012640
Relation: 9061777	CID	51	57	D016291	85	92	D012640	true
Relation: 9061777	CID	65	76	D010862	85	92	D012640	true

Sentence: Intraperitoneal injection of pilocarpine (400 mg/kg) induced tonic and clonic seizure.
Entity: 9061777	29	40	pilocarpine	Chemical	D010862
Entity: 9061777	61	85	tonic and clonic seizure	Disease	D012640
Relation: 9061777	CID	29	40	D010862	61	85	D012640	true

Sentence: Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine induced behavioral seizure but MK-801 (0.5 mg/kg) did not. 2.
Entity: 9061777	0	11	Scopolamine	Chemical	D012601
Entity: 9061777	27	40	pentobarbital	Chemical	D010424
Entity: 9061777	76	87	pilocarpine	Chemical	D010862
Entity: 9061777	107	114	seizure	Disease	D012640
Entity: 9061777	119	125	MK-801	Chemical	D016291
Relation: 9061777	CID	0	11	D012601	107	114	D012640	false
Relation: 9061777	CID	27	40	D010424	107	114	D012640	false
Relation: 9061777	CID	76	87	D010862	107	114	D012640	true
Relation: 9061777	CID	119	125	D016291	107	114	D012640	true

Sentence: An electrical seizure measured with hippocampal EEG appeared in the pilocarpine-treated group.
Entity: 9061777	14	21	seizure	Disease	D012640
Entity: 9061777	68	79	pilocarpine	Chemical	D010862
Relation: 9061777	CID	68	79	D010862	14	21	D012640	true

Sentence: Scopolamine and pentobarbital blocked the pilocarpine induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine. 3.
Entity: 9061777	0	11	Scopolamine	Chemical	D012601
Entity: 9061777	16	29	pentobarbital	Chemical	D010424
Entity: 9061777	42	53	pilocarpine	Chemical	D010862
Entity: 9061777	77	84	seizure	Disease	D012640
Entity: 9061777	86	92	MK-801	Chemical	D016291
Entity: 9061777	132	139	seizure	Disease	D012640
Entity: 9061777	151	162	pilocarpine	Chemical	D010862
Relation: 9061777	CID	0	11	D012601	77	84	D012640	false
Relation: 9061777	CID	0	11	D012601	132	139	D012640	false
Relation: 9061777	CID	16	29	D010424	77	84	D012640	false
Relation: 9061777	CID	16	29	D010424	132	139	D012640	false
Relation: 9061777	CID	42	53	D010862	77	84	D012640	true
Relation: 9061777	CID	42	53	D010862	132	139	D012640	true
Relation: 9061777	CID	86	92	D016291	77	84	D012640	true
Relation: 9061777	CID	86	92	D016291	132	139	D012640	true
Relation: 9061777	CID	151	162	D010862	77	84	D012640	true
Relation: 9061777	CID	151	162	D010862	132	139	D012640	true

Sentence: Pilocarpine produced neuronal death in the hippocampus, which showed pyknotic changes.
Entity: 9061777	0	11	Pilocarpine	Chemical	D010862
Entity: 9061777	21	35	neuronal death	Disease	D009410
Relation: 9061777	CID	0	11	D010862	21	35	D009410	true

Sentence: Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.
Entity: 9061777	0	13	Pentobarbital	Chemical	D010424
Entity: 9061777	15	26	scopolamine	Chemical	D012601
Entity: 9061777	31	37	MK-801	Chemical	D016291
Entity: 9061777	52	64	brain damage	Disease	D001930
Entity: 9061777	68	79	pilocarpine	Chemical	D010862
Entity: 9061777	95	101	MK-801	Chemical	D016291
Relation: 9061777	CID	0	13	D010424	52	64	D001930	false
Relation: 9061777	CID	15	26	D012601	52	64	D001930	false
Relation: 9061777	CID	31	37	D016291	52	64	D001930	false
Relation: 9061777	CID	68	79	D010862	52	64	D001930	false
Relation: 9061777	CID	95	101	D016291	52	64	D001930	false

Sentence: Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. 5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.
Entity: 9071336	0	10	Paclitaxel	Chemical	D017239
Entity: 9071336	12	26	5-fluorouracil	Chemical	D005472
Entity: 9071336	32	44	folinic acid	Chemical	D002955
Entity: 9071336	59	72	breast cancer	Disease	D001943
Entity: 9071336	100	114	5-Fluorouracil	Chemical	D005472
Entity: 9071336	120	132	folinic acid	Chemical	D002955
Entity: 9071336	137	147	paclitaxel	Chemical	D017239
Entity: 9071336	149	154	Taxol	Chemical	D017239
Entity: 9071336	248	261	breast cancer	Disease	D001943
Relation: 9071336	CID	0	10	D017239	59	72	D001943	false
Relation: 9071336	CID	0	10	D017239	248	261	D001943	false
Relation: 9071336	CID	12	26	D005472	59	72	D001943	false
Relation: 9071336	CID	12	26	D005472	248	261	D001943	false
Relation: 9071336	CID	32	44	D002955	59	72	D001943	false
Relation: 9071336	CID	32	44	D002955	248	261	D001943	false
Relation: 9071336	CID	100	114	D005472	59	72	D001943	false
Relation: 9071336	CID	100	114	D005472	248	261	D001943	false
Relation: 9071336	CID	120	132	D002955	59	72	D001943	false
Relation: 9071336	CID	120	132	D002955	248	261	D001943	false
Relation: 9071336	CID	137	147	D017239	59	72	D001943	false
Relation: 9071336	CID	137	147	D017239	248	261	D001943	false
Relation: 9071336	CID	149	154	D017239	59	72	D001943	false
Relation: 9071336	CID	149	154	D017239	248	261	D001943	false

Sentence: Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines.
Entity: 9071336	0	10	Paclitaxel	Chemical	D017239
Entity: 9071336	15	29	5-fluorouracil	Chemical	D005472
Entity: 9071336	44	56	cytotoxicity	Disease	D064420
Relation: 9071336	CID	0	10	D017239	44	56	D064420	false
Relation: 9071336	CID	15	29	D005472	44	56	D064420	false

Sentence: We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.
Entity: 9071336	33	43	paclitaxel	Chemical	D017239
Entity: 9071336	88	100	folinic acid	Chemical	D002955
Entity: 9071336	127	141	5-fluorouracil	Chemical	D005472
Entity: 9071336	212	225	breast cancer	Disease	D001943
Relation: 9071336	CID	33	43	D017239	212	225	D001943	false
Relation: 9071336	CID	88	100	D002955	212	225	D001943	false
Relation: 9071336	CID	127	141	D005472	212	225	D001943	false

Sentence: Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions.
Entity: 9071336	164	175	neutropenia	Disease	D009503
Entity: 9071336	246	283	granulocyte colony-stimulating factor	Chemical	D016179
Entity: 9071336	291	302	neutropenia	Disease	D009503
Relation: 9071336	CID	246	283	D016179	164	175	D009503	false
Relation: 9071336	CID	246	283	D016179	291	302	D009503	false

Sentence: Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Entity: 9125676	13	26	proarrhythmia	Disease	-1
Entity: 9125676	43	54	d,l-sotalol	Chemical	D013015
Entity: 9125676	69	97	ventricular tachyarrhythmias	Disease	D017180
Relation: 9125676	CID	43	54	D013015	13	26	-1	false
Relation: 9125676	CID	43	54	D013015	69	97	D017180	false

Sentence: This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.
Entity: 9125676	75	94	torsades de pointes	Disease	D016171
Entity: 9125676	132	151	torsades de pointes	Disease	D016171
Entity: 9125676	177	188	d,l-sotalol	Chemical	D013015
Entity: 9125676	203	231	ventricular tachyarrhythmias	Disease	D017180
Relation: 9125676	CID	177	188	D013015	75	94	D016171	true
Relation: 9125676	CID	177	188	D013015	132	151	D016171	true
Relation: 9125676	CID	177	188	D013015	203	231	D017180	false

Sentence: Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.
Entity: 9125676	41	64	coronary artery disease	Disease	D003324
Entity: 9125676	78	100	dilated cardiomyopathy	Disease	D002311
Entity: 9125676	127	150	ventricular tachycardia	Disease	D017180
Entity: 9125676	154	178	ventricular fibrillation	Disease	D014693
Entity: 9125676	193	204	d,l-sotalol	Chemical	D013015
Entity: 9125676	233	260	ventricular tachyarrhythmia	Disease	D017180
Relation: 9125676	CID	193	204	D013015	41	64	D003324	false
Relation: 9125676	CID	193	204	D013015	78	100	D002311	false
Relation: 9125676	CID	193	204	D013015	127	150	D017180	false
Relation: 9125676	CID	193	204	D013015	154	178	D014693	false
Relation: 9125676	CID	193	204	D013015	233	260	D017180	false

Sentence: Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/- 18 months.
Entity: 9125676	23	34	d,l-sotalol	Chemical	D013015
Entity: 9125676	58	81	ventricular tachycardia	Disease	D017180
Entity: 9125676	85	109	ventricular fibrillation	Disease	D014693
Relation: 9125676	CID	23	34	D013015	58	81	D017180	false
Relation: 9125676	CID	23	34	D013015	85	109	D014693	false

Sentence: Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.
Entity: 9125676	17	44	ventricular tachyarrhythmia	Disease	D017180
Entity: 9125676	67	78	d,l-sotalol	Chemical	D013015
Entity: 9125676	105	132	ventricular tachyarrhythmia	Disease	D017180
Entity: 9125676	229	240	d,l-sotalol	Chemical	D013015
Relation: 9125676	CID	67	78	D013015	17	44	D017180	false
Relation: 9125676	CID	67	78	D013015	105	132	D017180	false
Relation: 9125676	CID	229	240	D013015	17	44	D017180	false
Relation: 9125676	CID	229	240	D013015	105	132	D017180	false

Sentence: Four (5%) patients had from torsades de pointes during the initial oral treatment with d,l-sotalol.
Entity: 9125676	28	47	torsades de pointes	Disease	D016171
Entity: 9125676	87	98	d,l-sotalol	Chemical	D013015
Relation: 9125676	CID	87	98	D013015	28	47	D016171	true

Sentence: However, the oral dose of d,l-sotalol was significantly lower in patients with torsades de pointes (200 +/- 46 vs. 328 +/- 53 mg/day; p = 0.0017).
Entity: 9125676	26	37	d,l-sotalol	Chemical	D013015
Entity: 9125676	79	98	torsades de pointes	Disease	D016171
Relation: 9125676	CID	26	37	D013015	79	98	D016171	true

Sentence: One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.
Entity: 9125676	31	46	cardiac disease	Disease	D006331
Entity: 9125676	61	80	torsades de pointes	Disease	D016171
Entity: 9125676	124	135	d,l-sotalol	Chemical	D013015
Relation: 9125676	CID	124	135	D013015	31	46	D006331	false
Relation: 9125676	CID	124	135	D013015	61	80	D016171	true

Sentence: Torsades de pointes occurred early during treatment even with low doses of oral d,l-sotalol.
Entity: 9125676	0	19	Torsades de pointes	Disease	D016171
Entity: 9125676	80	91	d,l-sotalol	Chemical	D013015
Relation: 9125676	CID	80	91	D013015	0	19	D016171	true

Sentence: Pronounced changes in the surface ECG (cycle length, QT, and QTc) in relation to the dose of oral d,l-sotalol might identify a subgroup of patients with an increased risk for torsades de pointes.
Entity: 9125676	98	109	d,l-sotalol	Chemical	D013015
Entity: 9125676	175	194	torsades de pointes	Disease	D016171
Relation: 9125676	CID	98	109	D013015	175	194	D016171	true

Sentence: Other ECG parameters before the application of d,l-sotalol did not identify patients at increased risk for torsades de pointes.
Entity: 9125676	47	58	d,l-sotalol	Chemical	D013015
Entity: 9125676	107	126	torsades de pointes	Disease	D016171
Relation: 9125676	CID	47	58	D013015	107	126	D016171	true

Sentence: Chronic hyperprolactinemia and changes in dopamine neurons.
Entity: 9128918	8	26	hyperprolactinemia	Disease	D006966
Entity: 9128918	42	50	dopamine	Chemical	D004298
Relation: 9128918	CID	42	50	D004298	8	26	D006966	false

Sentence: Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.
Entity: 9128918	0	18	Hyperprolactinemia	Disease	D006966
Entity: 9128918	49	60	haloperidol	Chemical	D006220
Entity: 9128918	64	72	dopamine	Chemical	D004298
Relation: 9128918	CID	49	60	D006220	0	18	D006966	true
Relation: 9128918	CID	64	72	D004298	0	18	D006966	false

Sentence: After 6 months of hyperprolactinemia, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.
Entity: 9128918	18	36	hyperprolactinemia	Disease	D006966
Entity: 9128918	38	46	dopamine	Chemical	D004298
Entity: 9128918	48	50	DA	Chemical	D004298
Relation: 9128918	CID	38	46	D004298	18	36	D006966	false
Relation: 9128918	CID	48	50	D004298	18	36	D006966	false

Sentence: Nine months of hyperprolactinemia produced a 50% increase in DA concentrations in the ME over the control group.
Entity: 9128918	15	33	hyperprolactinemia	Disease	D006966
Entity: 9128918	61	63	DA	Chemical	D004298
Relation: 9128918	CID	61	63	D004298	15	33	D006966	false

Sentence: However, DA response was lost if a 9-month long haloperidol induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.
Entity: 9128918	9	11	DA	Chemical	D004298
Entity: 9128918	48	59	haloperidol	Chemical	D006220
Entity: 9128918	68	86	hyperprolactinemia	Disease	D006966
Relation: 9128918	CID	9	11	D004298	68	86	D006966	false
Relation: 9128918	CID	48	59	D006220	68	86	D006966	true

Sentence: There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.
Entity: 9128918	37	39	DA	Chemical	D004298
Entity: 9128918	41	55	norepinephrine	Chemical	D009638
Entity: 9128918	57	59	NE	Chemical	D009638
Entity: 9128918	62	71	serotonin	Chemical	D012701
Entity: 9128918	73	77	5-HT	Chemical	D012701
Entity: 9128918	251	277	5-hydroxyindoleacetic acid	Chemical	D006897
Entity: 9128918	279	285	5-HIAA	Chemical	D006897
Entity: 9128918	315	333	hyperprolactinemia	Disease	D006966
Entity: 9128918	353	355	DA	Chemical	D004298
Entity: 9128918	399	417	hyperprolactinemia	Disease	D006966
Relation: 9128918	CID	37	39	D004298	315	333	D006966	false
Relation: 9128918	CID	37	39	D004298	399	417	D006966	false
Relation: 9128918	CID	41	55	D009638	315	333	D006966	false
Relation: 9128918	CID	41	55	D009638	399	417	D006966	false
Relation: 9128918	CID	57	59	D009638	315	333	D006966	false
Relation: 9128918	CID	57	59	D009638	399	417	D006966	false
Relation: 9128918	CID	62	71	D012701	315	333	D006966	false
Relation: 9128918	CID	62	71	D012701	399	417	D006966	false
Relation: 9128918	CID	73	77	D012701	315	333	D006966	false
Relation: 9128918	CID	73	77	D012701	399	417	D006966	false
Relation: 9128918	CID	251	277	D006897	315	333	D006966	false
Relation: 9128918	CID	251	277	D006897	399	417	D006966	false
Relation: 9128918	CID	279	285	D006897	315	333	D006966	false
Relation: 9128918	CID	279	285	D006897	399	417	D006966	false
Relation: 9128918	CID	353	355	D004298	315	333	D006966	false
Relation: 9128918	CID	353	355	D004298	399	417	D006966	false

Sentence: This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.
Entity: 9132810	157	176	leukoencephalopathy	Disease	D056784
Entity: 9132810	199	227	acute lymphoblastic leukemia	Disease	D054198
Entity: 9132810	251	263	methotrexate	Chemical	D008727
Relation: 9132810	CID	251	263	D008727	157	176	D056784	true
Relation: 9132810	CID	251	263	D008727	199	227	D054198	false

Sentence: Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.
Entity: 9158667	0	10	Thrombotic	Disease	D013927
Entity: 9158667	28	56	acute promyelocytic leukemia	Disease	D015473
Entity: 9158667	64	87	all-trans-retinoic acid	Chemical	D014212
Relation: 9158667	CID	64	87	D014212	0	10	D013927	true
Relation: 9158667	CID	64	87	D014212	28	56	D015473	false

Sentence: A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.
Entity: 9158667	10	29	acute renal failure	Disease	D058186
Entity: 9158667	38	64	occlusion of renal vessels	Disease	-1
Entity: 9158667	83	111	acute promyelocytic leukemia	Disease	D015473
Entity: 9158667	113	116	APL	Disease	D015473
Entity: 9158667	131	154	all-trans-retinoic acid	Chemical	D014212
Entity: 9158667	156	160	ATRA	Chemical	D014212
Entity: 9158667	166	181	tranexamic acid	Chemical	D014148
Relation: 9158667	CID	131	154	D014212	10	29	D058186	true
Relation: 9158667	CID	131	154	D014212	38	64	-1	false
Relation: 9158667	CID	131	154	D014212	83	111	D015473	false
Relation: 9158667	CID	131	154	D014212	113	116	D015473	false
Relation: 9158667	CID	156	160	D014212	10	29	D058186	true
Relation: 9158667	CID	156	160	D014212	38	64	-1	false
Relation: 9158667	CID	156	160	D014212	83	111	D015473	false
Relation: 9158667	CID	156	160	D014212	113	116	D015473	false
Relation: 9158667	CID	166	181	D014148	10	29	D058186	false
Relation: 9158667	CID	166	181	D014148	38	64	-1	false
Relation: 9158667	CID	166	181	D014148	83	111	D015473	false
Relation: 9158667	CID	166	181	D014148	113	116	D015473	false

Sentence: We report a case of acute renal failure in an APL patient treated with ATRA alone.
Entity: 9158667	20	39	acute renal failure	Disease	D058186
Entity: 9158667	46	49	APL	Disease	D015473
Entity: 9158667	71	75	ATRA	Chemical	D014212
Relation: 9158667	CID	71	75	D014212	20	39	D058186	true
Relation: 9158667	CID	71	75	D014212	46	49	D015473	false

Sentence: This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.
Entity: 9158667	45	59	thromboembolic	Disease	D013923
Entity: 9158667	90	94	ATRA	Chemical	D014212
Entity: 9158667	106	109	APL	Disease	D015473
Relation: 9158667	CID	90	94	D014212	45	59	D013923	false
Relation: 9158667	CID	90	94	D014212	106	109	D015473	false

Sentence: The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA.
Entity: 9158667	73	76	APL	Disease	D015473
Entity: 9158667	123	127	ATRA	Chemical	D014212
Relation: 9158667	CID	123	127	D014212	73	76	D015473	false

Sentence: We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected.
Entity: 9158667	17	21	ATRA	Chemical	D014212
Entity: 9158667	70	73	APL	Disease	D015473
Relation: 9158667	CID	17	21	D014212	70	73	D015473	false

Sentence: A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.
Entity: 9197951	14	21	cocaine	Chemical	D003042
Entity: 9197951	129	143	diethylpropion	Chemical	D004053
Entity: 9197951	145	148	DEP	Chemical	D004053
Entity: 9197951	157	162	manic	Disease	D001714
Relation: 9197951	CID	14	21	D003042	157	162	D001714	false
Relation: 9197951	CID	129	143	D004053	157	162	D001714	true
Relation: 9197951	CID	145	148	D004053	157	162	D001714	true

Sentence: Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.
Entity: 9197951	31	34	DEP	Chemical	D004053
Entity: 9197951	77	98	pupillary oscillation	Disease	D011681
Entity: 9197951	201	206	manic	Disease	D001714
Relation: 9197951	CID	31	34	D004053	77	98	D011681	false
Relation: 9197951	CID	31	34	D004053	201	206	D001714	true

Sentence: Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml.s-1).
Entity: 9272404	7	11	pain	Disease	D010146
Entity: 9272404	52	55	CO2	Chemical	D002245
Entity: 9272404	143	147	pain	Disease	D010146
Relation: 9272404	CID	52	55	D002245	7	11	D010146	false
Relation: 9272404	CID	52	55	D002245	143	147	D010146	false

Sentence: Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli.
Entity: 9272404	60	64	pain	Disease	D010146
Entity: 9272404	98	101	CO2	Chemical	D002245
Relation: 9272404	CID	98	101	D002245	60	64	D010146	false

Sentence: RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.
Entity: 9272404	49	58	ibuprofen	Chemical	D007052
Entity: 9272404	95	99	pain	Disease	D010146
Entity: 9272404	160	164	pain	Disease	D010146
Entity: 9272404	198	207	ibuprofen	Chemical	D007052
Entity: 9272404	239	243	pain	Disease	D010146
Relation: 9272404	CID	49	58	D007052	95	99	D010146	true
Relation: 9272404	CID	49	58	D007052	160	164	D010146	true
Relation: 9272404	CID	49	58	D007052	239	243	D010146	true
Relation: 9272404	CID	198	207	D007052	95	99	D010146	true
Relation: 9272404	CID	198	207	D007052	160	164	D010146	true
Relation: 9272404	CID	198	207	D007052	239	243	D010146	true

Sentence: Acute severe depression following peri-operative ondansetron.
Entity: 9323412	13	23	depression	Disease	D003866
Entity: 9323412	49	60	ondansetron	Chemical	D017294
Relation: 9323412	CID	49	60	D017294	13	23	D003866	false

Sentence: A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used.
Entity: 9323412	45	78	postoperative nausea and vomiting	Disease	D020250
Entity: 9323412	160	171	ondansetron	Chemical	D017294
Relation: 9323412	CID	160	171	D017294	45	78	D020250	false

Sentence: She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist.
Entity: 9323412	33	58	major depression disorder	Disease	D003865
Entity: 9323412	123	132	serotonin	Chemical	D012701
Relation: 9323412	CID	123	132	D012701	33	58	D003865	false

Sentence: Hypertensive response during dobutamine stress echocardiography.
Entity: 9382023	0	12	Hypertensive	Disease	D006973
Entity: 9382023	29	39	dobutamine	Chemical	D004280
Relation: 9382023	CID	29	39	D004280	0	12	D006973	true

Sentence: Among 3,129 dobutamine stress echocardiographic studies, a hypertensive response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%).
Entity: 9382023	12	22	dobutamine	Chemical	D004280
Entity: 9382023	59	71	hypertensive	Disease	D006973
Relation: 9382023	CID	12	22	D004280	59	71	D006973	true

Sentence: Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.
Entity: 9428298	23	32	albuterol	Chemical	D000420
Entity: 9428298	60	66	asthma	Disease	D001249
Relation: 9428298	CID	23	32	D000420	60	66	D001249	false

Sentence: A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.
Entity: 9428298	132	138	asthma	Disease	D001249
Entity: 9428298	175	184	albuterol	Chemical	D000420
Entity: 9428298	211	220	albuterol	Chemical	D000420
Relation: 9428298	CID	175	184	D000420	132	138	D001249	false
Relation: 9428298	CID	211	220	D000420	132	138	D001249	false

Sentence: Hyperosmolar nonketotic coma precipitated by lithium induced nephrogenic diabetes insipidus.
Entity: 9538487	0	28	Hyperosmolar nonketotic coma	Disease	D006944
Entity: 9538487	45	52	lithium	Chemical	D008094
Entity: 9538487	61	91	nephrogenic diabetes insipidus	Disease	D018500
Relation: 9538487	CID	45	52	D008094	0	28	D006944	true
Relation: 9538487	CID	45	52	D008094	61	91	D018500	true

Sentence: A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.
Entity: 9538487	45	61	manic depression	Disease	D001714
Entity: 9538487	75	82	lithium	Chemical	D008094
Entity: 9538487	102	131	hyperosmolar, nonketotic coma	Disease	D006944
Relation: 9538487	CID	75	82	D008094	45	61	D001714	false
Relation: 9538487	CID	75	82	D008094	102	131	D006944	true

Sentence: He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for glucose.
Entity: 9538487	31	39	polyuria	Disease	D011141
Entity: 9538487	44	54	polydipsia	Disease	D059606
Entity: 9538487	107	114	glucose	Chemical	D005947
Relation: 9538487	CID	107	114	D005947	31	39	D011141	false
Relation: 9538487	CID	107	114	D005947	44	54	D059606	false

Sentence: After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium induced.
Entity: 9538487	20	34	hyperglycaemia	Disease	-1
Entity: 9538487	48	56	polyuric	Disease	D011141
Entity: 9538487	78	85	glucose	Chemical	D005947
Entity: 9538487	138	168	nephrogenic diabetes insipidus	Disease	D018500
Entity: 9538487	183	190	lithium	Chemical	D008094
Relation: 9538487	CID	78	85	D005947	20	34	-1	false
Relation: 9538487	CID	78	85	D005947	48	56	D011141	false
Relation: 9538487	CID	78	85	D005947	138	168	D018500	false
Relation: 9538487	CID	183	190	D008094	20	34	-1	false
Relation: 9538487	CID	183	190	D008094	48	56	D011141	true
Relation: 9538487	CID	183	190	D008094	138	168	D018500	true

Sentence: BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.
Entity: 9570197	51	58	cocaine	Chemical	D003042
Entity: 9570197	77	133	deterioration of left ventricular (LV) systolic function	Disease	D018487
Relation: 9570197	CID	51	58	D003042	77	133	D018487	true

Sentence: METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).
Entity: 9570197	136	146	chest pain	Disease	D002637
Entity: 9570197	402	423	cocaine hydrochloride	Chemical	D003042
Relation: 9570197	CID	402	423	D003042	136	146	D002637	false

Sentence: Heparin induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.
Entity: 9646784	0	7	Heparin	Chemical	D006493
Entity: 9646784	16	32	thrombocytopenia	Disease	D013921
Entity: 9646784	46	61	thromboembolism	Disease	D013923
Entity: 9646784	89	96	heparin	Chemical	D006493
Relation: 9646784	CID	0	7	D006493	16	32	D013921	true
Relation: 9646784	CID	0	7	D006493	46	61	D013923	true
Relation: 9646784	CID	89	96	D006493	16	32	D013921	true
Relation: 9646784	CID	89	96	D006493	46	61	D013923	true

Sentence: Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.
Entity: 9725303	37	57	ureteric obstruction	Disease	D014517
Entity: 9725303	90	99	indinavir	Chemical	D019469
Relation: 9725303	CID	90	99	D019469	37	57	D014517	false

Sentence: OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.
Entity: 9725303	49	65	ureteric calculi	Disease	D014514
Entity: 9725303	73	85	HIV-infected	Disease	D015658
Entity: 9725303	105	114	indinavir	Chemical	D019469
Entity: 9725303	214	226	urolithiasis	Disease	D052878
Relation: 9725303	CID	105	114	D019469	49	65	D014514	true
Relation: 9725303	CID	105	114	D019469	73	85	D015658	false
Relation: 9725303	CID	105	114	D019469	214	226	D052878	false

Sentence: CONCLUSION: Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT.
Entity: 9725303	12	32	Ureteric obstruction	Disease	D014517
Entity: 9725303	56	65	indinavir	Chemical	D019469
Relation: 9725303	CID	56	65	D019469	12	32	D014517	false

Sentence: Ischemic colitis and sumatriptan use.
Entity: 9759693	0	16	Ischemic colitis	Disease	D017091
Entity: 9759693	21	32	sumatriptan	Chemical	D018170
Relation: 9759693	CID	21	32	D018170	0	16	D017091	true

Sentence: Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.
Entity: 9759693	29	47	coronary vasospasm	Disease	D003329
Entity: 9759693	49	68	myocardial ischemia	Disease	D017202
Entity: 9759693	74	95	myocardial infarction	Disease	D009203
Entity: 9759693	112	123	sumatriptan	Chemical	D018170
Relation: 9759693	CID	112	123	D018170	29	47	D003329	false
Relation: 9759693	CID	112	123	D018170	49	68	D017202	false
Relation: 9759693	CID	112	123	D018170	74	95	D009203	false

Sentence: Pallidotomy with the gamma knife: a positive experience. 51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA induced dyskinesias.
Entity: 9782254	95	114	Parkinson's disease	Disease	D010300
Entity: 9782254	219	231	bradykinesia	Disease	D018476
Entity: 9782254	233	241	rigidity	Disease	D009127
Entity: 9782254	247	253	L-DOPA	Chemical	D007980
Entity: 9782254	262	273	dyskinesias	Disease	D004409
Relation: 9782254	CID	247	253	D007980	95	114	D010300	false
Relation: 9782254	CID	247	253	D007980	219	231	D018476	false
Relation: 9782254	CID	247	253	D007980	233	241	D009127	false
Relation: 9782254	CID	247	253	D007980	262	273	D004409	true

Sentence: Neuroleptic malignant syndrome and methylphenidate.
Entity: 9831002	0	30	Neuroleptic malignant syndrome	Disease	D009459
Entity: 9831002	35	50	methylphenidate	Chemical	D008774
Relation: 9831002	CID	35	50	D008774	0	30	D009459	true

Sentence: A 1-year-old female presented with neuroleptic malignant syndrome probably caused by methylphenidate.
Entity: 9831002	35	65	neuroleptic malignant syndrome	Disease	D009459
Entity: 9831002	85	100	methylphenidate	Chemical	D008774
Relation: 9831002	CID	85	100	D008774	35	65	D009459	true

Sentence: This study shows that 17alpha-ethinylestradiol (EE) induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.
Entity: 9869655	22	46	17alpha-ethinylestradiol	Chemical	D004997
Entity: 9869655	48	50	EE	Chemical	D004997
Entity: 9869655	60	84	intrahepatic cholestasis	Disease	D002780
Entity: 9869655	159	168	bile salt	Chemical	D001647
Entity: 9869655	170	172	BS	Chemical	D001647
Relation: 9869655	CID	22	46	D004997	60	84	D002780	true
Relation: 9869655	CID	48	50	D004997	60	84	D002780	true
Relation: 9869655	CID	159	168	D001647	60	84	D002780	false
Relation: 9869655	CID	170	172	D001647	60	84	D002780	false

Sentence: Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.
Entity: 9881641	0	13	Glibenclamide	Chemical	D005905
Entity: 9881641	24	35	hypotension	Disease	D007022
Entity: 9881641	48	58	helodermin	Chemical	C040442
Relation: 9881641	CID	0	13	D005905	24	35	D007022	false
Relation: 9881641	CID	48	58	C040442	24	35	D007022	true

Sentence: Helodermin produced hypotension in a dose-dependent manner with approximately similar potency and duration to VIP.
Entity: 9881641	0	10	Helodermin	Chemical	C040442
Entity: 9881641	20	31	hypotension	Disease	D007022
Relation: 9881641	CID	0	10	C040442	20	31	D007022	true

Sentence: Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.
Entity: 9881641	0	11	Hypotension	Disease	D007022
Entity: 9881641	69	82	glibenclamide	Chemical	D005905
Entity: 9881641	102	115	levcromakalim	Chemical	D019806
Relation: 9881641	CID	69	82	D005905	0	11	D007022	false
Relation: 9881641	CID	102	115	D019806	0	11	D007022	true

Sentence: Oxyhemoglobin did not affect helodermin induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.
Entity: 9881641	29	39	helodermin	Chemical	C040442
Entity: 9881641	48	59	hypotension	Disease	D007022
Entity: 9881641	98	111	acetylcholine	Chemical	D000109
Entity: 9881641	113	116	ACh	Chemical	D000109
Entity: 9881641	127	138	hypotension	Disease	D007022
Relation: 9881641	CID	29	39	C040442	48	59	D007022	true
Relation: 9881641	CID	29	39	C040442	127	138	D007022	true
Relation: 9881641	CID	98	111	D000109	48	59	D007022	true
Relation: 9881641	CID	98	111	D000109	127	138	D007022	true
Relation: 9881641	CID	113	116	D000109	48	59	D007022	true
Relation: 9881641	CID	113	116	D000109	127	138	D007022	true

Sentence: These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.
Entity: 9881641	28	38	helodermin	Chemical	C040442
Entity: 9881641	48	59	hypotension	Disease	D007022
Entity: 9881641	104	117	glibenclamide	Chemical	D005905
Entity: 9881641	128	129	K	Chemical	D011188
Entity: 9881641	141	142	K	Chemical	D011188
Entity: 9881641	143	146	ATP	Chemical	D000255
Relation: 9881641	CID	28	38	C040442	48	59	D007022	true
Relation: 9881641	CID	104	117	D005905	48	59	D007022	false
Relation: 9881641	CID	128	129	D011188	48	59	D007022	false
Relation: 9881641	CID	141	142	D011188	48	59	D007022	false
Relation: 9881641	CID	143	146	D000255	48	59	D007022	false

Sentence: Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A induced hypertension in patients with psoriasis.
Entity: 9889429	40	50	nifedipine	Chemical	D009543
Entity: 9889429	81	94	cyclosporin A	Chemical	D016572
Entity: 9889429	103	115	hypertension	Disease	D006973
Entity: 9889429	133	142	psoriasis	Disease	D011565
Relation: 9889429	CID	40	50	D009543	103	115	D006973	false
Relation: 9889429	CID	40	50	D009543	133	142	D011565	false
Relation: 9889429	CID	81	94	D016572	103	115	D006973	true
Relation: 9889429	CID	81	94	D016572	133	142	D011565	false

Sentence: Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.
Entity: 9889429	9	18	psoriatic	Disease	D011565
Entity: 9889429	33	45	hypertension	Disease	D006973
Entity: 9889429	67	80	cyclosporin A	Chemical	D016572
Entity: 9889429	123	130	calcium	Chemical	D002118
Entity: 9889429	166	176	nifedipine	Chemical	D009543
Relation: 9889429	CID	67	80	D016572	9	18	D011565	false
Relation: 9889429	CID	67	80	D016572	33	45	D006973	true
Relation: 9889429	CID	123	130	D002118	9	18	D011565	false
Relation: 9889429	CID	123	130	D002118	33	45	D006973	false
Relation: 9889429	CID	166	176	D009543	9	18	D011565	false
Relation: 9889429	CID	166	176	D009543	33	45	D006973	false

Sentence: Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy.
Entity: 9889429	53	65	hypertensive	Disease	D006973
Entity: 9889429	79	92	cyclosporin A	Chemical	D016572
Relation: 9889429	CID	79	92	D016572	53	65	D006973	true

Sentence: The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.
Entity: 9889429	48	61	cyclosporin A	Chemical	D016572
Entity: 9889429	66	76	nifedipine	Chemical	D009543
Entity: 9889429	101	120	blood urea nitrogen	Chemical	D001806
Entity: 9889429	171	191	gingival hyperplasia	Disease	D005885
Relation: 9889429	CID	48	61	D016572	171	191	D005885	true
Relation: 9889429	CID	66	76	D009543	171	191	D005885	true
Relation: 9889429	CID	101	120	D001806	171	191	D005885	false

Sentence: Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
Entity: 10087562	0	18	Torsade de pointes	Disease	D016171
Entity: 10087562	19	42	ventricular tachycardia	Disease	D017180
Entity: 10087562	72	82	dobutamine	Chemical	D004280
Entity: 10087562	111	133	dilated cardiomyopathy	Disease	D002311
Entity: 10087562	138	162	congestive heart failure	Disease	D006333
Relation: 10087562	CID	72	82	D004280	0	18	D016171	true
Relation: 10087562	CID	72	82	D004280	19	42	D017180	false
Relation: 10087562	CID	72	82	D004280	111	133	D002311	false
Relation: 10087562	CID	72	82	D004280	138	162	D006333	false

Sentence: The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.
Entity: 10087562	74	87	heart failure	Disease	D006333
Entity: 10087562	101	123	dilated cardiomyopathy	Disease	D002311
Entity: 10087562	151	174	ventricular arrhythmias	Disease	D001145
Entity: 10087562	189	204	QT prolongation	Disease	D008133
Entity: 10087562	209	227	torsade de pointes	Disease	D016171
Entity: 10087562	228	251	ventricular tachycardia	Disease	D017180
Entity: 10087562	315	325	dobutamine	Chemical	D004280
Relation: 10087562	CID	315	325	D004280	74	87	D006333	false
Relation: 10087562	CID	315	325	D004280	101	123	D002311	false
Relation: 10087562	CID	315	325	D004280	151	174	D001145	false
Relation: 10087562	CID	315	325	D004280	189	204	D008133	false
Relation: 10087562	CID	315	325	D004280	209	227	D016171	true
Relation: 10087562	CID	315	325	D004280	228	251	D017180	false

Sentence: This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.
Entity: 10087562	15	33	torsade de pointes	Disease	D016171
Entity: 10087562	34	57	ventricular tachycardia	Disease	D017180
Entity: 10087562	78	88	dobutamine	Chemical	D004280
Entity: 10087562	138	149	arrhythmias	Disease	D001145
Relation: 10087562	CID	78	88	D004280	15	33	D016171	true
Relation: 10087562	CID	78	88	D004280	34	57	D017180	false
Relation: 10087562	CID	78	88	D004280	138	149	D001145	false

Sentence: Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.
Entity: 10327032	18	32	hyperammonemic	Disease	D022124
Entity: 10327032	33	47	encephalopathy	Disease	D001927
Entity: 10327032	51	57	cancer	Disease	D009369
Entity: 10327032	103	117	5-fluorouracil	Chemical	D005472
Entity: 10327032	143	154	dehydration	Disease	D003681
Entity: 10327032	159	168	infection	Disease	D007239
Relation: 10327032	CID	103	117	D005472	18	32	D022124	true
Relation: 10327032	CID	103	117	D005472	33	47	D001927	true
Relation: 10327032	CID	103	117	D005472	51	57	D009369	false
Relation: 10327032	CID	103	117	D005472	143	154	D003681	false
Relation: 10327032	CID	103	117	D005472	159	168	D007239	false

Sentence: From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.
Entity: 10327032	22	28	cancer	Disease	D009369
Entity: 10327032	71	85	hyperammonemic	Disease	D022124
Entity: 10327032	86	100	encephalopathy	Disease	D001927
Entity: 10327032	135	149	5-fluorouracil	Chemical	D005472
Entity: 10327032	151	155	5-FU	Chemical	D005472
Relation: 10327032	CID	135	149	D005472	22	28	D009369	false
Relation: 10327032	CID	135	149	D005472	71	85	D022124	true
Relation: 10327032	CID	135	149	D005472	86	100	D001927	true
Relation: 10327032	CID	151	155	D005472	22	28	D009369	false
Relation: 10327032	CID	151	155	D005472	71	85	D022124	true
Relation: 10327032	CID	151	155	D005472	86	100	D001927	true

Sentence: Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).
Entity: 10327032	14	22	ammonium	Chemical	D000644
Entity: 10327032	54	68	hyperammonemia	Disease	D022124
Entity: 10327032	99	119	bacterial infections	Disease	D001424
Entity: 10327032	227	231	5-FU	Chemical	D005472
Relation: 10327032	CID	14	22	D000644	54	68	D022124	false
Relation: 10327032	CID	14	22	D000644	99	119	D001424	false
Relation: 10327032	CID	227	231	D005472	54	68	D022124	true
Relation: 10327032	CID	227	231	D005472	99	119	D001424	false

Sentence: In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5-FU.
Entity: 10327032	15	29	hyperammonemic	Disease	D022124
Entity: 10327032	30	44	encephalopathy	Disease	D001927
Entity: 10327032	100	104	5-FU	Chemical	D005472
Relation: 10327032	CID	100	104	D005472	15	29	D022124	true
Relation: 10327032	CID	100	104	D005472	30	44	D001927	true

Sentence: In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine induced hypoactivity, but both K(+)-channel blockers prevented morphine induced secondary hyperactivity. 3.
Entity: 10390729	81	82	K	Chemical	D011188
Entity: 10390729	112	120	morphine	Chemical	D009020
Entity: 10390729	129	141	hypoactivity	Disease	D009069
Entity: 10390729	152	153	K	Chemical	D011188
Entity: 10390729	184	192	morphine	Chemical	D009020
Entity: 10390729	211	224	hyperactivity	Disease	D006948
Relation: 10390729	CID	81	82	D011188	129	141	D009069	false
Relation: 10390729	CID	81	82	D011188	211	224	D006948	false
Relation: 10390729	CID	112	120	D009020	129	141	D009069	false
Relation: 10390729	CID	112	120	D009020	211	224	D006948	true
Relation: 10390729	CID	152	153	D011188	129	141	D009069	false
Relation: 10390729	CID	152	153	D011188	211	224	D006948	false
Relation: 10390729	CID	184	192	D009020	129	141	D009069	false
Relation: 10390729	CID	184	192	D009020	211	224	D006948	true

Sentence: Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. 1.
Entity: 10401555	0	10	Nociceptin	Chemical	C096012
Entity: 10401555	11	22	orphanin FQ	Chemical	C096012
Entity: 10401555	27	37	nocistatin	Chemical	C111148
Entity: 10401555	41	49	learning	Disease	D007859
Entity: 10401555	54	60	memory	Disease	D008569
Entity: 10401555	83	94	scopolamine	Chemical	D012601
Relation: 10401555	CID	0	10	C096012	41	49	D007859	false
Relation: 10401555	CID	0	10	C096012	54	60	D008569	false
Relation: 10401555	CID	11	22	C096012	41	49	D007859	false
Relation: 10401555	CID	11	22	C096012	54	60	D008569	false
Relation: 10401555	CID	27	37	C111148	41	49	D007859	false
Relation: 10401555	CID	27	37	C111148	54	60	D008569	false
Relation: 10401555	CID	83	94	D012601	41	49	D007859	true
Relation: 10401555	CID	83	94	D012601	54	60	D008569	true

Sentence: On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin induced allodynia and hyperalgesia. 2.
Entity: 10401555	19	29	nocistatin	Chemical	C111148
Entity: 10401555	78	88	nociceptin	Chemical	C096012
Entity: 10401555	100	110	nociceptin	Chemical	C096012
Entity: 10401555	119	128	allodynia	Disease	D006930
Entity: 10401555	133	145	hyperalgesia	Disease	D006930
Relation: 10401555	CID	19	29	C111148	119	128	D006930	false
Relation: 10401555	CID	19	29	C111148	133	145	D006930	false
Relation: 10401555	CID	78	88	C096012	119	128	D006930	false
Relation: 10401555	CID	78	88	C096012	133	145	D006930	false
Relation: 10401555	CID	100	110	C096012	119	128	D006930	false
Relation: 10401555	CID	100	110	C096012	133	145	D006930	false

Sentence: The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice. 4.
Entity: 10401555	54	64	nociceptin	Chemical	C096012
Entity: 10401555	65	76	orphanin FQ	Chemical	C096012
Entity: 10401555	81	91	nocistatin	Chemical	C111148
Entity: 10401555	107	117	impairment	Disease	D007859
Entity: 10401555	107	117	impairment	Disease	D008569
Entity: 10401555	152	163	scopolamine	Chemical	D012601
Relation: 10401555	CID	54	64	C096012	107	117	D007859	false
Relation: 10401555	CID	54	64	C096012	107	117	D008569	false
Relation: 10401555	CID	65	76	C096012	107	117	D007859	false
Relation: 10401555	CID	65	76	C096012	107	117	D008569	false
Relation: 10401555	CID	81	91	C111148	107	117	D007859	false
Relation: 10401555	CID	81	91	C111148	107	117	D008569	false
Relation: 10401555	CID	152	163	D012601	107	117	D007859	true
Relation: 10401555	CID	152	163	D012601	107	117	D008569	true

Sentence: Meloxicam induced liver toxicity.
Entity: 10427794	0	9	Meloxicam	Chemical	C065757
Entity: 10427794	18	32	liver toxicity	Disease	D056486
Relation: 10427794	CID	0	9	C065757	18	32	D056486	true

Sentence: We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.
Entity: 10427794	44	64	rheumatoid arthritis	Disease	D001172
Entity: 10427794	95	104	hepatitis	Disease	D056486
Entity: 10427794	112	121	meloxicam	Chemical	C065757
Relation: 10427794	CID	112	121	C065757	44	64	D001172	false
Relation: 10427794	CID	112	121	C065757	95	104	D056486	true

Sentence: The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.
Entity: 10427794	20	29	hepatitis	Disease	D056486
Entity: 10427794	53	62	meloxicam	Chemical	C065757
Entity: 10427794	157	173	hypersensitivity	Disease	D004342
Relation: 10427794	CID	53	62	C065757	20	29	D056486	true
Relation: 10427794	CID	53	62	C065757	157	173	D004342	true

Sentence: Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride induced aplastic anemia.
Entity: 10462057	26	37	remoxipride	Chemical	D017330
Entity: 10462057	133	144	remoxipride	Chemical	D017330
Entity: 10462057	153	168	aplastic anemia	Disease	D000741
Relation: 10462057	CID	26	37	D017330	153	168	D000741	true
Relation: 10462057	CID	133	144	D017330	153	168	D000741	true

Sentence: The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired aplastic anemia.
Entity: 10462057	25	36	remoxipride	Chemical	D017330
Entity: 10462057	38	112	(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide	Chemical	D017330
Entity: 10462057	148	163	aplastic anemia	Disease	D000741
Relation: 10462057	CID	25	36	D017330	148	163	D000741	true
Relation: 10462057	CID	38	112	D017330	148	163	D000741	true

Sentence: No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.
Entity: 10462057	3	11	necrosis	Disease	D009336
Entity: 10462057	47	53	NCQ436	Chemical	C084325
Entity: 10462057	58	64	NCQ344	Chemical	C112341
Entity: 10462057	154	162	necrosis	Disease	D009336
Relation: 10462057	CID	47	53	C084325	3	11	D009336	false
Relation: 10462057	CID	47	53	C084325	154	162	D009336	false
Relation: 10462057	CID	58	64	C112341	3	11	D009336	false
Relation: 10462057	CID	58	64	C112341	154	162	D009336	false

Sentence: Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol induced catalepsy and the number of NADPH-diaphorase neurons in mice.
Entity: 10672628	26	38	nitric-oxide	Chemical	D009569
Entity: 10672628	58	69	haloperidol	Chemical	D006220
Entity: 10672628	78	87	catalepsy	Disease	D002375
Entity: 10672628	106	111	NADPH	Chemical	D009249
Relation: 10672628	CID	26	38	D009569	78	87	D002375	false
Relation: 10672628	CID	58	69	D006220	78	87	D002375	true
Relation: 10672628	CID	106	111	D009249	78	87	D002375	false

Sentence: RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice.
Entity: 10672628	11	30	NG-nitro-L-arginine	Chemical	D019335
Entity: 10672628	32	39	L-NOARG	Chemical	D019335
Entity: 10672628	58	70	nitric-oxide	Chemical	D009569
Entity: 10672628	95	104	catalepsy	Disease	D002375
Relation: 10672628	CID	11	30	D019335	95	104	D002375	false
Relation: 10672628	CID	32	39	D019335	95	104	D002375	false
Relation: 10672628	CID	58	70	D009569	95	104	D002375	false

Sentence: Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.
Entity: 10672628	26	37	haloperidol	Chemical	D006220
Entity: 10672628	51	59	dopamine	Chemical	D004298
Entity: 10672628	82	91	catalepsy	Disease	D002375
Relation: 10672628	CID	26	37	D006220	82	91	D002375	true
Relation: 10672628	CID	51	59	D004298	82	91	D002375	false

Sentence: OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol induced catalepsy and the number of NOS neurons in areas related to motor control.
Entity: 10672628	53	60	L-NOARG	Chemical	D019335
Entity: 10672628	74	85	haloperidol	Chemical	D006220
Entity: 10672628	94	103	catalepsy	Disease	D002375
Relation: 10672628	CID	53	60	D019335	94	103	D002375	false
Relation: 10672628	CID	74	85	D006220	94	103	D002375	true

Sentence: RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol induced catalepsy.
Entity: 10672628	9	16	L-NOARG	Chemical	D019335
Entity: 10672628	66	73	L-NOARG	Chemical	D019335
Entity: 10672628	81	92	haloperidol	Chemical	D006220
Entity: 10672628	101	110	catalepsy	Disease	D002375
Relation: 10672628	CID	9	16	D019335	101	110	D002375	false
Relation: 10672628	CID	66	73	D019335	101	110	D002375	false
Relation: 10672628	CID	81	92	D006220	101	110	D002375	true

Sentence: Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.
Entity: 10677406	10	38	left ventricular dysfunction	Disease	D018487
Entity: 10677406	63	86	coronary artery disease	Disease	D003324
Entity: 10677406	98	108	dobutamine	Chemical	D004280
Entity: 10677406	130	150	myocardial ischaemia	Disease	D017202
Relation: 10677406	CID	98	108	D004280	10	38	D018487	true
Relation: 10677406	CID	98	108	D004280	63	86	D003324	false
Relation: 10677406	CID	98	108	D004280	130	150	D017202	false

Sentence: DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia.
Entity: 10677406	125	135	dobutamine	Chemical	D004280
Entity: 10677406	144	153	ischaemia	Disease	D007511
Relation: 10677406	CID	125	135	D004280	144	153	D007511	false

Sentence: CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.
Entity: 10677406	30	53	coronary artery disease	Disease	D003324
Entity: 10677406	55	65	dobutamine	Chemical	D004280
Entity: 10677406	74	83	ischaemia	Disease	D007511
Entity: 10677406	116	144	left ventricular dysfunction	Disease	D018487
Entity: 10677406	161	180	myocardial stunning	Disease	D017682
Relation: 10677406	CID	55	65	D004280	30	53	D003324	false
Relation: 10677406	CID	55	65	D004280	74	83	D007511	false
Relation: 10677406	CID	55	65	D004280	116	144	D018487	true
Relation: 10677406	CID	55	65	D004280	161	180	D017682	true

Sentence: However, of the medications surveyed, only the fenfluramines had a significant preferential association with PPH as compared with SPH (adjusted odds ratio for use > 6 months, 7.5; 95% confidence interval, 1.7 to 32.4).
Entity: 10713017	47	60	fenfluramines	Chemical	D005277
Entity: 10713017	109	112	PPH	Disease	D006976
Relation: 10713017	CID	47	60	D005277	109	112	D006976	true

Sentence: CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.
Entity: 10713017	50	53	PPH	Disease	D006976
Entity: 10713017	140	153	fenfluramines	Chemical	D005277
Entity: 10713017	207	220	fenfluramines	Chemical	D005277
Entity: 10713017	245	248	PPH	Disease	D006976
Relation: 10713017	CID	140	153	D005277	50	53	D006976	true
Relation: 10713017	CID	140	153	D005277	245	248	D006976	true
Relation: 10713017	CID	207	220	D005277	50	53	D006976	true
Relation: 10713017	CID	207	220	D005277	245	248	D006976	true

Sentence: Clinical aspects of heparin induced thrombocytopenia and thrombosis and other side effects of heparin therapy.
Entity: 10726030	20	27	heparin	Chemical	D006493
Entity: 10726030	36	52	thrombocytopenia	Disease	D013921
Entity: 10726030	57	67	thrombosis	Disease	D013927
Entity: 10726030	94	101	heparin	Chemical	D006493
Relation: 10726030	CID	20	27	D006493	36	52	D013921	true
Relation: 10726030	CID	20	27	D006493	57	67	D013927	false
Relation: 10726030	CID	94	101	D006493	36	52	D013921	true
Relation: 10726030	CID	94	101	D006493	57	67	D013927	false

Sentence: Heparin, first used to prevent the clotting of blood in vitro, has been clinically used to treat thrombosis for more than 50 years.
Entity: 10726030	0	7	Heparin	Chemical	D006493
Entity: 10726030	97	107	thrombosis	Disease	D013927
Relation: 10726030	CID	0	7	D006493	97	107	D013927	false

Sentence: Although several new anticoagulant drugs are in development, heparin remains the anticoagulant of choice to treat acute thrombotic episodes.
Entity: 10726030	61	68	heparin	Chemical	D006493
Entity: 10726030	120	130	thrombotic	Disease	D013927
Relation: 10726030	CID	61	68	D006493	120	130	D013927	false

Sentence: Bleeding is the primary untoward effect of heparin.
Entity: 10726030	0	8	Bleeding	Disease	D006470
Entity: 10726030	43	50	heparin	Chemical	D006493
Relation: 10726030	CID	43	50	D006493	0	8	D006470	false

Sentence: Major bleeding is of primary concern in patients receiving heparin therapy.
Entity: 10726030	6	14	bleeding	Disease	D006470
Entity: 10726030	59	66	heparin	Chemical	D006493
Relation: 10726030	CID	59	66	D006493	6	14	D006470	false

Sentence: However, additional important untoward effects of heparin therapy include heparin induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.
Entity: 10726030	50	57	heparin	Chemical	D006493
Entity: 10726030	74	81	heparin	Chemical	D006493
Entity: 10726030	90	106	thrombocytopenia	Disease	D013921
Entity: 10726030	108	115	heparin	Chemical	D006493
Entity: 10726030	127	139	osteoporosis	Disease	D010024
Entity: 10726030	141	153	eosinophilia	Disease	D004802
Entity: 10726030	155	169	skin reactions	Disease	D012871
Entity: 10726030	171	189	allergic reactions	Disease	D004342
Entity: 10726030	201	217	thrombocytopenia	Disease	D013921
Entity: 10726030	219	227	alopecia	Disease	D000505
Entity: 10726030	246	258	hyperkalemia	Disease	D006947
Entity: 10726030	260	277	hypoaldosteronism	Disease	D006994
Entity: 10726030	283	291	priapism	Disease	D011317
Relation: 10726030	CID	50	57	D006493	90	106	D013921	true
Relation: 10726030	CID	50	57	D006493	127	139	D010024	true
Relation: 10726030	CID	50	57	D006493	141	153	D004802	true
Relation: 10726030	CID	50	57	D006493	155	169	D012871	true
Relation: 10726030	CID	50	57	D006493	171	189	D004342	true
Relation: 10726030	CID	50	57	D006493	201	217	D013921	true
Relation: 10726030	CID	50	57	D006493	219	227	D000505	true
Relation: 10726030	CID	50	57	D006493	246	258	D006947	true
Relation: 10726030	CID	50	57	D006493	260	277	D006994	true
Relation: 10726030	CID	50	57	D006493	283	291	D011317	true
Relation: 10726030	CID	74	81	D006493	90	106	D013921	true
Relation: 10726030	CID	74	81	D006493	127	139	D010024	true
Relation: 10726030	CID	74	81	D006493	141	153	D004802	true
Relation: 10726030	CID	74	81	D006493	155	169	D012871	true
Relation: 10726030	CID	74	81	D006493	171	189	D004342	true
Relation: 10726030	CID	74	81	D006493	201	217	D013921	true
Relation: 10726030	CID	74	81	D006493	219	227	D000505	true
Relation: 10726030	CID	74	81	D006493	246	258	D006947	true
Relation: 10726030	CID	74	81	D006493	260	277	D006994	true
Relation: 10726030	CID	74	81	D006493	283	291	D011317	true
Relation: 10726030	CID	108	115	D006493	90	106	D013921	true
Relation: 10726030	CID	108	115	D006493	127	139	D010024	true
Relation: 10726030	CID	108	115	D006493	141	153	D004802	true
Relation: 10726030	CID	108	115	D006493	155	169	D012871	true
Relation: 10726030	CID	108	115	D006493	171	189	D004342	true
Relation: 10726030	CID	108	115	D006493	201	217	D013921	true
Relation: 10726030	CID	108	115	D006493	219	227	D000505	true
Relation: 10726030	CID	108	115	D006493	246	258	D006947	true
Relation: 10726030	CID	108	115	D006493	260	277	D006994	true
Relation: 10726030	CID	108	115	D006493	283	291	D011317	true

Sentence: These side effects are relatively rare in a given individual, but given the extremely widespread use of heparin, some are quite common, particularly HITT and osteoporosis.
Entity: 10726030	104	111	heparin	Chemical	D006493
Entity: 10726030	149	153	HITT	Disease	D013921
Entity: 10726030	149	153	HITT	Disease	D013927
Entity: 10726030	158	170	osteoporosis	Disease	D010024
Relation: 10726030	CID	104	111	D006493	149	153	D013921	true
Relation: 10726030	CID	104	111	D006493	149	153	D013927	false
Relation: 10726030	CID	104	111	D006493	158	170	D010024	true

Sentence: A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.
Entity: 10764869	20	36	optic neuropathy	Disease	D009901
Entity: 10764869	53	63	tacrolimus	Chemical	D016559
Entity: 10764869	65	70	FK506	Chemical	D016559
Relation: 10764869	CID	53	63	D016559	20	36	D009901	true
Relation: 10764869	CID	65	70	D016559	20	36	D009901	true

Sentence: PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.
Entity: 10764869	39	55	optic neuropathy	Disease	D009901
Entity: 10764869	79	89	tacrolimus	Chemical	D016559
Entity: 10764869	91	97	FK 506	Chemical	D016559
Relation: 10764869	CID	79	89	D016559	39	55	D009901	true
Relation: 10764869	CID	91	97	D016559	39	55	D009901	true

Sentence: Deterioration of vision occurred despite discontinuation of the tacrolimus.
Entity: 10764869	0	23	Deterioration of vision	Disease	D015354
Entity: 10764869	64	74	tacrolimus	Chemical	D016559
Relation: 10764869	CID	64	74	D016559	0	23	D015354	false

Sentence: Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.
Entity: 10770468	21	28	bipolar	Disease	D001714
Entity: 10770468	59	66	lithium	Chemical	D008094
Entity: 10770468	89	102	hypercalcemia	Disease	D006934
Entity: 10770468	114	129	bradyarrhythmia	Disease	D001919
Entity: 10770468	187	194	bipolar	Disease	D001714
Entity: 10770468	209	216	lithium	Chemical	D008094
Entity: 10770468	228	241	hypercalcemia	Disease	D006934
Relation: 10770468	CID	59	66	D008094	21	28	D001714	false
Relation: 10770468	CID	59	66	D008094	89	102	D006934	true
Relation: 10770468	CID	59	66	D008094	114	129	D001919	false
Relation: 10770468	CID	59	66	D008094	187	194	D001714	false
Relation: 10770468	CID	59	66	D008094	228	241	D006934	true
Relation: 10770468	CID	209	216	D008094	21	28	D001714	false
Relation: 10770468	CID	209	216	D008094	89	102	D006934	true
Relation: 10770468	CID	209	216	D008094	114	129	D001919	false
Relation: 10770468	CID	209	216	D008094	187	194	D001714	false
Relation: 10770468	CID	209	216	D008094	228	241	D006934	true

Sentence: After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).
Entity: 10770468	27	41	hypercalcemias	Disease	D006934
Entity: 10770468	117	124	lithium	Chemical	D008094
Entity: 10770468	147	161	hypercalcemias	Disease	D006934
Entity: 10770468	173	185	malignancies	Disease	D009369
Entity: 10770468	246	253	lithium	Chemical	D008094
Entity: 10770468	265	278	hypercalcemia	Disease	D006934
Relation: 10770468	CID	117	124	D008094	27	41	D006934	true
Relation: 10770468	CID	117	124	D008094	147	161	D006934	true
Relation: 10770468	CID	117	124	D008094	173	185	D009369	false
Relation: 10770468	CID	117	124	D008094	265	278	D006934	true
Relation: 10770468	CID	246	253	D008094	27	41	D006934	true
Relation: 10770468	CID	246	253	D008094	147	161	D006934	true
Relation: 10770468	CID	246	253	D008094	173	185	D009369	false
Relation: 10770468	CID	246	253	D008094	265	278	D006934	true

Sentence: Thus, two control groups were generated: group C1, which included age- and sex-comparable lithium-treated bipolar normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.
Entity: 10770468	90	97	lithium	Chemical	D008094
Entity: 10770468	106	113	bipolar	Disease	D001714
Entity: 10770468	167	174	bipolar	Disease	D001714
Relation: 10770468	CID	90	97	D008094	106	113	D001714	false
Relation: 10770468	CID	90	97	D008094	167	174	D001714	false

Sentence: Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.
Entity: 10933650	15	29	nephrotoxicity	Disease	D007674
Entity: 10933650	81	95	amphotericin B	Chemical	D000666
Relation: 10933650	CID	81	95	D000666	15	29	D007674	false

Sentence: NS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.
Entity: 10933650	41	55	amphotericin B	Chemical	D000666
Entity: 10933650	107	115	toxicity	Disease	D064420
Relation: 10933650	CID	41	55	D000666	107	115	D064420	false

Sentence: We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.
Entity: 10933650	16	24	toxicity	Disease	D064420
Entity: 10933650	48	57	Fungizone	Chemical	D000666
Entity: 10933650	59	93	amphotericin B-sodium deoxycholate	Chemical	C059765
Entity: 10933650	95	100	D-AmB	Chemical	C059765
Entity: 10933650	241	255	amphotericin B	Chemical	D000666
Relation: 10933650	CID	48	57	D000666	16	24	D064420	false
Relation: 10933650	CID	59	93	C059765	16	24	D064420	false
Relation: 10933650	CID	95	100	C059765	16	24	D064420	false
Relation: 10933650	CID	241	255	D000666	16	24	D064420	false

Sentence: Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.
Entity: 10933650	51	67	tubular necrosis	Disease	D007683
Entity: 10933650	71	76	D-AmB	Chemical	C059765
Relation: 10933650	CID	71	76	C059765	51	67	D007683	true

Sentence: Patterns of sulfadiazine acute nephrotoxicity.
Entity: 10939760	12	24	sulfadiazine	Chemical	D013411
Entity: 10939760	25	45	acute nephrotoxicity	Disease	D058186
Relation: 10939760	CID	12	24	D013411	25	45	D058186	true

Sentence: Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.
Entity: 10939760	0	12	Sulfadiazine	Chemical	D013411
Entity: 10939760	13	33	acute nephrotoxicity	Disease	D058186
Entity: 10939760	78	91	toxoplasmosis	Disease	D014123
Relation: 10939760	CID	0	12	D013411	13	33	D058186	true
Relation: 10939760	CID	0	12	D013411	78	91	D014123	false

Sentence: Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.
Entity: 10939760	21	33	sulfadiazine	Chemical	D013411
Entity: 10939760	49	57	oliguria	Disease	D009846
Entity: 10939760	59	73	abdominal pain	Disease	D015746
Entity: 10939760	75	88	renal failure	Disease	D051437
Entity: 10939760	121	134	renal calculi	Disease	D007669
Relation: 10939760	CID	21	33	D013411	49	57	D009846	false
Relation: 10939760	CID	21	33	D013411	59	73	D015746	false
Relation: 10939760	CID	21	33	D013411	75	88	D051437	false
Relation: 10939760	CID	21	33	D013411	121	134	D007669	true

Sentence: Downbeat nystagmus associated with intravenous patient-controlled administration of morphine.
Entity: 10960401	0	18	Downbeat nystagmus	Disease	D009759
Entity: 10960401	84	92	morphine	Chemical	D009020
Relation: 10960401	CID	84	92	D009020	0	18	D009759	true

Sentence: IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.
Entity: 10960401	58	67	dizziness	Disease	D004244
Entity: 10960401	73	94	downbeating nystagmus	Disease	D009759
Entity: 10960401	170	178	morphine	Chemical	D009020
Relation: 10960401	CID	170	178	D009020	58	67	D004244	true
Relation: 10960401	CID	170	178	D009020	73	94	D009759	true

Sentence: Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
Entity: 10975596	42	53	dronedarone	Chemical	C118667
Entity: 10975596	58	68	amiodarone	Chemical	D000638
Entity: 10975596	94	115	myocardial infarction	Disease	D009203
Relation: 10975596	CID	42	53	C118667	94	115	D009203	false
Relation: 10975596	CID	58	68	D000638	94	115	D009203	false

Sentence: The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction.
Entity: 10975596	46	57	dronedarone	Chemical	C118667
Entity: 10975596	107	117	amiodarone	Chemical	D000638
Entity: 10975596	147	157	amiodarone	Chemical	D000638
Entity: 10975596	275	296	myocardial infarction	Disease	D009203
Relation: 10975596	CID	46	57	C118667	275	296	D009203	false
Relation: 10975596	CID	107	117	D000638	275	296	D009203	false
Relation: 10975596	CID	147	157	D000638	275	296	D009203	false

Sentence: Both dronedarone and amiodarone significantly reduced the exercise induced tachycardia and, at the highest dose, decreased the isoproterenol induced tachycardia.
Entity: 10975596	5	16	dronedarone	Chemical	C118667
Entity: 10975596	21	31	amiodarone	Chemical	D000638
Entity: 10975596	75	86	tachycardia	Disease	D013610
Entity: 10975596	127	140	isoproterenol	Chemical	D007545
Entity: 10975596	149	160	tachycardia	Disease	D013610
Relation: 10975596	CID	5	16	C118667	75	86	D013610	false
Relation: 10975596	CID	5	16	C118667	149	160	D013610	false
Relation: 10975596	CID	21	31	D000638	75	86	D013610	false
Relation: 10975596	CID	21	31	D000638	149	160	D013610	false
Relation: 10975596	CID	127	140	D007545	75	86	D013610	true
Relation: 10975596	CID	127	140	D007545	149	160	D013610	true

Sentence: Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Entity: 10985896	27	38	doxorubicin	Chemical	D004317
Entity: 10985896	55	63	platinum	Chemical	D010984
Entity: 10985896	64	74	paclitaxel	Chemical	D017239
Entity: 10985896	86	93	ovarian	Disease	D010051
Entity: 10985896	98	107	fallopian	Disease	D005185
Entity: 10985896	133	160	carcinoma of the peritoneum	Disease	D010534
Relation: 10985896	CID	27	38	D004317	86	93	D010051	false
Relation: 10985896	CID	27	38	D004317	98	107	D005185	false
Relation: 10985896	CID	27	38	D004317	133	160	D010534	false
Relation: 10985896	CID	55	63	D010984	86	93	D010051	false
Relation: 10985896	CID	55	63	D010984	98	107	D005185	false
Relation: 10985896	CID	55	63	D010984	133	160	D010534	false
Relation: 10985896	CID	64	74	D017239	86	93	D010051	false
Relation: 10985896	CID	64	74	D017239	98	107	D005185	false
Relation: 10985896	CID	64	74	D017239	133	160	D010534	false

Sentence: BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis.
Entity: 10985896	56	67	doxorubicin	Chemical	D004317
Entity: 10985896	69	74	Doxil	Chemical	D004317
Entity: 10985896	116	124	platinum	Chemical	D010984
Entity: 10985896	135	149	ovarian cancer	Disease	D010051
Entity: 10985896	170	178	toxicity	Disease	D064420
Entity: 10985896	246	264	erythrodysesthesia	Disease	D060831
Entity: 10985896	267	285	hand-foot syndrome	Disease	D060831
Entity: 10985896	292	302	stomatitis	Disease	D013280
Relation: 10985896	CID	56	67	D004317	135	149	D010051	false
Relation: 10985896	CID	56	67	D004317	170	178	D064420	false
Relation: 10985896	CID	56	67	D004317	246	264	D060831	true
Relation: 10985896	CID	56	67	D004317	267	285	D060831	true
Relation: 10985896	CID	56	67	D004317	292	302	D013280	true
Relation: 10985896	CID	69	74	D004317	135	149	D010051	false
Relation: 10985896	CID	69	74	D004317	170	178	D064420	false
Relation: 10985896	CID	69	74	D004317	246	264	D060831	true
Relation: 10985896	CID	69	74	D004317	267	285	D060831	true
Relation: 10985896	CID	69	74	D004317	292	302	D013280	true
Relation: 10985896	CID	116	124	D010984	135	149	D010051	false
Relation: 10985896	CID	116	124	D010984	170	178	D064420	false
Relation: 10985896	CID	116	124	D010984	246	264	D060831	false
Relation: 10985896	CID	116	124	D010984	267	285	D060831	false
Relation: 10985896	CID	116	124	D010984	292	302	D013280	false

Sentence: METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.
Entity: 10985896	37	44	ovarian	Disease	D010051
Entity: 10985896	48	57	fallopian	Disease	D005185
Entity: 10985896	82	102	peritoneal carcinoma	Disease	D010534
Entity: 10985896	108	116	platinum	Chemical	D010984
Entity: 10985896	117	127	paclitaxel	Chemical	D017239
Entity: 10985896	298	309	doxorubicin	Chemical	D004317
Relation: 10985896	CID	108	116	D010984	37	44	D010051	false
Relation: 10985896	CID	108	116	D010984	48	57	D005185	false
Relation: 10985896	CID	108	116	D010984	82	102	D010534	false
Relation: 10985896	CID	117	127	D017239	37	44	D010051	false
Relation: 10985896	CID	117	127	D017239	48	57	D005185	false
Relation: 10985896	CID	117	127	D017239	82	102	D010534	false
Relation: 10985896	CID	298	309	D004317	37	44	D010051	false
Relation: 10985896	CID	298	309	D004317	48	57	D005185	false
Relation: 10985896	CID	298	309	D004317	82	102	D010534	false

Sentence: CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.
Entity: 10985896	36	47	doxorubicin	Chemical	D004317
Entity: 10985896	72	80	toxicity	Disease	D064420
Entity: 10985896	82	92	stomatitis	Disease	D013280
Entity: 10985896	94	112	hand-foot syndrome	Disease	D060831
Relation: 10985896	CID	36	47	D004317	72	80	D064420	false
Relation: 10985896	CID	36	47	D004317	82	92	D013280	true
Relation: 10985896	CID	36	47	D004317	94	112	D060831	true

Sentence: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.
Entity: 10986547	12	22	olanzapine	Chemical	C076029
Entity: 10986547	32	45	bipolar mania	Disease	D001714
Relation: 10986547	CID	12	22	C076029	32	45	D001714	false

Sentence: BACKGROUND: We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania.
Entity: 10986547	51	61	olanzapine	Chemical	C076029
Entity: 10986547	100	113	bipolar mania	Disease	D001714
Relation: 10986547	CID	51	61	C076029	100	113	D001714	false

Sentence: A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).
Entity: 10986547	51	67	bipolar disorder	Disease	D001714
Entity: 10986547	69	74	manic	Disease	D001714
Entity: 10986547	104	114	olanzapine	Chemical	C076029
Relation: 10986547	CID	104	114	C076029	51	67	D001714	false
Relation: 10986547	CID	104	114	C076029	69	74	D001714	false

Sentence: However, olanzapine-treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2.1 +/- 2.8 vs 0.45 +/- 2.3 kg, respectively) and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respectively).
Entity: 10986547	9	19	olanzapine	Chemical	C076029
Entity: 10986547	91	102	weight gain	Disease	D015430
Entity: 10986547	225	235	somnolence	Disease	D006970
Relation: 10986547	CID	9	19	C076029	91	102	D015430	true
Relation: 10986547	CID	9	19	C076029	225	235	D006970	true

Sentence: The effect of pupil dilation with tropicamide on vision and driving simulator performance.
Entity: 11026989	14	28	pupil dilation	Disease	D015878
Entity: 11026989	34	45	tropicamide	Chemical	D014331
Relation: 11026989	CID	34	45	D014331	14	28	D015878	true

Sentence: METHODS: A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers, before and after pupil dilation using guttae tropicamide 1%.
Entity: 11026989	157	171	pupil dilation	Disease	D015878
Entity: 11026989	185	196	tropicamide	Chemical	D014331
Relation: 11026989	CID	185	196	D014331	157	171	D015878	true

Sentence: We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.
Entity: 11105626	63	69	anotia	Disease	D065817
Entity: 11105626	74	99	Taussig-Bing malformation	Disease	D004310
Entity: 11105626	120	132	isotretinoin	Chemical	D015474
Relation: 11105626	CID	120	132	D015474	63	69	D065817	true
Relation: 11105626	CID	120	132	D015474	74	99	D004310	true

Sentence: Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study.
Entity: 11135381	10	21	methoxamine	Chemical	D008729
Entity: 11135381	73	92	stress incontinence	Disease	D014550
Relation: 11135381	CID	10	21	D008729	73	92	D014550	false

Sentence: Half log incremental doses of intravenous methoxamine or placebo (saline) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects.
Entity: 11135381	42	53	methoxamine	Chemical	D008729
Entity: 11135381	125	144	stress incontinence	Disease	D014550
Relation: 11135381	CID	42	53	D008729	125	144	D014550	false

Sentence: Methoxamine evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage.
Entity: 11135381	0	11	Methoxamine	Chemical	D008729
Entity: 11135381	92	137	a significant rise in systolic blood pressure	Disease	D006973
Relation: 11135381	CID	0	11	D008729	92	137	D006973	true

Sentence: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial.
Entity: 11176729	28	68	angiotensin-converting enzyme inhibitors	Chemical	D000806
Entity: 11176729	94	107	heart failure	Disease	D006333
Relation: 11176729	CID	28	68	D000806	94	107	D006333	false

Sentence: BACKGROUND: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.
Entity: 11176729	27	73	angiotensin-converting enzyme (ACE) inhibitors	Chemical	D000806
Entity: 11176729	131	144	heart failure	Disease	D006333
Entity: 11176729	146	149	CHF	Disease	D006333
Relation: 11176729	CID	27	73	D000806	131	144	D006333	false
Relation: 11176729	CID	27	73	D000806	146	149	D006333	false

Sentence: The present study examines the safety and tolerability of high- compared with low-dose lisinopril in CHF.
Entity: 11176729	87	97	lisinopril	Chemical	D017706
Entity: 11176729	101	104	CHF	Disease	D006333
Relation: 11176729	CID	87	97	D017706	101	104	D006333	false

Sentence: RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).
Entity: 11176729	53	66	ACE inhibitor	Chemical	D000806
Entity: 11176729	196	207	hypotension	Disease	D007022
Entity: 11176729	229	246	renal dysfunction	Disease	D007674
Entity: 11176729	250	262	hyperkalemia	Disease	D006947
Relation: 11176729	CID	53	66	D000806	196	207	D007022	false
Relation: 11176729	CID	53	66	D000806	229	246	D007674	false
Relation: 11176729	CID	53	66	D000806	250	262	D006947	false

Sentence: Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; creatinine, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy.
Entity: 11176729	44	57	ACE inhibitor	Chemical	D000806
Entity: 11176729	99	109	creatinine	Chemical	D003404
Entity: 11176729	192	200	diabetes	Disease	D003920
Relation: 11176729	CID	44	57	D000806	192	200	D003920	false
Relation: 11176729	CID	99	109	D003404	192	200	D003920	false

Sentence: Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.
Entity: 11229942	0	7	Cocaine	Chemical	D003042
Entity: 11229942	9	16	ethanol	Chemical	D000431
Entity: 11229942	22	34	cocaethylene	Chemical	C066444
Entity: 11229942	35	47	cardiotoxity	Disease	D066126
Entity: 11229942	70	77	cocaine	Disease	D019970
Entity: 11229942	82	89	ethanol	Disease	D000437
Relation: 11229942	CID	0	7	D003042	35	47	D066126	false
Relation: 11229942	CID	0	7	D003042	70	77	D019970	false
Relation: 11229942	CID	0	7	D003042	82	89	D000437	false
Relation: 11229942	CID	9	16	D000431	35	47	D066126	false
Relation: 11229942	CID	9	16	D000431	70	77	D019970	false
Relation: 11229942	CID	9	16	D000431	82	89	D000437	false
Relation: 11229942	CID	22	34	C066444	35	47	D066126	false
Relation: 11229942	CID	22	34	C066444	70	77	D019970	false
Relation: 11229942	CID	22	34	C066444	82	89	D000437	false

Sentence: Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.
Entity: 11229942	15	31	cardiac toxicity	Disease	D066126
Entity: 11229942	113	125	cocaethylene	Chemical	C066444
Entity: 11229942	127	129	CE	Chemical	C066444
Entity: 11229942	134	141	cocaine	Chemical	D003042
Entity: 11229942	184	191	ethanol	Chemical	D000431
Relation: 11229942	CID	113	125	C066444	15	31	D066126	false
Relation: 11229942	CID	127	129	C066444	15	31	D066126	false
Relation: 11229942	CID	134	141	D003042	15	31	D066126	false
Relation: 11229942	CID	184	191	D000431	15	31	D066126	false

Sentence: The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.
Entity: 11229942	55	57	CE	Chemical	C066444
Entity: 11229942	74	88	cardiotoxicity	Disease	D066126
Entity: 11229942	92	99	cocaine	Chemical	D003042
Entity: 11229942	104	111	ethanol	Chemical	D000431
Relation: 11229942	CID	55	57	C066444	74	88	D066126	false
Relation: 11229942	CID	92	99	D003042	74	88	D066126	false
Relation: 11229942	CID	104	111	D000431	74	88	D066126	false

Sentence: Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025).
Entity: 11229942	5	7	CE	Chemical	C066444
Entity: 11229942	76	102	decrease in cardiac output	Disease	D002303
Relation: 11229942	CID	5	7	C066444	76	102	D002303	true

Sentence: Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
Entity: 11299446	13	25	Parkinsonism	Disease	D010302
Entity: 11299446	43	54	veralipride	Chemical	C027429
Relation: 11299446	CID	43	54	C027429	13	25	D010302	true

Sentence: We describe a female patient with stable Parkinson's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride, as well as the improvement of her symptoms back to baseline after discontinuation of the drug.
Entity: 11299446	41	60	Parkinson's disease	Disease	D010302
Entity: 11299446	170	181	veralipride	Chemical	C027429
Relation: 11299446	CID	170	181	C027429	41	60	D010302	true

Sentence: Viracept and irregular heartbeat warning.
Entity: 11366874	0	8	Viracept	Chemical	D019888
Entity: 11366874	13	32	irregular heartbeat	Disease	D001145
Relation: 11366874	CID	0	8	D019888	13	32	D001145	false

Sentence: A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.
Entity: 11366874	62	70	Viracept	Chemical	D019888
Entity: 11366874	84	104	irregular heart beat	Disease	D001145
Entity: 11366874	115	126	bradycardia	Disease	D001919
Relation: 11366874	CID	62	70	D019888	84	104	D001145	false
Relation: 11366874	CID	62	70	D019888	115	126	D001919	true

Sentence: Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
Entity: 11380496	93	108	Graves' disease	Disease	D006111
Entity: 11380496	131	147	propylthiouracil	Chemical	D011441
Relation: 11380496	CID	131	147	D011441	93	108	D006111	false

Sentence: OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).
Entity: 11380496	83	93	vasculitis	Disease	D014657
Entity: 11380496	129	144	Graves' disease	Disease	D006111
Entity: 11380496	167	183	propylthiouracil	Chemical	D011441
Entity: 11380496	185	188	PTU	Chemical	D011441
Relation: 11380496	CID	167	183	D011441	83	93	D014657	false
Relation: 11380496	CID	167	183	D011441	129	144	D006111	false
Relation: 11380496	CID	185	188	D011441	83	93	D014657	false
Relation: 11380496	CID	185	188	D011441	129	144	D006111	false

Sentence: Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.
Entity: 11380496	109	119	vasculitis	Disease	D014657
Entity: 11380496	127	130	PTU	Chemical	D011441
Entity: 11380496	185	200	Graves' disease	Disease	D006111
Relation: 11380496	CID	127	130	D011441	109	119	D014657	false
Relation: 11380496	CID	127	130	D011441	185	200	D006111	false

Sentence: PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.
Entity: 11380496	54	69	hyperthyroidism	Disease	D006980
Entity: 11380496	77	92	Graves' disease	Disease	D006111
Entity: 11380496	147	157	vasculitis	Disease	D014657
Entity: 11380496	173	176	PTU	Chemical	D011441
Relation: 11380496	CID	173	176	D011441	54	69	D006980	false
Relation: 11380496	CID	173	176	D011441	77	92	D006111	false
Relation: 11380496	CID	173	176	D011441	147	157	D014657	false

Sentence: In two of them, the MPO-ANCA titres transiently increased to 12.8 and 15.0 U/ml, respectively, despite continued PTU therapy, but no vasculitic disorders developed.
Entity: 11380496	113	116	PTU	Chemical	D011441
Entity: 11380496	133	153	vasculitic disorders	Disease	D014652
Relation: 11380496	CID	113	116	D011441	133	153	D014652	false

Sentence: In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.
Entity: 11380496	90	95	fever	Disease	D005334
Entity: 11380496	97	108	oral ulcers	Disease	D019226
Entity: 11380496	113	127	polyarthralgia	Disease	D018771
Entity: 11380496	178	181	PTU	Chemical	D011441
Entity: 11380496	269	272	PTU	Chemical	D011441
Relation: 11380496	CID	178	181	D011441	90	95	D005334	true
Relation: 11380496	CID	178	181	D011441	97	108	D019226	true
Relation: 11380496	CID	178	181	D011441	113	127	D018771	true
Relation: 11380496	CID	269	272	D011441	90	95	D005334	true
Relation: 11380496	CID	269	272	D011441	97	108	D019226	true
Relation: 11380496	CID	269	272	D011441	113	127	D018771	true

Sentence: Prevalence of heart disease in asymptomatic chronic cocaine users.
Entity: 11385188	14	27	heart disease	Disease	D006331
Entity: 11385188	52	59	cocaine	Chemical	D003042
Relation: 11385188	CID	52	59	D003042	14	27	D006331	false

Sentence: To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.
Entity: 11385188	31	44	heart disease	Disease	D006331
Entity: 11385188	86	93	cocaine	Chemical	D003042
Entity: 11385188	104	111	cocaine	Chemical	D003042
Relation: 11385188	CID	86	93	D003042	31	44	D006331	false
Relation: 11385188	CID	104	111	D003042	31	44	D006331	false

Sentence: The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.
Entity: 11395263	35	42	ethanol	Chemical	D000431
Entity: 11395263	100	113	isoproterenol	Chemical	D007545
Entity: 11395263	122	143	myocardial infarction	Disease	D009203
Relation: 11395263	CID	35	42	D000431	122	143	D009203	false
Relation: 11395263	CID	100	113	D007545	122	143	D009203	true

Sentence: BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.
Entity: 11401944	119	137	torsade de pointes	Disease	D016171
Entity: 11401944	139	142	TdP	Disease	D016171
Entity: 11401944	149	164	QT prolongation	Disease	D008133
Entity: 11401944	179	186	sotalol	Chemical	D013015
Entity: 11401944	191	200	azimilide	Chemical	C086123
Relation: 11401944	CID	179	186	D013015	119	137	D016171	true
Relation: 11401944	CID	179	186	D013015	139	142	D016171	true
Relation: 11401944	CID	179	186	D013015	149	164	D008133	true
Relation: 11401944	CID	191	200	C086123	119	137	D016171	false
Relation: 11401944	CID	191	200	C086123	139	142	D016171	false
Relation: 11401944	CID	191	200	C086123	149	164	D008133	false

Sentence: METHODS AND RESULTS: Transmembrane action potentials from epicardium, midmyocardium, and endocardium were recorded simultaneously, together with a transmural ECG, in arterially perfused canine and rabbit left ventricular preparations. dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to QT prolongation and an increase in TDR.
Entity: 11401944	238	245	Sotalol	Chemical	D013015
Entity: 11401944	365	380	QT prolongation	Disease	D008133
Relation: 11401944	CID	238	245	D013015	365	380	D008133	true

Sentence: Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen.
Entity: 11401944	17	24	sotalol	Chemical	D013015
Entity: 11401944	29	38	azimilide	Chemical	C086123
Entity: 11401944	151	166	QT prolongation	Disease	D008133
Relation: 11401944	CID	17	24	D013015	151	166	D008133	true
Relation: 11401944	CID	29	38	C086123	151	166	D008133	false

Sentence: An increase in TDR by dl-sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles.
Entity: 11401944	25	32	sotalol	Chemical	D013015
Entity: 11401944	124	127	TdP	Disease	D016171
Relation: 11401944	CID	25	32	D013015	124	127	D016171	true

Sentence: Prenatal cocaine exposure and cranial sonographic findings in preterm infants.
Entity: 11425091	9	16	cocaine	Chemical	D003042
Entity: 11425091	62	77	preterm infants	Disease	D007235
Relation: 11425091	CID	9	16	D003042	62	77	D007235	true

Sentence: PURPOSE: Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term.
Entity: 11425091	18	25	cocaine	Chemical	D003042
Entity: 11425091	69	79	hemorrhage	Disease	D006470
Entity: 11425091	101	106	cysts	Disease	D003560
Relation: 11425091	CID	18	25	D003042	69	79	D006470	false
Relation: 11425091	CID	18	25	D003042	101	106	D003560	true

Sentence: We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants.
Entity: 11425091	35	42	cocaine	Chemical	D003042
Entity: 11425091	79	91	subependymal	Disease	D001927
Entity: 11425091	92	97	cysts	Disease	D003560
Entity: 11425091	101	116	preterm infants	Disease	D007235
Relation: 11425091	CID	35	42	D003042	79	91	D001927	true
Relation: 11425091	CID	35	42	D003042	92	97	D003560	true
Relation: 11425091	CID	35	42	D003042	101	116	D007235	true

Sentence: Infants were assigned to the cocaine-exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery.
Entity: 11425091	29	36	cocaine	Chemical	D003042
Entity: 11425091	86	99	cocaine abuse	Disease	D019970
Relation: 11425091	CID	29	36	D003042	86	99	D019970	false

Sentence: The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0.01).
Entity: 11425091	17	29	subependymal	Disease	D001927
Entity: 11425091	30	35	cysts	Disease	D003560
Entity: 11425091	58	65	cocaine	Chemical	D003042
Relation: 11425091	CID	58	65	D003042	17	29	D001927	true
Relation: 11425091	CID	58	65	D003042	30	35	D003560	true

Sentence: Thalidomide neuropathy in patients treated for metastatic prostate cancer.
Entity: 11439380	0	11	Thalidomide	Chemical	D013792
Entity: 11439380	12	22	neuropathy	Disease	D009422
Entity: 11439380	58	73	prostate cancer	Disease	D011471
Relation: 11439380	CID	0	11	D013792	12	22	D009422	false
Relation: 11439380	CID	0	11	D013792	58	73	D011471	false

Sentence: We prospectively evaluated thalidomide induced neuropathy using electrodiagnostic studies.
Entity: 11439380	27	38	thalidomide	Chemical	D013792
Entity: 11439380	47	57	neuropathy	Disease	D009422
Relation: 11439380	CID	27	38	D013792	47	57	D009422	false

Sentence: Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.
Entity: 11439380	32	40	androgen	Chemical	D000728
Entity: 11439380	53	68	prostate cancer	Disease	D011471
Entity: 11439380	100	111	thalidomide	Chemical	D013792
Relation: 11439380	CID	32	40	D000728	53	68	D011471	false
Relation: 11439380	CID	100	111	D013792	53	68	D011471	false

Sentence: Neuropathy may thus be a common complication of thalidomide in older patients.
Entity: 11439380	0	10	Neuropathy	Disease	D009422
Entity: 11439380	48	59	thalidomide	Chemical	D013792
Relation: 11439380	CID	48	59	D013792	0	10	D009422	false

Sentence: Overexpression of copper/zinc-superoxide dismutase protects from kanamycin induced hearing loss.
Entity: 11474137	18	24	copper	Chemical	D003300
Entity: 11474137	25	29	zinc	Chemical	D015032
Entity: 11474137	30	40	superoxide	Chemical	D013481
Entity: 11474137	65	74	kanamycin	Chemical	D007612
Entity: 11474137	83	95	hearing loss	Disease	D034381
Relation: 11474137	CID	18	24	D003300	83	95	D034381	false
Relation: 11474137	CID	25	29	D015032	83	95	D034381	false
Relation: 11474137	CID	30	40	D013481	83	95	D034381	false
Relation: 11474137	CID	65	74	D007612	83	95	D034381	true

Sentence: The participation of reactive oxygen species in aminoglycoside induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.
Entity: 11474137	30	36	oxygen	Chemical	D010100
Entity: 11474137	48	62	aminoglycoside	Chemical	D000617
Entity: 11474137	71	82	ototoxicity	Disease	D006311
Entity: 11474137	123	137	aminoglycoside	Chemical	D000617
Entity: 11474137	138	142	iron	Chemical	D007501
Entity: 11474137	179	189	superoxide	Chemical	D013481
Entity: 11474137	240	251	ototoxicity	Disease	D006311
Relation: 11474137	CID	30	36	D010100	71	82	D006311	false
Relation: 11474137	CID	30	36	D010100	240	251	D006311	false
Relation: 11474137	CID	48	62	D000617	71	82	D006311	false
Relation: 11474137	CID	48	62	D000617	240	251	D006311	false
Relation: 11474137	CID	123	137	D000617	71	82	D006311	false
Relation: 11474137	CID	123	137	D000617	240	251	D006311	false
Relation: 11474137	CID	138	142	D007501	71	82	D006311	false
Relation: 11474137	CID	138	142	D007501	240	251	D006311	false
Relation: 11474137	CID	179	189	D013481	71	82	D006311	false
Relation: 11474137	CID	179	189	D013481	240	251	D006311	false

Sentence: We therefore hypothesized that overexpression of Cu/Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity.
Entity: 11474137	49	51	Cu	Chemical	D003300
Entity: 11474137	52	54	Zn	Chemical	D015032
Entity: 11474137	55	65	superoxide	Chemical	D013481
Entity: 11474137	121	132	ototoxicity	Disease	D006311
Relation: 11474137	CID	49	51	D003300	121	132	D006311	false
Relation: 11474137	CID	52	54	D015032	121	132	D006311	false
Relation: 11474137	CID	55	65	D013481	121	132	D006311	false

Sentence: Prednisone induces anxiety and glial cerebral changes in rats.
Entity: 11708428	0	10	Prednisone	Chemical	D011241
Entity: 11708428	19	26	anxiety	Disease	D001008
Relation: 11708428	CID	0	10	D011241	19	26	D001008	true

Sentence: OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.
Entity: 11708428	29	39	prednisone	Chemical	D011241
Entity: 11708428	41	44	PDN	Chemical	D011241
Entity: 11708428	55	62	anxiety	Disease	D001008
Relation: 11708428	CID	29	39	D011241	55	62	D001008	true
Relation: 11708428	CID	41	44	D011241	55	62	D001008	true

Sentence: RESULTS: Anxiety was documented in both groups of PDN treated rats compared with controls.
Entity: 11708428	9	16	Anxiety	Disease	D001008
Entity: 11708428	50	53	PDN	Chemical	D011241
Relation: 11708428	CID	50	53	D011241	9	16	D001008	true

Sentence: CONCLUSION: Subacute exposure to PDN induced anxiety and reactivity of microglia.
Entity: 11708428	33	36	PDN	Chemical	D011241
Entity: 11708428	45	52	anxiety	Disease	D001008
Relation: 11708428	CID	33	36	D011241	45	52	D001008	true

Sentence: Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
Entity: 11745287	18	29	carboplatin	Chemical	D016190
Entity: 11745287	44	55	doxorubicin	Chemical	D004317
Entity: 11745287	83	91	squamous	Disease	D002294
Entity: 11745287	97	106	carcinoma	Disease	D002583
Relation: 11745287	CID	18	29	D016190	83	91	D002294	false
Relation: 11745287	CID	18	29	D016190	97	106	D002583	false
Relation: 11745287	CID	44	55	D004317	83	91	D002294	false
Relation: 11745287	CID	44	55	D004317	97	106	D002583	false

Sentence: BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.
Entity: 11745287	47	58	carboplatin	Chemical	D016190
Entity: 11745287	73	84	doxorubicin	Chemical	D004317
Entity: 11745287	143	161	cervical carcinoma	Disease	D002583
Relation: 11745287	CID	47	58	D016190	143	161	D002583	false
Relation: 11745287	CID	73	84	D004317	143	161	D002583	false

Sentence: METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.
Entity: 11745287	28	39	carboplatin	Chemical	D016190
Entity: 11745287	100	111	doxorubicin	Chemical	D004317
Entity: 11745287	113	118	Doxil	Chemical	D004317
Entity: 11745287	222	230	squamous	Disease	D002294
Entity: 11745287	236	244	cervical	Disease	D002583
Entity: 11745287	291	299	toxicity	Disease	D064420
Relation: 11745287	CID	28	39	D016190	222	230	D002294	false
Relation: 11745287	CID	28	39	D016190	236	244	D002583	false
Relation: 11745287	CID	28	39	D016190	291	299	D064420	false
Relation: 11745287	CID	100	111	D004317	222	230	D002294	false
Relation: 11745287	CID	100	111	D004317	236	244	D002583	false
Relation: 11745287	CID	100	111	D004317	291	299	D064420	false
Relation: 11745287	CID	113	118	D004317	222	230	D002294	false
Relation: 11745287	CID	113	118	D004317	236	244	D002583	false
Relation: 11745287	CID	113	118	D004317	291	299	D064420	false

Sentence: Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.
Entity: 11799346	0	13	Cotrimoxazole	Chemical	D015662
Entity: 11799346	15	28	metronidazole	Chemical	D008795
Entity: 11799346	34	46	erythromycin	Chemical	D004917
Entity: 11799346	76	81	manic	Disease	D001714
Relation: 11799346	CID	0	13	D015662	76	81	D001714	true
Relation: 11799346	CID	15	28	D008795	76	81	D001714	true
Relation: 11799346	CID	34	46	D004917	76	81	D001714	true

Sentence: Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.
Entity: 11799346	33	47	clarithromycin	Chemical	D017291
Entity: 11799346	52	65	ciprofloxacin	Chemical	D002939
Entity: 11799346	127	132	mania	Disease	D001714
Relation: 11799346	CID	33	47	D017291	127	132	D001714	true
Relation: 11799346	CID	52	65	D002939	127	132	D001714	true

Sentence: Levodopa induced ocular dyskinesias in Parkinson's disease.
Entity: 11835460	0	8	Levodopa	Chemical	D007980
Entity: 11835460	17	35	ocular dyskinesias	Disease	D015835
Entity: 11835460	39	58	Parkinson's disease	Disease	D010300
Relation: 11835460	CID	0	8	D007980	17	35	D015835	true
Relation: 11835460	CID	0	8	D007980	39	58	D010300	false

Sentence: Levodopa induced ocular dyskinesias are very uncommon.
Entity: 11835460	0	8	Levodopa	Chemical	D007980
Entity: 11835460	17	35	ocular dyskinesias	Disease	D015835
Relation: 11835460	CID	0	8	D007980	17	35	D015835	true

Sentence: A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.
Entity: 11915580	16	35	glyceryl trinitrate	Chemical	D005996
Entity: 11915580	41	51	diclofenac	Chemical	D004008
Entity: 11915580	81	93	dysmenorrhea	Disease	D004412
Relation: 11915580	CID	16	35	D005996	81	93	D004412	false
Relation: 11915580	CID	41	51	D004008	81	93	D004412	false

Sentence: Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.
Entity: 11915580	8	20	dysmenorrhea	Disease	D004412
Entity: 11915580	124	138	prostaglandins	Chemical	D011453
Relation: 11915580	CID	124	138	D011453	8	20	D004412	false

Sentence: The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).
Entity: 11915580	62	81	glyceryl trinitrate	Chemical	D005996
Entity: 11915580	83	86	GTN	Chemical	D005996
Entity: 11915580	92	94	NO	Chemical	D009569
Entity: 11915580	131	143	dysmenorrhea	Disease	D004412
Entity: 11915580	163	173	diclofenac	Chemical	D004008
Entity: 11915580	175	178	DCF	Chemical	D004008
Relation: 11915580	CID	62	81	D005996	131	143	D004412	false
Relation: 11915580	CID	83	86	D005996	131	143	D004412	false
Relation: 11915580	CID	92	94	D009569	131	143	D004412	false
Relation: 11915580	CID	163	173	D004008	131	143	D004412	false
Relation: 11915580	CID	175	178	D004008	131	143	D004412	false

Sentence: However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001).
Entity: 11915580	9	12	DCF	Chemical	D004008
Entity: 11915580	51	62	pelvic pain	Disease	D017699
Entity: 11915580	86	89	GTN	Chemical	D005996
Entity: 11915580	200	203	GTN	Chemical	D005996
Entity: 11915580	262	265	GTN	Chemical	D005996
Relation: 11915580	CID	9	12	D004008	51	62	D017699	false
Relation: 11915580	CID	86	89	D005996	51	62	D017699	false
Relation: 11915580	CID	200	203	D005996	51	62	D017699	false
Relation: 11915580	CID	262	265	D005996	51	62	D017699	false

Sentence: Headache was significantly increased by GTN but not by DCF.
Entity: 11915580	0	8	Headache	Disease	D006261
Entity: 11915580	40	43	GTN	Chemical	D005996
Entity: 11915580	55	58	DCF	Chemical	D004008
Relation: 11915580	CID	40	43	D005996	0	8	D006261	true
Relation: 11915580	CID	55	58	D004008	0	8	D006261	false

Sentence: Eight patients stopped using GTN because headache--attributed to its use--became intolerable.
Entity: 11915580	29	32	GTN	Chemical	D005996
Entity: 11915580	41	49	headache	Disease	D006261
Relation: 11915580	CID	29	32	D005996	41	49	D006261	true

Sentence: Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.
Entity: 11936424	0	10	Temocapril	Chemical	C055603
Entity: 11936424	39	50	angiotensin	Chemical	D000809
Entity: 11936424	90	107	glomerular injury	Disease	D007674
Entity: 11936424	119	144	puromycin aminonucleoside	Chemical	D011692
Entity: 11936424	145	154	nephrosis	Disease	D009401
Relation: 11936424	CID	0	10	C055603	90	107	D007674	false
Relation: 11936424	CID	0	10	C055603	145	154	D009401	false
Relation: 11936424	CID	39	50	D000809	90	107	D007674	false
Relation: 11936424	CID	39	50	D000809	145	154	D009401	false
Relation: 11936424	CID	119	144	D011692	90	107	D007674	false
Relation: 11936424	CID	119	144	D011692	145	154	D009401	true

Sentence: The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.
Entity: 11936424	84	94	temocapril	Chemical	C055603
Entity: 11936424	123	134	angiotensin	Chemical	D000809
Entity: 11936424	178	189	proteinuria	Disease	D011507
Entity: 11936424	212	223	hypertrophy	Disease	D006984
Entity: 11936424	238	256	glomerulosclerosis	Disease	D005921
Entity: 11936424	268	293	puromycin aminonucleoside	Chemical	D011692
Entity: 11936424	295	298	PAN	Chemical	D011692
Entity: 11936424	310	319	nephrotic	Disease	D009404
Relation: 11936424	CID	84	94	C055603	178	189	D011507	false
Relation: 11936424	CID	84	94	C055603	212	223	D006984	false
Relation: 11936424	CID	84	94	C055603	238	256	D005921	false
Relation: 11936424	CID	84	94	C055603	310	319	D009404	false
Relation: 11936424	CID	123	134	D000809	178	189	D011507	false
Relation: 11936424	CID	123	134	D000809	212	223	D006984	false
Relation: 11936424	CID	123	134	D000809	238	256	D005921	false
Relation: 11936424	CID	123	134	D000809	310	319	D009404	false
Relation: 11936424	CID	268	293	D011692	178	189	D011507	true
Relation: 11936424	CID	268	293	D011692	212	223	D006984	false
Relation: 11936424	CID	268	293	D011692	238	256	D005921	false
Relation: 11936424	CID	268	293	D011692	310	319	D009404	false
Relation: 11936424	CID	295	298	D011692	178	189	D011507	true
Relation: 11936424	CID	295	298	D011692	212	223	D006984	false
Relation: 11936424	CID	295	298	D011692	238	256	D005921	false
Relation: 11936424	CID	295	298	D011692	310	319	D009404	false

Sentence: Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.
Entity: 11936424	0	9	Nephrosis	Disease	D009401
Entity: 11936424	38	41	PAN	Chemical	D011692
Relation: 11936424	CID	38	41	D011692	0	9	D009401	true

Sentence: Temocapril did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20.
Entity: 11936424	0	10	Temocapril	Chemical	C055603
Entity: 11936424	29	40	proteinuria	Disease	D011507
Relation: 11936424	CID	0	10	C055603	29	40	D011507	false

Sentence: The glomerulosclerosis index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the PAN group.
Entity: 11936424	4	22	glomerulosclerosis	Disease	D005921
Entity: 11936424	120	123	PAN	Chemical	D011692
Relation: 11936424	CID	120	123	D011692	4	22	D005921	false

Sentence: Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
Entity: 11988250	0	22	Pulmonary hypertension	Disease	D006976
Entity: 11988250	29	38	ibuprofen	Chemical	D007052
Relation: 11988250	CID	29	38	D007052	0	22	D006976	true

Sentence: We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.
Entity: 11988250	32	42	hypoxaemia	Disease	D000860
Entity: 11988250	49	58	ibuprofen	Chemical	D007052
Entity: 11988250	140	164	patent ductus arteriosus	Disease	D004374
Entity: 11988250	170	179	ibuprofen	Chemical	D007052
Relation: 11988250	CID	49	58	D007052	32	42	D000860	true
Relation: 11988250	CID	49	58	D007052	140	164	D004374	false
Relation: 11988250	CID	170	179	D007052	32	42	D000860	true
Relation: 11988250	CID	170	179	D007052	140	164	D004374	false

Sentence: Hypoxaemia resolved quickly on inhaled nitric oxide therapy.
Entity: 11988250	0	10	Hypoxaemia	Disease	D000860
Entity: 11988250	39	51	nitric oxide	Chemical	D009569
Relation: 11988250	CID	39	51	D009569	0	10	D000860	false

Sentence: Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians.
Entity: 12051122	0	12	Hyponatremia	Disease	D007010
Entity: 12051122	17	64	syndrome of inappropriate anti-diuretic hormone	Disease	D007177
Entity: 12051122	90	101	Vincristine	Chemical	D014750
Relation: 12051122	CID	90	101	D014750	0	12	D007010	true
Relation: 12051122	CID	90	101	D014750	17	64	D007177	true

Sentence: PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.
Entity: 12051122	124	136	hyponatremia	Disease	D007010
Entity: 12051122	144	204	syndrome of inappropriate secretion of anti-diuretic hormone	Disease	D007177
Entity: 12051122	206	211	SIADH	Disease	D007177
Entity: 12051122	219	230	vincristine	Chemical	D014750
Relation: 12051122	CID	219	230	D014750	124	136	D007010	true
Relation: 12051122	CID	219	230	D014750	144	204	D007177	true
Relation: 12051122	CID	219	230	D014750	206	211	D007177	true

Sentence: METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or SIADH as of 1 November 1999 that had been reported during the use of vincristine.
Entity: 12051122	110	122	hyponatremia	Disease	D007010
Entity: 12051122	130	135	SIADH	Disease	D007177
Entity: 12051122	199	210	vincristine	Chemical	D014750
Relation: 12051122	CID	199	210	D014750	110	122	D007010	true
Relation: 12051122	CID	199	210	D014750	130	135	D007177	true

Sentence: RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.
Entity: 12051122	32	44	hyponatremia	Disease	D007010
Entity: 12051122	52	57	SIADH	Disease	D007177
Entity: 12051122	74	85	vincristine	Chemical	D014750
Relation: 12051122	CID	74	85	D014750	32	44	D007010	true
Relation: 12051122	CID	74	85	D014750	52	57	D007177	true

Sentence: CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.
Entity: 12051122	77	89	hyponatremia	Disease	D007010
Entity: 12051122	97	102	SIADH	Disease	D007177
Entity: 12051122	119	130	vincristine	Chemical	D014750
Relation: 12051122	CID	119	130	D014750	77	89	D007010	true
Relation: 12051122	CID	119	130	D014750	97	102	D007177	true

Sentence: Delayed toxicity of cyclophosphamide on the bladder of DBA/2 and C57BL/6 female mouse.
Entity: 12059909	8	16	toxicity	Disease	D064420
Entity: 12059909	20	36	cyclophosphamide	Chemical	D003520
Relation: 12059909	CID	20	36	D003520	8	16	D064420	false

Sentence: Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.
Entity: 12059909	6	8	CY	Chemical	D003520
Entity: 12059909	9	17	toxicity	Disease	D064420
Entity: 12059909	35	47	haemorrhagic	Disease	D006470
Entity: 12059909	48	56	cystitis	Disease	D003556
Relation: 12059909	CID	6	8	D003520	9	17	D064420	false
Relation: 12059909	CID	6	8	D003520	35	47	D006470	true
Relation: 12059909	CID	6	8	D003520	48	56	D003556	true

Sentence: After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.
Entity: 12059909	17	19	CY	Chemical	D003520
Entity: 12059909	73	81	cystitis	Disease	D003556
Relation: 12059909	CID	17	19	D003520	73	81	D003556	true

Sentence: These results indicate that delayed toxicity of CY in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice.
Entity: 12059909	36	44	toxicity	Disease	D064420
Entity: 12059909	48	50	CY	Chemical	D003520
Relation: 12059909	CID	48	50	D003520	36	44	D064420	false

Sentence: High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.
Entity: 12119460	10	24	5-fluorouracil	Chemical	D005472
Entity: 12119460	27	39	folinic acid	Chemical	D002955
Entity: 12119460	73	84	mitomycin C	Chemical	D016685
Entity: 12119460	114	128	gastric cancer	Disease	D013274
Relation: 12119460	CID	10	24	D005472	114	128	D013274	false
Relation: 12119460	CID	27	39	D002955	114	128	D013274	false
Relation: 12119460	CID	73	84	D016685	114	128	D013274	false

Sentence: BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.
Entity: 12119460	47	61	5-fluorouracil	Chemical	D005472
Entity: 12119460	63	67	5-FU	Chemical	D005472
Entity: 12119460	73	85	folinic acid	Chemical	D002955
Entity: 12119460	87	89	FA	Chemical	D002955
Entity: 12119460	158	172	gastric cancer	Disease	D013274
Entity: 12119460	174	177	AGC	Disease	D013274
Entity: 12119460	215	223	toxicity	Disease	D064420
Relation: 12119460	CID	47	61	D005472	158	172	D013274	false
Relation: 12119460	CID	47	61	D005472	174	177	D013274	false
Relation: 12119460	CID	47	61	D005472	215	223	D064420	false
Relation: 12119460	CID	63	67	D005472	158	172	D013274	false
Relation: 12119460	CID	63	67	D005472	174	177	D013274	false
Relation: 12119460	CID	63	67	D005472	215	223	D064420	false
Relation: 12119460	CID	73	85	D002955	158	172	D013274	false
Relation: 12119460	CID	73	85	D002955	174	177	D013274	false
Relation: 12119460	CID	73	85	D002955	215	223	D064420	false
Relation: 12119460	CID	87	89	D002955	158	172	D013274	false
Relation: 12119460	CID	87	89	D002955	174	177	D013274	false
Relation: 12119460	CID	87	89	D002955	215	223	D064420	false

Sentence: In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.
Entity: 12119460	49	53	5-FU	Chemical	D005472
Entity: 12119460	55	57	FA	Chemical	D002955
Entity: 12119460	62	73	mitomycin C	Chemical	D016685
Entity: 12119460	75	78	MMC	Chemical	D016685
Entity: 12119460	95	103	toxicity	Disease	D064420
Relation: 12119460	CID	49	53	D005472	95	103	D064420	false
Relation: 12119460	CID	55	57	D002955	95	103	D064420	false
Relation: 12119460	CID	62	73	D016685	95	103	D064420	false
Relation: 12119460	CID	75	78	D016685	95	103	D064420	false

Sentence: PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.
Entity: 12119460	91	94	AGC	Disease	D013274
Entity: 12119460	121	125	5-FU	Chemical	D005472
Entity: 12119460	159	161	FA	Chemical	D002955
Relation: 12119460	CID	121	125	D005472	91	94	D013274	false
Relation: 12119460	CID	159	161	D002955	91	94	D013274	false

Sentence: CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).
Entity: 12119460	23	27	5-FU	Chemical	D005472
Entity: 12119460	28	30	FA	Chemical	D002955
Entity: 12119460	31	34	MMC	Chemical	D016685
Entity: 12119460	93	96	AGC	Disease	D013274
Relation: 12119460	CID	23	27	D005472	93	96	D013274	false
Relation: 12119460	CID	28	30	D002955	93	96	D013274	false
Relation: 12119460	CID	31	34	D016685	93	96	D013274	false

Sentence: Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.
Entity: 12165618	19	31	leukocyturia	Disease	-1
Entity: 12165618	51	74	impaired renal function	Disease	D007674
Entity: 12165618	78	122	human immunodeficiency virus type 1-infected	Disease	D015658
Entity: 12165618	145	154	indinavir	Chemical	D019469
Relation: 12165618	CID	145	154	D019469	19	31	-1	false
Relation: 12165618	CID	145	154	D019469	51	74	D007674	true
Relation: 12165618	CID	145	154	D019469	78	122	D015658	false

Sentence: DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.
Entity: 12165618	39	48	indinavir	Chemical	D019469
Entity: 12165618	57	71	nephrotoxicity	Disease	D007674
Entity: 12165618	90	134	human immunodeficiency virus type 1-infected	Disease	D015658
Entity: 12165618	157	166	indinavir	Chemical	D019469
Relation: 12165618	CID	39	48	D019469	57	71	D007674	true
Relation: 12165618	CID	39	48	D019469	90	134	D015658	false
Relation: 12165618	CID	157	166	D019469	57	71	D007674	true
Relation: 12165618	CID	157	166	D019469	90	134	D015658	false

Sentence: Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.
Entity: 12165618	19	31	leukocyturia	Disease	-1
Entity: 12165618	100	110	creatinine	Chemical	D003404
Entity: 12165618	136	145	hematuria	Disease	D006417
Relation: 12165618	CID	100	110	D003404	19	31	-1	false
Relation: 12165618	CID	100	110	D003404	136	145	D006417	false

Sentence: Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia.
Entity: 12165618	33	45	leukocyturia	Disease	-1
Entity: 12165618	72	82	creatinine	Chemical	D003404
Entity: 12165618	157	169	leukocyturia	Disease	-1
Relation: 12165618	CID	72	82	D003404	33	45	-1	false
Relation: 12165618	CID	72	82	D003404	157	169	-1	false

Sentence: A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of indinavir >12 mg/L.
Entity: 12165618	44	56	leukocyturia	Disease	-1
Entity: 12165618	146	155	indinavir	Chemical	D019469
Relation: 12165618	CID	146	155	D019469	44	56	-1	false

Sentence: In 4 children, indinavir was discontinued because of nephrotoxicity.
Entity: 12165618	15	24	indinavir	Chemical	D019469
Entity: 12165618	53	67	nephrotoxicity	Disease	D007674
Relation: 12165618	CID	15	24	D019469	53	67	D007674	true

Sentence: Subsequently, the serum creatinine levels decreased, the urine albumin/creatinine ratios returned to zero, and the leukocyturia disappeared within 3 months.
Entity: 12165618	24	34	creatinine	Chemical	D003404
Entity: 12165618	71	81	creatinine	Chemical	D003404
Entity: 12165618	115	127	leukocyturia	Disease	-1
Relation: 12165618	CID	24	34	D003404	115	127	-1	false
Relation: 12165618	CID	71	81	D003404	115	127	-1	false

Sentence: CONCLUSIONS: Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia.
Entity: 12165618	35	44	indinavir	Chemical	D019469
Entity: 12165618	100	112	leukocyturia	Disease	-1
Relation: 12165618	CID	35	44	D019469	100	112	-1	false

Sentence: Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of >50% above normal.
Entity: 12165618	33	45	leukocyturia	Disease	-1
Entity: 12165618	87	97	creatinine	Chemical	D003404
Relation: 12165618	CID	87	97	D003404	33	45	-1	false

Sentence: Utility of troponin I in patients with cocaine-associated chest pain.
Entity: 12359538	39	46	cocaine	Chemical	D003042
Entity: 12359538	58	68	chest pain	Disease	D002637
Relation: 12359538	CID	39	46	D003042	58	68	D002637	false

Sentence: Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.
Entity: 12359538	83	102	myocardial necrosis	Disease	D009202
Entity: 12359538	130	151	myocardial infarction	Disease	D009203
Entity: 12359538	153	155	MI	Disease	D009203
Entity: 12359538	184	191	cocaine	Chemical	D003042
Entity: 12359538	203	213	chest pain	Disease	D002637
Relation: 12359538	CID	184	191	D003042	83	102	D009202	false
Relation: 12359538	CID	184	191	D003042	130	151	D009203	true
Relation: 12359538	CID	184	191	D003042	153	155	D009203	true
Relation: 12359538	CID	184	191	D003042	203	213	D002637	false

Sentence: OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.
Entity: 12359538	76	83	cocaine	Chemical	D003042
Entity: 12359538	84	94	chest pain	Disease	D002637
Entity: 12359538	121	123	MI	Disease	D009203
Relation: 12359538	CID	76	83	D003042	84	94	D002637	false
Relation: 12359538	CID	76	83	D003042	121	123	D009203	true

Sentence: METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use.
Entity: 12359538	66	68	MI	Disease	D009203
Entity: 12359538	75	82	cocaine	Chemical	D003042
Relation: 12359538	CID	75	82	D003042	66	68	D009203	true

Sentence: Acute interstitial nephritis due to nicergoline (Sermion).
Entity: 12372954	6	28	interstitial nephritis	Disease	D009395
Entity: 12372954	36	47	nicergoline	Chemical	D009530
Entity: 12372954	49	56	Sermion	Chemical	D009530
Relation: 12372954	CID	36	47	D009530	6	28	D009395	true
Relation: 12372954	CID	49	56	D009530	6	28	D009395	true

Sentence: We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).
Entity: 12372954	26	48	interstitial nephritis	Disease	D009395
Entity: 12372954	50	53	AIN	Disease	D009395
Entity: 12372954	62	73	nicergoline	Chemical	D009530
Entity: 12372954	75	82	Sermion	Chemical	D009530
Relation: 12372954	CID	62	73	D009530	26	48	D009395	true
Relation: 12372954	CID	62	73	D009530	50	53	D009395	true
Relation: 12372954	CID	75	82	D009530	26	48	D009395	true
Relation: 12372954	CID	75	82	D009530	50	53	D009395	true

Sentence: Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.
Entity: 12372954	37	48	nicergoline	Chemical	D009530
Entity: 12372954	53	68	bendazac lysine	Chemical	C036067
Entity: 12372954	76	98	retinal vein occlusion	Disease	D012170
Relation: 12372954	CID	37	48	D009530	76	98	D012170	false
Relation: 12372954	CID	53	68	C036067	76	98	D012170	false

Sentence: A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.
Entity: 12452552	15	36	chronic renal failure	Disease	D007676
Entity: 12452552	38	41	CRF	Disease	D007676
Entity: 12452552	53	83	neuroleptic malignant syndrome	Disease	D009459
Entity: 12452552	85	88	NMS	Disease	D009459
Entity: 12452552	114	125	risperidone	Chemical	D018967
Entity: 12452552	130	145	levomepromazine	Chemical	D008728
Relation: 12452552	CID	114	125	D018967	15	36	D007676	false
Relation: 12452552	CID	114	125	D018967	38	41	D007676	false
Relation: 12452552	CID	114	125	D018967	53	83	D009459	true
Relation: 12452552	CID	114	125	D018967	85	88	D009459	true
Relation: 12452552	CID	130	145	D008728	15	36	D007676	false
Relation: 12452552	CID	130	145	D008728	38	41	D007676	false
Relation: 12452552	CID	130	145	D008728	53	83	D009459	true
Relation: 12452552	CID	130	145	D008728	85	88	D009459	true

Sentence: Adrenaline induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.
Entity: 12487093	0	10	Adrenaline	Chemical	D004837
Entity: 12487093	19	31	hypertension	Disease	D006973
Entity: 12487093	87	107	triphenyltetrazolium	Chemical	C009591
Entity: 12487093	109	112	TTC	Chemical	C009591
Entity: 12487093	161	171	adrenaline	Chemical	D004837
Relation: 12487093	CID	0	10	D004837	19	31	D006973	true
Relation: 12487093	CID	87	107	C009591	19	31	D006973	false
Relation: 12487093	CID	109	112	C009591	19	31	D006973	false
Relation: 12487093	CID	161	171	D004837	19	31	D006973	true

Sentence: Carvedilol protects against doxorubicin induced mitochondrial cardiomyopathy.
Entity: 12498738	0	10	Carvedilol	Chemical	C043211
Entity: 12498738	28	39	doxorubicin	Chemical	D004317
Entity: 12498738	62	76	cardiomyopathy	Disease	D009202
Relation: 12498738	CID	0	10	C043211	62	76	D009202	false
Relation: 12498738	CID	28	39	D004317	62	76	D009202	true

Sentence: Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin.
Entity: 12498738	107	121	cardiomyopathy	Disease	D009202
Entity: 12498738	132	143	doxorubicin	Chemical	D004317
Relation: 12498738	CID	132	143	D004317	107	121	D009202	true

Sentence: The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.
Entity: 12498738	68	78	carvedilol	Chemical	C043211
Entity: 12498738	274	285	doxorubicin	Chemical	D004317
Entity: 12498738	286	294	toxicity	Disease	D064420
Relation: 12498738	CID	68	78	C043211	286	294	D064420	false
Relation: 12498738	CID	274	285	D004317	286	294	D064420	false

Sentence: Cocaine induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine induced hyperactivity.
Entity: 12523489	0	7	Cocaine	Chemical	D003042
Entity: 12523489	16	29	hyperactivity	Disease	D006948
Entity: 12523489	52	61	adenosine	Chemical	D000241
Entity: 12523489	85	96	amphetamine	Chemical	D000661
Entity: 12523489	105	118	hyperactivity	Disease	D006948
Relation: 12523489	CID	0	7	D003042	16	29	D006948	false
Relation: 12523489	CID	0	7	D003042	105	118	D006948	false
Relation: 12523489	CID	52	61	D000241	16	29	D006948	false
Relation: 12523489	CID	52	61	D000241	105	118	D006948	false
Relation: 12523489	CID	85	96	D000661	16	29	D006948	false
Relation: 12523489	CID	85	96	D000661	105	118	D006948	false

Sentence: The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine induced hyperactivity was examined in mice.
Entity: 12523489	17	26	adenosine	Chemical	D000241
Entity: 12523489	64	71	cocaine	Chemical	D003042
Entity: 12523489	76	87	amphetamine	Chemical	D000661
Entity: 12523489	96	109	hyperactivity	Disease	D006948
Relation: 12523489	CID	17	26	D000241	96	109	D006948	false
Relation: 12523489	CID	64	71	D003042	96	109	D006948	false
Relation: 12523489	CID	76	87	D000661	96	109	D006948	false

Sentence: All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent.
Entity: 12523489	4	13	adenosine	Chemical	D000241
Entity: 12523489	46	78	decreased the locomotor activity	Disease	D004409
Relation: 12523489	CID	4	13	D000241	46	78	D004409	false

Sentence: Similarly, all adenosine receptor agonists decreased amphetamine induced hyperactivity, but at the higher doses than those which were active in cocaine induced hyperactivity.
Entity: 12523489	15	24	adenosine	Chemical	D000241
Entity: 12523489	53	64	amphetamine	Chemical	D000661
Entity: 12523489	73	86	hyperactivity	Disease	D006948
Entity: 12523489	144	151	cocaine	Chemical	D003042
Entity: 12523489	160	173	hyperactivity	Disease	D006948
Relation: 12523489	CID	15	24	D000241	73	86	D006948	false
Relation: 12523489	CID	15	24	D000241	160	173	D006948	false
Relation: 12523489	CID	53	64	D000661	73	86	D006948	false
Relation: 12523489	CID	53	64	D000661	160	173	D006948	false
Relation: 12523489	CID	144	151	D003042	73	86	D006948	false
Relation: 12523489	CID	144	151	D003042	160	173	D006948	false

Sentence: Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
Entity: 12535818	0	10	Amiodarone	Chemical	D000638
Entity: 12535818	27	42	bradyarrhythmia	Disease	D001919
Entity: 12535818	98	117	atrial fibrillation	Disease	D001281
Entity: 12535818	128	149	myocardial infarction	Disease	D009203
Relation: 12535818	CID	0	10	D000638	27	42	D001919	true
Relation: 12535818	CID	0	10	D000638	98	117	D001281	false
Relation: 12535818	CID	0	10	D000638	128	149	D009203	false

Sentence: OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.
Entity: 12535818	70	80	amiodarone	Chemical	D000638
Entity: 12535818	98	117	atrial fibrillation	Disease	D001281
Entity: 12535818	119	121	AF	Disease	D001281
Entity: 12535818	145	160	bradyarrhythmia	Disease	D001919
Relation: 12535818	CID	70	80	D000638	98	117	D001281	false
Relation: 12535818	CID	70	80	D000638	119	121	D001281	false
Relation: 12535818	CID	70	80	D000638	145	160	D001919	true

Sentence: BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.
Entity: 12535818	30	45	bradyarrhythmia	Disease	D001919
Entity: 12535818	53	63	amiodarone	Chemical	D000638
Entity: 12535818	173	196	ventricular arrhythmias	Disease	D001145
Relation: 12535818	CID	53	63	D000638	30	45	D001919	true
Relation: 12535818	CID	53	63	D000638	173	196	D001145	false

Sentence: CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.
Entity: 12535818	49	59	amiodarone	Chemical	D000638
Entity: 12535818	85	87	AF	Disease	D001281
Entity: 12535818	103	105	MI	Disease	D009203
Entity: 12535818	128	143	bradyarrhythmia	Disease	D001919
Relation: 12535818	CID	49	59	D000638	85	87	D001281	false
Relation: 12535818	CID	49	59	D000638	103	105	D009203	false
Relation: 12535818	CID	49	59	D000638	128	143	D001919	true

Sentence: CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.
Entity: 12559315	13	25	Indomethacin	Chemical	D007213
Entity: 12559315	74	95	interstitial cystitis	Disease	D018856
Entity: 12559315	142	154	mastocytosis	Disease	D008415
Relation: 12559315	CID	13	25	D007213	74	95	D018856	true
Relation: 12559315	CID	13	25	D007213	142	154	D008415	true

Sentence: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.
Entity: 12644816	41	52	thalidomide	Chemical	D013792
Entity: 12644816	56	64	androgen	Chemical	D000728
Entity: 12644816	77	92	prostate cancer	Disease	D011471
Relation: 12644816	CID	41	52	D013792	77	92	D011471	false
Relation: 12644816	CID	56	64	D000728	77	92	D011471	false

Sentence: The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies.
Entity: 12644816	30	41	thalidomide	Chemical	D013792
Entity: 12644816	115	142	haematological malignancies	Disease	D019337
Relation: 12644816	CID	30	41	D013792	115	142	D019337	false

Sentence: We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer.
Entity: 12644816	39	50	thalidomide	Chemical	D013792
Entity: 12644816	103	111	androgen	Chemical	D000728
Entity: 12644816	124	139	prostate cancer	Disease	D011471
Relation: 12644816	CID	39	50	D013792	124	139	D011471	false
Relation: 12644816	CID	103	111	D000728	124	139	D011471	false

Sentence: In the seven men who completed six months on thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing.
Entity: 12644816	45	56	thalidomide	Chemical	D013792
Entity: 12644816	82	103	peripheral neuropathy	Disease	D010523
Relation: 12644816	CID	45	56	D013792	82	103	D010523	true

Sentence: Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases.
Entity: 12677626	0	31	Central nervous system toxicity	Disease	D020258
Entity: 12677626	64	79	levobupivacaine	Chemical	C476513
Relation: 12677626	CID	64	79	C476513	0	31	D020258	false

Sentence: We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine.
Entity: 12677626	23	41	grand mal seizures	Disease	D004830
Entity: 12677626	90	105	levobupivacaine	Chemical	C476513
Relation: 12677626	CID	90	105	C476513	23	41	D004830	true

Sentence: Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.
Entity: 12677626	40	55	levobupivacaine	Chemical	C476513
Entity: 12677626	66	77	epinephrine	Chemical	D004837
Entity: 12677626	119	137	grand mal seizures	Disease	D004830
Entity: 12677626	214	225	epinephrine	Chemical	D004837
Relation: 12677626	CID	40	55	C476513	119	137	D004830	true
Relation: 12677626	CID	66	77	D004837	119	137	D004830	false
Relation: 12677626	CID	214	225	D004837	119	137	D004830	false

Sentence: The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.
Entity: 12677626	4	12	seizures	Disease	D012640
Entity: 12677626	44	61	sodium thiopental	Chemical	D013874
Entity: 12677626	77	92	succinylcholine	Chemical	D013390
Relation: 12677626	CID	44	61	D013874	4	12	D012640	false
Relation: 12677626	CID	77	92	D013390	4	12	D012640	false

Sentence: CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.
Entity: 12677626	22	37	levobupivacaine	Chemical	C476513
Entity: 12677626	55	71	cardiac toxicity	Disease	D066126
Entity: 12677626	93	104	bupivacaine	Chemical	D002045
Entity: 12677626	129	144	levobupivacaine	Chemical	C476513
Entity: 12677626	186	197	convulsions	Disease	D012640
Relation: 12677626	CID	22	37	C476513	55	71	D066126	false
Relation: 12677626	CID	22	37	C476513	186	197	D012640	false
Relation: 12677626	CID	93	104	D002045	55	71	D066126	false
Relation: 12677626	CID	93	104	D002045	186	197	D012640	false
Relation: 12677626	CID	129	144	C476513	55	71	D066126	false
Relation: 12677626	CID	129	144	C476513	186	197	D012640	false

Sentence: Myotonia congenita (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.
Entity: 12699527	0	18	Myotonia congenita	Disease	D009224
Entity: 12699527	20	22	MC	Disease	D009224
Entity: 12699527	69	77	chloride	Chemical	D002712
Entity: 12699527	112	145	sustained membrane depolarisation	Disease	-1
Relation: 12699527	CID	69	77	D002712	0	18	D009224	false
Relation: 12699527	CID	69	77	D002712	20	22	D009224	false
Relation: 12699527	CID	69	77	D002712	112	145	-1	false

Sentence: We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium.
Entity: 12699527	84	96	muscle spasm	Disease	D013035
Entity: 12699527	174	187	suxamethonium	Chemical	D013390
Relation: 12699527	CID	174	187	D013390	84	96	D013035	true

Sentence: Here we sought to generate information with regard to the interictal period in animals with pilocarpine induced epilepsy.
Entity: 12752472	92	103	pilocarpine	Chemical	D010862
Entity: 12752472	112	120	epilepsy	Disease	D004827
Relation: 12752472	CID	92	103	D010862	112	120	D004827	true

Sentence: RESULTS: The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine-treated and control rats.
Entity: 12752472	13	29	hyperventilation	Disease	D006985
Entity: 12752472	87	98	pilocarpine	Chemical	D010862
Relation: 12752472	CID	87	98	D010862	13	29	D006985	false

Sentence: Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
Entity: 12828076	45	64	acute liver failure	Disease	D017114
Entity: 12828076	72	83	paracetamol	Chemical	D000082
Entity: 12828076	84	92	overdose	Disease	D062787
Relation: 12828076	CID	72	83	D000082	45	64	D017114	true
Relation: 12828076	CID	72	83	D000082	84	92	D062787	false

Sentence: Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).
Entity: 12828076	51	70	acute liver failure	Disease	D017114
Entity: 12828076	78	89	paracetamol	Chemical	D000082
Entity: 12828076	90	98	overdose	Disease	D062787
Entity: 12828076	179	188	hepatitis	Disease	D056486
Relation: 12828076	CID	78	89	D000082	51	70	D017114	true
Relation: 12828076	CID	78	89	D000082	90	98	D062787	false
Relation: 12828076	CID	78	89	D000082	179	188	D056486	false

Sentence: METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa induced dyskinesias underwent bilateral implantation of electrodes in the STN.
Entity: 12865514	52	71	Parkinson's disease	Disease	D010300
Entity: 12865514	129	141	bradykinesia	Disease	D018476
Entity: 12865514	143	151	rigidity	Disease	D009127
Entity: 12865514	157	165	levodopa	Chemical	D007980
Entity: 12865514	174	185	dyskinesias	Disease	D004409
Relation: 12865514	CID	157	165	D007980	52	71	D010300	false
Relation: 12865514	CID	157	165	D007980	129	141	D018476	false
Relation: 12865514	CID	157	165	D007980	143	151	D009127	false
Relation: 12865514	CID	157	165	D007980	174	185	D004409	true

Sentence: Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.
Entity: 12912689	39	50	carboplatin	Chemical	D016190
Entity: 12912689	68	82	retinoblastoma	Disease	D012175
Relation: 12912689	CID	39	50	D016190	68	82	D012175	false

Sentence: BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma.
Entity: 12912689	27	38	carboplatin	Chemical	D016190
Entity: 12912689	90	98	toxicity	Disease	D064420
Entity: 12912689	153	167	retinoblastoma	Disease	D012175
Relation: 12912689	CID	27	38	D016190	90	98	D064420	false
Relation: 12912689	CID	27	38	D016190	153	167	D012175	false

Sentence: OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.
Entity: 12912689	50	74	abnormal ocular motility	Disease	D015835
Entity: 12912689	109	120	carboplatin	Chemical	D016190
Relation: 12912689	CID	109	120	D016190	50	74	D015835	true

Sentence: METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.
Entity: 12912689	18	42	abnormal ocular motility	Disease	D015835
Entity: 12912689	75	89	retinoblastoma	Disease	D012175
Entity: 12912689	116	127	carboplatin	Chemical	D016190
Relation: 12912689	CID	116	127	D016190	18	42	D015835	true
Relation: 12912689	CID	116	127	D016190	75	89	D012175	false

Sentence: RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.
Entity: 12912689	106	120	retinoblastoma	Disease	D012175
Entity: 12912689	156	167	carboplatin	Chemical	D016190
Relation: 12912689	CID	156	167	D016190	106	120	D012175	false

Sentence: CONCLUSIONS: Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.
Entity: 12912689	22	33	carboplatin	Chemical	D016190
Entity: 12912689	78	86	fibrosis	Disease	D005355
Relation: 12912689	CID	22	33	D016190	78	86	D005355	true

Sentence: Ethambutol and optic neuropathy.
Entity: 12948256	0	10	Ethambutol	Chemical	D004977
Entity: 12948256	15	31	optic neuropathy	Disease	D009901
Relation: 12948256	CID	0	10	D004977	15	31	D009901	true

Sentence: PURPOSE: To demonstrate the association between ethambutol and optic neuropathy.
Entity: 12948256	48	58	ethambutol	Chemical	D004977
Entity: 12948256	63	79	optic neuropathy	Disease	D009901
Relation: 12948256	CID	48	58	D004977	63	79	D009901	true

Sentence: METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.
Entity: 12948256	40	56	optic neuropathy	Disease	D009901
Entity: 12948256	82	92	ethambutol	Chemical	D004977
Entity: 12948256	97	109	tuberculosis	Disease	D014397
Entity: 12948256	97	109	tuberculosis	Disease	D014388
Relation: 12948256	CID	82	92	D004977	40	56	D009901	true
Relation: 12948256	CID	82	92	D004977	97	109	D014397	false
Relation: 12948256	CID	82	92	D004977	97	109	D014388	false

Sentence: RESULTS: All patients had optic neuropathy between 1 to 6 months (mean = 2.9 months) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day).
Entity: 12948256	26	42	optic neuropathy	Disease	D009901
Entity: 12948256	100	110	ethambutol	Chemical	D004977
Relation: 12948256	CID	100	110	D004977	26	42	D009901	true

Sentence: CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ethambutol therapy.
Entity: 12948256	33	49	optic neuropathy	Disease	D009901
Entity: 12948256	88	98	ethambutol	Chemical	D004977
Relation: 12948256	CID	88	98	D004977	33	49	D009901	true

Sentence: Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate.
Entity: 12950111	26	49	gustatory hyperhidrosis	Disease	D013547
Entity: 12950111	63	77	glycopyrrolate	Chemical	D006024
Relation: 12950111	CID	63	77	D006024	26	49	D013547	false

Sentence: After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%).
Entity: 12950111	23	37	glycopyrrolate	Chemical	D006024
Entity: 12950111	79	87	sweating	Disease	D013547
Entity: 12950111	165	173	sweating	Disease	D013547
Relation: 12950111	CID	23	37	D006024	79	87	D013547	false
Relation: 12950111	CID	23	37	D006024	165	173	D013547	false

Sentence: Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).
Entity: 12950111	34	43	dry mouth	Disease	D014987
Entity: 12950111	50	61	sore throat	Disease	D010612
Entity: 12950111	80	94	glycopyrrolate	Chemical	D006024
Entity: 12950111	105	113	headache	Disease	D006261
Entity: 12950111	133	147	glycopyrrolate	Chemical	D006024
Relation: 12950111	CID	80	94	D006024	34	43	D014987	false
Relation: 12950111	CID	80	94	D006024	50	61	D010612	true
Relation: 12950111	CID	80	94	D006024	105	113	D006261	true
Relation: 12950111	CID	133	147	D006024	34	43	D014987	false
Relation: 12950111	CID	133	147	D006024	50	61	D010612	true
Relation: 12950111	CID	133	147	D006024	105	113	D006261	true

Sentence: Pain on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with Disoprivan.
Entity: 14616590	0	4	Pain	Disease	D010146
Entity: 14616590	45	61	thrombophlebitis	Disease	D013924
Entity: 14616590	135	145	Disoprivan	Chemical	D015742
Relation: 14616590	CID	135	145	D015742	0	4	D010146	true
Relation: 14616590	CID	135	145	D015742	45	61	D013924	true

Sentence: In order to quantify the incidence of these cardiac events, we performed a meta-analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies.
Entity: 14748761	118	121	VNR	Chemical	C030852
Entity: 14748761	185	197	malignancies	Disease	D009369
Relation: 14748761	CID	118	121	C030852	185	197	D009369	false

Sentence: Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002.
Entity: 14748761	37	40	VNR	Chemical	C030852
Entity: 14748761	78	84	cancer	Disease	D009369
Relation: 14748761	CID	37	40	C030852	78	84	D009369	false

Sentence: The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].
Entity: 14748761	12	15	VNR	Chemical	C030852
Entity: 14748761	46	55	vindesine	Chemical	D014751
Entity: 14748761	57	60	VDS	Chemical	D014751
Entity: 14748761	72	83	cardiotoxic	Disease	D066126
Entity: 14748761	91	103	fluorouracil	Chemical	D005472
Entity: 14748761	105	119	anthracyclines	Chemical	D018943
Entity: 14748761	121	132	gemcitabine	Chemical	C056507
Entity: 14748761	134	137	GEM	Chemical	C056507
Relation: 14748761	CID	12	15	C030852	72	83	D066126	true
Relation: 14748761	CID	46	55	D014751	72	83	D066126	false
Relation: 14748761	CID	57	60	D014751	72	83	D066126	false
Relation: 14748761	CID	91	103	D005472	72	83	D066126	false
Relation: 14748761	CID	105	119	D018943	72	83	D066126	false
Relation: 14748761	CID	121	132	C056507	72	83	D066126	false
Relation: 14748761	CID	134	137	C056507	72	83	D066126	false

Sentence: We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.
Entity: 15018178	97	113	hemolytic anemia	Disease	D000743
Entity: 15018178	132	161	trimethoprim-sulfomethoxazole	Chemical	D015662
Entity: 15018178	176	191	cerebral anoxia	Disease	D002534
Relation: 15018178	CID	132	161	D015662	97	113	D000743	true
Relation: 15018178	CID	132	161	D015662	176	191	D002534	false

Sentence: The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
Entity: 15094729	23	33	Vigabatrin	Chemical	D020888
Entity: 15094729	45	65	visual field defects	Disease	D014786
Relation: 15094729	CID	23	33	D020888	45	65	D014786	true

Sentence: PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.
Entity: 15094729	45	65	visual field defects	Disease	D014786
Entity: 15094729	103	113	Vigabatrin	Chemical	D020888
Entity: 15094729	188	195	seizure	Disease	D012640
Relation: 15094729	CID	103	113	D020888	45	65	D014786	true
Relation: 15094729	CID	103	113	D020888	188	195	D012640	false

Sentence: CONCLUSION: Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.
Entity: 15094729	24	44	visual field defects	Disease	D014786
Entity: 15094729	67	77	Vigabatrin	Chemical	D020888
Relation: 15094729	CID	67	77	D020888	24	44	D014786	true

Sentence: Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
Entity: 15096374	25	35	dermatitis	Disease	D003872
Entity: 15096374	56	86	facial inflammatory dermatoses	Disease	D005148
Entity: 15096374	92	102	tacrolimus	Chemical	D016559
Relation: 15096374	CID	92	102	D016559	25	35	D003872	false
Relation: 15096374	CID	92	102	D016559	56	86	D005148	false

Sentence: BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.
Entity: 15096374	12	22	Tacrolimus	Chemical	D016559
Entity: 15096374	190	197	steroid	Chemical	D013256
Entity: 15096374	209	216	rosacea	Disease	D012393
Entity: 15096374	221	240	perioral dermatitis	Disease	D019557
Relation: 15096374	CID	12	22	D016559	209	216	D012393	true
Relation: 15096374	CID	12	22	D016559	221	240	D019557	false
Relation: 15096374	CID	190	197	D013256	209	216	D012393	false
Relation: 15096374	CID	190	197	D013256	221	240	D019557	false

Sentence: We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.
Entity: 15096374	25	35	dermatitis	Disease	D003872
Entity: 15096374	72	82	tacrolimus	Chemical	D016559
Relation: 15096374	CID	72	82	D016559	25	35	D003872	false

Sentence: OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments.
Entity: 15096374	38	68	inflammatory facial dermatoses	Disease	D005148
Entity: 15096374	87	97	tacrolimus	Chemical	D016559
Relation: 15096374	CID	87	97	D016559	38	68	D005148	false

Sentence: CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous.
Entity: 15096374	71	81	dermatitis	Disease	D003872
Entity: 15096374	118	128	tacrolimus	Chemical	D016559
Relation: 15096374	CID	118	128	D016559	71	81	D003872	false

Sentence: We visualize, for the first time, the profile of structural deficits in the human brain associated with chronic methamphetamine (MA) abuse.
Entity: 15229250	49	87	structural deficits in the human brain	Disease	D001930
Entity: 15229250	112	127	methamphetamine	Chemical	D008694
Entity: 15229250	129	131	MA	Chemical	D008694
Relation: 15229250	CID	112	127	D008694	49	87	D001930	true
Relation: 15229250	CID	129	131	D008694	49	87	D001930	true

Sentence: Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.
Entity: 15229250	40	42	MA	Chemical	D008694
Entity: 15229250	132	155	metabolic abnormalities	Disease	D008659
Relation: 15229250	CID	40	42	D008694	132	155	D008659	false

Sentence: Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment.
Entity: 15229250	169	171	MA	Chemical	D008694
Entity: 15229250	226	246	cognitive impairment	Disease	D003072
Relation: 15229250	CID	169	171	D008694	226	246	D003072	false

Sentence: We used high-resolution MRI and surface-based computational image analyses to map regional abnormalities in the cortex, hippocampus, white matter, and ventricles in 22 human subjects who used MA and 21 age-matched, healthy controls.
Entity: 15229250	91	161	abnormalities in the cortex, hippocampus, white matter, and ventricles	Disease	D001930
Entity: 15229250	192	194	MA	Chemical	D008694
Relation: 15229250	CID	192	194	D008694	91	161	D001930	true

Sentence: On average, MA abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter hypertrophy (7.0%; p < 0.01).
Entity: 15229250	12	14	MA	Chemical	D008694
Entity: 15229250	155	166	hypertrophy	Disease	D006984
Relation: 15229250	CID	12	14	D008694	155	166	D006984	false

Sentence: MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance.
Entity: 15229250	36	51	methamphetamine	Chemical	D008694
Entity: 15229250	131	158	impaired memory performance	Disease	D008569
Relation: 15229250	CID	36	51	D008694	131	158	D008569	true

Sentence: Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause hepatotoxicity in some patients.
Entity: 15265979	0	10	Amiodarone	Chemical	D000638
Entity: 15265979	92	106	hepatotoxicity	Disease	D056486
Relation: 15265979	CID	0	10	D000638	92	106	D056486	true

Sentence: Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.
Entity: 15265979	0	10	Amiodarone	Chemical	D000638
Entity: 15265979	19	31	hepatomegaly	Disease	D006529
Entity: 15265979	115	128	triglycerides	Chemical	D014280
Entity: 15265979	133	140	glucose	Chemical	D005947
Relation: 15265979	CID	0	10	D000638	19	31	D006529	true
Relation: 15265979	CID	115	128	D014280	19	31	D006529	false
Relation: 15265979	CID	133	140	D005947	19	31	D006529	false

Sentence: The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.
Entity: 15265979	51	63	hepatomegaly	Disease	D006529
Entity: 15265979	136	146	amiodarone	Chemical	D000638
Relation: 15265979	CID	136	146	D000638	51	63	D006529	true

Sentence: Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss.
Entity: 15265979	64	74	amiodarone	Chemical	D000638
Entity: 15265979	130	141	weight loss	Disease	D015431
Relation: 15265979	CID	64	74	D000638	130	141	D015431	false

Sentence: The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.
Entity: 15265979	17	27	amiodarone	Chemical	D000638
Entity: 15265979	118	126	hepatoma	Disease	D006528
Entity: 15265979	163	173	amiodarone	Chemical	D000638
Relation: 15265979	CID	17	27	D000638	118	126	D006528	false
Relation: 15265979	CID	163	173	D000638	118	126	D006528	false

Sentence: Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.
Entity: 15276093	0	34	Niacin extended-release/lovastatin	Chemical	C451780
Entity: 15276093	98	118	hypercholesterolemia	Disease	D006937
Entity: 15276093	129	141	dyslipidemia	Disease	D050171
Relation: 15276093	CID	0	34	C451780	98	118	D006937	false
Relation: 15276093	CID	0	34	C451780	129	141	D050171	false

Sentence: Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin.
Entity: 15276093	145	157	dyslipidemia	Disease	D050171
Entity: 15276093	162	196	niacin extended-release/lovastatin	Chemical	C451780
Relation: 15276093	CID	162	196	C451780	145	157	D050171	false

Sentence: An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug induced myopathy were observed.
Entity: 15276093	15	23	creatine	Chemical	D003401
Entity: 15276093	136	144	myopathy	Disease	D009135
Relation: 15276093	CID	15	23	D003401	136	144	D009135	false

Sentence: Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.
Entity: 15282950	21	39	Terminalia chebula	Chemical	D010936
Entity: 15282950	61	78	myocardial injury	Disease	D009202
Entity: 15282950	90	103	isoproterenol	Chemical	D007545
Relation: 15282950	CID	21	39	D010936	61	78	D009202	false
Relation: 15282950	CID	90	103	D007545	61	78	D009202	true

Sentence: Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced myocardial damage in rats.
Entity: 15282950	27	73	ethanolic extract of Terminalia chebula fruits	Chemical	D010936
Entity: 15282950	110	123	isoproterenol	Chemical	D007545
Entity: 15282950	152	169	myocardial damage	Disease	D009202
Relation: 15282950	CID	27	73	D010936	152	169	D009202	false
Relation: 15282950	CID	110	123	D007545	152	169	D009202	true

Sentence: A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.
Entity: 15321332	24	31	anxiety	Disease	D001008
Entity: 15321332	48	58	droperidol	Chemical	D004329
Relation: 15321332	CID	48	58	D004329	24	31	D001008	true

Sentence: The diagnosis of droperidol induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history.
Entity: 15321332	17	27	droperidol	Chemical	D004329
Entity: 15321332	36	61	psychological disturbance	Disease	D001008
Relation: 15321332	CID	17	27	D004329	36	61	D001008	true

Sentence: The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing lithium use.
Entity: 15366550	102	112	polydipsia	Disease	D059606
Entity: 15366550	131	138	lithium	Chemical	D008094
Relation: 15366550	CID	131	138	D008094	102	112	D059606	false

Sentence: Lithium is implicated in drug induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.
Entity: 15366550	0	7	Lithium	Chemical	D008094
Entity: 15366550	38	52	nephrogenic DI	Disease	D018500
Entity: 15366550	95	102	lithium	Chemical	D008094
Entity: 15366550	175	189	nephrogenic DI	Disease	D018500
Relation: 15366550	CID	0	7	D008094	38	52	D018500	true
Relation: 15366550	CID	0	7	D008094	175	189	D018500	true
Relation: 15366550	CID	95	102	D008094	38	52	D018500	true
Relation: 15366550	CID	95	102	D008094	175	189	D018500	true

Sentence: By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.
Entity: 15366550	196	203	lithium	Chemical	D008094
Entity: 15366550	212	226	nephrogenic DI	Disease	D018500
Entity: 15366550	241	254	neurogenic DI	Disease	D018500
Entity: 15366550	268	280	brain trauma	Disease	D001930
Relation: 15366550	CID	196	203	D008094	212	226	D018500	true
Relation: 15366550	CID	196	203	D008094	241	254	D018500	true
Relation: 15366550	CID	196	203	D008094	268	280	D001930	false

Sentence: Factors contributing to ribavirin induced anemia.
Entity: 15482540	24	33	ribavirin	Chemical	D012254
Entity: 15482540	42	48	anemia	Disease	D000740
Relation: 15482540	CID	24	33	D012254	42	48	D000740	false

Sentence: BACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.
Entity: 15482540	20	30	Interferon	Chemical	D016898
Entity: 15482540	35	44	ribavirin	Chemical	D012254
Entity: 15482540	69	88	chronic hepatitis C	Disease	D019698
Entity: 15482540	98	114	hemolytic anemia	Disease	D000743
Relation: 15482540	CID	20	30	D016898	69	88	D019698	false
Relation: 15482540	CID	20	30	D016898	98	114	D000743	true
Relation: 15482540	CID	35	44	D012254	69	88	D019698	false
Relation: 15482540	CID	35	44	D012254	98	114	D000743	true

Sentence: This study was conducted to identify the factors contributing to ribavirin induced anemia.
Entity: 15482540	65	74	ribavirin	Chemical	D012254
Entity: 15482540	83	89	anemia	Disease	D000740
Relation: 15482540	CID	65	74	D012254	83	89	D000740	false

Sentence: METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.
Entity: 15482540	36	55	chronic hepatitis C	Disease	D019698
Entity: 15482540	69	88	interferon-alpha-2b	Chemical	D016898
Entity: 15482540	169	178	ribavirin	Chemical	D012254
Relation: 15482540	CID	69	88	D016898	36	55	D019698	false
Relation: 15482540	CID	169	178	D012254	36	55	D019698	false

Sentence: A hemoglobin concentration of <10 g/dL was defined as ribavirin induced anemia.
Entity: 15482540	54	63	ribavirin	Chemical	D012254
Entity: 15482540	72	78	anemia	Disease	D000740
Relation: 15482540	CID	54	63	D012254	72	78	D000740	false

Sentence: RESULTS: Ribavirin induced anemia occurred in 18 (20.5%) patients during treatment.
Entity: 15482540	9	18	Ribavirin	Chemical	D012254
Entity: 15482540	27	33	anemia	Disease	D000740
Relation: 15482540	CID	9	18	D012254	27	33	D000740	false

Sentence: Oxidative damage precedes nitrative damage in adriamycin induced cardiac mitochondrial injury.
Entity: 15605432	46	56	adriamycin	Chemical	D004317
Entity: 15605432	73	93	mitochondrial injury	Disease	D028361
Relation: 15605432	CID	46	56	D004317	73	93	D028361	true

Sentence: The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR) induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.
Entity: 15605432	71	77	oxygen	Chemical	D010100
Entity: 15605432	84	92	nitrogen	Chemical	D009584
Entity: 15605432	133	143	adriamycin	Chemical	D004317
Entity: 15605432	145	148	ADR	Chemical	D004317
Entity: 15605432	158	172	cardiotoxicity	Disease	D066126
Relation: 15605432	CID	71	77	D010100	158	172	D066126	false
Relation: 15605432	CID	84	92	D009584	158	172	D066126	false
Relation: 15605432	CID	133	143	D004317	158	172	D066126	false
Relation: 15605432	CID	145	148	D004317	158	172	D066126	false

Sentence: Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared.
Entity: 15605432	16	19	ADR	Chemical	D004317
Entity: 15605432	28	32	4HNE	Chemical	C027576
Entity: 15605432	96	116	mitochondrial injury	Disease	D028361
Relation: 15605432	CID	16	19	D004317	96	116	D028361	true
Relation: 15605432	CID	28	32	C027576	96	116	D028361	false

Sentence: Sotalol induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.
Entity: 15609701	0	7	Sotalol	Chemical	D013015
Entity: 15609701	16	30	coronary spasm	Disease	D003329
Entity: 15609701	49	71	dilated cardiomyopathy	Disease	D002311
Entity: 15609701	98	121	ventricular tachycardia	Disease	D017180
Relation: 15609701	CID	0	7	D013015	16	30	D003329	true
Relation: 15609701	CID	0	7	D013015	49	71	D002311	false
Relation: 15609701	CID	0	7	D013015	98	121	D017180	false

Sentence: After the administration of nifekalant hydrochloride, sustained VT was terminated.
Entity: 15609701	28	52	nifekalant hydrochloride	Chemical	C076259
Entity: 15609701	64	66	VT	Disease	D017180
Relation: 15609701	CID	28	52	C076259	64	66	D017180	false

Sentence: An alternate class III agent, sotalol, was also effective for the prevention of VT.
Entity: 15609701	30	37	sotalol	Chemical	D013015
Entity: 15609701	80	82	VT	Disease	D017180
Relation: 15609701	CID	30	37	D013015	80	82	D017180	false

Sentence: METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine induced wet dog shake (WDS) behavior and fluoxetine induced penile erections was studied in rats.
Entity: 15614572	41	50	trazodone	Chemical	D014196
Entity: 15614572	54	68	dexamphetamine	Chemical	D003913
Entity: 15614572	74	85	apomorphine	Chemical	D001058
Entity: 15614572	94	111	oral stereotypies	Disease	D009062
Entity: 15614572	116	125	catalepsy	Disease	D002375
Entity: 15614572	137	148	haloperidol	Chemical	D006220
Entity: 15614572	153	164	apomorphine	Chemical	D001058
Entity: 15614572	188	199	ergometrine	Chemical	D004874
Entity: 15614572	241	251	fluoxetine	Chemical	D005473
Relation: 15614572	CID	41	50	D014196	94	111	D009062	false
Relation: 15614572	CID	41	50	D014196	116	125	D002375	false
Relation: 15614572	CID	54	68	D003913	94	111	D009062	false
Relation: 15614572	CID	54	68	D003913	116	125	D002375	false
Relation: 15614572	CID	74	85	D001058	94	111	D009062	false
Relation: 15614572	CID	74	85	D001058	116	125	D002375	true
Relation: 15614572	CID	137	148	D006220	94	111	D009062	false
Relation: 15614572	CID	137	148	D006220	116	125	D002375	true
Relation: 15614572	CID	153	164	D001058	94	111	D009062	false
Relation: 15614572	CID	153	164	D001058	116	125	D002375	true
Relation: 15614572	CID	188	199	D004874	94	111	D009062	false
Relation: 15614572	CID	188	199	D004874	116	125	D002375	false
Relation: 15614572	CID	241	251	D005473	94	111	D009062	false
Relation: 15614572	CID	241	251	D005473	116	125	D002375	false

Sentence: We also investigated whether trazodone induces catalepsy in rats.
Entity: 15614572	29	38	trazodone	Chemical	D014196
Entity: 15614572	47	56	catalepsy	Disease	D002375
Relation: 15614572	CID	29	38	D014196	47	56	D002375	false

Sentence: RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg) induced catalepsy.
Entity: 15614572	9	18	Trazodone	Chemical	D014196
Entity: 15614572	55	64	catalepsy	Disease	D002375
Entity: 15614572	89	100	apomorphine	Chemical	D001058
Entity: 15614572	134	145	apomorphine	Chemical	D001058
Entity: 15614572	167	176	catalepsy	Disease	D002375
Relation: 15614572	CID	9	18	D014196	55	64	D002375	false
Relation: 15614572	CID	9	18	D014196	167	176	D002375	false
Relation: 15614572	CID	89	100	D001058	55	64	D002375	true
Relation: 15614572	CID	89	100	D001058	167	176	D002375	true
Relation: 15614572	CID	134	145	D001058	55	64	D002375	true
Relation: 15614572	CID	134	145	D001058	167	176	D002375	true

Sentence: However, pretreatment with 5, 10 and 20 mg/kg i.p. trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine induced WDS behavior and fluoxetine induced penile erections.
Entity: 15614572	51	60	trazodone	Chemical	D014196
Entity: 15614572	70	84	dexamphetamine	Chemical	D003913
Entity: 15614572	113	124	haloperidol	Chemical	D006220
Entity: 15614572	125	134	catalepsy	Disease	D002375
Entity: 15614572	136	147	ergometrine	Chemical	D004874
Entity: 15614572	173	183	fluoxetine	Chemical	D005473
Relation: 15614572	CID	51	60	D014196	125	134	D002375	false
Relation: 15614572	CID	70	84	D003913	125	134	D002375	false
Relation: 15614572	CID	113	124	D006220	125	134	D002375	true
Relation: 15614572	CID	136	147	D004874	125	134	D002375	false
Relation: 15614572	CID	173	183	D005473	125	134	D002375	false

Sentence: Trazodone at 30, 40 and 50 mg/kg i.p. induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.
Entity: 15614572	0	9	Trazodone	Chemical	D014196
Entity: 15614572	46	55	catalepsy	Disease	D002375
Entity: 15614572	72	83	apomorphine	Chemical	D001058
Entity: 15614572	88	102	dexamphetamine	Chemical	D003913
Relation: 15614572	CID	0	9	D014196	46	55	D002375	false
Relation: 15614572	CID	72	83	D001058	46	55	D002375	true
Relation: 15614572	CID	88	102	D003913	46	55	D002375	false

Sentence: The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa induced dyskinesia.
Entity: 15625689	72	74	PD	Disease	D010300
Entity: 15625689	101	109	levodopa	Chemical	D007980
Entity: 15625689	118	128	dyskinesia	Disease	D004409
Relation: 15625689	CID	101	109	D007980	72	74	D010300	false
Relation: 15625689	CID	101	109	D007980	118	128	D004409	true

Sentence: In the current study, dyskinetic patients performed better in swallowing function, which could be explained on the basis of a greater levodopa dose.
Entity: 15625689	22	32	dyskinetic	Disease	D004409
Entity: 15625689	134	142	levodopa	Chemical	D007980
Relation: 15625689	CID	134	142	D007980	22	32	D004409	true

Sentence: Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.
Entity: 15627798	58	86	tubulointerstitial nephritis	Disease	D009395
Entity: 15627798	98	108	gentamicin	Chemical	D005839
Relation: 15627798	CID	98	108	D005839	58	86	D009395	true

Sentence: BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex.
Entity: 15627798	33	43	gentamicin	Chemical	D005839
Entity: 15627798	84	92	fibrosis	Disease	D005355
Relation: 15627798	CID	33	43	D005839	84	92	D005355	false

Sentence: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Entity: 15630069	0	7	Glucose	Chemical	D005947
Entity: 15630069	36	49	schizophrenia	Disease	D012559
Entity: 15630069	127	134	glucose	Chemical	D005947
Relation: 15630069	CID	0	7	D005947	36	49	D012559	false
Relation: 15630069	CID	127	134	D005947	36	49	D012559	false

Sentence: BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.
Entity: 15630069	45	62	diabetes mellitus	Disease	D003920
Entity: 15630069	98	111	schizophrenia	Disease	D012559
Entity: 15630069	230	237	glucose	Chemical	D005947
Entity: 15630069	293	301	diabetes	Disease	D003920
Relation: 15630069	CID	230	237	D005947	45	62	D003920	false
Relation: 15630069	CID	230	237	D005947	98	111	D012559	false
Relation: 15630069	CID	230	237	D005947	293	301	D003920	false

Sentence: DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.
Entity: 15630069	66	79	schizophrenia	Disease	D012559
Entity: 15630069	129	136	glucose	Chemical	D005947
Relation: 15630069	CID	129	136	D005947	66	79	D012559	false

Sentence: Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.
Entity: 15630069	34	47	schizophrenia	Disease	D012559
Entity: 15630069	51	75	schizoaffective disorder	Disease	D011618
Entity: 15630069	128	137	clozapine	Chemical	D003024
Entity: 15630069	139	149	olanzapine	Chemical	C076029
Entity: 15630069	154	165	risperidone	Chemical	D018967
Relation: 15630069	CID	128	137	D003024	34	47	D012559	false
Relation: 15630069	CID	128	137	D003024	51	75	D011618	false
Relation: 15630069	CID	139	149	C076029	34	47	D012559	false
Relation: 15630069	CID	139	149	C076029	51	75	D011618	false
Relation: 15630069	CID	154	165	D018967	34	47	D012559	false
Relation: 15630069	CID	154	165	D018967	51	75	D011618	false

Sentence: MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.
Entity: 15630069	38	45	glucose	Chemical	D005947
Entity: 15630069	80	99	insulin sensitivity	Disease	D007333
Entity: 15630069	139	157	insulin resistance	Disease	D007333
Entity: 15630069	163	170	glucose	Chemical	D005947
Relation: 15630069	CID	38	45	D005947	80	99	D007333	false
Relation: 15630069	CID	38	45	D005947	139	157	D007333	false
Relation: 15630069	CID	163	170	D005947	80	99	D007333	false
Relation: 15630069	CID	163	170	D005947	139	157	D007333	false

Sentence: There was a significant difference in insulin sensitivity index among groups (F(33) = 10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t(33) = -4.29; P<.001; olanzapine vs risperidone, t(33) = -3.62; P = .001 [P<.001]).
Entity: 15630069	38	57	insulin sensitivity	Disease	D007333
Entity: 15630069	102	111	clozapine	Chemical	D003024
Entity: 15630069	112	122	olanzapine	Chemical	C076029
Entity: 15630069	123	134	risperidone	Chemical	D018967
Entity: 15630069	164	173	clozapine	Chemical	D003024
Entity: 15630069	178	188	olanzapine	Chemical	C076029
Entity: 15630069	212	230	insulin resistance	Disease	D007333
Entity: 15630069	276	287	risperidone	Chemical	D018967
Entity: 15630069	289	298	clozapine	Chemical	D003024
Entity: 15630069	302	313	risperidone	Chemical	D018967
Entity: 15630069	338	348	olanzapine	Chemical	C076029
Entity: 15630069	352	363	risperidone	Chemical	D018967
Relation: 15630069	CID	102	111	D003024	38	57	D007333	true
Relation: 15630069	CID	102	111	D003024	212	230	D007333	true
Relation: 15630069	CID	112	122	C076029	38	57	D007333	true
Relation: 15630069	CID	112	122	C076029	212	230	D007333	true
Relation: 15630069	CID	123	134	D018967	38	57	D007333	false
Relation: 15630069	CID	123	134	D018967	212	230	D007333	false
Relation: 15630069	CID	164	173	D003024	38	57	D007333	true
Relation: 15630069	CID	164	173	D003024	212	230	D007333	true
Relation: 15630069	CID	178	188	C076029	38	57	D007333	true
Relation: 15630069	CID	178	188	C076029	212	230	D007333	true
Relation: 15630069	CID	276	287	D018967	38	57	D007333	false
Relation: 15630069	CID	276	287	D018967	212	230	D007333	false
Relation: 15630069	CID	289	298	D003024	38	57	D007333	true
Relation: 15630069	CID	289	298	D003024	212	230	D007333	true
Relation: 15630069	CID	302	313	D018967	38	57	D007333	false
Relation: 15630069	CID	302	313	D018967	212	230	D007333	false
Relation: 15630069	CID	338	348	C076029	38	57	D007333	true
Relation: 15630069	CID	338	348	C076029	212	230	D007333	true
Relation: 15630069	CID	352	363	D018967	38	57	D007333	false
Relation: 15630069	CID	352	363	D018967	212	230	D007333	false

Sentence: The homeostasis model assessment of insulin resistance also differed significantly among groups (F(33) = 4.92; P = .01) (clozapine>olanzapine>risperidone) (clozapine vs risperidone, t(33) = 2.94; P = .006; olanzapine vs risperidone, t(33) = 2.42; P = .02).
Entity: 15630069	36	54	insulin resistance	Disease	D007333
Entity: 15630069	121	130	clozapine	Chemical	D003024
Entity: 15630069	131	141	olanzapine	Chemical	C076029
Entity: 15630069	142	153	risperidone	Chemical	D018967
Entity: 15630069	156	165	clozapine	Chemical	D003024
Entity: 15630069	169	180	risperidone	Chemical	D018967
Entity: 15630069	206	216	olanzapine	Chemical	C076029
Entity: 15630069	220	231	risperidone	Chemical	D018967
Relation: 15630069	CID	121	130	D003024	36	54	D007333	true
Relation: 15630069	CID	131	141	C076029	36	54	D007333	true
Relation: 15630069	CID	142	153	D018967	36	54	D007333	false
Relation: 15630069	CID	156	165	D003024	36	54	D007333	true
Relation: 15630069	CID	169	180	D018967	36	54	D007333	false
Relation: 15630069	CID	206	216	C076029	36	54	D007333	true
Relation: 15630069	CID	220	231	D018967	36	54	D007333	false

Sentence: CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.
Entity: 15630069	27	36	clozapine	Chemical	D003024
Entity: 15630069	42	52	olanzapine	Chemical	C076029
Entity: 15630069	90	108	insulin resistance	Disease	D007333
Entity: 15630069	127	134	glucose	Chemical	D005947
Entity: 15630069	163	174	risperidone	Chemical	D018967
Relation: 15630069	CID	27	36	D003024	90	108	D007333	true
Relation: 15630069	CID	42	52	C076029	90	108	D007333	true
Relation: 15630069	CID	127	134	D005947	90	108	D007333	false
Relation: 15630069	CID	163	174	D018967	90	108	D007333	false

Sentence: Focal cerebral ischemia in rats: effect of phenylephrine induced hypertension during reperfusion.
Entity: 15815446	6	23	cerebral ischemia	Disease	D002545
Entity: 15815446	43	56	phenylephrine	Chemical	D010656
Entity: 15815446	65	77	hypertension	Disease	D006973
Relation: 15815446	CID	43	56	D010656	6	23	D002545	false
Relation: 15815446	CID	43	56	D010656	65	77	D006973	true

Sentence: After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.
Entity: 15815446	27	59	middle cerebral artery occlusion	Disease	D020244
Entity: 15815446	77	89	hypertensive	Disease	D006973
Entity: 15815446	110	123	phenylephrine	Chemical	D010656
Entity: 15815446	132	144	hypertension	Disease	D006973
Entity: 15815446	148	169	ischemic brain injury	Disease	D001930
Relation: 15815446	CID	110	123	D010656	27	59	D020244	false
Relation: 15815446	CID	110	123	D010656	77	89	D006973	true
Relation: 15815446	CID	110	123	D010656	132	144	D006973	true
Relation: 15815446	CID	110	123	D010656	148	169	D001930	false

Sentence: Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.
Entity: 15815446	37	49	brain injury	Disease	D001930
Entity: 15815446	89	124	2,3,5-triphenyltetrazolium chloride	Chemical	C009591
Entity: 15815446	129	134	edema	Disease	D004487
Relation: 15815446	CID	89	124	C009591	37	49	D001930	false
Relation: 15815446	CID	89	124	C009591	129	134	D004487	false

Sentence: Evans Blue (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2).
Entity: 15815446	0	10	Evans Blue	Chemical	D005070
Entity: 15815446	59	62	HTN	Disease	D006973
Entity: 15815446	163	166	HTN	Disease	D006973
Relation: 15815446	CID	0	10	D005070	59	62	D006973	false
Relation: 15815446	CID	0	10	D005070	163	166	D006973	false

Sentence: People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.
Entity: 15817013	23	42	atrial fibrillation	Disease	D001281
Entity: 15817013	46	54	warfarin	Chemical	D014859
Entity: 15817013	74	84	hemorrhage	Disease	D006470
Entity: 15817013	89	95	stroke	Disease	D020521
Relation: 15817013	CID	46	54	D014859	23	42	D001281	false
Relation: 15817013	CID	46	54	D014859	74	84	D006470	true
Relation: 15817013	CID	46	54	D014859	89	95	D020521	false

Sentence: OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.
Entity: 15817013	48	58	hemorrhage	Disease	D006470
Entity: 15817013	63	69	stroke	Disease	D020521
Entity: 15817013	103	122	atrial fibrillation	Disease	D001281
Entity: 15817013	140	148	warfarin	Chemical	D014859
Relation: 15817013	CID	140	148	D014859	48	58	D006470	true
Relation: 15817013	CID	140	148	D014859	63	69	D020521	false
Relation: 15817013	CID	140	148	D014859	103	122	D001281	false

Sentence: PARTICIPANTS: Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.
Entity: 15817013	150	169	atrial fibrillation	Disease	D001281
Entity: 15817013	173	181	warfarin	Chemical	D014859
Relation: 15817013	CID	173	181	D014859	150	169	D001281	false

Sentence: MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.
Entity: 15817013	42	50	bleeding	Disease	D006470
Entity: 15817013	61	68	strokes	Disease	D020521
Entity: 15817013	74	82	warfarin	Chemical	D014859
Relation: 15817013	CID	74	82	D014859	42	50	D006470	true
Relation: 15817013	CID	74	82	D014859	61	68	D020521	false

Sentence: The annual stroke rate after initiation of warfarin was 2.6%.
Entity: 15817013	11	17	stroke	Disease	D020521
Entity: 15817013	43	51	warfarin	Chemical	D014859
Relation: 15817013	CID	43	51	D014859	11	17	D020521	false

Sentence: Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Entity: 15859361	10	19	celecoxib	Chemical	C105934
Entity: 15859361	45	59	skin reactions	Disease	D003875
Entity: 15859361	63	76	acetaminophen	Chemical	D000082
Entity: 15859361	78	89	paracetamol	Chemical	D000082
Entity: 15859361	95	105	nimesulide	Chemical	C012655
Relation: 15859361	CID	10	19	C105934	45	59	D003875	false
Relation: 15859361	CID	63	76	D000082	45	59	D003875	true
Relation: 15859361	CID	78	89	D000082	45	59	D003875	true
Relation: 15859361	CID	95	105	C012655	45	59	D003875	true

Sentence: OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.
Entity: 15859361	44	46	CE	Chemical	C105934
Entity: 15859361	105	124	cutaneous reactions	Disease	D003875
Entity: 15859361	128	129	P	Chemical	D000082
Entity: 15859361	134	135	N	Chemical	C012655
Relation: 15859361	CID	44	46	C105934	105	124	D003875	false
Relation: 15859361	CID	128	129	D000082	105	124	D003875	true
Relation: 15859361	CID	134	135	C012655	105	124	D003875	true

Sentence: METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.
Entity: 15859361	36	52	hypersensitivity	Disease	D004342
Entity: 15859361	56	57	P	Chemical	D000082
Entity: 15859361	62	63	N	Chemical	C012655
Relation: 15859361	CID	56	57	D000082	36	52	D004342	false
Relation: 15859361	CID	62	63	C012655	36	52	D004342	false

Sentence: The diagnosis of P and N induced skin reactions was based in vivo challenge.
Entity: 15859361	17	18	P	Chemical	D000082
Entity: 15859361	23	24	N	Chemical	C012655
Entity: 15859361	33	47	skin reactions	Disease	D003875
Relation: 15859361	CID	17	18	D000082	33	47	D003875	true
Relation: 15859361	CID	23	24	C012655	33	47	D003875	true

Sentence: CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.
Entity: 15859361	21	37	hypersensitivity	Disease	D004342
Entity: 15859361	50	52	CE	Chemical	C105934
Entity: 15859361	76	77	P	Chemical	D000082
Entity: 15859361	82	83	N	Chemical	C012655
Relation: 15859361	CID	50	52	C105934	21	37	D004342	false
Relation: 15859361	CID	76	77	D000082	21	37	D004342	false
Relation: 15859361	CID	82	83	C012655	21	37	D004342	false

Sentence: BACKGROUND: Studies on the association between the long-term use of aspirin and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (ESRD) have given conflicting results.
Entity: 15882284	68	75	aspirin	Chemical	D001241
Entity: 15882284	150	173	end-stage renal disease	Disease	D007676
Entity: 15882284	175	179	ESRD	Disease	D007676
Relation: 15882284	CID	68	75	D001241	150	173	D007676	true
Relation: 15882284	CID	68	75	D001241	175	179	D007676	true

Sentence: The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].
Entity: 15882284	12	16	ESRD	Disease	D007676
Entity: 15882284	33	40	aspirin	Chemical	D001241
Entity: 15882284	168	179	nephropathy	Disease	D007674
Relation: 15882284	CID	33	40	D001241	12	16	D007676	true
Relation: 15882284	CID	33	40	D001241	168	179	D007674	false

Sentence: Two cases of amisulpride overdose: a cause for prolonged QT syndrome.
Entity: 15953230	13	24	amisulpride	Chemical	C012052
Entity: 15953230	25	33	overdose	Disease	D062787
Entity: 15953230	47	68	prolonged QT syndrome	Disease	D008133
Relation: 15953230	CID	13	24	C012052	25	33	D062787	false
Relation: 15953230	CID	13	24	C012052	47	68	D008133	true

Sentence: Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported.
Entity: 15953230	29	38	poisoning	Disease	D011041
Entity: 15953230	61	72	amisulpride	Chemical	C012052
Relation: 15953230	CID	61	72	C012052	29	38	D011041	false

Sentence: Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide.
Entity: 15987266	82	91	epileptic	Disease	D004827
Entity: 15987266	110	123	cycloheximide	Chemical	D003513
Relation: 15987266	CID	110	123	D003513	82	91	D004827	false

Sentence: To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.
Entity: 15987266	218	236	status epilepticus	Disease	D013226
Entity: 15987266	248	259	pilocarpine	Chemical	D010862
Entity: 15987266	261	265	Pilo	Chemical	D010862
Entity: 15987266	300	313	cycloheximide	Chemical	D003513
Entity: 15987266	315	318	CHX	Chemical	D003513
Relation: 15987266	CID	248	259	D010862	218	236	D013226	true
Relation: 15987266	CID	261	265	D010862	218	236	D013226	true
Relation: 15987266	CID	300	313	D003513	218	236	D013226	false
Relation: 15987266	CID	315	318	D003513	218	236	D013226	false

Sentence: OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.
Entity: 15991002	58	66	nicotine	Chemical	D009538
Entity: 15991002	70	77	anxiety	Disease	D001008
Entity: 15991002	89	97	caffeine	Chemical	D002110
Entity: 15991002	127	145	pentylenetetrazole	Chemical	D010433
Relation: 15991002	CID	58	66	D009538	70	77	D001008	false
Relation: 15991002	CID	89	97	D002110	70	77	D001008	true
Relation: 15991002	CID	127	145	D010433	70	77	D001008	true

Sentence: Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole induced anxiety.
Entity: 15991002	0	8	Nicotine	Chemical	D009538
Entity: 15991002	47	55	caffeine	Chemical	D002110
Entity: 15991002	65	83	pentylenetetrazole	Chemical	D010433
Entity: 15991002	92	99	anxiety	Disease	D001008
Relation: 15991002	CID	0	8	D009538	92	99	D001008	false
Relation: 15991002	CID	47	55	D002110	92	99	D001008	true
Relation: 15991002	CID	65	83	D010433	92	99	D001008	true

Sentence: CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.
Entity: 15991002	65	73	nicotine	Chemical	D009538
Entity: 15991002	77	85	caffeine	Chemical	D002110
Entity: 15991002	94	101	anxiety	Disease	D001008
Entity: 15991002	117	125	caffeine	Chemical	D002110
Relation: 15991002	CID	65	73	D009538	94	101	D001008	false
Relation: 15991002	CID	77	85	D002110	94	101	D001008	true
Relation: 15991002	CID	117	125	D002110	94	101	D001008	true

Sentence: Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.
Entity: 16034922	10	19	oestrogen	Chemical	D004967
Entity: 16034922	69	75	stroke	Disease	D020521
Entity: 16034922	80	99	gallbladder disease	Disease	D005705
Relation: 16034922	CID	10	19	D004967	69	75	D020521	true
Relation: 16034922	CID	10	19	D004967	80	99	D005705	true

Sentence: Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).
Entity: 16083708	43	68	fulminant hepatic failure	Disease	D017114
Entity: 16083708	211	220	bilirubin	Chemical	D001663
Relation: 16083708	CID	211	220	D001663	43	68	D017114	false

Sentence: Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.
Entity: 16092435	42	50	d-ribose	Chemical	D012266
Entity: 16092435	54	64	adriamycin	Chemical	D004317
Entity: 16092435	72	86	cardiotoxicity	Disease	D066126
Relation: 16092435	CID	42	50	D012266	72	86	D066126	false
Relation: 16092435	CID	54	64	D004317	72	86	D066126	false

Sentence: The influence of d-ribose on adriamycin induced myocardiopathy in rats was studied.
Entity: 16092435	17	25	d-ribose	Chemical	D012266
Entity: 16092435	29	39	adriamycin	Chemical	D004317
Entity: 16092435	48	62	myocardiopathy	Disease	D009202
Relation: 16092435	CID	17	25	D012266	48	62	D009202	false
Relation: 16092435	CID	29	39	D004317	48	62	D009202	true

Sentence: Adriamycin in the cumulative dose of 25 mg/kg evoked fully developed cardiac toxicity.
Entity: 16092435	0	10	Adriamycin	Chemical	D004317
Entity: 16092435	69	85	cardiac toxicity	Disease	D066126
Relation: 16092435	CID	0	10	D004317	69	85	D066126	false

Sentence: In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin induced nephrotoxicity: protection by erdosteine.
Entity: 16112787	77	87	vancomycin	Chemical	D014640
Entity: 16112787	96	110	nephrotoxicity	Disease	D007674
Entity: 16112787	126	136	erdosteine	Chemical	C048498
Relation: 16112787	CID	77	87	D014640	96	110	D007674	true
Relation: 16112787	CID	126	136	C048498	96	110	D007674	false

Sentence: The aims of this study were to examine vancomycin (VCM) induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM induced renal impairment in rats.
Entity: 16112787	39	49	vancomycin	Chemical	D014640
Entity: 16112787	51	54	VCM	Chemical	D014640
Entity: 16112787	118	124	oxygen	Chemical	D010100
Entity: 16112787	170	180	erdosteine	Chemical	C048498
Entity: 16112787	281	284	VCM	Chemical	D014640
Entity: 16112787	293	309	renal impairment	Disease	D007674
Relation: 16112787	CID	39	49	D014640	293	309	D007674	true
Relation: 16112787	CID	51	54	D014640	293	309	D007674	true
Relation: 16112787	CID	118	124	D010100	293	309	D007674	false
Relation: 16112787	CID	170	180	C048498	293	309	D007674	false
Relation: 16112787	CID	281	284	D014640	293	309	D007674	true

Sentence: VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.
Entity: 16112787	0	3	VCM	Chemical	D014640
Entity: 16112787	65	80	malondialdehyde	Chemical	D008315
Entity: 16112787	82	85	MDA	Chemical	D008315
Entity: 16112787	149	169	renal tubular injury	Disease	D007674
Entity: 16112787	195	205	superoxide	Chemical	D013481
Relation: 16112787	CID	0	3	D014640	149	169	D007674	true
Relation: 16112787	CID	65	80	D008315	149	169	D007674	false
Relation: 16112787	CID	82	85	D008315	149	169	D007674	false
Relation: 16112787	CID	195	205	D013481	149	169	D007674	false

Sentence: Erdosteine showed histopathological protection against VCM induced nephrotoxicity.
Entity: 16112787	0	10	Erdosteine	Chemical	C048498
Entity: 16112787	55	58	VCM	Chemical	D014640
Entity: 16112787	67	81	nephrotoxicity	Disease	D007674
Relation: 16112787	CID	0	10	C048498	67	81	D007674	false
Relation: 16112787	CID	55	58	D014640	67	81	D007674	true

Sentence: There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.
Entity: 16112787	96	103	atrophy	Disease	D001284
Entity: 16112787	105	117	desquamation	Disease	-1
Entity: 16112787	123	131	necrosis	Disease	D009336
Entity: 16112787	135	138	VCM	Chemical	D014640
Entity: 16112787	191	201	erdosteine	Chemical	C048498
Relation: 16112787	CID	135	138	D014640	96	103	D001284	false
Relation: 16112787	CID	135	138	D014640	105	117	-1	false
Relation: 16112787	CID	135	138	D014640	123	131	D009336	false
Relation: 16112787	CID	191	201	C048498	96	103	D001284	false
Relation: 16112787	CID	191	201	C048498	105	117	-1	false
Relation: 16112787	CID	191	201	C048498	123	131	D009336	false

Sentence: Does domperidone potentiate mirtazapine-associated restless legs syndrome.
Entity: 16309808	5	16	domperidone	Chemical	D004294
Entity: 16309808	28	39	mirtazapine	Chemical	C035133
Entity: 16309808	51	73	restless legs syndrome	Disease	D012148
Relation: 16309808	CID	5	16	D004294	51	73	D012148	false
Relation: 16309808	CID	28	39	C035133	51	73	D012148	true

Sentence: For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.
Entity: 16309808	29	32	RLS	Disease	D012148
Entity: 16309808	65	73	levodopa	Chemical	D007980
Entity: 16309808	78	86	dopamine	Chemical	D004298
Entity: 16309808	113	121	dopamine	Chemical	D004298
Entity: 16309808	170	173	RLS	Disease	D012148
Relation: 16309808	CID	65	73	D007980	29	32	D012148	false
Relation: 16309808	CID	65	73	D007980	170	173	D012148	false
Relation: 16309808	CID	78	86	D004298	29	32	D012148	false
Relation: 16309808	CID	78	86	D004298	170	173	D012148	false
Relation: 16309808	CID	113	121	D004298	29	32	D012148	false
Relation: 16309808	CID	113	121	D004298	170	173	D012148	false

Sentence: To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.
Entity: 16309808	64	75	domperidone	Chemical	D004294
Entity: 16309808	90	98	dopamine	Chemical	D004298
Entity: 16309808	164	167	RLS	Disease	D012148
Relation: 16309808	CID	64	75	D004294	164	167	D012148	false
Relation: 16309808	CID	90	98	D004298	164	167	D012148	false

Sentence: Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.
Entity: 16309808	0	11	Mirtazapine	Chemical	C035133
Entity: 16309808	112	115	RLS	Disease	D012148
Relation: 16309808	CID	0	11	C035133	112	115	D012148	true

Sentence: The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.
Entity: 16309808	58	80	postprandial dyspepsia	Disease	D004415
Entity: 16309808	95	98	RLS	Disease	D012148
Entity: 16309808	105	116	mirtazapine	Chemical	C035133
Entity: 16309808	139	150	domperidone	Chemical	D004294
Relation: 16309808	CID	105	116	C035133	58	80	D004415	false
Relation: 16309808	CID	105	116	C035133	95	98	D012148	true
Relation: 16309808	CID	139	150	D004294	58	80	D004415	false
Relation: 16309808	CID	139	150	D004294	95	98	D012148	false

Sentence: Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.
Entity: 16309808	40	43	RLS	Disease	D012148
Entity: 16309808	80	91	mirtazapine	Chemical	C035133
Entity: 16309808	101	104	RLS	Disease	D012148
Entity: 16309808	162	173	mirtazapine	Chemical	C035133
Relation: 16309808	CID	80	91	C035133	40	43	D012148	true
Relation: 16309808	CID	80	91	C035133	101	104	D012148	true
Relation: 16309808	CID	162	173	C035133	40	43	D012148	true
Relation: 16309808	CID	162	173	C035133	101	104	D012148	true

Sentence: Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.
Entity: 16309808	48	59	mirtazapine	Chemical	C035133
Entity: 16309808	80	83	RLS	Disease	D012148
Entity: 16309808	140	150	domperione	Chemical	D004294
Entity: 16309808	154	165	mirtazapine	Chemical	C035133
Entity: 16309808	177	180	RLS	Disease	D012148
Relation: 16309808	CID	48	59	C035133	80	83	D012148	true
Relation: 16309808	CID	48	59	C035133	177	180	D012148	true
Relation: 16309808	CID	140	150	D004294	80	83	D012148	false
Relation: 16309808	CID	140	150	D004294	177	180	D012148	false
Relation: 16309808	CID	154	165	C035133	80	83	D012148	true
Relation: 16309808	CID	154	165	C035133	177	180	D012148	true

Sentence: MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
Entity: 16323982	83	95	cholesterols	Chemical	D002784
Entity: 16323982	97	98	C	Chemical	D002784
Entity: 16323982	101	114	triglycerides	Chemical	D014280
Entity: 16323982	116	118	TG	Chemical	D014280
Entity: 16323982	248	263	prostate cancer	Disease	D011471
Entity: 16323982	323	342	cyproterone acetate	Chemical	D017373
Entity: 16323982	344	347	CPA	Chemical	D017373
Relation: 16323982	CID	83	95	D002784	248	263	D011471	false
Relation: 16323982	CID	97	98	D002784	248	263	D011471	false
Relation: 16323982	CID	101	114	D014280	248	263	D011471	false
Relation: 16323982	CID	116	118	D014280	248	263	D011471	false
Relation: 16323982	CID	323	342	D017373	248	263	D011471	false
Relation: 16323982	CID	344	347	D017373	248	263	D011471	false

Sentence: After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.
Entity: 16323982	31	34	CPA	Chemical	D017373
Entity: 16323982	108	130	coronary heart disease	Disease	D003327
Relation: 16323982	CID	31	34	D017373	108	130	D003327	false

Sentence: 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Entity: 16369751	0	14	5-Fluorouracil	Chemical	D005472
Entity: 16369751	15	29	cardiotoxicity	Disease	D066126
Entity: 16369751	41	66	alpha-fluoro-beta-alanine	Chemical	C032348
Relation: 16369751	CID	0	14	D005472	15	29	D066126	false
Relation: 16369751	CID	41	66	C032348	15	29	D066126	false

Sentence: Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.
Entity: 16369751	0	14	Cardiotoxicity	Disease	D066126
Entity: 16369751	55	69	5-fluorouracil	Chemical	D005472
Entity: 16369751	71	75	5-FU	Chemical	D005472
Entity: 16369751	91	103	malignancies	Disease	D009369
Relation: 16369751	CID	55	69	D005472	0	14	D066126	false
Relation: 16369751	CID	55	69	D005472	91	103	D009369	false
Relation: 16369751	CID	71	75	D005472	0	14	D066126	false
Relation: 16369751	CID	71	75	D005472	91	103	D009369	false

Sentence: We herein report the case of a 70-year-old man with 5-FU induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.
Entity: 16369751	52	56	5-FU	Chemical	D005472
Entity: 16369751	65	79	cardiotoxicity	Disease	D066126
Entity: 16369751	111	136	alpha-fluoro-beta-alanine	Chemical	C032348
Entity: 16369751	138	142	FBAL	Chemical	C032348
Relation: 16369751	CID	52	56	D005472	65	79	D066126	false
Relation: 16369751	CID	111	136	C032348	65	79	D066126	false
Relation: 16369751	CID	138	142	C032348	65	79	D066126	false

Sentence: After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.
Entity: 16369751	75	79	5-FU	Chemical	D005472
Entity: 16369751	108	123	precordial pain	Disease	D002637
Entity: 16369751	129	154	right bundle branch block	Disease	D002037
Entity: 16369751	196	200	FBAL	Chemical	C032348
Relation: 16369751	CID	75	79	D005472	108	123	D002637	true
Relation: 16369751	CID	75	79	D005472	129	154	D002037	true
Relation: 16369751	CID	196	200	C032348	108	123	D002637	false
Relation: 16369751	CID	196	200	C032348	129	154	D002037	false

Sentence: Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.
Entity: 16369751	9	24	precordial pain	Disease	D002637
Entity: 16369751	117	121	5-FU	Chemical	D005472
Relation: 16369751	CID	117	121	D005472	9	24	D002637	true

Sentence: As the precordial pain in this patient was considered to have been due to 5-FU induced cardiotoxicity, the administration of 5-FU was abandoned.
Entity: 16369751	7	22	precordial pain	Disease	D002637
Entity: 16369751	74	78	5-FU	Chemical	D005472
Entity: 16369751	87	101	cardiotoxicity	Disease	D066126
Entity: 16369751	125	129	5-FU	Chemical	D005472
Relation: 16369751	CID	74	78	D005472	7	22	D002637	true
Relation: 16369751	CID	74	78	D005472	87	101	D066126	false
Relation: 16369751	CID	125	129	D005472	7	22	D002637	true
Relation: 16369751	CID	125	129	D005472	87	101	D066126	false

Sentence: The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU induced cardiotoxicity.
Entity: 16369751	85	89	FBAL	Chemical	C032348
Entity: 16369751	104	108	5-FU	Chemical	D005472
Entity: 16369751	117	131	cardiotoxicity	Disease	D066126
Relation: 16369751	CID	85	89	C032348	117	131	D066126	false
Relation: 16369751	CID	104	108	D005472	117	131	D066126	false

Sentence: The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin induced cardiotoxicity in mice.
Entity: 16565833	43	50	monoHER	Chemical	C522803
Entity: 16565833	55	66	doxorubicin	Chemical	D004317
Entity: 16565833	108	119	doxorubicin	Chemical	D004317
Entity: 16565833	128	142	cardiotoxicity	Disease	D066126
Relation: 16565833	CID	43	50	C522803	128	142	D066126	false
Relation: 16565833	CID	55	66	D004317	128	142	D066126	false
Relation: 16565833	CID	108	119	D004317	128	142	D066126	false

Sentence: PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.
Entity: 16565833	32	46	cardiotoxicity	Disease	D066126
Entity: 16565833	65	76	doxorubicin	Chemical	D004317
Entity: 16565833	78	81	DOX	Chemical	D004317
Relation: 16565833	CID	65	76	D004317	32	46	D066126	false
Relation: 16565833	CID	78	81	D004317	32	46	D066126	false

Sentence: DOX induced cardiac damage presumably results from the formation of free radicals by DOX.
Entity: 16565833	0	3	DOX	Chemical	D004317
Entity: 16565833	12	26	cardiac damage	Disease	D006331
Entity: 16565833	85	88	DOX	Chemical	D004317
Relation: 16565833	CID	0	3	D004317	12	26	D006331	false
Relation: 16565833	CID	85	88	D004317	12	26	D006331	false

Sentence: The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX induced cardiotoxicity through its radical scavenging and iron chelating properties.
Entity: 16565833	18	27	flavonoid	Chemical	D005419
Entity: 16565833	28	52	monohydroxyethylrutoside	Chemical	C522803
Entity: 16565833	54	61	monoHER	Chemical	C522803
Entity: 16565833	95	98	DOX	Chemical	D004317
Entity: 16565833	107	121	cardiotoxicity	Disease	D066126
Entity: 16565833	157	161	iron	Chemical	D007501
Relation: 16565833	CID	18	27	D005419	107	121	D066126	false
Relation: 16565833	CID	28	52	C522803	107	121	D066126	false
Relation: 16565833	CID	54	61	C522803	107	121	D066126	false
Relation: 16565833	CID	95	98	D004317	107	121	D066126	false
Relation: 16565833	CID	157	161	D007501	107	121	D066126	false

Sentence: Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).
Entity: 16565833	52	55	DOX	Chemical	D004317
Entity: 16565833	82	96	cardiac damage	Disease	D006331
Relation: 16565833	CID	52	55	D004317	82	96	D006331	false

Sentence: Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.
Entity: 16723784	46	54	bepridil	Chemical	D015764
Entity: 16723784	74	80	atrial	Disease	D001281
Entity: 16723784	74	80	atrial	Disease	D001282
Relation: 16723784	CID	46	54	D015764	74	80	D001281	false
Relation: 16723784	CID	46	54	D015764	74	80	D001282	false

Sentence: BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).
Entity: 16723784	12	34	Bepridil hydrochloride	Chemical	D015764
Entity: 16723784	36	39	Bpd	Chemical	D015764
Entity: 16723784	90	109	atrial fibrillation	Disease	D001281
Entity: 16723784	111	113	AF	Disease	D001281
Entity: 16723784	119	133	atrial flutter	Disease	D001282
Entity: 16723784	135	138	AFL	Disease	D001282
Relation: 16723784	CID	12	34	D015764	90	109	D001281	false
Relation: 16723784	CID	12	34	D015764	111	113	D001281	false
Relation: 16723784	CID	12	34	D015764	119	133	D001282	false
Relation: 16723784	CID	12	34	D015764	135	138	D001282	false
Relation: 16723784	CID	36	39	D015764	90	109	D001281	false
Relation: 16723784	CID	36	39	D015764	111	113	D001281	false
Relation: 16723784	CID	36	39	D015764	119	133	D001282	false
Relation: 16723784	CID	36	39	D015764	135	138	D001282	false

Sentence: Bpd was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases.
Entity: 16723784	0	3	Bpd	Chemical	D015764
Entity: 16723784	83	85	AF	Disease	D001281
Entity: 16723784	93	96	AFL	Disease	D001282
Relation: 16723784	CID	0	3	D015764	83	85	D001281	false
Relation: 16723784	CID	0	3	D015764	93	96	D001282	false

Sentence: Enhanced isoproterenol induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
Entity: 16731636	9	22	isoproterenol	Chemical	D007545
Entity: 16731636	31	50	cardiac hypertrophy	Disease	D006332
Relation: 16731636	CID	9	22	D007545	31	50	D006332	true

Sentence: LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively).
Entity: 16731636	0	14	LV hypertrophy	Disease	D006332
Entity: 16731636	26	29	Iso	Chemical	D007545
Relation: 16731636	CID	26	29	D007545	0	14	D006332	true

Sentence: Drug induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.
Entity: 16801510	13	29	long QT syndrome	Disease	D008133
Entity: 16801510	64	73	methadone	Chemical	D008691
Relation: 16801510	CID	64	73	D008691	13	29	D008133	true

Sentence: In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.
Entity: 16801510	43	67	QT interval prolongation	Disease	D008133
Entity: 16801510	73	82	methadone	Chemical	D008691
Relation: 16801510	CID	73	82	D008691	43	67	D008133	true

Sentence: In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.
Entity: 16801510	15	24	methadone	Chemical	D008691
Entity: 16801510	135	150	QT prolongation	Disease	D008133
Relation: 16801510	CID	15	24	D008691	135	150	D008133	true

Sentence: Six patients (3.6%) in the methadone group presented torsades de pointes.
Entity: 16801510	27	36	methadone	Chemical	D008691
Entity: 16801510	53	72	torsades de pointes	Disease	D016171
Relation: 16801510	CID	27	36	D008691	53	72	D016171	false

Sentence: Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.
Entity: 16801510	84	93	methadone	Chemical	D008691
Entity: 16801510	145	156	hypokalemia	Disease	D007008
Relation: 16801510	CID	84	93	D008691	145	156	D007008	false

Sentence: CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.
Entity: 16801510	13	37	QT interval prolongation	Disease	D008133
Entity: 16801510	41	50	methadone	Chemical	D008691
Relation: 16801510	CID	41	50	D008691	13	37	D008133	true

Sentence: Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.
Entity: 16801510	0	9	Methadone	Chemical	D008691
Entity: 16801510	61	70	potassium	Chemical	D011188
Entity: 16801510	111	126	QT prolongation	Disease	D008133
Relation: 16801510	CID	0	9	D008691	111	126	D008133	true
Relation: 16801510	CID	61	70	D011188	111	126	D008133	false

Sentence: Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.
Entity: 16810074	14	26	hypertension	Disease	D006973
Entity: 16810074	38	50	nitric oxide	Chemical	D009569
Entity: 16810074	52	54	NO	Chemical	D009569
Relation: 16810074	CID	38	50	D009569	14	26	D006973	true
Relation: 16810074	CID	52	54	D009569	14	26	D006973	true

Sentence: Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.
Entity: 16810074	33	45	nitric oxide	Chemical	D009569
Entity: 16810074	47	49	NO	Chemical	D009569
Entity: 16810074	54	66	hypertension	Disease	D006973
Entity: 16810074	84	104	arterial dysfunction	Disease	D018754
Relation: 16810074	CID	33	45	D009569	54	66	D006973	true
Relation: 16810074	CID	33	45	D009569	84	104	D018754	false
Relation: 16810074	CID	47	49	D009569	54	66	D006973	true
Relation: 16810074	CID	47	49	D009569	84	104	D018754	false

Sentence: Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.
Entity: 16810074	13	25	hypertension	Disease	D006973
Entity: 16810074	52	54	NO	Chemical	D009569
Relation: 16810074	CID	52	54	D009569	13	25	D006973	true

Sentence: We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in Nomega-nitro-L-arginine (LNNA) hypertension through these mechanisms.
Entity: 16810074	85	108	Nomega-nitro-L-arginine	Chemical	D019335
Entity: 16810074	110	114	LNNA	Chemical	D019335
Entity: 16810074	116	128	hypertension	Disease	D006973
Relation: 16810074	CID	85	108	D019335	116	128	D006973	false
Relation: 16810074	CID	110	114	D019335	116	128	D006973	false

Sentence: Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA.
Entity: 16810074	93	97	LNNA	Chemical	D019335
Entity: 16810074	98	110	hypertension	Disease	D006973
Entity: 16810074	133	137	LNNA	Chemical	D019335
Relation: 16810074	CID	93	97	D019335	98	110	D006973	false
Relation: 16810074	CID	133	137	D019335	98	110	D006973	false

Sentence: Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg).
Entity: 16810074	36	49	hexamethonium	Chemical	D018738
Entity: 16810074	89	93	LNNA	Chemical	D019335
Entity: 16810074	94	106	hypertensive	Disease	D006973
Relation: 16810074	CID	36	49	D018738	94	106	D006973	false
Relation: 16810074	CID	89	93	D019335	94	106	D006973	false

Sentence: Association of DRD2 polymorphisms and chlorpromazine induced extrapyramidal syndrome in Chinese schizophrenic patients.
Entity: 16867246	38	52	chlorpromazine	Chemical	D002746
Entity: 16867246	61	84	extrapyramidal syndrome	Disease	D001480
Entity: 16867246	96	109	schizophrenic	Disease	D012559
Relation: 16867246	CID	38	52	D002746	61	84	D001480	true
Relation: 16867246	CID	38	52	D002746	96	109	D012559	false

Sentence: In this study, we evaluate the role DRD2 plays in chlorpromazine induced EPS in schizophrenic patients.
Entity: 16867246	50	64	chlorpromazine	Chemical	D002746
Entity: 16867246	73	76	EPS	Disease	D001480
Entity: 16867246	80	93	schizophrenic	Disease	D012559
Relation: 16867246	CID	50	64	D002746	73	76	D001480	true
Relation: 16867246	CID	50	64	D002746	80	93	D012559	false

Sentence: METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.
Entity: 16867246	155	168	schizophrenic	Disease	D012559
Entity: 16867246	189	192	EPS	Disease	D001480
Entity: 16867246	208	211	EPS	Disease	D001480
Entity: 16867246	263	277	chlorpromazine	Chemical	D002746
Relation: 16867246	CID	263	277	D002746	155	168	D012559	false
Relation: 16867246	CID	263	277	D002746	189	192	D001480	true
Relation: 16867246	CID	263	277	D002746	208	211	D001480	true

Sentence: CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.
Entity: 16867246	182	196	chlorpromazine	Chemical	D002746
Entity: 16867246	232	245	schizophrenia	Disease	D012559
Relation: 16867246	CID	182	196	D002746	232	245	D012559	false

Sentence: Physical training decreases susceptibility to subsequent pilocarpine induced seizures in the rat.
Entity: 16876986	57	68	pilocarpine	Chemical	D010862
Entity: 16876986	77	85	seizures	Disease	D012640
Relation: 16876986	CID	57	68	D010862	77	85	D012640	true

Sentence: Thereafter, seizures were induced by pilocarpine injections in trained and non-trained control groups.
Entity: 16876986	12	20	seizures	Disease	D012640
Entity: 16876986	37	48	pilocarpine	Chemical	D010862
Relation: 16876986	CID	37	48	D010862	12	20	D012640	true

Sentence: Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.
Entity: 16880771	22	30	dopamine	Chemical	D004298
Entity: 16880771	41	49	levodopa	Chemical	D007980
Entity: 16880771	92	98	stroke	Disease	D020521
Relation: 16880771	CID	22	30	D004298	92	98	D020521	false
Relation: 16880771	CID	41	49	D007980	92	98	D020521	false

Sentence: The dopamine agonist significantly impaired novel word learning compared to placebo.
Entity: 16880771	4	12	dopamine	Chemical	D004298
Entity: 16880771	35	63	impaired novel word learning	Disease	D007859
Relation: 16880771	CID	4	12	D004298	35	63	D007859	false

Sentence: Minocycline induced vasculitis fulfilling the criteria of polyarteritis nodosa.
Entity: 16906379	0	11	Minocycline	Chemical	D008911
Entity: 16906379	20	30	vasculitis	Disease	D014657
Entity: 16906379	58	78	polyarteritis nodosa	Disease	D010488
Relation: 16906379	CID	0	11	D008911	20	30	D014657	false
Relation: 16906379	CID	0	11	D008911	58	78	D010488	true

Sentence: A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).
Entity: 16906379	38	49	minocycline	Chemical	D008911
Entity: 16906379	54	77	palmoplantar pustulosis	Disease	D011565
Entity: 16906379	88	93	fever	Disease	D005334
Entity: 16906379	95	103	myalgias	Disease	D063806
Entity: 16906379	105	119	polyneuropathy	Disease	D011115
Entity: 16906379	125	140	testicular pain	Disease	D013733
Relation: 16906379	CID	38	49	D008911	54	77	D011565	false
Relation: 16906379	CID	38	49	D008911	88	93	D005334	false
Relation: 16906379	CID	38	49	D008911	95	103	D063806	false
Relation: 16906379	CID	38	49	D008911	105	119	D011115	false
Relation: 16906379	CID	38	49	D008911	125	140	D013733	false

Sentence: To our knowledge, this is the second case of minocycline induced vasculitis satisfying the criteria.
Entity: 16906379	45	56	minocycline	Chemical	D008911
Entity: 16906379	65	75	vasculitis	Disease	D014657
Relation: 16906379	CID	45	56	D008911	65	75	D014657	false

Sentence: Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.
Entity: 16911931	14	25	hepatitis B	Disease	D006509
Entity: 16911931	56	66	lamivudine	Chemical	D019259
Entity: 16911931	84	95	hepatitis B	Disease	D006509
Relation: 16911931	CID	56	66	D019259	14	25	D006509	false
Relation: 16911931	CID	56	66	D019259	84	95	D006509	false

Sentence: BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.
Entity: 16911931	21	32	hepatitis B	Disease	D006509
Entity: 16911931	60	70	lamivudine	Chemical	D019259
Entity: 16911931	107	118	hepatitis B	Disease	D006509
Entity: 16911931	190	195	HBsAg	Chemical	D006514
Relation: 16911931	CID	60	70	D019259	21	32	D006509	false
Relation: 16911931	CID	60	70	D019259	107	118	D006509	false
Relation: 16911931	CID	190	195	D006514	21	32	D006509	false
Relation: 16911931	CID	190	195	D006514	107	118	D006509	false

Sentence: Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.
Entity: 16920333	25	48	eslicarbazepine acetate	Chemical	C416835
Entity: 16920333	50	59	BIA 2-093	Chemical	C416835
Entity: 16920333	64	72	seizures	Disease	D012640
Entity: 16920333	102	112	picrotoxin	Chemical	D010852
Relation: 16920333	CID	25	48	C416835	64	72	D012640	false
Relation: 16920333	CID	50	59	C416835	64	72	D012640	false
Relation: 16920333	CID	102	112	D010852	64	72	D012640	true

Sentence: We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.
Entity: 16920333	51	74	eslicarbazepine acetate	Chemical	C416835
Entity: 16920333	116	124	seizures	Disease	D012640
Entity: 16920333	202	209	seizure	Disease	D012640
Relation: 16920333	CID	51	74	C416835	116	124	D012640	false
Relation: 16920333	CID	51	74	C416835	202	209	D012640	false

Sentence: In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.
Entity: 16920333	47	57	picrotoxin	Chemical	D010852
Entity: 16920333	81	89	seizures	Disease	D012640
Entity: 16920333	117	124	seizure	Disease	D012640
Relation: 16920333	CID	47	57	D010852	81	89	D012640	true
Relation: 16920333	CID	47	57	D010852	117	124	D012640	true

Sentence: Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.
Entity: 16920333	48	58	picrotoxin	Chemical	D010852
Entity: 16920333	84	92	seizures	Disease	D012640
Relation: 16920333	CID	48	58	D010852	84	92	D012640	true

Sentence: Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones.
Entity: 17028363	0	19	Acute renal failure	Disease	D058186
Entity: 17028363	82	96	anthraquinones	Chemical	D000880
Relation: 17028363	CID	82	96	D000880	0	19	D058186	false

Sentence: Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.
Entity: 17028363	0	11	Nephropathy	Disease	D007674
Entity: 17028363	22	35	Chinese herbs	Chemical	D004365
Entity: 17028363	95	113	aristolochic acids	Chemical	D034341
Relation: 17028363	CID	22	35	D004365	0	11	D007674	false
Relation: 17028363	CID	95	113	D034341	0	11	D007674	false

Sentence: We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).
Entity: 17028363	44	63	acute renal failure	Disease	D058186
Entity: 17028363	105	119	Chinese herbal	Chemical	D004365
Entity: 17028363	149	162	anthraquinone	Chemical	D000880
Relation: 17028363	CID	105	119	D004365	44	63	D058186	true
Relation: 17028363	CID	149	162	D000880	44	63	D058186	false

Sentence: The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.
Entity: 17028363	4	16	renal injury	Disease	D058186
Entity: 17028363	110	120	diclofenac	Chemical	D004008
Relation: 17028363	CID	110	120	D004008	4	16	D058186	true

Sentence: Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
Entity: 17035713	0	18	Chloroacetaldehyde	Chemical	C004656
Entity: 17035713	24	34	sulfhydryl	Chemical	-1
Entity: 17035713	65	70	thiol	Chemical	D013438
Entity: 17035713	81	91	ifosfamide	Chemical	D007069
Entity: 17035713	92	103	nephropathy	Disease	D007674
Relation: 17035713	CID	0	18	C004656	92	103	D007674	false
Relation: 17035713	CID	24	34	-1	92	103	D007674	false
Relation: 17035713	CID	65	70	D013438	92	103	D007674	false
Relation: 17035713	CID	81	91	D007069	92	103	D007674	true

Sentence: Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.
Entity: 17035713	0	18	Chloroacetaldehyde	Chemical	C004656
Entity: 17035713	20	23	CAA	Chemical	C004656
Entity: 17035713	65	75	ifosfamide	Chemical	D007069
Entity: 17035713	77	80	IFO	Chemical	D007069
Entity: 17035713	113	125	renal damage	Disease	D007674
Entity: 17035713	141	146	tumor	Disease	D009369
Entity: 17035713	160	163	IFO	Chemical	D007069
Relation: 17035713	CID	0	18	C004656	113	125	D007674	false
Relation: 17035713	CID	0	18	C004656	141	146	D009369	false
Relation: 17035713	CID	20	23	C004656	113	125	D007674	false
Relation: 17035713	CID	20	23	C004656	141	146	D009369	false
Relation: 17035713	CID	65	75	D007069	113	125	D007674	true
Relation: 17035713	CID	65	75	D007069	141	146	D009369	false
Relation: 17035713	CID	77	80	D007069	113	125	D007674	true
Relation: 17035713	CID	77	80	D007069	141	146	D009369	false
Relation: 17035713	CID	160	163	D007069	113	125	D007674	true
Relation: 17035713	CID	160	163	D007069	141	146	D009369	false

Sentence: Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.
Entity: 17035713	0	8	Toxicity	Disease	D064420
Entity: 17035713	12	15	CAA	Chemical	C004656
Entity: 17035713	77	88	trypan blue	Chemical	D014343
Relation: 17035713	CID	12	15	C004656	0	8	D064420	false
Relation: 17035713	CID	77	88	D014343	0	8	D064420	false

Sentence: CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.
Entity: 17035713	0	3	CAA	Chemical	C004656
Entity: 17035713	81	87	thiols	Chemical	D013438
Entity: 17035713	107	115	necrosis	Disease	D009336
Relation: 17035713	CID	0	3	C004656	107	115	D009336	false
Relation: 17035713	CID	81	87	D013438	107	115	D009336	false

Sentence: Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.
Entity: 17035713	44	47	CAA	Chemical	C004656
Entity: 17035713	53	58	thiol	Chemical	D013438
Entity: 17035713	99	102	CAA	Chemical	C004656
Entity: 17035713	106	114	necrosis	Disease	D009336
Entity: 17035713	124	129	thiol	Chemical	D013438
Entity: 17035713	144	152	cysteine	Chemical	D003545
Relation: 17035713	CID	44	47	C004656	106	114	D009336	false
Relation: 17035713	CID	53	58	D013438	106	114	D009336	false
Relation: 17035713	CID	99	102	C004656	106	114	D009336	false
Relation: 17035713	CID	124	129	D013438	106	114	D009336	false
Relation: 17035713	CID	144	152	D003545	106	114	D009336	false

Sentence: Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.
Entity: 17035713	6	9	CAA	Chemical	C004656
Entity: 17035713	64	70	thiols	Chemical	D013438
Entity: 17035713	86	94	toxicity	Disease	D064420
Relation: 17035713	CID	6	9	C004656	86	94	D064420	false
Relation: 17035713	CID	64	70	D013438	86	94	D064420	false

Sentence: Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine induced status epilepticus in the adult rat.
Entity: 17042797	96	107	pilocarpine	Chemical	D010862
Entity: 17042797	116	134	status epilepticus	Disease	D013226
Relation: 17042797	CID	96	107	D010862	116	134	D013226	true

Sentence: To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine induced status epilepticus.
Entity: 17042797	142	153	pilocarpine	Chemical	D010862
Entity: 17042797	162	180	status epilepticus	Disease	D013226
Relation: 17042797	CID	142	153	D010862	162	180	D013226	true

Sentence: A prospective, open-label trial of galantamine in autistic disorder.
Entity: 17069550	35	46	galantamine	Chemical	D005702
Entity: 17069550	50	67	autistic disorder	Disease	D001321
Relation: 17069550	CID	35	46	D005702	50	67	D001321	false

Sentence: The purpose of this study was to assess the use of galantamine, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with autism.
Entity: 17069550	51	62	galantamine	Chemical	D005702
Entity: 17069550	191	197	autism	Disease	D001321
Relation: 17069550	CID	51	62	D005702	191	197	D001321	false

Sentence: METHODS: Thirteen medication-free children with autism (mean age, 8.8 +/- 3.5 years) participated in a 12-week, open-label trial of galantamine.
Entity: 17069550	48	54	autism	Disease	D001321
Entity: 17069550	132	143	galantamine	Chemical	D005702
Relation: 17069550	CID	132	143	D005702	48	54	D001321	false

Sentence: Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient.
Entity: 17069550	9	20	galantamine	Chemical	D005702
Entity: 17069550	88	97	headaches	Disease	D006261
Relation: 17069550	CID	9	20	D005702	88	97	D006261	true

Sentence: Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Entity: 17151160	25	35	olanzapine	Chemical	C076029
Entity: 17151160	43	54	risperidone	Chemical	D018967
Entity: 17151160	90	103	schizophrenia	Disease	D012559
Relation: 17151160	CID	25	35	C076029	90	103	D012559	false
Relation: 17151160	CID	43	54	D018967	90	103	D012559	false

Sentence: OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.
Entity: 17151160	63	73	olanzapine	Chemical	C076029
Entity: 17151160	81	92	risperidone	Chemical	D018967
Entity: 17151160	124	137	schizophrenia	Disease	D012559
Relation: 17151160	CID	63	73	C076029	124	137	D012559	false
Relation: 17151160	CID	81	92	D018967	124	137	D012559	false

Sentence: METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).
Entity: 17151160	98	111	schizophrenia	Disease	D012559
Entity: 17151160	119	144	schizophreniform disorder	Disease	D011618
Entity: 17151160	155	179	schizoaffective disorder	Disease	D011618
Entity: 17151160	226	236	olanzapine	Chemical	C076029
Entity: 17151160	256	267	risperidone	Chemical	D018967
Relation: 17151160	CID	226	236	C076029	98	111	D012559	false
Relation: 17151160	CID	226	236	C076029	119	144	D011618	false
Relation: 17151160	CID	226	236	C076029	155	179	D011618	false
Relation: 17151160	CID	256	267	D018967	98	111	D012559	false
Relation: 17151160	CID	256	267	D018967	119	144	D011618	false
Relation: 17151160	CID	256	267	D018967	155	179	D011618	false

Sentence: Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.
Entity: 17151160	0	22	Extrapyramidal symptom	Disease	D001480
Entity: 17151160	70	81	risperidone	Chemical	D018967
Entity: 17151160	112	122	olanzapine	Chemical	C076029
Relation: 17151160	CID	70	81	D018967	0	22	D001480	true
Relation: 17151160	CID	112	122	C076029	0	22	D001480	true

Sentence: Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.
Entity: 17151160	19	30	weight gain	Disease	D015430
Entity: 17151160	45	55	olanzapine	Chemical	C076029
Entity: 17151160	66	77	risperidone	Chemical	D018967
Entity: 17151160	178	188	olanzapine	Chemical	C076029
Entity: 17151160	224	235	risperidone	Chemical	D018967
Relation: 17151160	CID	45	55	C076029	19	30	D015430	true
Relation: 17151160	CID	66	77	D018967	19	30	D015430	true
Relation: 17151160	CID	178	188	C076029	19	30	D015430	true
Relation: 17151160	CID	224	235	D018967	19	30	D015430	true

Sentence: Early paracentral visual field loss in patients taking hydroxychloroquine.
Entity: 17159032	18	35	visual field loss	Disease	D014786
Entity: 17159032	55	73	hydroxychloroquine	Chemical	D006886
Relation: 17159032	CID	55	73	D006886	18	35	D014786	true

Sentence: Thirty-five patients (13.4%) had visual field abnormalities, which were attributed to hydroxychloroquine treatment in 4 patients (1.5%).
Entity: 17159032	33	59	visual field abnormalities	Disease	D014786
Entity: 17159032	86	104	hydroxychloroquine	Chemical	D006886
Relation: 17159032	CID	86	104	D006886	33	59	D014786	true

Sentence: Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
Entity: 17223814	15	37	atrioventricular block	Disease	D054537
Entity: 17223814	71	81	epirubicin	Chemical	D015251
Entity: 17223814	86	96	paclitaxel	Chemical	D017239
Relation: 17223814	CID	71	81	D015251	15	37	D054537	true
Relation: 17223814	CID	86	96	D017239	15	37	D054537	true

Sentence: OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).
Entity: 17255138	24	51	acute myocardial infarction	Disease	D009203
Entity: 17255138	53	56	AMI	Disease	D009203
Entity: 17255138	63	79	COX-2 inhibitors	Chemical	D052246
Entity: 17255138	160	197	non-steroidal anti-inflammatory drugs	Chemical	D000894
Relation: 17255138	CID	63	79	D052246	24	51	D009203	true
Relation: 17255138	CID	63	79	D052246	53	56	D009203	true
Relation: 17255138	CID	160	197	D000894	24	51	D009203	true
Relation: 17255138	CID	160	197	D000894	53	56	D009203	true

Sentence: We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.
Entity: 17255138	53	56	AMI	Disease	D009203
Entity: 17255138	61	72	GI bleeding	Disease	D006471
Entity: 17255138	102	118	COX-2 inhibitors	Chemical	D052246
Entity: 17255138	134	147	acetaminophen	Chemical	D000082
Relation: 17255138	CID	102	118	D052246	53	56	D009203	true
Relation: 17255138	CID	102	118	D052246	61	72	D006471	false
Relation: 17255138	CID	134	147	D000082	53	56	D009203	false
Relation: 17255138	CID	134	147	D000082	61	72	D006471	false

Sentence: Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).
Entity: 17255138	19	26	aspirin	Chemical	D001241
Entity: 17255138	104	107	AMI	Disease	D009203
Entity: 17255138	118	131	acetaminophen	Chemical	D000082
Entity: 17255138	141	148	aspirin	Chemical	D001241
Entity: 17255138	162	171	rofecoxib	Chemical	C116926
Entity: 17255138	191	200	celecoxib	Chemical	C105934
Entity: 17255138	220	228	naproxen	Chemical	D009288
Entity: 17255138	248	258	diclofenac	Chemical	D004008
Entity: 17255138	281	290	ibuprofen	Chemical	D007052
Relation: 17255138	CID	19	26	D001241	104	107	D009203	false
Relation: 17255138	CID	118	131	D000082	104	107	D009203	false
Relation: 17255138	CID	141	148	D001241	104	107	D009203	false
Relation: 17255138	CID	162	171	C116926	104	107	D009203	true
Relation: 17255138	CID	191	200	C105934	104	107	D009203	false
Relation: 17255138	CID	220	228	D009288	104	107	D009203	true
Relation: 17255138	CID	248	258	D004008	104	107	D009203	false
Relation: 17255138	CID	281	290	D007052	104	107	D009203	false

Sentence: CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.
Entity: 17255138	31	38	aspirin	Chemical	D001241
Entity: 17255138	40	48	naproxen	Chemical	D009288
Entity: 17255138	86	89	AMI	Disease	D009203
Entity: 17255138	90	101	GI bleeding	Disease	D006471
Relation: 17255138	CID	31	38	D001241	86	89	D009203	false
Relation: 17255138	CID	31	38	D001241	90	101	D006471	false
Relation: 17255138	CID	40	48	D009288	86	89	D009203	true
Relation: 17255138	CID	40	48	D009288	90	101	D006471	true

Sentence: The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.
Entity: 17255138	4	7	AMI	Disease	D009203
Entity: 17255138	11	19	toxicity	Disease	D064420
Entity: 17255138	23	32	celecoxib	Chemical	C105934
Entity: 17255138	56	69	acetaminophen	Chemical	D000082
Entity: 17255138	108	117	rofecoxib	Chemical	C116926
Relation: 17255138	CID	23	32	C105934	4	7	D009203	false
Relation: 17255138	CID	23	32	C105934	11	19	D064420	false
Relation: 17255138	CID	56	69	D000082	4	7	D009203	false
Relation: 17255138	CID	56	69	D000082	11	19	D064420	false
Relation: 17255138	CID	108	117	C116926	4	7	D009203	true
Relation: 17255138	CID	108	117	C116926	11	19	D064420	false

Sentence: Quinine induced arrhythmia in a patient with severe malaria.
Entity: 17297207	0	7	Quinine	Chemical	D011803
Entity: 17297207	16	26	arrhythmia	Disease	D001145
Entity: 17297207	45	59	severe malaria	Disease	D016778
Relation: 17297207	CID	0	7	D011803	16	26	D001145	false
Relation: 17297207	CID	0	7	D011803	45	59	D016778	false

Sentence: It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.
Entity: 17297207	41	55	severe malaria	Disease	D016778
Entity: 17297207	69	77	jaundice	Disease	D007565
Entity: 17297207	97	107	arrhythmia	Disease	D001145
Entity: 17297207	109	142	premature ventricular contraction	Disease	D018879
Entity: 17297207	158	165	quinine	Chemical	D011803
Relation: 17297207	CID	158	165	D011803	41	55	D016778	false
Relation: 17297207	CID	158	165	D011803	69	77	D007565	false
Relation: 17297207	CID	158	165	D011803	97	107	D001145	false
Relation: 17297207	CID	158	165	D011803	109	142	D018879	true

Sentence: On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.
Entity: 17297207	80	89	bilirubin	Chemical	D001663
Entity: 17297207	113	122	bilirubin	Chemical	D001663
Entity: 17297207	148	157	bilirubin	Chemical	D001663
Entity: 17297207	170	179	potassium	Chemical	D011188
Entity: 17297207	216	230	severe malaria	Disease	D016778
Entity: 17297207	236	244	jaundice	Disease	D007565
Entity: 17297207	253	260	quinine	Chemical	D011803
Entity: 17297207	273	281	dextrose	Chemical	D005947
Relation: 17297207	CID	80	89	D001663	216	230	D016778	false
Relation: 17297207	CID	80	89	D001663	236	244	D007565	false
Relation: 17297207	CID	113	122	D001663	216	230	D016778	false
Relation: 17297207	CID	113	122	D001663	236	244	D007565	false
Relation: 17297207	CID	148	157	D001663	216	230	D016778	false
Relation: 17297207	CID	148	157	D001663	236	244	D007565	false
Relation: 17297207	CID	170	179	D011188	216	230	D016778	false
Relation: 17297207	CID	170	179	D011188	236	244	D007565	false
Relation: 17297207	CID	253	260	D011803	216	230	D016778	false
Relation: 17297207	CID	253	260	D011803	236	244	D007565	false
Relation: 17297207	CID	273	281	D005947	216	230	D016778	false
Relation: 17297207	CID	273	281	D005947	236	244	D007565	false

Sentence: After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.
Entity: 17297207	18	25	quinine	Chemical	D011803
Entity: 17297207	52	63	palpitation	Disease	-1
Entity: 17297207	111	144	premature ventricular contraction	Disease	D018879
Entity: 17297207	146	149	PVC	Disease	D018879
Entity: 17297207	191	207	sinoatrial block	Disease	D012848
Relation: 17297207	CID	18	25	D011803	52	63	-1	false
Relation: 17297207	CID	18	25	D011803	111	144	D018879	true
Relation: 17297207	CID	18	25	D011803	146	149	D018879	true
Relation: 17297207	CID	18	25	D011803	191	207	D012848	false

Sentence: Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L.
Entity: 17297207	60	63	PVC	Disease	D018879
Entity: 17297207	127	136	potassium	Chemical	D011188
Relation: 17297207	CID	127	136	D011188	60	63	D018879	false

Sentence: Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.
Entity: 17297207	0	7	Quinine	Chemical	D011803
Entity: 17297207	14	23	quinidine	Chemical	D011802
Entity: 17297207	62	72	arrhythmic	Disease	D001145
Entity: 17297207	104	114	arrhythmic	Disease	D001145
Entity: 17297207	138	149	arrhythmias	Disease	D001145
Entity: 17297207	168	178	arrhythmia	Disease	D001145
Entity: 17297207	196	199	PVC	Disease	D018879
Relation: 17297207	CID	0	7	D011803	62	72	D001145	false
Relation: 17297207	CID	0	7	D011803	104	114	D001145	false
Relation: 17297207	CID	0	7	D011803	138	149	D001145	false
Relation: 17297207	CID	0	7	D011803	168	178	D001145	false
Relation: 17297207	CID	0	7	D011803	196	199	D018879	true
Relation: 17297207	CID	14	23	D011802	62	72	D001145	false
Relation: 17297207	CID	14	23	D011802	104	114	D001145	false
Relation: 17297207	CID	14	23	D011802	138	149	D001145	false
Relation: 17297207	CID	14	23	D011802	168	178	D001145	false
Relation: 17297207	CID	14	23	D011802	196	199	D018879	false

Sentence: Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.
Entity: 17346443	0	13	Penicillamine	Chemical	D010396
Entity: 17346443	22	42	lichenoid dermatitis	Disease	D017512
Entity: 17346443	58	70	zinc acetate	Chemical	D019345
Entity: 17346443	76	90	Wilson disease	Disease	D006527
Entity: 17346443	126	133	anxiety	Disease	D001008
Relation: 17346443	CID	0	13	D010396	22	42	D017512	true
Relation: 17346443	CID	0	13	D010396	76	90	D006527	false
Relation: 17346443	CID	0	13	D010396	126	133	D001008	false
Relation: 17346443	CID	58	70	D019345	22	42	D017512	false
Relation: 17346443	CID	58	70	D019345	76	90	D006527	false
Relation: 17346443	CID	58	70	D019345	126	133	D001008	false

Sentence: Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders.
Entity: 17346443	0	16	Wilson's disease	Disease	D006527
Entity: 17346443	63	69	copper	Chemical	D003300
Entity: 17346443	97	103	copper	Chemical	D003300
Entity: 17346443	121	129	toxicity	Disease	D064420
Entity: 17346443	161	206	hepatic, neurologic and psychiatric disorders	Disease	D056486|D009422|D001523	hepatic disorders|neurologic disorders|psychiatric disorders
Relation: 17346443	CID	63	69	D003300	0	16	D006527	false
Relation: 17346443	CID	63	69	D003300	121	129	D064420	false
Relation: 17346443	CID	63	69	D003300	161	206	D056486|D009422|D001523	hepatic disorders|neurologic disorders|psychiatric disorders	false
Relation: 17346443	CID	97	103	D003300	0	16	D006527	false
Relation: 17346443	CID	97	103	D003300	121	129	D064420	false
Relation: 17346443	CID	97	103	D003300	161	206	D056486|D009422|D001523	hepatic disorders|neurologic disorders|psychiatric disorders	false

Sentence: During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.
Entity: 17346443	37	50	penicillamine	Chemical	D010396
Entity: 17346443	93	113	lichenoid dermatitis	Disease	D017512
Entity: 17346443	119	131	zinc acetate	Chemical	D019345
Relation: 17346443	CID	37	50	D010396	93	113	D017512	true
Relation: 17346443	CID	119	131	D019345	93	113	D017512	false

Sentence: In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.
Entity: 17346443	29	41	zinc acetate	Chemical	D019345
Entity: 17346443	83	99	Wilson's disease	Disease	D006527
Entity: 17346443	117	130	penicillamine	Chemical	D010396
Relation: 17346443	CID	29	41	D019345	83	99	D006527	false
Relation: 17346443	CID	117	130	D010396	83	99	D006527	false

Sentence: The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease.
Entity: 17346443	18	30	zinc acetate	Chemical	D019345
Entity: 17346443	194	210	Wilson's disease	Disease	D006527
Relation: 17346443	CID	18	30	D019345	194	210	D006527	false

Sentence: Since most of Wilson's disease penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.
Entity: 17346443	14	30	Wilson's disease	Disease	D006527
Entity: 17346443	31	44	penicillamine	Chemical	D010396
Entity: 17346443	90	101	skin lesion	Disease	D012871
Relation: 17346443	CID	31	44	D010396	14	30	D006527	false
Relation: 17346443	CID	31	44	D010396	90	101	D012871	false

Sentence: A dramatic drop in blood pressure following prehospital GTN administration.
Entity: 17351238	11	33	drop in blood pressure	Disease	D007022
Entity: 17351238	56	59	GTN	Chemical	D005996
Relation: 17351238	CID	56	59	D005996	11	33	D007022	true

Sentence: Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge.
Entity: 17351238	26	29	GTN	Chemical	D005996
Entity: 17351238	63	85	drop in blood pressure	Disease	D007022
Entity: 17351238	124	141	atropine sulphate	Chemical	D001285
Relation: 17351238	CID	26	29	D005996	63	85	D007022	true
Relation: 17351238	CID	124	141	D001285	63	85	D007022	false

Sentence: Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.
Entity: 17356399	0	20	Acute encephalopathy	Disease	D020803
Entity: 17356399	25	43	cerebral vasospasm	Disease	D020301
Entity: 17356399	84	100	PEG-asparaginase	Chemical	C042705
Entity: 17356399	117	127	cytarabine	Chemical	D003561
Entity: 17356399	149	177	acute lymphoblastic leukemia	Disease	D054198
Relation: 17356399	CID	84	100	C042705	0	20	D020803	false
Relation: 17356399	CID	84	100	C042705	25	43	D020301	true
Relation: 17356399	CID	84	100	C042705	149	177	D054198	false
Relation: 17356399	CID	117	127	D003561	0	20	D020803	false
Relation: 17356399	CID	117	127	D003561	25	43	D020301	true
Relation: 17356399	CID	117	127	D003561	149	177	D054198	false

Sentence: The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.
Entity: 17356399	22	42	acute encephalopathy	Disease	D020803
Entity: 17356399	76	83	aphasia	Disease	D001037
Entity: 17356399	85	97	incontinence	Disease	D014549
Entity: 17356399	99	120	visual hallucinations	Disease	D006212
Entity: 17356399	138	146	weakness	Disease	D018908
Entity: 17356399	160	178	cerebral vasospasm	Disease	D020301
Entity: 17356399	253	263	cytarabine	Chemical	D003561
Relation: 17356399	CID	253	263	D003561	22	42	D020803	false
Relation: 17356399	CID	253	263	D003561	76	83	D001037	true
Relation: 17356399	CID	253	263	D003561	85	97	D014549	true
Relation: 17356399	CID	253	263	D003561	99	120	D006212	true
Relation: 17356399	CID	253	263	D003561	138	146	D018908	true
Relation: 17356399	CID	253	263	D003561	160	178	D020301	true

Sentence: Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Entity: 17379047	14	23	valsartan	Chemical	C081489
Entity: 17379047	24	43	hydrochlorothiazide	Chemical	D006852
Entity: 17379047	195	207	hypertensive	Disease	D006973
Relation: 17379047	CID	14	23	C081489	195	207	D006973	false
Relation: 17379047	CID	24	43	D006852	195	207	D006973	false

Sentence: OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.
Entity: 17379047	68	77	valsartan	Chemical	C081489
Entity: 17379047	79	82	VAL	Chemical	C081489
Entity: 17379047	87	106	hydrochlorothiazide	Chemical	D006852
Entity: 17379047	108	112	HCTZ	Chemical	D006852
Entity: 17379047	172	194	essential hypertension	Disease	C562386
Relation: 17379047	CID	68	77	C081489	172	194	C562386	false
Relation: 17379047	CID	79	82	C081489	172	194	C562386	false
Relation: 17379047	CID	87	106	D006852	172	194	C562386	false
Relation: 17379047	CID	108	112	D006852	172	194	C562386	false

Sentence: Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.
Entity: 17379047	14	36	essential hypertension	Disease	C562386
Entity: 17379047	148	151	VAL	Chemical	C081489
Entity: 17379047	167	171	HCTZ	Chemical	D006852
Entity: 17379047	187	190	VAL	Chemical	C081489
Entity: 17379047	191	195	HCTZ	Chemical	D006852
Relation: 17379047	CID	148	151	C081489	14	36	C562386	false
Relation: 17379047	CID	167	171	D006852	14	36	C562386	false
Relation: 17379047	CID	187	190	C081489	14	36	C562386	false
Relation: 17379047	CID	191	195	D006852	14	36	C562386	false

Sentence: The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).
Entity: 17379047	17	28	hypokalemia	Disease	D007008
Entity: 17379047	44	47	VAL	Chemical	C081489
Entity: 17379047	48	52	HCTZ	Chemical	D006852
Entity: 17379047	88	92	HCTZ	Chemical	D006852
Relation: 17379047	CID	44	47	C081489	17	28	D007008	false
Relation: 17379047	CID	48	52	D006852	17	28	D007008	true
Relation: 17379047	CID	88	92	D006852	17	28	D007008	true

Sentence: Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.
Entity: 17384765	0	8	Succimer	Chemical	D004113
Entity: 17384765	75	79	lead	Chemical	D007854
Entity: 17384765	114	134	cognitive impairment	Disease	D003072
Entity: 17384765	153	157	lead	Chemical	D007854
Relation: 17384765	CID	0	8	D004113	114	134	D003072	true
Relation: 17384765	CID	75	79	D007854	114	134	D003072	false
Relation: 17384765	CID	153	157	D007854	114	134	D003072	false

Sentence: OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning.
Entity: 17384765	110	112	Pb	Chemical	D007854
Entity: 17384765	141	149	succimer	Chemical	D004113
Entity: 17384765	202	214	Pb poisoning	Disease	D007855
Relation: 17384765	CID	110	112	D007854	202	214	D007855	false
Relation: 17384765	CID	141	149	D004113	202	214	D007855	false

Sentence: RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children.
Entity: 17384765	9	11	Pb	Chemical	D007854
Entity: 17384765	38	49	impairments	Disease	D007859
Entity: 17384765	38	49	impairments	Disease	D019958
Entity: 17384765	163	165	Pb	Chemical	D007854
Relation: 17384765	CID	9	11	D007854	38	49	D007859	true
Relation: 17384765	CID	9	11	D007854	38	49	D019958	true
Relation: 17384765	CID	163	165	D007854	38	49	D007859	true
Relation: 17384765	CID	163	165	D007854	38	49	D019958	true

Sentence: In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen.
Entity: 17384765	13	21	succimer	Chemical	D004113
Entity: 17384765	66	68	Pb	Chemical	D007854
Entity: 17384765	100	109	cognitive	Disease	D003072
Entity: 17384765	114	123	affective	Disease	D019964
Entity: 17384765	191	193	Pb	Chemical	D007854
Relation: 17384765	CID	13	21	D004113	100	109	D003072	true
Relation: 17384765	CID	13	21	D004113	114	123	D019964	false
Relation: 17384765	CID	66	68	D007854	100	109	D003072	false
Relation: 17384765	CID	66	68	D007854	114	123	D019964	false
Relation: 17384765	CID	191	193	D007854	100	109	D003072	false
Relation: 17384765	CID	191	193	D007854	114	123	D019964	false

Sentence: CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.
Entity: 17384765	119	137	cognitive deficits	Disease	D003072
Entity: 17384765	145	147	Pb	Chemical	D007854
Relation: 17384765	CID	145	147	D007854	119	137	D003072	false

Sentence: Caffeine challenge test in panic disorder and depression with panic attacks.
Entity: 17445520	0	8	Caffeine	Chemical	D002110
Entity: 17445520	27	41	panic disorder	Disease	D016584
Entity: 17445520	46	56	depression	Disease	D003866
Entity: 17445520	62	75	panic attacks	Disease	D016584
Relation: 17445520	CID	0	8	D002110	27	41	D016584	true
Relation: 17445520	CID	0	8	D002110	46	56	D003866	false
Relation: 17445520	CID	0	8	D002110	62	75	D016584	true

Sentence: Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.
Entity: 17445520	40	54	panic disorder	Disease	D016584
Entity: 17445520	56	58	PD	Disease	D016584
Entity: 17445520	78	94	major depression	Disease	D003865
Entity: 17445520	100	113	panic attacks	Disease	D016584
Entity: 17445520	115	118	MDP	Disease	D003865
Entity: 17445520	115	118	MDP	Disease	D016584
Entity: 17445520	158	174	Mental Disorders	Disease	D001523
Entity: 17445520	246	259	panic attacks	Disease	D016584
Entity: 17445520	271	279	caffeine	Chemical	D002110
Relation: 17445520	CID	271	279	D002110	40	54	D016584	true
Relation: 17445520	CID	271	279	D002110	56	58	D016584	true
Relation: 17445520	CID	271	279	D002110	78	94	D003865	false
Relation: 17445520	CID	271	279	D002110	100	113	D016584	true
Relation: 17445520	CID	271	279	D002110	115	118	D003865	false
Relation: 17445520	CID	271	279	D002110	115	118	D016584	true
Relation: 17445520	CID	271	279	D002110	158	174	D001523	false
Relation: 17445520	CID	271	279	D002110	246	259	D016584	true

Sentence: In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.
Entity: 17445520	86	94	caffeine	Chemical	D002110
Entity: 17445520	101	109	caffeine	Chemical	D002110
Entity: 17445520	173	180	anxiety	Disease	D001008
Relation: 17445520	CID	86	94	D002110	173	180	D001008	false
Relation: 17445520	CID	101	109	D002110	173	180	D001008	false

Sentence: A total of 58.6% (n = 17) of patients with PD, 44.4% (n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test.
Entity: 17445520	43	45	PD	Disease	D016584
Entity: 17445520	79	82	MDP	Disease	D003865
Entity: 17445520	79	82	MDP	Disease	D016584
Entity: 17445520	115	117	MD	Disease	D003865
Entity: 17445520	161	173	panic attack	Disease	D016584
Entity: 17445520	191	199	caffeine	Chemical	D002110
Relation: 17445520	CID	191	199	D002110	43	45	D016584	true
Relation: 17445520	CID	191	199	D002110	79	82	D003865	false
Relation: 17445520	CID	191	199	D002110	79	82	D016584	true
Relation: 17445520	CID	191	199	D002110	115	117	D003865	false
Relation: 17445520	CID	191	199	D002110	161	173	D016584	true

Sentence: The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.
Entity: 17445520	18	20	PD	Disease	D016584
Entity: 17445520	25	28	MDP	Disease	D003865
Entity: 17445520	25	28	MDP	Disease	D016584
Entity: 17445520	52	60	caffeine	Chemical	D002110
Entity: 17445520	85	87	MD	Disease	D003865
Relation: 17445520	CID	52	60	D002110	18	20	D016584	true
Relation: 17445520	CID	52	60	D002110	25	28	D003865	false
Relation: 17445520	CID	52	60	D002110	25	28	D016584	true
Relation: 17445520	CID	52	60	D002110	85	87	D003865	false

Sentence: No panic attack was observed after the caffeine-free solution intake.
Entity: 17445520	3	15	panic attack	Disease	D016584
Entity: 17445520	39	47	caffeine	Chemical	D002110
Relation: 17445520	CID	39	47	D002110	3	15	D016584	true

Sentence: Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.
Entity: 17484470	6	19	heart failure	Disease	D006333
Entity: 17484470	35	46	propranolol	Chemical	D011433
Entity: 17484470	123	125	MR	Disease	D008944
Relation: 17484470	CID	35	46	D011433	6	19	D006333	true
Relation: 17484470	CID	35	46	D011433	123	125	D008944	false

Sentence: Piperacillin/tazobactam induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.
Entity: 17496739	0	23	Piperacillin/tazobactam	Chemical	C085143
Entity: 17496739	32	39	seizure	Disease	D012640
Relation: 17496739	CID	0	23	C085143	32	39	D012640	false

Sentence: Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.
Entity: 17496739	23	35	piperacillin	Chemical	D010878
Entity: 17496739	46	59	neurotoxicity	Disease	D020258
Entity: 17496739	76	88	piperacillin	Chemical	D010878
Relation: 17496739	CID	23	35	D010878	46	59	D020258	false
Relation: 17496739	CID	76	88	D010878	46	59	D020258	false

Sentence: We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.
Entity: 17496739	35	58	end-stage renal disease	Disease	D007676
Entity: 17496739	149	155	tremor	Disease	D014202
Entity: 17496739	194	203	confusion	Disease	D003221
Entity: 17496739	235	255	tonic-clonic seizure	Disease	D004830
Entity: 17496739	257	261	GTCS	Disease	D004830
Entity: 17496739	280	303	piperacillin/tazobactam	Chemical	C085143
Entity: 17496739	332	346	bronchiectasis	Disease	D001987
Entity: 17496739	352	371	secondary infection	Disease	D060085
Relation: 17496739	CID	280	303	C085143	35	58	D007676	false
Relation: 17496739	CID	280	303	C085143	149	155	D014202	true
Relation: 17496739	CID	280	303	C085143	194	203	D003221	true
Relation: 17496739	CID	280	303	C085143	235	255	D004830	true
Relation: 17496739	CID	280	303	C085143	257	261	D004830	true
Relation: 17496739	CID	280	303	C085143	332	346	D001987	false
Relation: 17496739	CID	280	303	C085143	352	371	D060085	false

Sentence: The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis.
Entity: 17496739	59	66	ammonia	Chemical	D000641
Entity: 17496739	78	90	leukocytosis	Disease	D007964
Relation: 17496739	CID	59	66	D000641	78	90	D007964	false

Sentence: Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam.
Entity: 17496739	49	53	GTCS	Disease	D004830
Entity: 17496739	95	118	piperacillin/tazobactam	Chemical	C085143
Relation: 17496739	CID	95	118	C085143	49	53	D004830	true

Sentence: Piperacillin induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.
Entity: 17496739	0	12	Piperacillin	Chemical	D010878
Entity: 17496739	21	35	encephalopathy	Disease	D001927
Entity: 17496739	64	70	uremic	Disease	D006463
Relation: 17496739	CID	0	12	D010878	21	35	D001927	false
Relation: 17496739	CID	0	12	D010878	64	70	D006463	false

Sentence: Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU induced cortical dysplasia.
Entity: 17572393	27	36	melatonin	Chemical	D008550
Entity: 17572393	94	98	BCNU	Chemical	D002330
Entity: 17572393	107	125	cortical dysplasia	Disease	D054220
Relation: 17572393	CID	27	36	D008550	107	125	D054220	false
Relation: 17572393	CID	94	98	D002330	107	125	D054220	true

Sentence: This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU induced cortical dysplasia, using histological and biochemical analyses.
Entity: 17572393	112	122	carmustine	Chemical	D002330
Entity: 17572393	124	160	1,3-bis (2-chloroethyl)-1-nitrosoure	Chemical	D002330
Entity: 17572393	163	167	BCNU	Chemical	D002330
Entity: 17572393	213	222	melatonin	Chemical	D008550
Entity: 17572393	239	243	BCNU	Chemical	D002330
Entity: 17572393	252	270	cortical dysplasia	Disease	D054220
Relation: 17572393	CID	112	122	D002330	252	270	D054220	true
Relation: 17572393	CID	124	160	D002330	252	270	D054220	true
Relation: 17572393	CID	163	167	D002330	252	270	D054220	true
Relation: 17572393	CID	213	222	D008550	252	270	D054220	false
Relation: 17572393	CID	239	243	D002330	252	270	D054220	true

Sentence: Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.
Entity: 17572393	169	173	BCNU	Chemical	D002330
Entity: 17572393	182	200	cortical dysplasia	Disease	D054220
Relation: 17572393	CID	169	173	D002330	182	200	D054220	true

Sentence: This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine induced seizures model.
Entity: 17828434	22	25	MIP	Chemical	C002647
Entity: 17828434	91	98	lithium	Chemical	D008094
Entity: 17828434	106	114	inositol	Chemical	D007294
Entity: 17828434	125	136	pilocarpine	Chemical	D010862
Entity: 17828434	145	153	seizures	Disease	D012640
Relation: 17828434	CID	22	25	C002647	145	153	D012640	false
Relation: 17828434	CID	91	98	D008094	145	153	D012640	false
Relation: 17828434	CID	106	114	D007294	145	153	D012640	false
Relation: 17828434	CID	125	136	D010862	145	153	D012640	true

Sentence: He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.
Entity: 17879100	14	21	aspirin	Chemical	D001241
Entity: 17879100	49	58	ibuprofen	Chemical	D007052
Entity: 17879100	63	68	fever	Disease	D005334
Relation: 17879100	CID	14	21	D001241	63	68	D005334	false
Relation: 17879100	CID	49	58	D007052	63	68	D005334	false

Sentence: Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.
Entity: 17879217	0	10	Rifampicin	Chemical	D012293
Entity: 17879217	44	62	glomerulonephritis	Disease	D005921
Entity: 17879217	66	80	staphylococcal	Disease	D013203
Entity: 17879217	81	93	endocarditis	Disease	D004696
Relation: 17879217	CID	0	10	D012293	44	62	D005921	true
Relation: 17879217	CID	0	10	D012293	66	80	D013203	false
Relation: 17879217	CID	0	10	D012293	81	93	D004696	false

Sentence: Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.
Entity: 17879217	22	40	glomerulonephritis	Disease	D005921
Entity: 17879217	78	88	rifampicin	Chemical	D012293
Entity: 17879217	133	145	tuberculosis	Disease	D014376
Relation: 17879217	CID	78	88	D012293	22	40	D005921	true
Relation: 17879217	CID	78	88	D012293	133	145	D014376	false

Sentence: Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.
Entity: 17879217	25	35	infections	Disease	D007239
Entity: 17879217	44	66	infective endocarditis	Disease	D004696
Entity: 17879217	68	70	IE	Disease	D004696
Entity: 17879217	109	119	rifampicin	Chemical	D012293
Entity: 17879217	124	149	Staphylococcal infections	Disease	D013203
Relation: 17879217	CID	109	119	D012293	25	35	D007239	false
Relation: 17879217	CID	109	119	D012293	44	66	D004696	false
Relation: 17879217	CID	109	119	D012293	68	70	D004696	false
Relation: 17879217	CID	109	119	D012293	124	149	D013203	false

Sentence: Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
Entity: 17954033	30	40	lamivudine	Chemical	D019259
Entity: 17954033	73	108	chronic hepatitis B virus infection	Disease	D019694
Relation: 17954033	CID	30	40	D019259	73	108	D019694	false

Sentence: BACKGROUND: Lamivudine is used for the treatment of chronic hepatitis B patients.
Entity: 17954033	12	22	Lamivudine	Chemical	D019259
Entity: 17954033	52	71	chronic hepatitis B	Disease	D019694
Relation: 17954033	CID	12	22	D019259	52	71	D019694	false

Sentence: Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.
Entity: 17954033	59	70	hepatitis B	Disease	D006509
Entity: 17954033	117	127	lamivudine	Chemical	D019259
Entity: 17954033	138	157	chronic hepatitis B	Disease	D019694
Relation: 17954033	CID	117	127	D019259	59	70	D006509	false
Relation: 17954033	CID	117	127	D019259	138	157	D019694	false

Sentence: In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.
Entity: 17954033	70	80	lamivudine	Chemical	D019259
Entity: 17954033	91	110	chronic hepatitis B	Disease	D019694
Relation: 17954033	CID	70	80	D019259	91	110	D019694	false

Sentence: PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study.
Entity: 17954033	36	55	chronic hepatitis B	Disease	D019694
Entity: 17954033	95	105	lamivudine	Chemical	D019259
Relation: 17954033	CID	95	105	D019259	36	55	D019694	false

Sentence: Branch retinal vein occlusion and fluoxetine.
Entity: 18025637	7	29	retinal vein occlusion	Disease	D012170
Entity: 18025637	34	44	fluoxetine	Chemical	D005473
Relation: 18025637	CID	34	44	D005473	7	29	D012170	true

Sentence: A case of branch retinal vein occlusion associated with fluoxetine induced secondary hypertension is described.
Entity: 18025637	17	39	retinal vein occlusion	Disease	D012170
Entity: 18025637	56	66	fluoxetine	Chemical	D005473
Entity: 18025637	85	97	hypertension	Disease	D006973
Relation: 18025637	CID	56	66	D005473	17	39	D012170	true
Relation: 18025637	CID	56	66	D005473	85	97	D006973	true

Sentence: The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.
Entity: 18165598	28	39	bupivacaine	Chemical	D002045
Entity: 18165598	44	53	lidocaine	Chemical	D008012
Entity: 18165598	57	73	prostaglandin E2	Chemical	D015232
Entity: 18165598	118	122	pain	Disease	D010146
Entity: 18165598	137	141	pain	Disease	D010146
Relation: 18165598	CID	28	39	D002045	118	122	D010146	false
Relation: 18165598	CID	28	39	D002045	137	141	D010146	false
Relation: 18165598	CID	44	53	D008012	118	122	D010146	false
Relation: 18165598	CID	44	53	D008012	137	141	D010146	false
Relation: 18165598	CID	57	73	D015232	118	122	D010146	false
Relation: 18165598	CID	57	73	D015232	137	141	D010146	false

Sentence: In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.
Entity: 18165598	65	76	bupivacaine	Chemical	D002045
Entity: 18165598	86	102	prostaglandin E2	Chemical	D015232
Entity: 18165598	104	108	PGE2	Chemical	D015232
Entity: 18165598	177	195	postoperative pain	Disease	D010149
Relation: 18165598	CID	65	76	D002045	177	195	D010149	true
Relation: 18165598	CID	86	102	D015232	177	195	D010149	false
Relation: 18165598	CID	104	108	D015232	177	195	D010149	false

Sentence: RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h.
Entity: 18165598	13	24	bupivacaine	Chemical	D002045
Entity: 18165598	25	34	rofecoxib	Chemical	C116926
Entity: 18165598	69	73	pain	Disease	D010146
Relation: 18165598	CID	13	24	D002045	69	73	D010146	false
Relation: 18165598	CID	25	34	C116926	69	73	D010146	false

Sentence: However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.
Entity: 18165598	13	24	bupivacaine	Chemical	D002045
Entity: 18165598	67	71	pain	Disease	D010146
Entity: 18165598	84	88	PGE2	Chemical	D015232
Relation: 18165598	CID	13	24	D002045	67	71	D010146	false
Relation: 18165598	CID	84	88	D015232	67	71	D010146	false

Sentence: p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide induced cystitis.
Entity: 18189308	78	94	cyclophosphamide	Chemical	D003520
Entity: 18189308	103	111	cystitis	Disease	D003556
Relation: 18189308	CID	78	94	D003520	103	111	D003556	true

Sentence: Previous studies have examined the expression and regulation of tyrosine kinase receptors (Trks) in micturition reflexes with urinary bladder inflammation.
Entity: 18189308	64	72	tyrosine	Chemical	D014443
Entity: 18189308	126	154	urinary bladder inflammation	Disease	D003556
Relation: 18189308	CID	64	72	D014443	126	154	D003556	false

Sentence: The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).
Entity: 18189308	134	154	bladder inflammation	Disease	D003556
Entity: 18189308	166	182	cyclophosphamide	Chemical	D003520
Entity: 18189308	184	187	CYP	Chemical	D003520
Relation: 18189308	CID	166	182	D003520	134	154	D003556	true
Relation: 18189308	CID	184	187	D003520	134	154	D003556	true

Sentence: CYP induced cystitis increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.
Entity: 18189308	0	3	CYP	Chemical	D003520
Entity: 18189308	12	20	cystitis	Disease	D003556
Relation: 18189308	CID	0	3	D003520	12	20	D003556	true

Sentence: The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with CYP induced cystitis (acute, intermediate, and chronic).
Entity: 18189308	131	134	CYP	Chemical	D003520
Entity: 18189308	143	151	cystitis	Disease	D003556
Relation: 18189308	CID	131	134	D003520	143	151	D003556	true

Sentence: Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic CYP induced cystitis.
Entity: 18189308	160	163	CYP	Chemical	D003520
Entity: 18189308	172	180	cystitis	Disease	D003556
Relation: 18189308	CID	160	163	D003520	172	180	D003556	true

Sentence: The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.
Entity: 18340638	20	32	azathioprine	Chemical	D001379
Entity: 18340638	41	47	anemia	Disease	D000740
Relation: 18340638	CID	20	32	D001379	41	47	D000740	true

Sentence: Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.
Entity: 18340638	15	21	anemia	Disease	D000740
Entity: 18340638	131	149	phosphatidylserine	Chemical	D010718
Entity: 18340638	151	153	PS	Chemical	D010718
Relation: 18340638	CID	131	149	D010718	15	21	D000740	false
Relation: 18340638	CID	151	153	D010718	15	21	D000740	false

Sentence: Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required epinephrine infusion to treat hypotension.
Entity: 18399341	103	114	epinephrine	Chemical	D004837
Entity: 18399341	133	144	hypotension	Disease	D007022
Relation: 18399341	CID	103	114	D004837	133	144	D007022	false

Sentence: Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).
Entity: 18422462	23	29	anemia	Disease	D000740
Entity: 18422462	112	121	hepatitis	Disease	D056486
Entity: 18422462	132	140	jaundice	Disease	D007565
Entity: 18422462	146	153	alanine	Chemical	D000409
Relation: 18422462	CID	146	153	D000409	23	29	D000740	false
Relation: 18422462	CID	146	153	D000409	112	121	D056486	false
Relation: 18422462	CID	146	153	D000409	132	140	D007565	false

Sentence: Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).
Entity: 18422462	45	48	NVP	Chemical	D019829
Entity: 18422462	102	106	rash	Disease	D005076
Entity: 18422462	111	114	d4T	Chemical	D018119
Entity: 18422462	139	160	peripheral neuropathy	Disease	D010523
Relation: 18422462	CID	45	48	D019829	102	106	D005076	true
Relation: 18422462	CID	45	48	D019829	139	160	D010523	false
Relation: 18422462	CID	111	114	D018119	102	106	D005076	false
Relation: 18422462	CID	111	114	D018119	139	160	D010523	true

Sentence: Thalidomide and sensory neurotoxicity: a neurophysiological study.
Entity: 18450790	0	11	Thalidomide	Chemical	D013792
Entity: 18450790	16	37	sensory neurotoxicity	Disease	D010523
Relation: 18450790	CID	0	11	D013792	16	37	D010523	true

Sentence: BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide.
Entity: 18450790	57	82	sensory axonal neuropathy	Disease	D010523
Entity: 18450790	127	138	thalidomide	Chemical	D013792
Relation: 18450790	CID	127	138	D013792	57	82	D010523	true

Sentence: The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.
Entity: 18450790	128	157	cutaneous lupus erythematosus	Disease	D008178
Entity: 18450790	159	162	CLE	Disease	D008178
Entity: 18450790	177	188	thalidomide	Chemical	D013792
Entity: 18450790	228	238	neurotoxic	Disease	D020258
Entity: 18450790	252	263	thalidomide	Chemical	D013792
Relation: 18450790	CID	177	188	D013792	128	157	D008178	false
Relation: 18450790	CID	177	188	D013792	159	162	D008178	false
Relation: 18450790	CID	177	188	D013792	228	238	D020258	false
Relation: 18450790	CID	252	263	D013792	128	157	D008178	false
Relation: 18450790	CID	252	263	D013792	159	162	D008178	false
Relation: 18450790	CID	252	263	D013792	228	238	D020258	false

Sentence: PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed.
Entity: 18450790	88	91	CLE	Disease	D008178
Entity: 18450790	114	125	thalidomide	Chemical	D013792
Relation: 18450790	CID	114	125	D013792	88	91	D008178	false

Sentence: Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.
Entity: 18801087	0	10	Amiodarone	Chemical	D000638
Entity: 18801087	19	33	pulmonary mass	Disease	D055370
Entity: 18801087	45	74	membranous glomerulonephritis	Disease	D015433
Entity: 18801087	93	115	valvular heart disease	Disease	D006349
Relation: 18801087	CID	0	10	D000638	19	33	D055370	true
Relation: 18801087	CID	0	10	D000638	45	74	D015433	true
Relation: 18801087	CID	0	10	D000638	93	115	D006349	false

Sentence: Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported.
Entity: 18801087	0	10	Amiodarone	Chemical	D000638
Entity: 18801087	22	32	arrhythmic	Disease	D001145
Entity: 18801087	59	70	tachycardia	Disease	D013610
Relation: 18801087	CID	0	10	D000638	22	32	D001145	false
Relation: 18801087	CID	0	10	D000638	59	70	D013610	false

Sentence: Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.
Entity: 18801087	38	60	valvular heart disease	Disease	D006349
Entity: 18801087	91	100	lung mass	Disease	D055370
Entity: 18801087	126	137	proteinuria	Disease	D011507
Entity: 18801087	172	182	amiodarone	Chemical	D000638
Relation: 18801087	CID	172	182	D000638	38	60	D006349	false
Relation: 18801087	CID	172	182	D000638	91	100	D055370	true
Relation: 18801087	CID	172	182	D000638	126	137	D011507	false

Sentence: The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.
Entity: 18801087	4	13	lung mass	Disease	D055370
Entity: 18801087	41	52	lung cancer	Disease	D008175
Entity: 18801087	310	320	amiodarone	Chemical	D000638
Relation: 18801087	CID	310	320	D000638	4	13	D055370	true
Relation: 18801087	CID	310	320	D000638	41	52	D008175	false

Sentence: Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Entity: 18945509	8	31	coronary artery disease	Disease	D003324
Entity: 18945509	56	69	sulphonylurea	Chemical	-1
Entity: 18945509	97	112	type 2 diabetes	Disease	D003924
Relation: 18945509	CID	56	69	-1	8	31	D003324	false
Relation: 18945509	CID	56	69	-1	97	112	D003924	false

Sentence: AIMS: This study sought to assess the risk of developing coronary artery disease (CAD) associated with initial treatment of type 2 diabetes with different sulphonylureas.
Entity: 18945509	57	80	coronary artery disease	Disease	D003324
Entity: 18945509	82	85	CAD	Disease	D003324
Entity: 18945509	124	139	type 2 diabetes	Disease	D003924
Entity: 18945509	155	169	sulphonylureas	Chemical	-1
Relation: 18945509	CID	155	169	-1	57	80	D003324	false
Relation: 18945509	CID	155	169	-1	82	85	D003324	false
Relation: 18945509	CID	155	169	-1	124	139	D003924	false

Sentence: The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.
Entity: 18945509	25	28	CAD	Disease	D003324
Entity: 18945509	118	131	glibenclamide	Chemical	D005905
Entity: 18945509	164	173	glipizide	Chemical	D005913
Entity: 18945509	239	248	metformin	Chemical	D008687
Relation: 18945509	CID	118	131	D005905	25	28	D003324	true
Relation: 18945509	CID	164	173	D005913	25	28	D003324	false
Relation: 18945509	CID	239	248	D008687	25	28	D003324	false

Sentence: CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.
Entity: 18945509	37	52	type 2 diabetes	Disease	D003924
Entity: 18945509	58	71	glibenclamide	Chemical	D005905
Entity: 18945509	75	84	glipizide	Chemical	D005913
Entity: 18945509	122	125	CAD	Disease	D003324
Entity: 18945509	143	153	gliclazide	Chemical	D005907
Entity: 18945509	157	168	glimepiride	Chemical	C057619
Relation: 18945509	CID	58	71	D005905	37	52	D003924	false
Relation: 18945509	CID	58	71	D005905	122	125	D003324	true
Relation: 18945509	CID	75	84	D005913	37	52	D003924	false
Relation: 18945509	CID	75	84	D005913	122	125	D003324	false
Relation: 18945509	CID	143	153	D005907	37	52	D003924	false
Relation: 18945509	CID	143	153	D005907	122	125	D003324	false
Relation: 18945509	CID	157	168	C057619	37	52	D003924	false
Relation: 18945509	CID	157	168	C057619	122	125	D003324	false

Sentence: Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.
Entity: 18987260	23	33	adriamycin	Chemical	D004317
Entity: 18987260	34	45	nephropathy	Disease	D007674
Entity: 18987260	63	75	hypertensive	Disease	D006973
Entity: 18987260	92	100	losartan	Chemical	D019808
Relation: 18987260	CID	23	33	D004317	34	45	D007674	false
Relation: 18987260	CID	23	33	D004317	63	75	D006973	false
Relation: 18987260	CID	92	100	D019808	34	45	D007674	false
Relation: 18987260	CID	92	100	D019808	63	75	D006973	false

Sentence: BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.
Entity: 18987260	84	98	angiotensin II	Chemical	D000804
Entity: 18987260	124	132	losartan	Chemical	D019808
Entity: 18987260	168	181	renal disease	Disease	D007674
Entity: 18987260	211	223	hypertensive	Disease	D006973
Entity: 18987260	240	250	adriamycin	Chemical	D004317
Entity: 18987260	252	255	ADR	Chemical	D004317
Entity: 18987260	257	268	nephropathy	Disease	D007674
Relation: 18987260	CID	84	98	D000804	168	181	D007674	false
Relation: 18987260	CID	84	98	D000804	211	223	D006973	false
Relation: 18987260	CID	84	98	D000804	257	268	D007674	false
Relation: 18987260	CID	124	132	D019808	168	181	D007674	false
Relation: 18987260	CID	124	132	D019808	211	223	D006973	false
Relation: 18987260	CID	124	132	D019808	257	268	D007674	false
Relation: 18987260	CID	240	250	D004317	168	181	D007674	false
Relation: 18987260	CID	240	250	D004317	211	223	D006973	false
Relation: 18987260	CID	240	250	D004317	257	268	D007674	false
Relation: 18987260	CID	252	255	D004317	168	181	D007674	false
Relation: 18987260	CID	252	255	D004317	211	223	D006973	false
Relation: 18987260	CID	252	255	D004317	257	268	D007674	false

Sentence: RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.
Entity: 18987260	20	28	losartan	Chemical	D019808
Entity: 18987260	125	143	glomerulosclerosis	Disease	D005921
Entity: 18987260	167	178	proteinuria	Disease	D011507
Relation: 18987260	CID	20	28	D019808	125	143	D005921	false
Relation: 18987260	CID	20	28	D019808	167	178	D011507	false

Sentence: Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.
Entity: 18987260	25	33	losartan	Chemical	D019808
Entity: 18987260	62	80	glomerulosclerosis	Disease	D005921
Entity: 18987260	128	135	atrophy	Disease	D001284
Entity: 18987260	140	161	interstitial fibrosis	Disease	D005355
Entity: 18987260	185	196	proteinuria	Disease	D011507
Entity: 18987260	201	222	chronic renal failure	Disease	D007676
Relation: 18987260	CID	25	33	D019808	62	80	D005921	false
Relation: 18987260	CID	25	33	D019808	128	135	D001284	false
Relation: 18987260	CID	25	33	D019808	140	161	D005355	false
Relation: 18987260	CID	25	33	D019808	185	196	D011507	false
Relation: 18987260	CID	25	33	D019808	201	222	D007676	false

Sentence: Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.
Entity: 18987260	0	8	Losartan	Chemical	D019808
Entity: 18987260	17	24	uraemia	Disease	D014511
Entity: 18987260	39	43	urea	Chemical	D014508
Entity: 18987260	66	69	ADR	Chemical	D004317
Entity: 18987260	70	81	nephropathy	Disease	D007674
Relation: 18987260	CID	0	8	D019808	17	24	D014511	false
Relation: 18987260	CID	0	8	D019808	70	81	D007674	false
Relation: 18987260	CID	39	43	D014508	17	24	D014511	false
Relation: 18987260	CID	39	43	D014508	70	81	D007674	false
Relation: 18987260	CID	66	69	D004317	17	24	D014511	true
Relation: 18987260	CID	66	69	D004317	70	81	D007674	false

Sentence: Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.
Entity: 18987260	37	45	losartan	Chemical	D019808
Entity: 18987260	68	75	atrophy	Disease	D001284
Entity: 18987260	107	115	fibrosis	Disease	D005355
Entity: 18987260	119	122	ADR	Chemical	D004317
Entity: 18987260	123	134	nephropathy	Disease	D007674
Relation: 18987260	CID	37	45	D019808	68	75	D001284	false
Relation: 18987260	CID	37	45	D019808	107	115	D005355	false
Relation: 18987260	CID	37	45	D019808	123	134	D007674	false
Relation: 18987260	CID	119	122	D004317	68	75	D001284	false
Relation: 18987260	CID	119	122	D004317	107	115	D005355	false
Relation: 18987260	CID	119	122	D004317	123	134	D007674	false

Sentence: The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. 1.
Entity: 19108278	52	63	propranolol	Chemical	D011433
Entity: 19108278	85	104	cardiac arrhythmias	Disease	D001145
Relation: 19108278	CID	52	63	D011433	85	104	D001145	false

Sentence: Both isomers of propranolol were capable of preventing adrenaline induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.
Entity: 19108278	16	27	propranolol	Chemical	D011433
Entity: 19108278	55	65	adrenaline	Chemical	D004837
Entity: 19108278	74	93	cardiac arrhythmias	Disease	D001145
Entity: 19108278	121	130	halothane	Chemical	D006221
Entity: 19108278	157	168	propranolol	Chemical	D011433
Entity: 19108278	211	222	propranolol	Chemical	D011433
Relation: 19108278	CID	16	27	D011433	74	93	D001145	false
Relation: 19108278	CID	55	65	D004837	74	93	D001145	true
Relation: 19108278	CID	121	130	D006221	74	93	D001145	true
Relation: 19108278	CID	157	168	D011433	74	93	D001145	false
Relation: 19108278	CID	211	222	D011433	74	93	D001145	false

Sentence: Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.
Entity: 19108278	12	23	arrhythmias	Disease	D001145
Entity: 19108278	85	95	adrenaline	Chemical	D004837
Relation: 19108278	CID	85	95	D004837	12	23	D001145	true

Sentence: Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.
Entity: 19108278	16	27	propranolol	Chemical	D011433
Entity: 19108278	59	82	ventricular tachycardia	Disease	D017180
Entity: 19108278	93	100	ouabain	Chemical	D010042
Relation: 19108278	CID	16	27	D011433	59	82	D017180	false
Relation: 19108278	CID	93	100	D010042	59	82	D017180	true

Sentence: Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.
Entity: 19139825	0	9	Topotecan	Chemical	D019772
Entity: 19139825	59	71	glioblastoma	Disease	D005909
Relation: 19139825	CID	0	9	D019772	59	71	D005909	false

Sentence: Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration.
Entity: 19139825	0	9	Topotecan	Chemical	D019772
Entity: 19139825	76	82	glioma	Disease	D005910
Relation: 19139825	CID	0	9	D019772	76	82	D005910	false

Sentence: The present study assessed the combination of radiotherapy (60 Gy/30 fractions/40 days) and topotecan (0.9 mg/m(2)/day on days 1-5 on weeks 1, 3 and 5) in 50 adults with histologically proven and untreated GBM.
Entity: 19139825	92	101	topotecan	Chemical	D019772
Entity: 19139825	206	209	GBM	Disease	D005909
Relation: 19139825	CID	92	101	D019772	206	209	D005909	false

Sentence: Long-term lithium therapy leading to hyperparathyroidism: a case report.
Entity: 19154241	10	17	lithium	Chemical	D008094
Entity: 19154241	37	56	hyperparathyroidism	Disease	D006961
Relation: 19154241	CID	10	17	D008094	37	56	D006961	true

Sentence: We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process.
Entity: 19154241	26	33	lithium	Chemical	D008094
Entity: 19154241	68	81	hypercalcemia	Disease	D006934
Relation: 19154241	CID	26	33	D008094	68	81	D006934	true

Sentence: CONCLUSION: Primary hyperparathyroidism is a rare but potentially life-threatening side effect of long-term lithium therapy.
Entity: 19154241	12	39	Primary hyperparathyroidism	Disease	D049950
Entity: 19154241	108	115	lithium	Chemical	D008094
Relation: 19154241	CID	108	115	D008094	12	39	D049950	false

Sentence: PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become hypercalcemic.
Entity: 19154241	42	49	lithium	Chemical	D008094
Entity: 19154241	74	87	hypercalcemic	Disease	D006934
Relation: 19154241	CID	42	49	D008094	74	87	D006934	true

Sentence: BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v. anesthesia (TIVA).
Entity: 19178808	113	121	bleeding	Disease	D006470
Entity: 19178808	327	338	hypotension	Disease	D007022
Entity: 19178808	361	369	propofol	Chemical	D015742
Entity: 19178808	370	382	remifentanil	Chemical	C071741
Relation: 19178808	CID	361	369	D015742	113	121	D006470	false
Relation: 19178808	CID	361	369	D015742	327	338	D007022	true
Relation: 19178808	CID	370	382	C071741	113	121	D006470	false
Relation: 19178808	CID	370	382	C071741	327	338	D007022	true

Sentence: METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.
Entity: 19178808	119	130	hypotension	Disease	D007022
Entity: 19178808	152	160	propofol	Chemical	D015742
Entity: 19178808	161	173	remifentanil	Chemical	C071741
Relation: 19178808	CID	152	160	D015742	119	130	D007022	true
Relation: 19178808	CID	161	173	C071741	119	130	D007022	true

Sentence: RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.
Entity: 19178808	20	31	hypotension	Disease	D007022
Entity: 19178808	111	123	remifentanil	Chemical	C071741
Entity: 19178808	157	169	remifentanil	Chemical	C071741
Relation: 19178808	CID	111	123	C071741	20	31	D007022	true
Relation: 19178808	CID	157	169	C071741	20	31	D007022	true

Sentence: Nonalcoholic fatty liver disease during valproate therapy.
Entity: 19184102	0	32	Nonalcoholic fatty liver disease	Disease	D065626
Entity: 19184102	40	49	valproate	Chemical	D014635
Relation: 19184102	CID	40	49	D014635	0	32	D065626	true

Sentence: Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight.
Entity: 19184102	0	13	Valproic acid	Chemical	D014635
Entity: 19184102	15	18	VPA	Chemical	D014635
Entity: 19184102	68	76	epilepsy	Disease	D004827
Relation: 19184102	CID	0	13	D014635	68	76	D004827	false
Relation: 19184102	CID	15	18	D014635	68	76	D004827	false

Sentence: We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.
Entity: 19184102	20	52	nonalcoholic fatty liver disease	Disease	D065626
Entity: 19184102	54	59	NAFLD	Disease	D065626
Entity: 19184102	94	101	obesity	Disease	D009765
Entity: 19184102	109	112	VPA	Chemical	D014635
Relation: 19184102	CID	109	112	D014635	20	52	D065626	true
Relation: 19184102	CID	109	112	D014635	54	59	D065626	true
Relation: 19184102	CID	109	112	D014635	94	101	D009765	true

Sentence: After the withdrawal of VPA therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization.
Entity: 19184102	24	27	VPA	Chemical	D014635
Entity: 19184102	70	81	weight loss	Disease	D015431
Relation: 19184102	CID	24	27	D014635	70	81	D015431	false

Sentence: Carbimazole induced ANCA positive vasculitis.
Entity: 19263707	0	11	Carbimazole	Chemical	D002231
Entity: 19263707	20	44	ANCA positive vasculitis	Disease	D056648
Relation: 19263707	CID	0	11	D002231	20	44	D056648	true

Sentence: Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.
Entity: 19263707	0	18	Anti-thyroid drugs	Chemical	D013956
Entity: 19263707	25	36	carbimazole	Chemical	D002231
Entity: 19263707	41	57	propylthiouracil	Chemical	D011441
Entity: 19263707	59	62	PTU	Chemical	D011441
Entity: 19263707	109	124	hyperthyroidism	Disease	D006980
Relation: 19263707	CID	0	18	D013956	109	124	D006980	false
Relation: 19263707	CID	25	36	D002231	109	124	D006980	false
Relation: 19263707	CID	41	57	D011441	109	124	D006980	false
Relation: 19263707	CID	59	62	D011441	109	124	D006980	false

Sentence: Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications.
Entity: 19263707	0	65	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis	Disease	D056648
Entity: 19263707	118	140	antithyroidmedications	Chemical	D013956
Relation: 19263707	CID	118	140	D013956	0	65	D056648	true

Sentence: We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.
Entity: 19263707	25	40	Graves' disease	Disease	D006111
Entity: 19263707	69	80	carbimazole	Chemical	D002231
Entity: 19263707	89	99	vasculitis	Disease	D014657
Relation: 19263707	CID	69	80	D002231	25	40	D006111	false
Relation: 19263707	CID	69	80	D002231	89	99	D014657	false

Sentence: Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease.
Entity: 19293073	85	92	aspirin	Chemical	D001241
Entity: 19293073	135	157	coronary heart disease	Disease	D003327
Relation: 19293073	CID	85	92	D001241	135	157	D003327	false

Sentence: PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.
Entity: 19293073	55	62	aspirin	Chemical	D001241
Entity: 19293073	93	115	myocardial infarctions	Disease	D009203
Entity: 19293073	117	124	strokes	Disease	D020521
Relation: 19293073	CID	55	62	D001241	93	115	D009203	false
Relation: 19293073	CID	55	62	D001241	117	124	D020521	true

Sentence: STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD.
Entity: 19293073	135	142	aspirin	Chemical	D001241
Entity: 19293073	188	210	cardiovascular disease	Disease	D002318
Entity: 19293073	212	215	CVD	Disease	D002318
Entity: 19293073	271	278	aspirin	Chemical	D001241
Entity: 19293073	311	318	strokes	Disease	D020521
Entity: 19293073	356	362	stroke	Disease	D020521
Entity: 19293073	411	414	CVD	Disease	D002318
Relation: 19293073	CID	135	142	D001241	188	210	D002318	false
Relation: 19293073	CID	135	142	D001241	212	215	D002318	false
Relation: 19293073	CID	135	142	D001241	311	318	D020521	true
Relation: 19293073	CID	135	142	D001241	356	362	D020521	true
Relation: 19293073	CID	135	142	D001241	411	414	D002318	false
Relation: 19293073	CID	271	278	D001241	188	210	D002318	false
Relation: 19293073	CID	271	278	D001241	212	215	D002318	false
Relation: 19293073	CID	271	278	D001241	311	318	D020521	true
Relation: 19293073	CID	271	278	D001241	356	362	D020521	true
Relation: 19293073	CID	271	278	D001241	411	414	D002318	false

Sentence: Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes.
Entity: 19293073	5	12	aspirin	Chemical	D001241
Entity: 19293073	22	47	gastrointestinal bleeding	Disease	D006471
Entity: 19293073	51	62	hemorrhagic	Disease	D020300
Entity: 19293073	63	70	strokes	Disease	D020521
Relation: 19293073	CID	5	12	D001241	22	47	D006471	true
Relation: 19293073	CID	5	12	D001241	51	62	D020300	true
Relation: 19293073	CID	5	12	D001241	63	70	D020521	true

Sentence: DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD.
Entity: 19293073	141	148	aspirin	Chemical	D001241
Entity: 19293073	175	178	CVD	Disease	D002318
Entity: 19293073	212	215	CVD	Disease	D002318
Relation: 19293073	CID	141	148	D001241	175	178	D002318	false
Relation: 19293073	CID	141	148	D001241	212	215	D002318	false

Sentence: Aspirin does not seem to affect CVD mortality or all-cause mortality in either men or women.
Entity: 19293073	0	7	Aspirin	Chemical	D001241
Entity: 19293073	32	35	CVD	Disease	D002318
Relation: 19293073	CID	0	7	D001241	32	35	D002318	false

Sentence: The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.
Entity: 19293073	11	18	aspirin	Chemical	D001241
Entity: 19293073	71	79	bleeding	Disease	D006470
Entity: 19293073	98	123	gastrointestinal bleeding	Disease	D006471
Relation: 19293073	CID	11	18	D001241	71	79	D006470	false
Relation: 19293073	CID	11	18	D001241	98	123	D006471	true

Sentence: Men have an increased risk for hemorrhagic strokes with aspirin use.
Entity: 19293073	31	42	hemorrhagic	Disease	D020300
Entity: 19293073	43	50	strokes	Disease	D020521
Entity: 19293073	56	63	aspirin	Chemical	D001241
Relation: 19293073	CID	56	63	D001241	31	42	D020300	true
Relation: 19293073	CID	56	63	D001241	43	50	D020521	true

Sentence: LIMITATIONS: New evidence on aspirin for the primary prevention of CVD is limited.
Entity: 19293073	29	36	aspirin	Chemical	D001241
Entity: 19293073	67	70	CVD	Disease	D002318
Relation: 19293073	CID	29	36	D001241	67	70	D002318	false

Sentence: CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.
Entity: 19293073	12	19	Aspirin	Chemical	D001241
Entity: 19293073	41	62	myocardial infarction	Disease	D009203
Entity: 19293073	74	81	strokes	Disease	D020521
Relation: 19293073	CID	12	19	D001241	41	62	D009203	false
Relation: 19293073	CID	12	19	D001241	74	81	D020521	true

Sentence: Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin induced thrombocytopenia.
Entity: 19338378	75	85	argatroban	Chemical	C031942
Entity: 19338378	97	104	heparin	Chemical	D006493
Entity: 19338378	113	129	thrombocytopenia	Disease	D013921
Relation: 19338378	CID	75	85	C031942	113	129	D013921	false
Relation: 19338378	CID	97	104	D006493	113	129	D013921	false

Sentence: Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).
Entity: 19338378	0	10	Argatroban	Chemical	C031942
Entity: 19338378	104	114	thrombosis	Disease	D013927
Entity: 19338378	118	125	heparin	Chemical	D006493
Entity: 19338378	134	150	thrombocytopenia	Disease	D013921
Entity: 19338378	152	155	HIT	Disease	D013921
Entity: 19338378	193	196	HIT	Disease	D013921
Relation: 19338378	CID	0	10	C031942	104	114	D013927	false
Relation: 19338378	CID	0	10	C031942	134	150	D013921	false
Relation: 19338378	CID	0	10	C031942	152	155	D013921	false
Relation: 19338378	CID	0	10	C031942	193	196	D013921	false
Relation: 19338378	CID	118	125	D006493	104	114	D013927	false
Relation: 19338378	CID	118	125	D006493	134	150	D013921	false
Relation: 19338378	CID	118	125	D006493	152	155	D013921	false
Relation: 19338378	CID	118	125	D006493	193	196	D013921	false

Sentence: The objective of this review is to summarize practical considerations of argatroban therapy in HIT.
Entity: 19338378	73	83	argatroban	Chemical	C031942
Entity: 19338378	95	98	HIT	Disease	D013921
Relation: 19338378	CID	73	83	C031942	95	98	D013921	false

Sentence: The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).
Entity: 19338378	23	33	argatroban	Chemical	C031942
Entity: 19338378	42	45	HIT	Disease	D013921
Entity: 19338378	91	109	hepatic impairment	Disease	D008107
Relation: 19338378	CID	23	33	C031942	42	45	D013921	false
Relation: 19338378	CID	23	33	C031942	91	109	D008107	false

Sentence: For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition.
Entity: 19338378	9	19	argatroban	Chemical	C031942
Entity: 19338378	149	156	obesity	Disease	D009765
Relation: 19338378	CID	9	19	C031942	149	156	D009765	false

Sentence: Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.
Entity: 19338378	6	14	bleeding	Disease	D006470
Entity: 19338378	20	30	argatroban	Chemical	C031942
Relation: 19338378	CID	20	30	C031942	6	14	D006470	true

Sentence: Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.
Entity: 19392810	0	14	Rhabdomyolysis	Disease	D012206
Entity: 19392810	25	40	ischemic stroke	Disease	D002544
Entity: 19392810	46	52	heroin	Chemical	D003932
Entity: 19392810	74	83	methadone	Chemical	D008691
Relation: 19392810	CID	46	52	D003932	0	14	D012206	true
Relation: 19392810	CID	46	52	D003932	25	40	D002544	false
Relation: 19392810	CID	74	83	D008691	0	14	D012206	true
Relation: 19392810	CID	74	83	D008691	25	40	D002544	false

Sentence: RESULTS: A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.
Entity: 19392810	42	56	rhabdomyolysis	Disease	D012206
Entity: 19392810	70	85	ischemic stroke	Disease	D002544
Entity: 19392810	104	110	heroin	Chemical	D003932
Relation: 19392810	CID	104	110	D003932	42	56	D012206	true
Relation: 19392810	CID	104	110	D003932	70	85	D002544	false

Sentence: CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.
Entity: 19392810	24	33	methadone	Chemical	D008691
Entity: 19392810	38	44	heroin	Chemical	D003932
Entity: 19392810	81	95	rhabdomyolysis	Disease	D012206
Entity: 19392810	100	115	ischemic stroke	Disease	D002544
Relation: 19392810	CID	24	33	D008691	81	95	D012206	true
Relation: 19392810	CID	24	33	D008691	100	115	D002544	false
Relation: 19392810	CID	38	44	D003932	81	95	D012206	true
Relation: 19392810	CID	38	44	D003932	100	115	D002544	false

Sentence: Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Entity: 19419794	27	44	6-hydroxydopamine	Chemical	D016627
Entity: 19419794	79	90	dyskinesias	Disease	D004409
Relation: 19419794	CID	27	44	D016627	79	90	D004409	false

Sentence: Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 KO than in WT mice.
Entity: 19419794	15	33	L-DOPA+benserazide	Chemical	C005177
Entity: 19419794	69	80	dyskinesias	Disease	D004409
Relation: 19419794	CID	15	33	C005177	69	80	D004409	false

Sentence: The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA induced dyskinesias.
Entity: 19419794	111	113	DA	Chemical	D004298
Entity: 19419794	134	140	L-DOPA	Chemical	D007980
Entity: 19419794	149	160	dyskinesias	Disease	D004409
Relation: 19419794	CID	111	113	D004298	149	160	D004409	false
Relation: 19419794	CID	134	140	D007980	149	160	D004409	true

Sentence: Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.
Entity: 19447152	16	21	mania	Disease	D001714
Entity: 19447152	33	40	ouabain	Chemical	D010042
Relation: 19447152	CID	33	40	D010042	16	21	D001714	true

Sentence: The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.
Entity: 19447152	52	59	ouabain	Chemical	D010042
Entity: 19447152	63	65	Na	Chemical	D012964
Entity: 19447152	69	70	K	Chemical	D011188
Entity: 19447152	151	164	bipolar mania	Disease	D001714
Relation: 19447152	CID	52	59	D010042	151	164	D001714	true
Relation: 19447152	CID	63	65	D012964	151	164	D001714	false
Relation: 19447152	CID	69	70	D011188	151	164	D001714	false

Sentence: Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced hyperlocomotion in rats, and this response remained up to 7 days following a single ICV injection.
Entity: 19447152	31	38	ouabain	Chemical	D010042
Entity: 19447152	69	84	hyperlocomotion	Disease	D009069
Relation: 19447152	CID	31	38	D010042	69	84	D009069	false

Sentence: Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity.
Entity: 19515070	48	55	citrate	Chemical	D019343
Entity: 19515070	129	136	citrate	Chemical	D019343
Entity: 19515070	137	145	toxicity	Disease	D064420
Relation: 19515070	CID	48	55	D019343	137	145	D064420	false
Relation: 19515070	CID	129	136	D019343	137	145	D064420	false

Sentence: We report a case of a 40-year-old female with acetaminophen induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.
Entity: 19515070	46	59	acetaminophen	Chemical	D000082
Entity: 19515070	68	91	fulminant liver failure	Disease	D017114
Entity: 19515070	108	111	AKI	Disease	D058186
Entity: 19515070	207	214	citrate	Chemical	D019343
Relation: 19515070	CID	46	59	D000082	68	91	D017114	true
Relation: 19515070	CID	46	59	D000082	108	111	D058186	true
Relation: 19515070	CID	207	214	D019343	68	91	D017114	false
Relation: 19515070	CID	207	214	D019343	108	111	D058186	false

Sentence: The patient tolerated the procedure well without any signs of citrate toxicity and maintained adequate anticoagulation for patency of the dialysis circuit.
Entity: 19515070	62	69	citrate	Chemical	D019343
Entity: 19515070	70	78	toxicity	Disease	D064420
Relation: 19515070	CID	62	69	D019343	70	78	D064420	false

Sentence: Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
Entity: 19531695	0	8	Delirium	Disease	D003693
Entity: 19531695	33	43	flecainide	Chemical	D005424
Entity: 19531695	119	129	paroxetine	Chemical	D017374
Relation: 19531695	CID	33	43	D005424	0	8	D003693	true
Relation: 19531695	CID	119	129	D017374	0	8	D003693	true

Sentence: OBJECTIVE: To describe a case of flecainide induced delirium associated with a pharmacokinetic drug interaction with paroxetine.
Entity: 19531695	33	43	flecainide	Chemical	D005424
Entity: 19531695	52	60	delirium	Disease	D003693
Entity: 19531695	117	127	paroxetine	Chemical	D017374
Relation: 19531695	CID	33	43	D005424	52	60	D003693	true
Relation: 19531695	CID	117	127	D017374	52	60	D003693	true

Sentence: Flecainide had been started 2 weeks prior for atrial fibrillation.
Entity: 19531695	0	10	Flecainide	Chemical	D005424
Entity: 19531695	46	65	atrial fibrillation	Disease	D001281
Relation: 19531695	CID	0	10	D005424	46	65	D001281	false

Sentence: DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.
Entity: 19531695	12	22	Flecainide	Chemical	D005424
Entity: 19531695	79	85	sodium	Chemical	D012964
Entity: 19531695	105	113	delirium	Disease	D003693
Relation: 19531695	CID	12	22	D005424	105	113	D003693	true
Relation: 19531695	CID	79	85	D012964	105	113	D003693	false

Sentence: A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide induced delirium.
Entity: 19531695	107	117	flecainide	Chemical	D005424
Entity: 19531695	143	153	paroxetine	Chemical	D017374
Entity: 19531695	204	214	flecainide	Chemical	D005424
Entity: 19531695	223	231	delirium	Disease	D003693
Relation: 19531695	CID	107	117	D005424	223	231	D003693	true
Relation: 19531695	CID	143	153	D017374	223	231	D003693	true
Relation: 19531695	CID	204	214	D005424	223	231	D003693	true

Sentence: According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.
Entity: 19531695	44	54	flecainide	Chemical	D005424
Entity: 19531695	95	103	delirium	Disease	D003693
Entity: 19531695	211	221	flecainide	Chemical	D005424
Entity: 19531695	226	236	paroxetine	Chemical	D017374
Relation: 19531695	CID	44	54	D005424	95	103	D003693	true
Relation: 19531695	CID	211	221	D005424	95	103	D003693	true
Relation: 19531695	CID	226	236	D017374	95	103	D003693	true

Sentence: CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium.
Entity: 19531695	30	40	flecainide	Chemical	D005424
Entity: 19531695	73	81	delirium	Disease	D003693
Relation: 19531695	CID	30	40	D005424	73	81	D003693	true

Sentence: Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
Entity: 19549709	12	22	everolimus	Chemical	C107135
Entity: 19549709	24	30	RAD001	Chemical	C107135
Entity: 19549709	58	63	NSCLC	Disease	D002289
Relation: 19549709	CID	12	22	C107135	58	63	D002289	false
Relation: 19549709	CID	24	30	C107135	58	63	D002289	false

Sentence: RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.
Entity: 19549709	0	6	RAD001	Chemical	C107135
Entity: 19549709	53	62	rapamycin	Chemical	D020123
Entity: 19549709	101	106	NSCLC	Disease	D002289
Relation: 19549709	CID	0	6	C107135	101	106	D002289	false
Relation: 19549709	CID	53	62	D020123	101	106	D002289	false

Sentence: METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.
Entity: 19549709	26	31	NSCLC	Disease	D002289
Entity: 19549709	93	101	platinum	Chemical	D010984
Entity: 19549709	178	186	tyrosine	Chemical	D014443
Entity: 19549709	227	233	RAD001	Chemical	C107135
Entity: 19549709	278	286	toxicity	Disease	D064420
Relation: 19549709	CID	93	101	D010984	26	31	D002289	false
Relation: 19549709	CID	93	101	D010984	278	286	D064420	false
Relation: 19549709	CID	178	186	D014443	26	31	D002289	false
Relation: 19549709	CID	178	186	D014443	278	286	D064420	false
Relation: 19549709	CID	227	233	C107135	26	31	D002289	false
Relation: 19549709	CID	227	233	C107135	278	286	D064420	false

Sentence: CONCLUSIONS: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC.
Entity: 19549709	13	19	RAD001	Chemical	C107135
Entity: 19549709	97	102	NSCLC	Disease	D002289
Relation: 19549709	CID	13	19	C107135	97	102	D002289	false

Sentence: Posttransplant anemia: the role of sirolimus.
Entity: 19553912	15	21	anemia	Disease	D000740
Entity: 19553912	35	44	sirolimus	Chemical	D020123
Relation: 19553912	CID	35	44	D020123	15	21	D000740	true

Sentence: Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia.
Entity: 19553912	0	9	Sirolimus	Chemical	D020123
Entity: 19553912	33	42	rapamycin	Chemical	D020123
Entity: 19553912	118	124	anemia	Disease	D000740
Relation: 19553912	CID	0	9	D020123	118	124	D000740	true
Relation: 19553912	CID	33	42	D020123	118	124	D000740	true

Sentence: Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain.
Entity: 19655282	91	98	cocaine	Chemical	D003042
Entity: 19655282	110	120	chest pain	Disease	D002637
Relation: 19655282	CID	91	98	D003042	110	120	D002637	true

Sentence: BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a "rule out acute coronary syndrome" protocol, often with noninvasive testing prior to discharge.
Entity: 19655282	73	80	cocaine	Chemical	D003042
Entity: 19655282	92	102	chest pain	Disease	D002637
Entity: 19655282	162	185	acute coronary syndrome	Disease	D054058
Relation: 19655282	CID	73	80	D003042	92	102	D002637	true
Relation: 19655282	CID	73	80	D003042	162	185	D054058	false

Sentence: It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.
Entity: 19655282	70	77	cocaine	Chemical	D003042
Entity: 19655282	89	99	chest pain	Disease	D002637
Entity: 19655282	104	122	coronary vasospasm	Disease	D003329
Entity: 19655282	151	159	ischemia	Disease	D007511
Relation: 19655282	CID	70	77	D003042	89	99	D002637	true
Relation: 19655282	CID	70	77	D003042	104	122	D003329	false
Relation: 19655282	CID	70	77	D003042	151	159	D007511	false

Sentence: We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.
Entity: 19655282	60	67	cocaine	Chemical	D003042
Entity: 19655282	79	89	chest pain	Disease	D002637
Relation: 19655282	CID	60	67	D003042	79	89	D002637	true

Sentence: RESULTS: A total of 59 patients with cocaine-associated chest pain were evaluated.
Entity: 19655282	37	44	cocaine	Chemical	D003042
Entity: 19655282	56	66	chest pain	Disease	D002637
Relation: 19655282	CID	37	44	D003042	56	66	D002637	true

Sentence: METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.
Entity: 19728177	131	134	FHF	Disease	D017114
Entity: 19728177	140	153	acetaminophen	Chemical	D000082
Entity: 19728177	168	182	cerebral edema	Disease	D001929
Relation: 19728177	CID	140	153	D000082	131	134	D017114	true
Relation: 19728177	CID	140	153	D000082	168	182	D001929	true

Sentence: RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.
Entity: 19728177	91	99	toxicity	Disease	D064420
Entity: 19728177	105	118	acetaminophen	Chemical	D000082
Relation: 19728177	CID	105	118	D000082	91	99	D064420	false

Sentence: Initial evaluation confirmed FHF from acetaminophen and cerebral edema.
Entity: 19728177	29	32	FHF	Disease	D017114
Entity: 19728177	38	51	acetaminophen	Chemical	D000082
Entity: 19728177	56	70	cerebral edema	Disease	D001929
Relation: 19728177	CID	38	51	D000082	29	32	D017114	true
Relation: 19728177	CID	38	51	D000082	56	70	D001929	true

Sentence: CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.
Entity: 19728177	29	32	FHF	Disease	D017114
Entity: 19728177	37	51	cerebral edema	Disease	D001929
Entity: 19728177	57	70	acetaminophen	Chemical	D000082
Entity: 19728177	71	79	overdose	Disease	D062787
Entity: 19728177	103	114	hypothermia	Disease	D007035
Relation: 19728177	CID	57	70	D000082	29	32	D017114	true
Relation: 19728177	CID	57	70	D000082	37	51	D001929	true
Relation: 19728177	CID	57	70	D000082	71	79	D062787	false
Relation: 19728177	CID	57	70	D000082	103	114	D007035	false

Sentence: Binasal visual field defects are not specific to vigabatrin.
Entity: 19815465	0	28	Binasal visual field defects	Disease	D014786
Entity: 19815465	49	59	vigabatrin	Chemical	D020888
Relation: 19815465	CID	49	59	D020888	0	28	D014786	true

Sentence: This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).
Entity: 19815465	28	42	visual defects	Disease	D014786
Entity: 19815465	82	92	vigabatrin	Chemical	D020888
Entity: 19815465	94	97	VGB	Chemical	D020888
Relation: 19815465	CID	82	92	D020888	28	42	D014786	true
Relation: 19815465	CID	94	97	D020888	28	42	D014786	true

Sentence: Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB).
Entity: 19815465	29	37	epilepsy	Disease	D004827
Entity: 19815465	132	135	VGB	Chemical	D020888
Relation: 19815465	CID	132	135	D020888	29	37	D004827	false

Sentence: Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.
Entity: 19841052	11	24	crack cocaine	Chemical	D016578
Entity: 19841052	46	59	HIV infection	Disease	D015658
Relation: 19841052	CID	11	24	D016578	46	59	D015658	false

Sentence: BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.
Entity: 19841052	65	78	crack cocaine	Chemical	D016578
Entity: 19841052	103	116	HIV infection	Disease	D015658
Relation: 19841052	CID	65	78	D016578	103	116	D015658	false

Sentence: Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection.
Entity: 19841052	28	41	crack cocaine	Chemical	D016578
Entity: 19841052	126	139	HIV infection	Disease	D015658
Relation: 19841052	CID	28	41	D016578	126	139	D015658	false

Sentence: To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov. 30, 1999 (period 1), Dec. 1, 1999-Nov. 30, 2002 (period 2), and Dec. 1, 2002-Dec. 30, 2005 (period 3).
Entity: 19841052	33	51	HIV seroconversion	Disease	D006679
Entity: 19841052	75	88	crack cocaine	Chemical	D016578
Relation: 19841052	CID	75	88	D016578	33	51	D006679	true

Sentence: After adjusting for potential confounders, we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time (period 1: hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.57-1.85; period 2: HR 1.68, 95% CI 1.01-2.80; and period 3: HR 2.74, 95% CI 1.06-7.11).
Entity: 19841052	69	87	HIV seroconversion	Disease	D006679
Entity: 19841052	133	146	crack cocaine	Chemical	D016578
Relation: 19841052	CID	133	146	D016578	69	87	D006679	true

Sentence: INTERPRETATION: Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users.
Entity: 19841052	27	40	crack cocaine	Chemical	D016578
Entity: 19841052	88	106	HIV seroconversion	Disease	D006679
Relation: 19841052	CID	27	40	D016578	88	106	D006679	true

Sentence: Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.
Entity: 19914299	0	10	Fluoxetine	Chemical	D005473
Entity: 19914299	24	39	memory deficits	Disease	D008569
Entity: 19914299	73	87	5-fluorouracil	Chemical	D005472
Relation: 19914299	CID	0	10	D005473	24	39	D008569	false
Relation: 19914299	CID	73	87	D005472	24	39	D008569	true

Sentence: Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.
Entity: 19920070	115	127	hepatomegaly	Disease	D006529
Entity: 19920070	134	147	phenobarbital	Chemical	D010634
Relation: 19920070	CID	134	147	D010634	115	127	D006529	true

Sentence: Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin induced Nephropathy.
Entity: 19967075	24	26	Na	Chemical	D012964
Entity: 19967075	27	28	K	Chemical	D011188
Entity: 19967075	65	75	Gentamicin	Chemical	D005839
Entity: 19967075	84	95	Nephropathy	Disease	D007674
Relation: 19967075	CID	24	26	D012964	84	95	D007674	false
Relation: 19967075	CID	27	28	D011188	84	95	D007674	false
Relation: 19967075	CID	65	75	D005839	84	95	D007674	true

Sentence: The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin induced nephropathy.
Entity: 19967075	107	117	gentamicin	Chemical	D005839
Entity: 19967075	126	137	nephropathy	Disease	D007674
Relation: 19967075	CID	107	117	D005839	126	137	D007674	true

Sentence: Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.
Entity: 20024739	28	35	alcohol	Chemical	D000431
Entity: 20024739	45	56	HIV disease	Disease	D015658
Relation: 20024739	CID	28	35	D000431	45	56	D015658	false

Sentence: We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.
Entity: 20024739	32	39	alcohol	Chemical	D000431
Entity: 20024739	56	66	depression	Disease	D003866
Entity: 20024739	89	100	HIV disease	Disease	D015658
Relation: 20024739	CID	32	39	D000431	56	66	D003866	true
Relation: 20024739	CID	32	39	D000431	89	100	D015658	false

Sentence: The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.
Entity: 20024739	136	146	depression	Disease	D003866
Entity: 20024739	214	224	Depression	Disease	D003866
Entity: 20024739	237	244	alcohol	Chemical	D000431
Relation: 20024739	CID	237	244	D000431	136	146	D003866	true
Relation: 20024739	CID	237	244	D000431	214	224	D003866	true

Sentence: The association between alcohol consumption and depression was significant (p<0.001).
Entity: 20024739	24	31	alcohol	Chemical	D000431
Entity: 20024739	48	58	depression	Disease	D003866
Relation: 20024739	CID	24	31	D000431	48	58	D003866	true

Sentence: Our findings suggest that alcohol consumption has a direct association with depression.
Entity: 20024739	26	33	alcohol	Chemical	D000431
Entity: 20024739	76	86	depression	Disease	D003866
Relation: 20024739	CID	26	33	D000431	76	86	D003866	true

Sentence: Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine induced status epilepticus.
Entity: 20034406	80	91	pilocarpine	Chemical	D010862
Entity: 20034406	100	118	status epilepticus	Disease	D013226
Relation: 20034406	CID	80	91	D010862	100	118	D013226	true

Sentence: In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.
Entity: 20034406	62	80	status epilepticus	Disease	D013226
Entity: 20034406	82	84	SE	Disease	D013226
Entity: 20034406	97	108	pilocarpine	Chemical	D010862
Relation: 20034406	CID	97	108	D010862	62	80	D013226	true
Relation: 20034406	CID	97	108	D010862	82	84	D013226	true

Sentence: METHODS: SE was induced by pilocarpine injection.
Entity: 20034406	9	11	SE	Disease	D013226
Entity: 20034406	27	38	pilocarpine	Chemical	D010862
Relation: 20034406	CID	27	38	D010862	9	11	D013226	true

Sentence: CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine induced SE.
Entity: 20034406	87	98	pilocarpine	Chemical	D010862
Entity: 20034406	107	109	SE	Disease	D013226
Relation: 20034406	CID	87	98	D010862	107	109	D013226	true

Sentence: The present study aimed to explore the effect of MT induction on carmustine (BCNU) induced hippocampal cognitive dysfunction in rats.
Entity: 20046642	49	51	MT	Chemical	D008668
Entity: 20046642	65	75	carmustine	Chemical	D002330
Entity: 20046642	77	81	BCNU	Chemical	D002330
Entity: 20046642	103	124	cognitive dysfunction	Disease	D003072
Relation: 20046642	CID	49	51	D008668	103	124	D003072	false
Relation: 20046642	CID	65	75	D002330	103	124	D003072	true
Relation: 20046642	CID	77	81	D002330	103	124	D003072	true

Sentence: The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content.
Entity: 20046642	32	36	BCNU	Chemical	D002330
Entity: 20046642	64	77	deterioration	Disease	D007859
Entity: 20046642	64	77	deterioration	Disease	D008569
Entity: 20046642	202	213	glutathione	Chemical	D005978
Entity: 20046642	250	261	glutathione	Chemical	D005978
Entity: 20046642	263	266	GSH	Chemical	D005978
Relation: 20046642	CID	32	36	D002330	64	77	D007859	true
Relation: 20046642	CID	32	36	D002330	64	77	D008569	true
Relation: 20046642	CID	202	213	D005978	64	77	D007859	false
Relation: 20046642	CID	202	213	D005978	64	77	D008569	false
Relation: 20046642	CID	250	261	D005978	64	77	D007859	false
Relation: 20046642	CID	250	261	D005978	64	77	D008569	false
Relation: 20046642	CID	263	266	D005978	64	77	D007859	false
Relation: 20046642	CID	263	266	D005978	64	77	D008569	false

Sentence: Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.
Entity: 20046642	6	10	BCNU	Chemical	D002330
Entity: 20046642	42	47	tumor	Disease	D009369
Entity: 20046642	48	56	necrosis	Disease	D009336
Entity: 20046642	94	96	MT	Chemical	D008668
Entity: 20046642	101	116	malondialdehyde	Chemical	D008315
Entity: 20046642	118	121	MDA	Chemical	D008315
Relation: 20046642	CID	6	10	D002330	42	47	D009369	false
Relation: 20046642	CID	6	10	D002330	48	56	D009336	false
Relation: 20046642	CID	94	96	D008668	42	47	D009369	false
Relation: 20046642	CID	94	96	D008668	48	56	D009336	false
Relation: 20046642	CID	101	116	D008315	42	47	D009369	false
Relation: 20046642	CID	101	116	D008315	48	56	D009336	false
Relation: 20046642	CID	118	121	D008315	42	47	D009369	false
Relation: 20046642	CID	118	121	D008315	48	56	D009336	false

Sentence: Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.
Entity: 20129423	6	19	carbamazepine	Chemical	D002220
Entity: 20129423	28	50	fulminant eosinophilic	Disease	D004802
Entity: 20129423	52	68	hypersensitivity	Disease	D004342
Entity: 20129423	70	81	myocarditis	Disease	D009205
Entity: 20129423	167	188	drug hypersensitivity	Disease	D004342
Relation: 20129423	CID	6	19	D002220	28	50	D004802	true
Relation: 20129423	CID	6	19	D002220	52	68	D004342	true
Relation: 20129423	CID	6	19	D002220	70	81	D009205	true
Relation: 20129423	CID	6	19	D002220	167	188	D004342	true

Sentence: A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.
Entity: 20129423	63	76	carbamazepine	Chemical	D002220
Entity: 20129423	106	122	hypersensitivity	Disease	D004342
Entity: 20129423	124	135	myocarditis	Disease	D009205
Relation: 20129423	CID	63	76	D002220	106	122	D004342	true
Relation: 20129423	CID	63	76	D002220	124	135	D009205	true

Sentence: We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.
Entity: 20129423	20	36	hypersensitivity	Disease	D004342
Entity: 20129423	37	48	myocarditis	Disease	D009205
Entity: 20129423	80	93	carbamazepine	Chemical	D002220
Relation: 20129423	CID	80	93	D002220	20	36	D004342	true
Relation: 20129423	CID	80	93	D002220	37	48	D009205	true

Sentence: Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
Entity: 20169779	34	38	MPTP	Chemical	D015632
Entity: 20169779	57	76	Parkinson's disease	Disease	D010302
Relation: 20169779	CID	34	38	D015632	57	76	D010302	false

Sentence: The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.
Entity: 20169779	4	12	levodopa	Chemical	D007980
Entity: 20169779	21	25	MPTP	Chemical	D015632
Entity: 20169779	67	92	neuropsychiatric symptoms	Disease	D001523
Entity: 20169779	96	98	PD	Disease	D010302
Relation: 20169779	CID	4	12	D007980	67	92	D001523	false
Relation: 20169779	CID	4	12	D007980	96	98	D010302	false
Relation: 20169779	CID	21	25	D015632	67	92	D001523	false
Relation: 20169779	CID	21	25	D015632	96	98	D010302	false

Sentence: Here we compare the time course of levodopa induced motor fluctuations and neuropsychiatric-like behaviors to determine the relationship between duration of treatment and onset of symptoms.
Entity: 20169779	35	43	levodopa	Chemical	D007980
Entity: 20169779	75	106	neuropsychiatric-like behaviors	Disease	D001523
Relation: 20169779	CID	35	43	D007980	75	106	D001523	false

Sentence: METHODS: Marmosets were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism.
Entity: 20169779	37	81	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	D015632
Entity: 20169779	134	146	parkinsonism	Disease	D010302
Relation: 20169779	CID	37	81	D015632	134	146	D010302	false

Sentence: Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.
Entity: 20169779	27	50	parkinsonian disability	Disease	D020734
Entity: 20169779	52	62	dyskinesia	Disease	D004409
Entity: 20169779	100	131	neuropsychiatric-like behaviors	Disease	D001523
Entity: 20169779	151	159	levodopa	Chemical	D007980
Relation: 20169779	CID	151	159	D007980	27	50	D020734	false
Relation: 20169779	CID	151	159	D007980	52	62	D004409	true
Relation: 20169779	CID	151	159	D007980	100	131	D001523	false

Sentence: As anticipated, animals exhibited a progressive increase in levodopa induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.
Entity: 20169779	60	68	levodopa	Chemical	D007980
Entity: 20169779	97	107	dyskinesia	Disease	D004409
Entity: 20169779	162	170	levodopa	Chemical	D007980
Relation: 20169779	CID	60	68	D007980	97	107	D004409	true
Relation: 20169779	CID	162	170	D007980	97	107	D004409	true

Sentence: In contrast, levodopa induced neuropsychiatric-like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment.
Entity: 20169779	13	21	levodopa	Chemical	D007980
Entity: 20169779	30	61	neuropsychiatric-like behaviors	Disease	D001523
Entity: 20169779	87	95	levodopa	Chemical	D007980
Relation: 20169779	CID	13	21	D007980	30	61	D001523	false
Relation: 20169779	CID	87	95	D007980	30	61	D001523	false

Sentence: Contrast medium nephrotoxicity after renal artery and coronary angioplasty.
Entity: 20192893	0	15	Contrast medium	Chemical	D003287
Entity: 20192893	16	30	nephrotoxicity	Disease	D007674
Relation: 20192893	CID	0	15	D003287	16	30	D007674	true

Sentence: BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).
Entity: 20192893	12	29	Renal dysfunction	Disease	D007674
Entity: 20192893	51	66	contrast medium	Chemical	D003287
Entity: 20192893	68	70	CM	Chemical	D003287
Relation: 20192893	CID	51	66	D003287	12	29	D007674	true
Relation: 20192893	CID	68	70	D003287	12	29	D007674	true

Sentence: PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).
Entity: 20192893	42	53	nephrotoxic	Disease	D007674
Entity: 20192893	64	66	CM	Chemical	D003287
Relation: 20192893	CID	64	66	D003287	42	53	D007674	true

Sentence: CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.
Entity: 20192893	98	110	renal damage	Disease	D007674
Entity: 20192893	122	124	CM	Chemical	D003287
Relation: 20192893	CID	122	124	D003287	98	110	D007674	true

Sentence: Medical and psychiatric outcomes for patients transplanted for acetaminophen induced acute liver failure: a case-control study.
Entity: 20408947	63	76	acetaminophen	Chemical	D000082
Entity: 20408947	85	104	acute liver failure	Disease	D017114
Relation: 20408947	CID	63	76	D000082	85	104	D017114	true

Sentence: BACKGROUND: Acetaminophen induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.
Entity: 20408947	12	25	Acetaminophen	Chemical	D000082
Entity: 20408947	34	48	hepatotoxicity	Disease	D056486
Entity: 20408947	77	96	acute liver failure	Disease	D017114
Entity: 20408947	98	101	ALF	Disease	D017114
Relation: 20408947	CID	12	25	D000082	34	48	D056486	true
Relation: 20408947	CID	12	25	D000082	77	96	D017114	true
Relation: 20408947	CID	12	25	D000082	98	101	D017114	true

Sentence: AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).
Entity: 20408947	223	236	acetaminophen	Chemical	D000082
Entity: 20408947	245	248	ALF	Disease	D017114
Entity: 20408947	322	335	acetaminophen	Chemical	D000082
Entity: 20408947	344	347	ALF	Disease	D017114
Entity: 20408947	375	396	chronic liver disease	Disease	D008107
Entity: 20408947	398	401	CLD	Disease	D008107
Relation: 20408947	CID	223	236	D000082	245	248	D017114	true
Relation: 20408947	CID	223	236	D000082	344	347	D017114	true
Relation: 20408947	CID	223	236	D000082	375	396	D008107	false
Relation: 20408947	CID	223	236	D000082	398	401	D008107	false
Relation: 20408947	CID	322	335	D000082	245	248	D017114	true
Relation: 20408947	CID	322	335	D000082	344	347	D017114	true
Relation: 20408947	CID	322	335	D000082	375	396	D008107	false
Relation: 20408947	CID	322	335	D000082	398	401	D008107	false

Sentence: RESULTS: Acetaminophen induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.
Entity: 20408947	9	22	Acetaminophen	Chemical	D000082
Entity: 20408947	31	34	ALF	Disease	D017114
Relation: 20408947	CID	9	22	D000082	31	34	D017114	true

Sentence: Twenty (56%) acetaminophen induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.
Entity: 20408947	13	26	acetaminophen	Chemical	D000082
Entity: 20408947	35	38	ALF	Disease	D017114
Entity: 20408947	98	111	acetaminophen	Chemical	D000082
Entity: 20408947	120	123	ALF	Disease	D017114
Entity: 20408947	130	133	CLD	Disease	D008107
Relation: 20408947	CID	13	26	D000082	35	38	D017114	true
Relation: 20408947	CID	13	26	D000082	120	123	D017114	true
Relation: 20408947	CID	13	26	D000082	130	133	D008107	false
Relation: 20408947	CID	98	111	D000082	35	38	D017114	true
Relation: 20408947	CID	98	111	D000082	120	123	D017114	true
Relation: 20408947	CID	98	111	D000082	130	133	D008107	false

Sentence: During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen induced ALF 1 year 87%, 5 years 75%; non-acetaminophen induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).
Entity: 20408947	153	166	acetaminophen	Chemical	D000082
Entity: 20408947	175	178	ALF	Disease	D017114
Entity: 20408947	208	221	acetaminophen	Chemical	D000082
Entity: 20408947	230	233	ALF	Disease	D017114
Entity: 20408947	244	247	CLD	Disease	D008107
Relation: 20408947	CID	153	166	D000082	175	178	D017114	true
Relation: 20408947	CID	153	166	D000082	230	233	D017114	true
Relation: 20408947	CID	153	166	D000082	244	247	D008107	false
Relation: 20408947	CID	208	221	D000082	175	178	D017114	true
Relation: 20408947	CID	208	221	D000082	230	233	D017114	true
Relation: 20408947	CID	208	221	D000082	244	247	D008107	false

Sentence: Two acetaminophen induced ALF patients reattempted suicide post-LT (one died 8 years post-LT).
Entity: 20408947	4	17	acetaminophen	Chemical	D000082
Entity: 20408947	26	29	ALF	Disease	D017114
Relation: 20408947	CID	4	17	D000082	26	29	D017114	true

Sentence: Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Entity: 20447294	27	35	morphine	Chemical	D009020
Entity: 20447294	48	54	sodium	Chemical	D012964
Entity: 20447294	72	79	CNSB002	Chemical	C401121
Entity: 20447294	115	131	neuropathic pain	Disease	D009437
Relation: 20447294	CID	27	35	D009020	115	131	D009437	false
Relation: 20447294	CID	48	54	D012964	115	131	D009437	false
Relation: 20447294	CID	72	79	C401121	115	131	D009437	false

Sentence: OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.
Entity: 20447294	64	71	CNSB002	Chemical	C401121
Entity: 20447294	75	81	sodium	Chemical	D012964
Entity: 20447294	163	171	morphine	Chemical	D009020
Entity: 20447294	206	222	neuropathic pain	Disease	D009437
Relation: 20447294	CID	64	71	C401121	206	222	D009437	false
Relation: 20447294	CID	75	81	D012964	206	222	D009437	false
Relation: 20447294	CID	163	171	D009020	206	222	D009437	false

Sentence: DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan induced paw inflammation and streptozotocin (STZ) induced diabetic neuropathy.
Entity: 20447294	54	62	morphine	Chemical	D009020
Entity: 20447294	67	74	CNSB002	Chemical	C401121
Entity: 20447294	229	233	pain	Disease	D010146
Entity: 20447294	242	253	carrageenan	Chemical	D002351
Entity: 20447294	266	278	inflammation	Disease	D007249
Entity: 20447294	283	297	streptozotocin	Chemical	D013311
Entity: 20447294	299	302	STZ	Chemical	D013311
Entity: 20447294	312	331	diabetic neuropathy	Disease	D003929
Relation: 20447294	CID	54	62	D009020	229	233	D010146	false
Relation: 20447294	CID	54	62	D009020	266	278	D007249	false
Relation: 20447294	CID	54	62	D009020	312	331	D003929	false
Relation: 20447294	CID	67	74	C401121	229	233	D010146	false
Relation: 20447294	CID	67	74	C401121	266	278	D007249	false
Relation: 20447294	CID	67	74	C401121	312	331	D003929	false
Relation: 20447294	CID	242	253	D002351	229	233	D010146	false
Relation: 20447294	CID	242	253	D002351	266	278	D007249	true
Relation: 20447294	CID	242	253	D002351	312	331	D003929	false
Relation: 20447294	CID	283	297	D013311	229	233	D010146	false
Relation: 20447294	CID	283	297	D013311	266	278	D007249	false
Relation: 20447294	CID	283	297	D013311	312	331	D003929	true
Relation: 20447294	CID	299	302	D013311	229	233	D010146	false
Relation: 20447294	CID	299	302	D013311	266	278	D007249	false
Relation: 20447294	CID	299	302	D013311	312	331	D003929	true

Sentence: The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).
Entity: 20447294	46	58	hyperalgesia	Disease	D006930
Entity: 20447294	106	117	carrageenan	Chemical	D002351
Entity: 20447294	164	167	STZ	Chemical	D013311
Entity: 20447294	176	186	neuropathy	Disease	D009422
Entity: 20447294	197	204	CNSB002	Chemical	C401121
Entity: 20447294	209	217	morphine	Chemical	D009020
Relation: 20447294	CID	106	117	D002351	46	58	D006930	true
Relation: 20447294	CID	106	117	D002351	176	186	D009422	false
Relation: 20447294	CID	164	167	D013311	46	58	D006930	true
Relation: 20447294	CID	164	167	D013311	176	186	D009422	false
Relation: 20447294	CID	197	204	C401121	46	58	D006930	false
Relation: 20447294	CID	197	204	C401121	176	186	D009422	false
Relation: 20447294	CID	209	217	D009020	46	58	D006930	false
Relation: 20447294	CID	209	217	D009020	176	186	D009422	false

Sentence: The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).
Entity: 20447294	20	28	morphine	Chemical	D009020
Entity: 20447294	60	67	CNSB002	Chemical	C401121
Entity: 20447294	142	153	carrageenan	Chemical	D002351
Entity: 20447294	183	193	neuropathy	Disease	D009422
Relation: 20447294	CID	20	28	D009020	183	193	D009422	false
Relation: 20447294	CID	60	67	C401121	183	193	D009422	false
Relation: 20447294	CID	142	153	D002351	183	193	D009422	false

Sentence: The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).
Entity: 20447294	26	34	morphine	Chemical	D009020
Entity: 20447294	87	94	CNSB002	Chemical	C401121
Entity: 20447294	146	158	hyperalgesia	Disease	D006930
Entity: 20447294	183	194	neuropathic	Disease	D009422
Relation: 20447294	CID	26	34	D009020	146	158	D006930	false
Relation: 20447294	CID	26	34	D009020	183	194	D009422	false
Relation: 20447294	CID	87	94	C401121	146	158	D006930	false
Relation: 20447294	CID	87	94	C401121	183	194	D009422	false

Sentence: Heparin induced thrombocytopenia: a practical review.
Entity: 20495512	0	7	Heparin	Chemical	D006493
Entity: 20495512	16	32	thrombocytopenia	Disease	D013921
Relation: 20495512	CID	0	7	D006493	16	32	D013921	true

Sentence: Heparin induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.
Entity: 20495512	0	7	Heparin	Chemical	D006493
Entity: 20495512	16	32	thrombocytopenia	Disease	D013921
Entity: 20495512	34	37	HIT	Disease	D013921
Relation: 20495512	CID	0	7	D006493	16	32	D013921	true
Relation: 20495512	CID	0	7	D006493	34	37	D013921	true

Sentence: HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.
Entity: 20495512	0	3	HIT	Disease	D013921
Entity: 20495512	58	68	thrombosis	Disease	D013927
Entity: 20495512	92	102	thrombosis	Disease	D013927
Entity: 20495512	116	123	heparin	Chemical	D006493
Relation: 20495512	CID	116	123	D006493	0	3	D013921	true
Relation: 20495512	CID	116	123	D006493	58	68	D013927	true
Relation: 20495512	CID	116	123	D006493	92	102	D013927	true

Sentence: The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.
Entity: 20495512	17	20	HIT	Disease	D013921
Entity: 20495512	60	67	heparin	Chemical	D006493
Entity: 20495512	149	174	direct thrombin inhibitor	Chemical	D000991
Relation: 20495512	CID	60	67	D006493	17	20	D013921	true
Relation: 20495512	CID	149	174	D000991	17	20	D013921	false

Sentence: Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.
Entity: 20495512	0	26	Direct thrombin inhibitors	Chemical	D000991
Entity: 20495512	75	82	heparin	Chemical	D006493
Entity: 20495512	113	116	HIT	Disease	D013921
Relation: 20495512	CID	0	26	D000991	113	116	D013921	false
Relation: 20495512	CID	75	82	D006493	113	116	D013921	true

Sentence: Abductor paralysis after botox injection for adductor spasmodic dysphonia.
Entity: 20513036	9	18	paralysis	Disease	D010243
Entity: 20513036	25	30	botox	Chemical	C542870
Entity: 20513036	45	73	adductor spasmodic dysphonia	Disease	D014826
Relation: 20513036	CID	25	30	C542870	9	18	D010243	false
Relation: 20513036	CID	25	30	C542870	45	73	D014826	true

Sentence: OBJECTIVES/HYPOTHESIS: Botulinum toxin (Botox) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia (ADSD).
Entity: 20513036	40	45	Botox	Chemical	C542870
Entity: 20513036	127	155	adductor spasmodic dysphonia	Disease	D014826
Entity: 20513036	157	161	ADSD	Disease	D014826
Relation: 20513036	CID	40	45	C542870	127	155	D014826	true
Relation: 20513036	CID	40	45	C542870	157	161	D014826	true

Sentence: Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD, a complication previously unreported.
Entity: 20513036	52	61	paralysis	Disease	D010243
Entity: 20513036	72	77	Botox	Chemical	C542870
Entity: 20513036	93	97	ADSD	Disease	D014826
Relation: 20513036	CID	72	77	C542870	52	61	D010243	false
Relation: 20513036	CID	72	77	C542870	93	97	D014826	true

Sentence: METHODS: Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated.
Entity: 20513036	32	37	Botox	Chemical	C542870
Entity: 20513036	53	72	spasmodic dysphonia	Disease	D055154
Relation: 20513036	CID	32	37	C542870	53	72	D055154	false

Sentence: For patients with bilateral abductor paralysis, age, sex, paralytic Botox dose, prior Botox dose, and course following paralysis were noted.
Entity: 20513036	37	46	paralysis	Disease	D010243
Entity: 20513036	68	73	Botox	Chemical	C542870
Entity: 20513036	86	91	Botox	Chemical	C542870
Entity: 20513036	119	128	paralysis	Disease	D010243
Relation: 20513036	CID	68	73	C542870	37	46	D010243	false
Relation: 20513036	CID	68	73	C542870	119	128	D010243	false
Relation: 20513036	CID	86	91	C542870	37	46	D010243	false
Relation: 20513036	CID	86	91	C542870	119	128	D010243	false

Sentence: RESULTS: From a database of 452 patients receiving Botox, 352 patients had been diagnosed with ADSD.
Entity: 20513036	51	56	Botox	Chemical	C542870
Entity: 20513036	95	99	ADSD	Disease	D014826
Relation: 20513036	CID	51	56	C542870	95	99	D014826	true

Sentence: The incidence of abductor paralysis after Botox injection for ADSD was 0.34%.
Entity: 20513036	26	35	paralysis	Disease	D010243
Entity: 20513036	42	47	Botox	Chemical	C542870
Entity: 20513036	62	66	ADSD	Disease	D014826
Relation: 20513036	CID	42	47	C542870	26	35	D010243	false
Relation: 20513036	CID	42	47	C542870	62	66	D014826	true

Sentence: CONCLUSIONS: Bilateral abductor paralysis is a rare complication of Botox injections for ADSD, causing difficulty with breathing upon exertion.
Entity: 20513036	32	41	paralysis	Disease	D010243
Entity: 20513036	68	73	Botox	Chemical	C542870
Entity: 20513036	89	93	ADSD	Disease	D014826
Relation: 20513036	CID	68	73	C542870	32	41	D010243	false
Relation: 20513036	CID	68	73	C542870	89	93	D014826	true

Sentence: The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles.
Entity: 20513036	24	33	paralysis	Disease	D010243
Entity: 20513036	50	55	Botox	Chemical	C542870
Relation: 20513036	CID	50	55	C542870	24	33	D010243	false

Sentence: Mitochondrial impairment contributes to cocaine induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.
Entity: 20566328	0	24	Mitochondrial impairment	Disease	D028361
Entity: 20566328	40	47	cocaine	Chemical	D003042
Entity: 20566328	56	75	cardiac dysfunction	Disease	D006331
Entity: 20566328	116	121	MitoQ	Chemical	C476756
Relation: 20566328	CID	40	47	D003042	0	24	D028361	false
Relation: 20566328	CID	40	47	D003042	56	75	D006331	true
Relation: 20566328	CID	116	121	C476756	0	24	D028361	false
Relation: 20566328	CID	116	121	C476756	56	75	D006331	false

Sentence: The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine induced cardiac dysfunction.
Entity: 20566328	107	114	cocaine	Chemical	D003042
Entity: 20566328	123	142	cardiac dysfunction	Disease	D006331
Relation: 20566328	CID	107	114	D003042	123	142	D006331	true

Sentence: This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine.
Entity: 20566328	100	107	cocaine	Chemical	D003042
Entity: 20566328	131	158	mitochondrial abnormalities	Disease	D028361
Entity: 20566328	231	238	cocaine	Chemical	D003042
Relation: 20566328	CID	100	107	D003042	131	158	D028361	false
Relation: 20566328	CID	231	238	D003042	131	158	D028361	false

Sentence: MitoQ, a mitochondrial-targeted antioxidant, was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data.
Entity: 20566328	0	5	MitoQ	Chemical	C476756
Entity: 20566328	83	110	mitochondrial abnormalities	Disease	D028361
Entity: 20566328	122	141	cardiac dysfunction	Disease	D006331
Entity: 20566328	166	187	diastolic dysfunction	Disease	-1
Relation: 20566328	CID	0	5	C476756	83	110	D028361	false
Relation: 20566328	CID	0	5	C476756	122	141	D006331	false
Relation: 20566328	CID	0	5	C476756	166	187	-1	false

Sentence: Trimethoprim induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.
Entity: 20589632	0	12	Trimethoprim	Chemical	D014295
Entity: 20589632	28	44	hemolytic anemia	Disease	D000743
Relation: 20589632	CID	0	12	D014295	28	44	D000743	true

Sentence: Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin induced diabetic nephropathy.
Entity: 20682692	100	114	streptozotocin	Chemical	D013311
Entity: 20682692	123	143	diabetic nephropathy	Disease	D003928
Relation: 20682692	CID	100	114	D013311	123	143	D003928	true

Sentence: OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).
Entity: 20682692	83	94	angiotensin	Chemical	D000804
Entity: 20682692	119	134	type 1 diabetes	Disease	D003922
Entity: 20682692	190	201	nephropathy	Disease	D007674
Entity: 20682692	280	300	diabetic nephropathy	Disease	D003928
Entity: 20682692	302	322	diabetic nephropathy	Disease	D003928
Relation: 20682692	CID	83	94	D000804	119	134	D003922	false
Relation: 20682692	CID	83	94	D000804	190	201	D007674	false
Relation: 20682692	CID	83	94	D000804	280	300	D003928	false
Relation: 20682692	CID	83	94	D000804	302	322	D003928	false

Sentence: We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ) induced diabetes.
Entity: 20682692	140	148	fibrosis	Disease	D005355
Entity: 20682692	196	210	streptozotocin	Chemical	D013311
Entity: 20682692	212	215	STZ	Chemical	D013311
Entity: 20682692	225	233	diabetes	Disease	D003920
Relation: 20682692	CID	196	210	D013311	140	148	D005355	false
Relation: 20682692	CID	196	210	D013311	225	233	D003920	false
Relation: 20682692	CID	212	215	D013311	140	148	D005355	false
Relation: 20682692	CID	212	215	D013311	225	233	D003920	false

Sentence: Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.
Entity: 20682692	118	121	STZ	Chemical	D013311
Entity: 20682692	130	150	diabetic nephropathy	Disease	D003928
Relation: 20682692	CID	118	121	D013311	130	150	D003928	true

Sentence: Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ induced diabetic nephropathy.
Entity: 20682692	119	122	STZ	Chemical	D013311
Entity: 20682692	131	151	diabetic nephropathy	Disease	D003928
Relation: 20682692	CID	119	122	D013311	131	151	D003928	true

Sentence: Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
Entity: 20828385	42	54	temsirolimus	Chemical	C401859
Entity: 20828385	69	89	mantle cell lymphoma	Disease	D020522
Relation: 20828385	CID	42	54	C401859	69	89	D020522	false

Sentence: However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.
Entity: 20828385	71	74	MCL	Disease	D020522
Entity: 20828385	88	100	temsirolimus	Chemical	C401859
Relation: 20828385	CID	88	100	C401859	71	74	D020522	false

Sentence: Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.
Entity: 20828385	58	61	MCL	Disease	D020522
Entity: 20828385	70	75	tumor	Disease	D009369
Entity: 20828385	104	116	temsirolimus	Chemical	C401859
Relation: 20828385	CID	104	116	C401859	58	61	D020522	false
Relation: 20828385	CID	104	116	C401859	70	75	D009369	false

Sentence: Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.
Entity: 20828385	43	55	temsirolimus	Chemical	C401859
Entity: 20828385	66	71	tumor	Disease	D009369
Entity: 20828385	175	180	tumor	Disease	D009369
Relation: 20828385	CID	43	55	C401859	66	71	D009369	false
Relation: 20828385	CID	43	55	C401859	175	180	D009369	false

Sentence: Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.
Entity: 20828385	35	47	temsirolimus	Chemical	C401859
Entity: 20828385	94	99	tumor	Disease	D009369
Relation: 20828385	CID	35	47	C401859	94	99	D009369	false

Sentence: Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.
Entity: 20828385	77	85	necrotic	Disease	D009336
Entity: 20828385	126	138	temsirolimus	Chemical	C401859
Relation: 20828385	CID	126	138	C401859	77	85	D009336	true

Sentence: Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.
Entity: 20828385	6	18	temsirolimus	Chemical	C401859
Entity: 20828385	27	32	tumor	Disease	D009369
Relation: 20828385	CID	6	18	C401859	27	32	D009369	false

Sentence: Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
Entity: 20859899	0	7	Syncope	Disease	D013575
Entity: 20859899	18	30	hyperkalemia	Disease	D006947
Entity: 20859899	73	84	angiotensin	Chemical	D000809
Entity: 20859899	117	131	spironolactone	Chemical	D013148
Relation: 20859899	CID	73	84	D000809	0	7	D013575	false
Relation: 20859899	CID	73	84	D000809	18	30	D006947	false
Relation: 20859899	CID	117	131	D013148	0	7	D013575	false
Relation: 20859899	CID	117	131	D013148	18	30	D006947	true

Sentence: The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.
Entity: 20859899	13	25	hyperkalemia	Disease	D006947
Entity: 20859899	64	78	spiranolactone	Chemical	D013148
Entity: 20859899	83	94	aldosterone	Chemical	D000450
Entity: 20859899	146	154	ramipril	Chemical	D017257
Relation: 20859899	CID	64	78	D013148	13	25	D006947	true
Relation: 20859899	CID	83	94	D000450	13	25	D006947	false
Relation: 20859899	CID	146	154	D017257	13	25	D006947	true

Sentence: Diffuse skeletal pain after administration of alendronate.
Entity: 20927253	17	21	pain	Disease	D010146
Entity: 20927253	46	57	alendronate	Chemical	D019386
Relation: 20927253	CID	46	57	D019386	17	21	D010146	true

Sentence: BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption.
Entity: 20927253	12	24	Osteoporosis	Disease	D010024
Entity: 20927253	87	102	bisphosphonates	Chemical	D004164
Relation: 20927253	CID	87	102	D004164	12	24	D010024	false

Sentence: Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women.
Entity: 20927253	0	11	Alendronate	Chemical	D019386
Entity: 20927253	15	28	biphosphonate	Chemical	-1
Entity: 20927253	84	96	osteoporosis	Disease	D010024
Relation: 20927253	CID	0	11	D019386	84	96	D010024	false
Relation: 20927253	CID	15	28	-1	84	96	D010024	false

Sentence: We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate.
Entity: 20927253	80	84	pain	Disease	D010146
Entity: 20927253	127	138	alendronate	Chemical	D019386
Relation: 20927253	CID	127	138	D019386	80	84	D010146	true

Sentence: Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.
Entity: 20959502	45	55	daptomycin	Chemical	D017576
Entity: 20959502	91	101	meningitis	Disease	D008581
Relation: 20959502	CID	45	55	D017576	91	101	D008581	false

Sentence: OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.
Entity: 20959502	31	42	methicillin	Chemical	D008712
Entity: 20959502	82	92	bacteremia	Disease	D016470
Entity: 20959502	113	123	meningitis	Disease	D008581
Entity: 20959502	147	157	daptomycin	Chemical	D017576
Relation: 20959502	CID	31	42	D008712	82	92	D016470	false
Relation: 20959502	CID	31	42	D008712	113	123	D008581	false
Relation: 20959502	CID	147	157	D017576	82	92	D016470	false
Relation: 20959502	CID	147	157	D017576	113	123	D008581	false

Sentence: On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).
Entity: 20959502	32	51	acute renal failure	Disease	D058186
Entity: 20959502	59	69	creatinine	Chemical	D003404
Relation: 20959502	CID	59	69	D003404	32	51	D058186	false

Sentence: Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.
Entity: 20959502	0	9	Nafcillin	Chemical	D009254
Entity: 20959502	31	41	daptomycin	Chemical	D017576
Entity: 20959502	84	94	meningitis	Disease	D008581
Relation: 20959502	CID	0	9	D009254	84	94	D008581	false
Relation: 20959502	CID	31	41	D017576	84	94	D008581	false

Sentence: DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin induced acute interstitial nephritis and relapsing bacteremia.
Entity: 20959502	12	22	Daptomycin	Chemical	D017576
Entity: 20959502	74	83	nafcillin	Chemical	D009254
Entity: 20959502	98	120	interstitial nephritis	Disease	D009395
Entity: 20959502	135	145	bacteremia	Disease	D016470
Relation: 20959502	CID	12	22	D017576	98	120	D009395	false
Relation: 20959502	CID	12	22	D017576	135	145	D016470	false
Relation: 20959502	CID	74	83	D009254	98	120	D009395	true
Relation: 20959502	CID	74	83	D009254	135	145	D016470	false

Sentence: CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.
Entity: 20959502	23	33	daptomycin	Chemical	D017576
Entity: 20959502	72	82	bacteremia	Disease	D016470
Relation: 20959502	CID	23	33	D017576	72	82	D016470	false

Sentence: The role of nitric oxide in convulsions induced by lindane in rats.
Entity: 21195121	12	24	nitric oxide	Chemical	D009569
Entity: 21195121	28	39	convulsions	Disease	D012640
Entity: 21195121	51	58	lindane	Chemical	D001556
Relation: 21195121	CID	12	24	D009569	28	39	D012640	false
Relation: 21195121	CID	51	58	D001556	28	39	D012640	true

Sentence: It evokes convulsions mainly trough the blockage of GABA(A) receptors.
Entity: 21195121	10	21	convulsions	Disease	D012640
Entity: 21195121	52	56	GABA	Chemical	D005680
Relation: 21195121	CID	52	56	D005680	10	21	D012640	false

Sentence: Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.
Entity: 21195121	0	12	Nitric oxide	Chemical	D009569
Entity: 21195121	14	16	NO	Chemical	D009569
Entity: 21195121	113	123	L-arginine	Chemical	D001120
Entity: 21195121	138	140	NO	Chemical	D009569
Entity: 21195121	162	168	L-NAME	Chemical	D019331
Entity: 21195121	207	215	epilepsy	Disease	D004827
Relation: 21195121	CID	0	12	D009569	207	215	D004827	false
Relation: 21195121	CID	14	16	D009569	207	215	D004827	false
Relation: 21195121	CID	113	123	D001120	207	215	D004827	false
Relation: 21195121	CID	138	140	D009569	207	215	D004827	false
Relation: 21195121	CID	162	168	D019331	207	215	D004827	false

Sentence: The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane induced epilepsy in male Wistar albino rats.
Entity: 21195121	61	63	NO	Chemical	D009569
Entity: 21195121	109	116	lindane	Chemical	D001556
Entity: 21195121	125	133	epilepsy	Disease	D004827
Relation: 21195121	CID	61	63	D009569	125	133	D004827	false
Relation: 21195121	CID	109	116	D001556	125	133	D004827	false

Sentence: The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).
Entity: 21195121	22	32	L-arginine	Chemical	D001120
Entity: 21195121	114	124	convulsion	Disease	D012640
Entity: 21195121	184	194	convulsion	Disease	D012640
Entity: 21195121	213	220	lindane	Chemical	D001556
Relation: 21195121	CID	22	32	D001120	114	124	D012640	false
Relation: 21195121	CID	22	32	D001120	184	194	D012640	false
Relation: 21195121	CID	213	220	D001556	114	124	D012640	true
Relation: 21195121	CID	213	220	D001556	184	194	D012640	true

Sentence: On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).
Entity: 21195121	35	41	L-NAME	Chemical	D019331
Entity: 21195121	83	93	convulsion	Disease	D012640
Entity: 21195121	147	157	convulsion	Disease	D012640
Entity: 21195121	185	195	convulsive	Disease	D012640
Entity: 21195121	204	211	lindane	Chemical	D001556
Relation: 21195121	CID	35	41	D019331	83	93	D012640	false
Relation: 21195121	CID	35	41	D019331	147	157	D012640	false
Relation: 21195121	CID	35	41	D019331	185	195	D012640	false
Relation: 21195121	CID	204	211	D001556	83	93	D012640	true
Relation: 21195121	CID	204	211	D001556	147	157	D012640	true
Relation: 21195121	CID	204	211	D001556	185	195	D012640	true

Sentence: Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.
Entity: 24055495	15	24	galactose	Chemical	D005690
Entity: 24055495	44	62	cognitive deficits	Disease	D003072
Entity: 24055495	122	136	streptozotocin	Chemical	D013311
Relation: 24055495	CID	15	24	D005690	44	62	D003072	true
Relation: 24055495	CID	122	136	D013311	44	62	D003072	true

Sentence: Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.
Entity: 24055495	50	58	dementia	Disease	D003704
Entity: 24055495	71	90	Alzheimer's disease	Disease	D000544
Entity: 24055495	191	198	glucose	Chemical	D005947
Entity: 24055495	213	220	glucose	Chemical	D005947
Entity: 24055495	253	260	glucose	Chemical	D005947
Relation: 24055495	CID	191	198	D005947	50	58	D003704	false
Relation: 24055495	CID	191	198	D005947	71	90	D000544	true
Relation: 24055495	CID	213	220	D005947	50	58	D003704	false
Relation: 24055495	CID	213	220	D005947	71	90	D000544	true
Relation: 24055495	CID	253	260	D005947	50	58	D003704	false
Relation: 24055495	CID	253	260	D005947	71	90	D000544	true

Sentence: Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested.
Entity: 24055495	43	52	galactose	Chemical	D005690
Entity: 24055495	60	80	memory deterioration	Disease	D008569
Entity: 24055495	161	170	galactose	Chemical	D005690
Relation: 24055495	CID	43	52	D005690	60	80	D008569	false
Relation: 24055495	CID	161	170	D005690	60	80	D008569	false

Sentence: We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.
Entity: 24055495	58	67	galactose	Chemical	D005690
Entity: 24055495	97	115	cognitive deficits	Disease	D003072
Entity: 24055495	119	133	streptozotocin	Chemical	D013311
Entity: 24055495	143	146	STZ	Chemical	D013311
Relation: 24055495	CID	58	67	D005690	97	115	D003072	true
Relation: 24055495	CID	119	133	D013311	97	115	D003072	true
Relation: 24055495	CID	143	146	D013311	97	115	D003072	true

Sentence: One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv induced cognitive deficits.
Entity: 24055495	18	27	galactose	Chemical	D005690
Entity: 24055495	70	73	STZ	Chemical	D013311
Entity: 24055495	136	139	STZ	Chemical	D013311
Entity: 24055495	152	170	cognitive deficits	Disease	D003072
Relation: 24055495	CID	18	27	D005690	152	170	D003072	true
Relation: 24055495	CID	70	73	D013311	152	170	D003072	true
Relation: 24055495	CID	136	139	D013311	152	170	D003072	true

